

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number

WO 01/05970 A2

(51) International Patent Classification<sup>7</sup>: C12N 15/12,  
C07K 14/47, G01N 33/53, C12Q 1/68, A61K 38/17,  
C07K 16/18, A01K 67/027

Drive, Santa Clara, CA 95054 (US). AU-YOUNG, Janice  
[US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005  
(US). REDDY, Roopa [IN/US]; 1233 W. McKinley Avenue, #3, Sunnyvale, CA 94086 (US). YANG, Junming  
[CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US).

(21) International Application Number: PCT/US00/19698

(22) International Filing Date: 19 July 2000 (19.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/144,595 19 July 1999 (19.07.1999) US  
60/150,460 23 August 1999 (23.08.1999) US  
60/159,849 15 October 1999 (15.10.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 60/144,595 (CIP)  
Filed on 19 July 1999 (19.07.1999)  
US 60/150,460 (CIP)  
Filed on 23 August 1999 (23.08.1999)  
US 60/159,849 (CIP)  
Filed on 15 October 1999 (15.10.1999)

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/05970 A2

(54) Title: GTP-BINDING ASSOCIATED PROTEINS

(57) Abstract: The invention provides human GTP-binding associated proteins (GBAP) and polynucleotides which identify and encode GBAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of GBAP.

**GTP-BINDING ASSOCIATED PROTEINS****TECHNICAL FIELD**

5 This invention relates to nucleic acid and amino acid sequences of GTP-binding associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer.

**10 BACKGROUND OF THE INVENTION**

Guanine nucleotide binding proteins (GTP-binding proteins) are present in all eukaryotic cells and function in processes including metabolism, cellular growth, differentiation, signal transduction, cytoskeletal organization, and intracellular vesicle transport and secretion. In higher organisms they are involved in signaling that regulates such processes as the immune response (Aussel, C. et al. (1988) J.

15 Immunol. 140:215-220), apoptosis, differentiation, and cell proliferation including oncogenesis (Dhanasekaran, N. et al. (1998) Oncogene 17:1383-1394).

The superfamily of GTP-binding proteins can be subdivided into groups such as translational factors, heterotrimeric GTP-binding proteins involved in transmembrane signaling processes (also called G-proteins), proto-oncogene Ras proteins, other low molecular weight GTP-binding proteins 20 including the products of rab, rap, rho, rac, smg21, smg25, YPT, SEC4, and ARF genes, and tubulins (Kaziro, Y. et al. (1991) Annu. Rev. Biochem. 60:349-400).

GTP-binding proteins are involved in protein biosynthesis and include initiation factor 2 (IF-2), elongation factor 2 (EF-Tu), and elongation factor G (EF-G), observed in prokaryotes; and initiation factor 2 (eIF-2), elongation factor I $\alpha$  (EF-I $\alpha$ ), elongation factor 2 (EF-2), and release factor 3 (eRF3) 25 observed in eukaryotes (Kaziro, *supra*). IF-2 promotes the GTP-dependent binding of the tRNA to the small subunit of the ribosome, the step that initiates protein translation. Elongation factors promote the binding of tRNA and GTP and the displacement of GDP after hydrolysis as protein biosynthesis proceeds. eRF3 participates in the recognition of stop codons and the release of nascent proteins from ribosomes.

30 Heterotrimeric GTP-binding proteins are composed of 3 subunits ( $\alpha$ ,  $\beta$  and  $\gamma$ ) which, in the resting state, associate as a trimer at the inner face of the plasma membrane. Heterotrimeric G-proteins may be classified based on the sequence similarity of  $\alpha$  subunits into the Gs, Gi, Gq and G12 subgroups. In the resting state, the  $\alpha$  subunit binds guanosine diphosphate (GDP), and stimulation of the G-protein by an activated receptor leads to exchange of GDP for guanosine triphosphate (GTP).

35 This exchange results in the separation of the  $\alpha$  from the  $\beta$  and  $\gamma$  subunits, which remain tightly

associated as a dimer. Both the  $\alpha$  subunit and  $\beta$ - $\gamma$  dimer are then able to interact with effectors, either individually or in a cooperative manner. The intrinsic GTPase activity of the  $\alpha$  subunit hydrolyzes the bound GTP to GDP. This returns the  $\alpha$  subunit to its inactive conformation and allows it to reassociate with the  $\beta$ - $\gamma$  complex, thus restoring the system to its resting state (Kaziro, *supra*). Some  $\alpha$  subunits show tissue-specific expression indicating a specialized signaling role (Dhanasekaran, *supra*).

The  $\alpha$ -s class of G-protein subunits is sensitive to ADP-ribosylation by pertussis toxin which uncouples the receptor:G-protein interaction. This uncoupling blocks signal transduction to receptors that decrease cAMP levels. cAMP levels regulate ion channels and activate phospholipases. The inhibitory  $\alpha$ -I class is also susceptible to modification by pertussis toxin, which prevents  $\alpha$ -I from lowering cAMP levels. Two novel classes of  $\alpha$  subunits refractory to pertussis toxin modification are  $\alpha$ -q, which activates phospholipase C, and  $\alpha$ -12, which has sequence homology with the *Drosophila* gene *concertina* and may contribute to the regulation of embryonic development (Simon, M.I. (1991) *Science* 252:802-808).

The mammalian G-protein  $\beta$  and  $\gamma$  subunits, each about 340 amino acids long, share more than 80% homology. The  $\beta$  subunit (also called  $\beta$ -transducin) contains seven repeating units, each about 43 amino acids long. This WD-repeat, or G-beta repeat motif, is found in a variety of proteins with regulatory function such as Sec13, a yeast WD repeat protein involved in vesicular traffic; coronin-2, a mammalian WD repeat protein involved in regulation of the actin cytoskeleton; and Bop1, a mammalian WD repeat protein involved in growth suppression (Garcia-Higuera, I. et al. (1998) *J. Biol. Chem.* 273:9041-9049; Okumura, M. et al. (1998) *DNA Cell Biol.* 17:779-787; Pestov, D.G. et al. (1998) *Oncogene* 17:3187-3197). The activity of the  $\beta$  and  $\gamma$  subunits may be regulated by other proteins such as calmodulin, phosducin, or the neural protein GAP 43 (Clapham, D.E. and E.J. Neer (1993) *Nature* 365:403-406). The  $\beta$  subunit sequences are highly conserved among species, suggesting that they perform a fundamentally important role in the organization and function of G-protein linked systems (Van der Voorn, L. and H.L. Ploegh (1992) *FEBS Lett.* 307:131-134).

Mutations and variant expression of  $\beta$ -transducin proteins are linked with various disorders. Mutations in LIS1, a subunit of the human platelet activating factor acetylhydrolase, cause Miller-Dieker lissencephaly. RACK1 binds activated protein kinase C, and RbAp48 binds retinoblastoma protein. CstF is required for polyadenylation of mammalian pre-mRNA *in vitro* and associates with subunits of cleavage-stimulating factor. Defects in the regulation of  $\beta$ -catenin contribute to the neoplastic transformation of human cells. The WD40 repeats of the human F-box protein  $\beta$ TrCP mediate binding to  $\beta$ -catenin, thus regulating the targeted degradation of  $\beta$ -catenin by ubiquitin ligase (Neer, E.J. et al. (1994) *Nature* 371:297-300; Hart, M. et al. (1999) *Curr. Biol.* 9:207-210).

The  $\gamma$  subunit sequences are more variable than those of the  $\beta$  subunits. They are often post-translationally modified by isoprenylation and carboxyl-methylation of a cysteine residue four amino

acids from the C-terminus. These modifications appear to be necessary for the interaction of the  $\beta$ - $\gamma$  dimer with the membrane and with other GTP-binding proteins. The  $\beta$ - $\gamma$  dimer has been shown to modulate the activity of adenylyl cyclase isoforms, phospholipase C, and some ion channels. It is involved in receptor phosphorylation via specific kinases and has been implicated in the p21ras-dependent activation of the MAP kinase cascade and the recognition of specific receptors by GTP-binding proteins (Clapham and Neer, *supra*).

G-proteins interact with a variety of effectors including adenylyl cyclase (Clapham and Neer, *supra*). The signaling pathway mediated by cAMP is mitogenic in hormone-dependent endocrine tissues such as adrenal cortex, thyroid, ovary, pituitary, and testes. Cancers in these tissues have been related to a mutationally activated form of a  $\text{G}\alpha_s$  known as the gsp (Gs protein) oncogene (Dhanasekaran, *supra*). Another effector is phosducin, a retinal phosphoprotein, which forms a specific complex with retinal G-protein  $\beta$  and  $\gamma$  subunits and modulates the ability of the  $\beta$ - $\gamma$  dimer to interact with retinal  $\alpha$  subunits (Clapham and Neer, *supra*). Additional G-protein effectors include RIN1 (Ras interaction/interference), which acts as an effector of H-Ras and interferes with the Ras signal transduction pathway; Rabin3, which associates with the Ras-like GTPase Rab3A; and Rhotekin, a protein that binds with, and inhibits, Rho GTPase activity (Han, L. and J. Colicelli (1995) Mol. Cell Biol. 15:1318-1323; Brondyke, W.H. et al. (1995) Mol. Cell Biol. 15:1137-1143; and Reid, T. et al. (1996) J. Biol. Chem. 27:13556-13560).

The low molecular weight GTP-binding proteins regulate cell growth, cell cycle control, protein secretion, and intracellular vesicle interaction. These GTP-binding proteins respond to extracellular signals from receptors and activating proteins by transducing mitogenic signals (Tavitian, A. (1995) C. R. Seances Soc. Biol. Fil. 189:7-12). Low molecular weight GTP-binding proteins consist of single polypeptides of 21-30kD which, like the  $\alpha$  subunit of heterotrimeric GTP-binding proteins, are able to bind to and hydrolyze GTP, thus cycling from an inactive to an active state. The intrinsic rate of GTP hydrolysis of these GTP-binding proteins is typically very slow, but it can be stimulated by several orders of magnitude by GTPase-activating proteins (GAPs), such as  $\beta$ 2-chimaerin (Geyer, M. and Wittinghofer, A. (1997) Curr. Opin. Struct. Biol. 7:786-792; Caloca, M. J. et al. (1997) J. Biol. Chem. 272:26488-26496).

Low molecular weight GTP-binding proteins play critical roles in cellular protein trafficking events, such as the translocation of proteins and soluble complexes from the cytosol to the membrane through an exchange of GDP for GTP (Klistakis, N.T. (1998) BioEssays 20:495-504). In vesicle transport, the interaction between vesicle- and target- specific identifiers (v-SNAREs and tSNAREs) docks the vesicle to the acceptor membrane. The budding process is regulated by GTPases such as the closely related ADP ribosylation factors (ARFs) and SAR proteins, while GTPases such as Rab allow assembly of SNARE complexes and may play a role in removal of defective complexes (Rothman, J.E.

and F.T. Wieland (1996) *Science* 272:227-234). The rab proteins control the translocation of vesicles to and from membranes for protein localization, protein processing, and secretion. The rho GTP-binding proteins control signal transduction pathways that link growth factor receptors to actin polymerization which is necessary for normal cellular growth and division. The ran GTP-binding 5 proteins are located in the nucleus of cells and have a key role in nuclear protein import, the control of DNA synthesis, and cell-cycle progression (Hall, A. (1990) *Science* 249:635-640; Scheffzek, K. et al. (1995) *Nature* 374:378-381).

The Ras proteins Ras1, Ras2 and G<sub>s</sub> $\alpha$  stimulate adenylyl cyclase (Kaziro, *supra*) which affects a broad array of cellular processes including determination of whether cells continue to grow or 10 become terminally differentiated. Stimulation of cell surface receptors activates Ras which, in turn, activates cytoplasmic kinases. These kinases translocate to the nucleus and activate key transcription factors that control gene expression and protein synthesis (Barbacid, M. (1987) *Annu. Rev. Biochem.* 56:779-827; Treisman, R. (1994) *Curr. Opin. Genet. Dev.* 4:96-101). Mutant Ras-family proteins 15 which bind but cannot hydrolyze GTP are permanently activated and are thus rendered oncogenic (Drivas, G.T. et al. (1990) *Mol. Cell. Biol.* 10:1793-1798).

Ras-like proteins have also been implicated in tumor suppression. For example, NOEY2, a novel gene encoding a Ras-like protein, is expressed in normal ovarian and breast epithelial cells. However, NOEY2 expression is reduced or abrogated in ovarian and breast carcinomas, suggesting a 20 role for the NOEY2 gene product in tumor suppression (Yu, Y. et al. (1999) *Proc. Natl. Acad. Sci. USA* 96:214-219).

Irregularities in GTP-binding protein signaling cascades may result in abnormal activation of leukocytes and lymphocytes, leading to the tissue damage and destruction seen in many inflammatory and autoimmune diseases such as rheumatoid arthritis, biliary cirrhosis, hemolytic anemia, lupus erythematosus, and thyroiditis. Abnormal cell proliferation, including cyclic AMP-mediated 25 stimulation of brain, thyroid, adrenal, and gonadal tissue proliferation is regulated by G proteins. Mutations in G<sub>a</sub> subunits have been found in growth-hormone-secreting pituitary somatotroph tumors, hyperfunctioning thyroid adenomas, and ovarian and adrenal neoplasms (Meij, J.T.A. (1996) *Mol. Cell. Biochem.* 157:31-38; Aussel, *supra*).

The discovery of new GTP-binding associated proteins and the polynucleotides encoding them 30 satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer.

## SUMMARY OF THE INVENTION

35 The invention features purified polypeptides, GTP-binding associated proteins, referred to

collectively as "GBAP" and individually as "GBAP-1," "GBAP-2," "GBAP-3," "GBAP-4," "GBAP-5," "GBAP-6," "GBAP-7," "GBAP-8," "GBAP-9," "GBAP-10," "GBAP-11," "GBAP-12," "GBAP-13," "GBAP-14," "GBAP-15," "GBAP-16," "GBAP-17," "GBAP-18," "GBAP-19," "GBAP-20," "GBAP-21," "GBAP-22," "GBAP-23," "GBAP-24," "GBAP-25," "GBAP-26," "GBAP-27," 5 "GBAP-28," "GBAP-29," "GBAP-30," "GBAP-31," "GBAP-32," "GBAP-33," "GBAP-34," "GBAP-35," "GBAP-36," "GBAP-37," "GBAP-38," "GBAP-39," "GBAP-40," "GBAP-41," "GBAP-42," "GBAP-43," "GBAP-44," "GBAP-45," "GBAP-46," "GBAP-47," "GBAP-48," "GBAP-49," "GBAP-50," "GBAP-51," "GBAP-52," "GBAP-53," "GBAP-54," "GBAP-55," "GBAP-56," "GBAP-57," "GBAP-58," "GBAP-59," "GBAP-60," "GBAP-61," "GBAP-62," 10 "GBAP-63," "GBAP-64," "GBAP-65," and "GBAP-66." In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence 15 selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-66.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the 20 group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. In one alternative, the polynucleotide encodes a polypeptide selected 25 from the group consisting of SEQ ID NO:1-66. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:67-132.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group 30 consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. In one alternative, the invention provides a cell transformed with the 35 recombinant polynucleotide. In another alternative, the invention provides a transgenic organism

comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66.

The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or

fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said 5 target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) 10 an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide 15 comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected 20 from the group consisting of SEQ ID NO:1-66, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional GBAP, comprising administering to a patient in need of such treatment the composition.

25 The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence 30 selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the 35 invention provides a method of treating a disease or condition associated with decreased expression of

functional GBAP, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional GBAP, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a

change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:67-132, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, ii) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, ii) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of the above polynucleotide sequence; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

#### BRIEF DESCRIPTION OF THE TABLES

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding GBAP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of GBAP.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression

patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding GBAP were isolated.

5 Table 5 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

#### DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood 10 that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," 15 and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings 20 as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, 25 protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

#### DEFINITIONS

"GBAP" refers to the amino acid sequences of substantially purified GBAP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and 30 human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GBAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GBAP either by directly interacting with GBAP or by acting on components of the biological pathway in which GBAP participates.

35 An "allelic variant" is an alternative form of the gene encoding GBAP. Allelic variants may

result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.

- 5 Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding GBAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GBAP or a polypeptide with at least one functional characteristic of GBAP. Included within this definition are 10 polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GBAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GBAP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GBAP. Deliberate 15 amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GBAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may 20 include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic 25 molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known 30 in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of GBAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GBAP either by directly interacting with GBAP or by acting on components of the biological pathway in which GBAP 35 participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind GBAP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used 5 to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that 10 makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

15 The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having 20 modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the 25 designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic GBAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific 30 antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a 35 given amino acid sequence" refer broadly to any composition containing the given polynucleotide or

amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GBAP or fragments of GBAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be 5 deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (PE Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from 10 one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least 15 interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
20	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
25	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
30	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
35	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

40 Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the

side chain.

. A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

10 A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

A "fragment" is a unique portion of GBAP or the polynucleotide encoding GBAP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a 15 fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected 20 from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:67-132 comprises a region of unique polynucleotide sequence that 25 specifically identifies SEQ ID NO:67-132, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:67-132 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:67-132 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:67-132 and the region of SEQ ID NO:67-132 to which the fragment corresponds are routinely 30 determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-66 is encoded by a fragment of SEQ ID NO:67-132. A fragment of SEQ ID NO:1-66 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-66. For example, a fragment of SEQ ID NO:1-66 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-66. 35 The precise length of a fragment of SEQ ID NO:1-66 and the region of SEQ ID NO:1-66 to which the

fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full-length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full-length" polynucleotide sequence encodes a "full-length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191.

For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

35           Matrix: BLOSUM62

*Reward for match: 1*

*Penalty for mismatch: -2*

*Open Gap: 5 and Extension Gap: 2 penalties*

*Gap x drop-off: 50*

5       *Expect: 10*

*Word Size: 11*

*Filter: on*

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over 10 the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

15       Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to 20 the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

25       Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with 30 polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (Apr-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

35       *Matrix: BLOSUM62*

*Open Gap: 11 and Extension Gap: 1 penalties*

*Gap x drop-off: 50*

*Expect: 10*

*Word Size: 3*

5       *Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 10 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for 15 chromosome replication, segregation and maintenance.

The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to the process by which a polynucleotide strand anneals with a 20 complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., 25 binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) 30 SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the 35 target sequence hybridizes to a perfectly matched probe. An equation for calculating  $T_m$  and conditions

for nucleic acid hybridization are well known and can be found in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention 5 include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as 10 formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

15 The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C<sub>0</sub>t or R<sub>0</sub>t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells 20 or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of 25 various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GBAP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of 30 GBAP which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

35 The term "modulate" refers to a change in the activity of GBAP. For example, modulation

may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of GBAP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an GBAP may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of GBAP.

"Probe" refers to nucleic acid sequences encoding GBAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

35 Methods for preparing and using probes and primers are described in the references, for

example Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 10 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences 15 and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from 20 their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and 25 polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

30 A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have 35 been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a

recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

10 "Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

15 An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

20 The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding GBAP, or fragments thereof, or GBAP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

25 The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

30 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

35 "Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters,

chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type 5 or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type 10 of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

15 A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with 20 a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants, and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, 25 transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the 30 nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant 35 identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides

due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic 5 variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at 10 least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

## 15 THE INVENTION

The invention is based on the discovery of new human GTP-binding associated proteins (GBAP), the polynucleotides encoding GBAP, and the use of these compositions for the diagnosis, treatment, or prevention of immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer.

20 Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding GBAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each GBAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries.

25 Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. In some cases, GenBank sequence identifiers are also shown in column 5. The Incyte clones and GenBank cDNA sequences, where indicated, in column 5 were used to assemble the consensus nucleotide sequence of each GBAP and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: 30 column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods and in some cases, searchable databases to which the analytical methods were applied. The methods of 35 column 7 were used to characterize each polypeptide through sequence homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding GBAP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:67-132 and 5 to distinguish between SEQ ID NO:67-132 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express GBAP as a fraction of total tissues expressing GBAP. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing GBAP as a fraction of total tissues expressing GBAP. Column 5 lists the vectors used to subclone each cDNA library. Of 10 particular note is the expression of SEQ ID NO:84 in lung tissues, and the tissue-specific expression of SEQ ID NO:132. Over 90% of tissues expressing SEQ ID NO:132 are derived from the nervous system, particularly the brain.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding GBAP were isolated. Column 1 references the nucleotide SEQ ID 15 NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

SEQ ID NO:70 maps to chromosome 7 within the interval from 111.6 to 123.4 centiMorgans. This interval contains a gene that is down regulated in adenoma. SEQ ID NO:74 maps to chromosome 11 within the interval from 104.8 to 123.5 centiMorgans. This interval contains a gene associated with 20 the cerebellar degenerative disorder, ataxia telangiectasia. SEQ ID NO:75 maps to chromosome 17 within the interval from 62.9 to 65.0 centiMorgans. SEQ ID NO:77 maps to chromosome 3 within the interval from 12.9 to 16.5 centiMorgans. SEQ ID NO:80 maps to chromosome 9 within the interval from 42.0 to 57.3 centiMorgans. SEQ ID NO:86 maps to chromosome 1 within the interval from 159.6 to 164.1 centiMorgans. SEQ ID NO:87 maps to chromosome 11 within the interval from 147.2 to 25 151.6. SEQ ID NO:90 maps to chromosome 1 within the interval from 219.2 to 223.0 centiMorgans. This interval contains a gene encoding a RAB interacting protein. SEQ ID NO:92 and SEQ ID NO:106 both map to chromosome 1 within the interval from 48.8 to 81.6 centiMorgans. This interval also contains genes associated with familial hypercholesterolemia, glucose transport defect, infantile 30 hypophosphatasia, infantile neuronal ceroid lipofuscinosis, Kostmann disease, multiple epiphyseal dysplasia, porphyria cutanea tarda, and T-cell acute lymphocytic leukemia 1. SEQ ID NO:93 maps to chromosome 12 within the interval from 76.5 to 87.6 centiMorgans. This interval also contains genes associated with mucopolysaccharidosis type IIID, pseudovitamin D deficiency rickets, and renal amyloidosis. SEQ ID NO:94 and SEQ ID NO:109 both map to chromosome 1 within the interval from 143.1 to 146.6 centiMorgans, to chromosome 14 within the interval from 46.8 to 50.9 centiMorgans, to 35 chromosome 16 within the interval from 88.1 to 90.2 centiMorgans, and to chromosome 19 within the

interval from 58.7 to 97.5 centiMorgans. The interval on chromosome 14 from 46.8 to 50.9 centiMorgans also contains a gene associated with dopa-responsive dystonia. The interval on chromosome 19 from 58.7 to 97.5 centiMorgans also contains genes associated with colorectal cancer, DNA ligase I deficiency, glutaricaciduria IIB, myotonic dystrophy, renal amyloidosis, T-cell acute lymphoblastic leukemia, and xeroderma pigmentosum D. SEQ ID NO:97 maps to chromosome 2 within the interval from 236.2 to 269.5 centiMorgans. This interval also contains genes associated with Crigler-Najjar syndrome, familial hypercholesterolemia, Oguchi disease, and primary hyperoxaluria. SEQ ID NO:101 maps to chromosome 2 within the interval from 225.6 to 233.1 centiMorgans, to chromosome 6 within the interval from 132.7 to 144.4 centiMorgans, and to chromosome 11 within the interval from 117.9 to 120.8 centiMorgans. The interval on chromosome 2 from 225.6 to 233.1 centiMorgans also contains a gene associated with Waardenburg syndrome 1. The interval on chromosome 6 from 132.7 to 144.4 centiMorgans also contains genes associated with familial disseminated atypical mycobacterial infection and rhizomelic chondrodysplasia punctata. The interval on chromosome 11 from 117.9 to 120.8 centiMorgans also contains a gene associated with acute intermittent porphyria. SEQ ID NO:111 maps to chromosome 19 within the interval from 35.5 to 49.4 centiMorgans, to chromosome 1 within the interval from the p-terminus to 16.4 centiMorgans, and to chromosome 11 within the interval from 147.2 centiMorgans to the q-terminus. SEQ ID NO:112 maps to chromosome 19 within the interval from 41.7 to 49.4 centiMorgans. SEQ ID NO:113 maps to chromosome 9 within the interval from 136.2 to 163.0 centiMorgans. SEQ ID NO:115 maps to chromosome 14 within the interval from 95.5 to 103.7 centiMorgans and to the X chromosome (23) within the interval from the p-terminus to 55.5 centiMorgans. SEQ ID NO:117 maps to chromosome 13 at 46.9 centiMorgans. SEQ ID NO:118 maps to chromosome 1 within the interval from 16.4 to 22.9 centiMorgans. SEQ ID NO:121 maps to chromosome 12 within the interval from 116.6 to 118.9 centiMorgans. SEQ ID NO:128 maps to chromosome 1 within the interval from the p-terminus to 16.4 centiMorgans.

The invention also encompasses GBAP variants. A preferred GBAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the GBAP amino acid sequence, and which contains at least one functional or structural characteristic of GBAP.

The invention also encompasses polynucleotides which encode GBAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:67-132, which encodes GBAP. The polynucleotide sequences of SEQ ID NO:67-132, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding GBAP. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GBAP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:67-132 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:67-132. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GBAP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GBAP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GBAP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GBAP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring GBAP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GBAP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GBAP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GBAP and GBAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GBAP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:67-132 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol.

152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of 5 DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (PE Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), 10 PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (PE Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (PE Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in 15 Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding GBAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, 20 restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids 25 Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences 30 are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, 35 Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a

GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, PE Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GBAP may be cloned in recombinant DNA molecules that direct expression of GBAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express GBAP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GBAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULAR BREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of GBAP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then

subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random 5 point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

10 In another embodiment, sequences encoding GBAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, GBAP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., 15 Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (PE Biosystems). Additionally, the amino acid sequence of GBAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a 20 sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

25 In order to express a biologically active GBAP, the nucleotide sequences encoding GBAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences 30 encoding GBAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GBAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GBAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be 35 needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous

translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.*

5 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GBAP and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. (See, e.g., Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory*

10 *Manual*, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding GBAP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with 15 yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, *supra*; Ausubel, *supra*; Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509; Bitter, G.A. et al. (1987) *Methods Enzymol.* 153:516-544;

20 Scorer, C.A. et al. (1994) *Bio/Technology* 12:181-184; Engelhard, E.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-3227; Sandig, V. et al. (1996) *Hum. Gene Ther.* 7:1937-1945; Takamatsu, N. (1987) *EMBO J.* 6:307-311; Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp.

25 191-196; Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659; and Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids; may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) *Cancer Gen. Ther.* 5(6):350-356; Yu, M. et al., (1993) *Proc. Natl. Acad. Sci.*

30 USA 90(13):6340-6344; Buller, R.M. et al. (1985) *Nature* 317(6040):813-815; McGregor, D.P. et al. (1994) *Mol. Immunol.* 31(3):219-226; and Verma, I.M. and N. Somia (1997) *Nature* 389:239-242.)

The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GBAP. For example, routine cloning, 35 subcloning, and propagation of polynucleotide sequences encoding GBAP can be achieved using a

multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding GBAP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of GBAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of GBAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

10 Yeast expression systems may be used for production of GBAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, *supra*;

15 Bitter, *supra*; and Scorer, *supra*.)

Plant systems may also be used for expression of GBAP. Transcription of sequences encoding GBAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, *supra*; Broglie, *supra*; and Winter, *supra*.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., *The McGraw Hill Yearbook of Science and Technology* (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GBAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses GBAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of GBAP in cell lines is preferred. For example, sequences encoding GBAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the 5 introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

10 Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers 15 resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements 20 for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech),  $\beta$ -glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. 25 (1995) Methods Mol. Biol. 55:121-131.)

25 Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GBAP is inserted within a marker gene sequence, transformed cells containing sequences encoding GBAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GBAP under the control of a single 30 promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding GBAP and that express GBAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and 35 protein bioassay or immunoassay techniques which include membrane, solution, or chip based

technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of GBAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence

- 5 activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GBAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New
- 10 York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GBAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the

15 sequences encoding GBAP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US

20 Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GBAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein

25 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GBAP may be designed to contain signal sequences which direct secretion of GBAP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the

30 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "pro" or "pre" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities

35 (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture

Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GBAP may be ligated to a heterologous sequence resulting in translation of a fusion 5 protein in any of the aforementioned host systems. For example, a chimeric GBAP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GBAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose 10 binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion 15 proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GBAP encoding sequence and the heterologous protein sequence, so that GBAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

20 In a further embodiment of the invention, synthesis of radiolabeled GBAP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, <sup>35</sup>S-methionine.

25 GBAP of the present invention or fragments thereof may be used to screen for compounds that specifically bind to GBAP. At least one and up to a plurality of test compounds may be screened for specific binding to GBAP. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of 30 GBAP, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, Coligan, J.E. et al. (1991) *Current Protocols in Immunology* 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which GBAP binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for 35 these compounds involves producing appropriate cells which express GBAP, either as a secreted

protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing GBAP or cell membrane fractions which contain GBAP are then contacted with a test compound and binding, stimulation, or inhibition of activity of either GBAP or the compound is analyzed.

5 An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with GBAP, either in solution or affixed to a solid support, and detecting the binding of GBAP to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a  
10 labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

GBAP of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of GBAP. Such compounds may include agonists, antagonists, or partial or  
15 inverse agonists. In one embodiment, an assay is performed under conditions permissive for GBAP activity, wherein GBAP is combined with at least one test compound, and the activity of GBAP in the presence of a test compound is compared with the activity of GBAP in the absence of the test compound. A change in the activity of GBAP in the presence of the test compound is indicative of a compound that modulates the activity of GBAP. Alternatively, a test compound is combined with an  
20 in vitro or cell-free system comprising GBAP under conditions suitable for GBAP activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of GBAP may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding GBAP or their mammalian homologs may  
25 be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of  
30 interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell  
35 blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred

to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding GBAP may also be manipulated *in vitro* in ES cells derived from 5 human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) *Science* 282:1145-1147).

Polynucleotides encoding GBAP can also be used to create "knockin" humanized animals 10 (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding GBAP is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. 15 Alternatively, a mammal inbred to overexpress GBAP, e.g., by secreting GBAP in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) *Biotechnol. Annu. Rev.* 4:55-74).

## THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists 20 between regions of GBAP and GTP-binding associated proteins. In addition, the expression of GBAP is closely associated with reproductive tissues, inflammation and the immune response, trauma, cell proliferation, and cancer. Therefore, GBAP appears to play a role in immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer. In the treatment of disorders associated with increased GBAP expression or activity, it is desirable to decrease the expression or activity of GBAP. In the treatment of disorders associated with decreased 25 GBAP expression or activity, it is desirable to increase the expression or activity of GBAP.

Therefore, in one embodiment, GBAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GBAP. Examples of such disorders include, but are not limited to, an immune system disorder such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), 30 Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, 35 Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable

bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, 5 systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; a reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, a disruption of the estrous cycle, a disruption of 10 the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, an endometrial or ovarian tumor, a uterine fibroid, autoimmune disorders, an ectopic pregnancy, and teratogenesis, cancer of the breast, fibrocystic breast disease, and galactorrhea, a disruption of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; a nervous 15 system disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural 20 abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central 25 nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, akathesia, amnesia, catatonia, diabetic neuropathy, 30 tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; a cell signaling disorder including endocrine disorders such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with 35 hyperpituitarism including acromegaly, gigantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma; disorders associated with

hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalcemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5  $\alpha$ -reductase, and gynecomastia; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a vector capable of expressing GBAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GBAP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified GBAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GBAP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of GBAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GBAP including, but not limited to, those listed above.

In a further embodiment, an antagonist of GBAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GBAP. Examples of such disorders include, but are not limited to, those immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer, described above. In one aspect, an antibody which specifically binds GBAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GBAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GBAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GBAP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of GBAP may be produced using methods which are generally known in the art. In particular, purified GBAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GBAP. Antibodies to GBAP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GBAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GBAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of GBAP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to GBAP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and

Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc.

- 5 Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GBAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton,
- 10 D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

- 15 Antibody fragments which contain specific binding sites for GBAP may also be generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al.
- 20 (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GBAP and its specific 25 antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GBAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GBAP. Affinity is expressed as an association 30 constant, K<sub>a</sub>, which is defined as the molar concentration of GBAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K<sub>a</sub> determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GBAP epitopes, represents the average affinity, or avidity, of the antibodies for GBAP. The K<sub>a</sub> determined for a preparation of monoclonal antibodies, which are monospecific for a particular GBAP 35 epitope, represents a true measure of affinity. High-affinity antibody preparations with K<sub>a</sub> ranging from

about 10<sup>9</sup> to 10<sup>12</sup> L/mole are preferred for use in immunoassays in which the GBAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K<sub>a</sub> ranging from about 10<sup>6</sup> to 10<sup>7</sup> L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GBAP, preferably in active form, from the antibody (Catty, D. (1988)

- 5 Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg 10 specific antibody/ml, is generally employed in procedures requiring precipitation of GBAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al., supra.)

In another embodiment of the invention, the polynucleotides encoding GBAP, or any fragment 15 or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding GBAP. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GBAP.

- 20 (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totowa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., 25 Slater, J.E. et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other 30 systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M.C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding GBAP may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency 35 (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked

inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and Somia, N. (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in GBAP expression or regulation causes disease, the expression of GBAP from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in GBAP are treated by constructing mammalian expression vectors encoding GBAP and introducing these vectors by mechanical means into GBAP-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev. Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr. Opin. Biotechnol.* 9:445-450).

Expression vectors that may be effective for the expression of GBAP include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). GBAP may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or  $\beta$ -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Gossen, M. et al. (1995) *Science* 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) *Curr. Opin. Biotechnol.* 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V.

and H.M. Blau, supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding GBAP from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver 5 polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

10 In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to GBAP expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding GBAP under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences 15 required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. 20 (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. 25 Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4<sup>+</sup> T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

30 In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding GBAP to cells which have one or more genetic abnormalities with respect to the expression of GBAP. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas 35 (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are

described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544; and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

5 In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding GBAP to target cells which have one or more genetic abnormalities with respect to the expression of GBAP. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing GBAP to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with  
10 ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV  
15 d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus  
20 sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to  
25 deliver polynucleotides encoding GBAP to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotech. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the  
30 overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for GBAP into the alphavirus genome in place of the capsid-coding region results in the production of a large number of GBAP-coding RNAs and the synthesis of high levels of GBAP in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in  
35 hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic

replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the introduction of GBAP into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones 5 of alphaviruses, performing alphavirus cDNA and RNA transfactions, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes 10 inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by 15 preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze 20 endonucleolytic cleavage of sequences encoding GBAP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for 25 secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for 30 chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis.

Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding GBAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or 35 tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiester linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutoxine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding GBAP. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased GBAP expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding GBAP may be therapeutically useful, and in the treatment of disorders associated with decreased GBAP expression or activity, a compound which specifically promotes expression of the polynucleotide encoding GBAP may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding GBAP is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding GBAP are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding GBAP. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of

the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

10 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.

15 Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such pharmaceutical compositions may consist of GBAP, antibodies to GBAP, and mimetics, agonists, antagonists, or 25 inhibitors of GBAP.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

30 Pharmaceutical compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of 35 the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g.,

Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The 5 determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of pharmaceutical compositions may be prepared for direct intracellular delivery of macromolecules comprising GBAP or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, GBAP or a fragment thereof may be joined to a short 10 cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, 15 or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example GBAP or fragments thereof, antibodies of GBAP, and agonists, antagonists or inhibitors of GBAP, which 20 ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) or LD<sub>50</sub> (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD<sub>50</sub>/ED<sub>50</sub> ratio. Pharmaceutical compositions which 25 exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

30 The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. 35 Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or

biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1  $\mu\text{g}$  to 100,000  $\mu\text{g}$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.

- 5 Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

#### DIAGNOSTICS

In another embodiment, antibodies which specifically bind GBAP may be used for the diagnosis  
10 of disorders characterized by expression of GBAP, or in assays to monitor patients being treated with  
GBAP or agonists, antagonists, or inhibitors of GBAP. Antibodies useful for diagnostic purposes may  
be prepared in the same manner as described above for therapeutics. Diagnostic assays for GBAP  
include methods which utilize the antibody and a label to detect GBAP in human body fluids or in  
extracts of cells or tissues. The antibodies may be used with or without modification, and may be  
15 labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter  
molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring GBAP, including ELISAs, RIAs, and FACS, are known  
in the art and provide a basis for diagnosing altered or abnormal levels of GBAP expression. Normal  
or standard values for GBAP expression are established by combining body fluids or cell extracts taken  
20 from normal mammalian subjects, for example, human subjects, with antibody to GBAP under  
conditions suitable for complex formation. The amount of standard complex formation may be  
quantitated by various methods, such as photometric means. Quantities of GBAP expressed in subject,  
control, and disease samples from biopsied tissues are compared with the standard values. Deviation  
between standard and subject values establishes the parameters for diagnosing disease.

25 In another embodiment of the invention, the polynucleotides encoding GBAP may be used for  
diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences,  
complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and  
quantify gene expression in biopsied tissues in which expression of GBAP may be correlated with  
disease. The diagnostic assay may be used to determine absence, presence, and excess expression of  
30 GBAP, and to monitor regulation of GBAP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide  
sequences, including genomic sequences, encoding GBAP or closely related molecules may be used to  
identify nucleic acid sequences which encode GBAP. The specificity of the probe, whether it is made  
from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a  
35 conserved motif, and the stringency of the hybridization or amplification will determine whether the

probe identifies only naturally occurring sequences encoding GBAP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the GBAP encoding sequences. The hybridization probes of the subject 5 invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:67-132 or from genomic sequences including promoters, enhancers, and introns of the GBAP gene.

Means for producing specific hybridization probes for DNAs encoding GBAP include the cloning of polynucleotide sequences encoding GBAP or GBAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may 10 be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GBAP may be used for the diagnosis of disorders 15 associated with expression of GBAP. Examples of such disorders include, but are not limited to, an immune system disorder such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, 20 Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial 25 inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, 30 leukemia, and myeloma; a reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, an endometrial or ovarian tumor, a uterine fibroid, autoimmune disorders, an ectopic pregnancy, and teratogenesis, cancer of the breast, fibrocystic breast disease, and galactorrhea, a disruption of 35 spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign

prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; a nervous system disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; a cell signaling disorder including endocrine disorders such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with hyperpituitarism including acromegaly, gigantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma; disorders associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalcemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5  $\alpha$ -reductase, and gynecomastia; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal

hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, 5 penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. The polynucleotide sequences encoding GBAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GBAP expression. Such qualitative or quantitative methods are well known in the art.

10 In a particular aspect, the nucleotide sequences encoding GBAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GBAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard 15 value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GBAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

20 In order to provide a basis for the diagnosis of a disorder associated with expression of GBAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GBAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with 25 values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, 30 hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or 35 overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development

of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

- 5        Additional diagnostic uses for oligonucleotides designed from the sequences encoding GBAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding GBAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding GBAP, and will be employed under optimized conditions for identification of a specific gene or condition.
- 10      Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding GBAP may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease 15 in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding GBAP are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary 20 and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluoresently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual 25 overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

- 30      Methods which may also be used to quantify the expression of GBAP include radiolabeling or biotinylation of nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of 35 interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid

quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described in Seilhamer, J.J. et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 5,840,484, incorporated herein by reference. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, antibodies specific for GBAP, or GBAP or fragments thereof may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity

(Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently

positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry.

- 5 The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for GBAP to quantify the levels of GBAP expression. In one embodiment, the antibodies are used as elements on a microarray, 10 and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoza, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

- 15 Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the 20 proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein 25 is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

- In another embodiment, the toxicity of a test compound is assessed by treating a biological 30 sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

35 Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g.,

Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding GBAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, e.g., Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding GBAP on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may

also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, GBAP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GBAP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with GBAP, or fragments thereof, and washed. Bound GBAP is then detected by methods well known in the art. Purified GBAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

15 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GBAP specifically compete with a test compound for binding GBAP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GBAP.

In additional embodiments, the nucleotide sequences which encode GBAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific 25 embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/144,595, U.S Ser. No. 60/150,460, and U.S. Ser. No. 60/159,849, are hereby expressly incorporated by reference.

30

## EXAMPLES

### I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed 35 in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic

solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), pcDNA2.1 plasmid (Invitrogen, Carlsbad CA), or pINCY plasmid (Incyte Genomics, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 $\alpha$ , DH10B, or ElectroMAX DH10B from Life Technologies.

## II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by *in vivo* excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using

PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSCAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

### III. Sequencing and Analysis

- Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows.
- 5 Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (PE Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI
- 10 PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (PE Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA
- 15 sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VI.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between 20 two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

- 25 The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation
- 30 using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full

length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the 5 GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and 10 amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:67-132. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

#### IV. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene 15 and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is 20 much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar.

The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \min\{\text{length(Seq. 1)}, \text{length(Seq. 2)}\}}$$

25

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by 30 assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter 35 of the two sequences being compared. A product score of 70 is produced either by 100% identity and

70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding GBAP occurred. Analysis involved the categorization of cDNA libraries by 5 organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories.

10 Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

#### V. Chromosomal Mapping of GBAP Encoding Polynucleotides

The cDNA sequences which were used to assemble SEQ ID NO:67-132 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other 15 implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:67-132 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 5). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences 20 had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

The genetic map locations of SEQ ID NO:70, 74, 75, 77, 80, 86, 87, 90, 92, 93, 94, 97, 101, 106, 109, 111, 112, 113, 115, 117, 118, 121, and 128 are described in The Invention as ranges, or intervals, of human chromosomes. More than one map location is reported for SEQ ID NO:94, 101, 25 109, 111, and 115, indicating that previously mapped sequences having similarity, but not complete identity, to SEQ ID NO:94, 101, 109, 111, and 115 were assembled into their respective clusters.

The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase 30 (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters.

#### VI. Extension of GBAP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:67-132 were produced by extension of an 35 appropriate fragment of the full length molecule using oligonucleotide primers designed from this

fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at 5 temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR 10 was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg<sup>2+</sup>, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 15 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN 20 quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis 25 on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose 30 gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x 35 carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems).

10 In like manner, the polynucleotide sequences of SEQ ID NO:67-132 are used to obtain 5' regulatory sequences using the procedure above, along with oligonucleotides designed for such extension, and an appropriate genomic library.

#### VII. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:67-132 are employed to screen cDNAs, 15 genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μCi of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston 20 MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

25 The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and 30 compared.

#### VIII. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, *supra*), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned 35 technologies should be uniform and solid with a non-porous surface (Schena (1999), *supra*). Suggested

substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may 5 contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be 10 selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a 15 fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

#### Tissue or Cell Sample Preparation

20 Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)<sup>+</sup> RNA is purified using the oligo-(dT) cellulose method. Each poly(A)<sup>+</sup> RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ $\mu$ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ $\mu$ l RNase inhibitor, 500  $\mu$ M dATP, 500  $\mu$ M dGTP, 500  $\mu$ M dTTP, 40  $\mu$ M dCTP, 40  $\mu$ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse 25 transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)<sup>+</sup> RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)<sup>+</sup> RNAs are synthesized by *in vitro* transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified 30 using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14  $\mu$ l 5X SSC/0.2% SDS.

#### Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60 °C followed by washes in 0.2% SDS and distilled water as before.

#### Hybridization

Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65 °C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm<sup>2</sup> coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60 °C. The arrays are washed for 10 min at 45 °C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45 °C in a second wash buffer (0.1X SSC), and dried.

#### Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide

containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.

5 Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source,  
10 although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples  
15 from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital  
20 (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping  
25 emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

### 30 IX. Complementary Polynucleotides

Sequences complementary to the GBAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GBAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO  
35 4.06 software (National Biosciences) and the coding sequence of GBAP. To inhibit transcription, a

complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GBAP-encoding transcript.

#### X. Expression of GBAP

5 Expression and purification of GBAP is achieved using bacterial or virus-based expression systems. For expression of GBAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).

Antibiotic resistant bacteria express GBAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GBAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant *Autographica californica* nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GBAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect *Spodoptera frugiperda* (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, GBAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from *Schistosoma japonicum*, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GBAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10 and 16). Purified GBAP obtained by these methods can be used directly in the assays shown in Examples XI and XV.

#### XI. Demonstration of GBAP Activity

35 GTP-binding activity of GBAP is determined in an assay that measures the binding of GBAP

to  $\alpha$ -P<sup>32</sup>-labeled GTP. Purified GBAP is first blotted onto filters and rinsed in a suitable buffer. The filters are then incubated in buffer containing radiolabeled  $\alpha$ -<sup>32</sup>P-GTP. The filters are washed in buffer to remove unbound GTP and counted in a radioisotope counter. Non-specific binding is determined in an assay that contains a 100-fold excess of unlabeled GTP. The amount of specific binding is proportional to the activity of GBAP.

GTPase activity of GBAP is determined in an assay that measures the conversion of  $\alpha$ -<sup>32</sup>P-GTP to  $\alpha$ -<sup>32</sup>P-GDP. GBAP is incubated with  $\alpha$ -<sup>32</sup>P-GTP in buffer for an appropriate period of time, and the reaction is terminated by heating or acid precipitation followed by centrifugation. An aliquot of the supernatant is subjected to polyacrylamide gel electrophoresis (PAGE) to separate GDP and GTP together with unlabeled standards. The GDP spot is cut out and counted in a radioisotope counter. The amount of radioactivity recovered in GDP is proportional to GTPase activity of GBAP.

## XII. Functional Assays

GBAP function is assessed by expressing the sequences encoding GBAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT plasmid (Life Technologies) and pCR3.1 plasmid (Invitrogen), both of which contain the cytomegalovirus promoter. 5-10  $\mu$ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2  $\mu$ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of GBAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding GBAP and either CD64 or CD64-GFP. CD64 and CD64-

GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression 5 of mRNA encoding GBAP and other genes of interest can be analyzed by northern analysis or microarray techniques.

### XIII. Production of GBAP Specific Antibodies

GBAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to 10 immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the GBAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well 15 described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (PE Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH 20 complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GBAP activity by, for example, binding the peptide or GBAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

### XIV. Purification of Naturally Occurring GBAP Using Specific Antibodies

Naturally occurring or recombinant GBAP is substantially purified by immunoaffinity 25 chromatography using antibodies specific for GBAP. An immunoaffinity column is constructed by covalently coupling anti-GBAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GBAP are passed over the immunoaffinity column, and the column is washed 30 under conditions that allow the preferential absorbance of GBAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GBAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GBAP is collected.

### XV. Identification of Molecules Which Interact with GBAP

35 GBAP, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent.

(See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GBAP, washed, and any wells with labeled GBAP complex are assayed. Data obtained using different concentrations of GBAP are used to calculate values for the number, affinity, and association of GBAP with the  
5 candidate molecules.

Alternatively, molecules interacting with GBAP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989, Nature 340:245-246), or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

GBAP may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT)  
10 which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Various modifications and variations of the described methods and systems of the invention will  
15 be apparent to those skilled in the art without departing from the scope and spirit of the invention.  
Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following  
20 claims.

Table 1

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments	
1	67	1405545	LATRTUT02	1405545F6 (LATRTUT02), 1405545H1 (LATRTUT02), 2926327F7 (TLYMMNOT04), 2926327T6 (TLYMMNOT04)	
2	68	1451265	PENITUT01	700515X14 (SYNORAT03), 758541H1 (BRAITUT02), 1348685F6 (PROSNOT11), 1451265H1 (PENITUT01), 1872777F6 (LEUKNOT02)	
3	69	1556311	BLADTUT04	1556311H1 (BLADTUT04), 3221281T6 (COLNNON03), 3350311F6 (BRAITUT24), SBFA02256F1, SBFA01440F1, SBFA01098F1, SBFA04741F1	
4	70	1901373	BLADTUT06	758057H1 (BRAITUT02), 1255886H1 (MENITUT03), 1887731X12C1 (BLADTUT06), 1901373H1 (BLADTUT06), 2866863H1 (KIDNNNOT20), 3090943H1 (BRSTNOT19), 3215237H1 (TESTNOT07), 3719233H1 (PENCNOT10), 4319601H1 (BRADDIT02)	
5	71	2367767	ADRENNOT07	1331124F1 (PANCNOT07), 2367767H1 (ADRENNOT07), 2367779F6 (ADRENNOT07) 2782232F6 (BRSTNOT13), 3079286H2 (BRAINTUT01), 3584043T6 (293TE4T01), 4994696H1 (LIVRTUT11)	
6	72	3090433	BRSTNOT19	312565H1 (LUNGNOT02), 841829R6 (PROSTUT05), 1340809H1 (COLNTUT03), 1842057H1 (COLANNOT07), 2693513F6 (LUNGNOT23), 3090433H1 (BRSTNOT19), 4895874H1 (LIVRTUT12)	
7	73	3800591	SPLNNNOT12	554715F1 (SCORNNOT01), 882035X23 (THYRNNOT02), 3042234F7 (BRSTNOT16), 3630695H1 (COLNNOT38), 3800591H1 (SPINNOT12), 4975447H1 (HELATXT03)	
8	74	5308471	MONOTXT02	790680R1 (PROSTUT03), 870507R1 (LUNGAST01), 948177R1 (PANCNOT05), 1682469T7 (PROSNOT15), 2897215H1 (KIDNTUT14), 5308471H1 (MONOTXT02)	
9	75	5324322	FIBPFEN06	1001977R1 (BRSTNOT03), 1312045F1 (COLNFET02), 1334040F2 (COLNNOT13), 1488082F6 (UCMCL5T01), 1570077F1 (UTRSNOT05), 1929845H1 (COLNTUT03), 2306061H1 (NGANNNOT01), 3127730F7 (LUNGUT12), 3494367H1 (ADRETUT07), 3578924H1 (293TF3T01), 4619513H1 (ENDVNNOT01), 4932823H1 (BRSTTUT20), 5324322H1 (FIBPFEN06)	
10	76	067184	HUVESTB01	067184H1 (HUVESTB01), 067184R1 (HUVESTB01), 067184X12 (HUVESTB01), 067184X23C1 (HUVESTB01), 067184X29C1 (HUVESTB01), 968551H1 (BRSTNOT05), 2611874T6 (LUNGUT10)	
11	77	722896	SYNOOAT01	722896H1 (SYNOOAT01), 722896X19C1 (SYNOOAT01), 14333775T1 (BEPINON01), 1477633T6 (CORPNOT02), 2676923F6 (KIDNNNOT19), 3230945H1 (COTRNNOT01), 3389989H1 (LUNGUT17)	
12	78	1571739	UTRSNOT05	1571739H1 (UTRSNOT05), 1571739X12R1 (UTRSNOT05), 2799982H1 (PENCNOT01), 4059114F6 (BRAINOT21)	

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments	
13	79	1739479	HIPONON01	511157H1 (MPHGNOT03), 511157T6 (MPHGNOT03), 1739479H1 (HIPONON01), 2092446T6 (PANCNOT04), 3880948F6 (SPLANNOT11)	
14	80	1999147	BRSTTUT03	1339243T6 (COLNTUT03), 1999147H1 (BRSTTUT03), 2094940X11F1 (BRAITUT02), 2670959T6 (ESOGTUT02), 3297709H1 (TLYJINT01), 3396927H1 (UTRSNOT16), SCBA00828V1, SCBA00615V1, SCBA04422V1, SCBA04646V1, SCBA01715V1, 5544151H1 (TESTNO01)	
15	81	2182085	SININCT01	767764R6 (LUNGNOT04), 16555010F6 (PROSTIT08), 1701703T6 (BLADTUT05), 1871360F6 (SKINBIT01), 2081835F6 (UTRSNOT08), 2411644H1 (BSTMNON02)	
16	82	2216640	SINTFFET03	489759H1 (HNT2AGT01), 2057454T6 (BEPINOT01), 2097739H1 (BRAITUT02), 2216640H1 (SINTFFET03), 2325135H1 (OVARNOT02), 2361273R6 (LUNGFFET05), 2667958H1 (ESOGTUT02), 3462348H1 (293TE2T01), 3478754H1 (OVARNOT11), 4163069F6 (BRSTNOT32)	
17	83	2417361	HNT3AZT01	1394742F1 (THYRNNOT03), 2417361F6 (HNT3AZT01), 2417361H1 (HNT3AZT01)	
18	84	2454384	ENDANOT01	2454384H1 (ENDANOT01), 2454384T6 (ENDANOT01), 2589653T6 (LUNGNOT22), 2643485F6 (LUNGTTU12), 3130367H1 (LUNGTTU12)	
19	85	2610262	LUNGTTU08	1226946R6 (COLNNNOT01), 1226946T6 (COLNNNOT01), 2610262F6 (LUNGTTU08), 2610262H1 (LUNGTTU08)	
20	86	2700075	OVERTUT10	604199R1 (BRSTTUT01), 1225126R1 (COLNTUT02), 1923323R6 (BRSTTUT01), 2301778R6 (BRSTNOT05), 2506882F6 (CONUTTUT01), 2700075F6 (OVERTUT10), 2700075H1 (OVARTUT10), 2744960F6 (LUNGTTU11), 28333994F6 (TLYMMNOT03), 2915413H1 (THYMFET03), 3647274H1 (ENDINOT01)	
21	87	2786701	BRSTNOT13	754370R1 (BRAITUT02), 1426163R6 (BEPINON01), 1850667F6 (LUNGFFET03), 1923562R6 (BRSTTUT01), 2215161F6 (SINTFFET03), 2215161T6 (SINTFFET03), 2498589H1 (ADRETUT05), 2991672F6 (KIDNFET02), 3028991H1 (HEARFET02), 3729514H1 (SMCCCN03), 5065467H1 (ARTFTDT01)	
22	88	3068538	UTRSNR01	908465R2 (COLNNNOT09), 957130R6 (KIDNNNOT05), 1301520F6 (BRSTNOT07), 1580628H1 (DUODNOT01), 2631247F6 (COLNTUT15), 3068538H1 (UTRSNR01), 3532286T6 (KIDNNNOT25)	
23	89	5159072	BRSTTMT02	412241R1 (BRSTNOT01), 660435H1 (BRAINOT03), 881160H1 (THYRNNOT02), 1304119F6 (PLACNOT02), 1324073F1 (LPARNOT02), 2520427H1 (BRAITUT21), 5159072H1 (BRSTTMT02)	

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
24	90	5519057	LIVRDIR01	066809H1 (HUVESTB01), 3279230H1 (STOMFET02), 5370305F6 (BRAINTNOT22), 5508943F6 (BRADDIRO1), 5508943R6 (BRADDIRO1), 5519057H1 (LIVRDIR01)
25	91	035379	HUVENCB01	035379H1 (HUVENOBO1), 035379X11 (HUVENOBO1), 035379X12 (HUVENOBO1), 035379X13 (HUVENOBO1), 035379X311D1 (HUVENOBO1), 112161R1 (PTTUNOT01), 1922877R6 (BRSTTUT01), 2133108F6 (ENDCNCNOT01), 3107232H1 (BRSTITUT15), 4798135H1 (LIVRTUT09), SCHRA01519V1, g1802757
26	92	275354	TESTNOT03	275354H1 (TESTINOT03), 275354X1 (TESTINOT03), 16663122T6 (BRAITUT02), 2738788T6 (OVARNOT09), 3584082T6 (293TF4T01), SCGA07807V1
27	93	311658	LUNGNOT02	207452X12 (SPLNNNOT02), 238306X85F1 (SINTNOT02), 264489H1 (HNT2AGT01), 311658H1 (LUNGNOT02), 1292829F6 (PGANNNOT03), 1298271F1 (BRSTNOT07), 1488285H1 (UCMCL5T01), 255575H1 (THYMNNOT03), 2665984F6 (ADRENOT08), 2665984T6 (ADRENOT08), 3079209H1 (BRAINT01)
28	94	1251632	LUNGFFET03	1251632H1 (LUNGFFET03), 1251632X11 (LUNGFFET03), 1251632X13 (LUNGFFET03), 1316814T1 (BLADTUT02), 1384212F1 (BRAITUT08), 1711274F6 (PROSNOT16), 3128230H1 (LUNGUT12), 4819602H1 (PROSTUT17), SZZZ00620R1
29	95	1331955	PANCNOT07	1363667X12 (LUNGNOT12), 1363667X13 (LUNGNOT12), SBA01528F1
30	96	1412614	BRAINOT12	1412614F6 (BRAINOT12), 1412614H1 (BRAINOT12), 2278130T6 (PROSNON01), 5105388T6 (PROSTUS19) (PROSNON01), 2278130T6 (PROSNON01), 5105388T6 (PROSTUS19)
31	97	1750781	LIVRTUT01	452712T6 (TLYNNNOT02), 483862R6 (HNT2RAT01), 777229R6 (COLNNNOT05), 1394724F1 (THYRNNOT03), 1652134F6 (PROSTUT08), 1750781F6 (LIVRTUT01), 1750781H1 (LIVRTUT01), 1750781X307D2 (LIVRTUT01), 322147H1 (COLNNON03), SCHAO2984V1, SXAA02156D1, SXAA00802D1
32	98	1821658	GBLATUT01	909674H1 (STOMNOT02), 1579095F1 (DODDNNOT01), 1821658H1 (GBLATUT01), 1821658T6 (GBLATUT01), 2508922F6 (CONUTUT01), 2584263H1 (BRAITUT22), 5571821H1 (TLYNNNOT08)
33	99	1872574	LEUKNOT02	305920F1 (HEARNOT01), 908252R2 (COLNNNOT09), 1872574H1 (LEUKNOT02), 2051868F6 (LIVRFET02), 2285632R6 (BRAINNON01), 3181732F6 (TLYJNOT01), 3285854F6 (HEAONOT05), 3332012H1 (BRAIFET01), SBWA02849V1, SBWA02751V1, SBWA00180V1

Table 1 (cont.)

Protein SEQ ID	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments	
34	104	2590967	LUNGNOT22	1340471F6 (COLNTUT03), 2590967F6 (LUNGNOT22), 2771160F6 (COLANOT02), 3150287R6 (ADRENON04)	2590967H1 (LUNGNOT22), 3150287R6 (ADRENON04)
35	101	2824491	ADRETTU06	1381834X14 (BRAITTUT08), 1381834X16 (BRAITTUT08), 1381834X31 (BRAITTUT08), 2824491H1 (ADRETTUT06), 3413970H1 (PTHYNOT04)	1381834X17 (BRAITTUT08), 1972345F6 (UCMCL5T01), 3413970H1 (PTHYNOT04)
36	102	2825460	ADRETTU06	870873R6 (LUNGAST01), 1440326F1 (THYRNTO03), 2825460H1 (ADRETTUT06), 2825460T6 (ADRETTUT06), 5068209H1 (PANCNOT23), 5068209H1 (PANCNOT23), SBLA03097F1	1440326F1 (THYRNTO03), 2825460H1 (ADRETTUT06), 4154518H1 (MUSLTMT01), 5068209H1 (PANCNOT23), SBLA03097F1
37	103	2871116	THYRNTO10	357664R6 (PROSNOT01), 1419595F1 (KIDNNOT09), 1577877F6 (LNODNOT03), 2767635H1 (COLANOT02), 2871116F6 (THYRNTO10), 2871116H1 (THYRNTO10), 4650546H1 (PROSTUT20), SBHA03160F1, SBHA02613F1, SBHA02703F1	1419595T1 (KIDNNOT09), 1577877T1 (LNODNOT03), 2871116H1 (THYRNTO10), 2871116F1 (THYRNTO10), 4650546H1 (PROSTUT20), SBHA03160F1, SBHA02613F1, SBHA02703F1
38	104	2942212	CONNNTUT05	1270807H1 (TESTTUT02), 1270807X301D1 (TESTTUT02), 1270807X309D2 (TESTTUT02), 2942212H2 (CONNNTUT05), 91924758	1270807X309D2 (TESTTUT02), 1270807X301D1 (TESTTUT02), 1270807X309D2 (TESTTUT02), 2942212H2 (CONNNTUT05), 91924758
39	105	36885151	HEAANOT01	860843R1 (BRAITTUT03), 1932207F6 (COLNNOT16), 1932207T6 (COLNNOT16), 2210580F6 (SINTFET03), 3043060H1 (HE2ANOT01), 3685151H1 (HEAANOT01), 4960825H1 (TLYMNNOT05)	860843R1 (BRAITTUT03), 1932207F6 (COLNNOT16), 1932207T6 (COLNNOT16), 2210580F6 (SINTFET03), 3043060H1 (HE2ANOT01), 3685151H1 (HEAANOT01), 4960825H1 (TLYMNNOT05)
40	106	4881515	UTRMNTMT01	925415R1 (BRAINNOT04), 1337450F6 (COLNNOT13), 19612388R6 (BRSTINOT04), 3581069H1 (293TF3T01), 3583842T6 (293TF4T01), 4881515H1 (UTRMNTMT01), 5488514H1 (DRG1TNON04), 91156606	925415R1 (BRAINNOT04), 1337450F6 (COLNNOT13), 19612388R6 (BRSTINOT04), 3581069H1 (293TF3T01), 3583842T6 (293TF4T01), 4881515H1 (UTRMNTMT01), 5488514H1 (DRG1TNON04), 91156606
41	107	5324681	FIBPFEN06	2455960T6 (ENDANOT01), 2458281F6 (ENDANOT01), 3834084F6 (PANCNOT17), 4046332H1 (LUNGNOT35), 5324681H1 (FIBPFEN06), 91133388, 91522074	2455960T6 (ENDANOT01), 2458281F6 (ENDANOT01), 3834084F6 (PANCNOT17), 4046332H1 (LUNGNOT35), 5324681H1 (FIBPFEN06), 91133388, 91522074
42	108	5387651	BRAINNOT19	810934T1 (LUNGNOT04), 822997R1 (KERANOT02), 1282647F1 (COLNNOT16), 1282647T1 (COLNNOT16), 1571430T6 (UTRSNOT05), 2208839F6 (SINTFET03), 2844187H1 (DRGLINOT01), 2908748H1 (THYMNNOT05), 5387651H1 (BRAINNOT19)	810934T1 (LUNGNOT04), 822997R1 (KERANOT02), 1282647F1 (COLNNOT16), 1282647T1 (COLNNOT16), 1571430T6 (UTRSNOT05), 2208839F6 (SINTFET03), 2844187H1 (DRGLINOT01), 2908748H1 (THYMNNOT05), 5387651H1 (BRAINNOT19)
43	109	5595679	COLCDIT03	044292R6 (TBLYNNOT01), 826501R1 (PROSNOT06), 1251632X12 (LUNGFEI03), 1303934F1 (PLACNOT02), 1316814F1 (BLADTUT02), 1339567T1 (COLNTUT03), 2806159H1 (BLADTUT08), 2837021H1 (TBLYNNOT03), 3037493H1 (BRSTINOT16), 3119883H1 (LUNGUT13), 3395946H1 (LUNGNOT28), 3748742H1 (UTRSNOT18)	044292R6 (TBLYNNOT01), 826501R1 (PROSNOT06), 1251632X12 (LUNGFEI03), 1303934F1 (PLACNOT02), 1316814F1 (BLADTUT02), 1339567T1 (COLNTUT03), 2806159H1 (BLADTUT08), 2837021H1 (TBLYNNOT03), 3037493H1 (BRSTINOT16), 3119883H1 (LUNGUT13), 3395946H1 (LUNGNOT28), 3748742H1 (UTRSNOT18)
44	110	5782457	BRAXNOT03	532593T6 (BRAINNOT03), 532593R6 (BRAINNOT03), 5782457H1 (BRAXNOT03)	532593T6 (BRAINNOT03), 532593R6 (BRAINNOT03), 5782457H1 (BRAXNOT03)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
45	111	7606777	BRAITUT02	745006X13 (BRAITUT01), 760677H1 (BRAITUT02), 760677X19 (BRAITUT02), 763135X12 (BRAITUT02), 946075H1 (RATRNOT02), 953938H1 (SCORNON01)
46	112	1348567	PROSNOT11	1348567H1 (PROSNOT11), 1505075F6 (BRAITUT07), 1620627F6 (BRAITUT13), 2069105F6 (ISLTINOT01), 2417901F6 (HNT3AZT01), 2494683H1 (ADRETUT05), 3320166H1 (PROSBPT03)
47	113	1751354	LIVRTUT01	029909F1 (SPLNFET01), 029909R1 (SPLNFET01), 512371H1 (MPHGNOT03), 1439362F6 (PANCNOT08), 1751354F6 (LIVRTUT01), 1751354H1 (LIVRTUT01), 1900168F6 (BLADTUT06)
48	114	1976780	PANCTUT02	001347H1 (U937NCT01), 1755035X307D2 (LIVRTUT01), 1976780H1 (PANCNT02), 2798389H1 (NPOLNOT01), 405007H1 (SINTNOT18), 4228943H1 (BRAMDIT01), 4291877H1 (BRABDIRO1), 5514957H1 (BRADDIRO1), SCHA04173V1, SCHA02986V1, SCHA01162V1, SCIA02096V1
49	115	2048234	LIVRFET02	1553355F6 (BLADTUT04), 1929455F6 (COLNTUT03), 2048234H1 (LIVRFET02), 2699864T6 (OVARITUT10)
50	116	2111754	BRAITUT03	1335055F6 (COLNNOT13), 2105233R6 (BRAITUT03), 2111754H1 (BRAITUT03), 2111754R6 (BRAITUT03), 3706377H1 (PENCNOT07)
51	117	2123286	BRSTNOT07	4111359F1 (BRSTNOT01), 4111359R1 (BRSTNOT01), 708105R6 (SYNORAT04), 1322780F6 (BLADNOT04), 2123286H1 (BRSTNOT07), 2719651F6 (LUNGUT10), 2880143F6 (UTRSITUT05), 3206153F6 (PENCNOT03), 3210501F6 (BLADNOT08), 3346625F6 (BRAITUT24), 3489118H1 (EPIGNOT01), 3605764H1 (LUNGNOT30), 4242993H1 (SYNWDIT01), 5089472H1 (UTRSTMTR01)
52	118	2477507	SMCANOT01	488096H1 (INT2AGT01), 1672690F6 (BLADNOT05), 1802830F6 (COLNNOT27), 1818538H1 (PROSNOT20), 2171841H1 (ENDCNOT03), 2477507H1 (SMCANOT01), 3434030F6 (PENCNOT05)
53	119	2759119	THP1AZS08	496782H1 (HNT2NOT01), 1251166H1 (LUNGFEI03), 1289067F1 (BRAINOT11), 1295658T6 (PGANNNOT03), 1510901F1 (LUNGNOT14), 1531583F1 (SPLNNNOT04), 1533488F1 (SPLNNNOT04), 1817447H1 (PROSNOT20), 2154846F6 (BRAINOT09), 246887H1 (THYRNNOT08), 2498852F6 (ADRETUT05), 2506652F6 (CONUTUT01), 2630812F6 (COLNTUT15), 2759119H1 (THP1AZS08), 2991227H1 (KIDNFET02), 3036646F6 (PENCNOT02), 3213032H1 (BLADNOT08)
54	120	28233818	ADRETUT06	618671R6 (PGANNNOT01), 28233818H1 (ADRETTUT06), 2950988F6 (KIDNFET01), q1679455

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments	
55	121	2859730	SININOT03	103901X6 (BMARNOT02), 510695H1 (MPHGNOT03), 145208H1 (PENITUT01), 1527095F6 (UCMCL5T01), 2285371H1 (BRAINON01), 2843029H1 (DRGLNOT01), 2859730H1 (SININOT03)	
56	122	2861155	SININOT03	875215T1 (LUNGCAST01), 999673H1 (KIDNTUT01), 1425091R6 (BEPINON01), 2861155F6 (SINTINOT03), 286115H1 (SININOT03), 2901915F6 (DRGCNOT01), 3621947H2 (ENDANOT03),	
57	123	3002667	TLYMNNOT06	2277882F1 (PANCNOT01), 2277882R1 (PANCNOT01), 260725H1 (HNT2RAT01), 1432542R1 (BEPINON01), 2474761F6 (SMCANOT01), 3002667H1 (TLYMNNOT06), 3188977H1 (THYMNNON04), 3461163H1 (293TF1T01), 4860339F6 (PROSTUT09)	
58	124	3043734	HEAANOT01	3043734H1 (HEAANOT01), 3043734T6 (HEAANOT01), 3209823H1 (BLADNOT08), 5277071H1 (MUSLNOT01)	
59	125	3294893	TLYJINT01	389234H1 (THYMNNOT02), 1242886H1 (LUNGNOT03), 1539958T1 (SINTTUT01), 1870567H1 (SKINB1T01), 2069284F6 (ISLTNOT01), 2280217R6 (PROSNON01), 2353465T6 (LUNGNOT20), 279890F6 (NPOLNOT01), 3180440H1 (TLYJNOT01), 3294893H1 (TLYJINT01), 3816962H1 (TONSNOT03), 5039889H2 (COLHTUT01), 5118831H1 (SMCBBUNTO1)	
60	126	3349052	BRAITTUT24	7311775H1 (LUNGNOT03), 1449575H1 (PLACNOT02), 1899442F6 (BLADTUT06), 1967162T6 (BRSTNOT04), 2630025F6 (COLNTUT15), 2717821H1 (THYRNNOT09), 3180478T6 (TLYJNOT01), 3349052H1 (BRAITTUT24), 4523961F6 (HNT2TXT01), 5565623H1 (TLYMNNOT08), 6141909H1 (BMARTXT03)	
61	127	3357264	PROSTUT16	2378150F6 (ISLTNOT01), 2378150X304B1 (ISLTNOT01), 2378150X304D1 (ISLTNOT01), 2807493F6 (BLADTUT08), 2881251F6 (UTRSTUT05), 3357264F6 (PROSTUT16), 3357264H1 (PROSTUT16), 3593272H1 (293TF5T01), 4163652T6 (BRSTNOT32), 4821588F6 (PRCSTUT17), 4872125H1 (COLDNOT01)	
62	128	3576329	BRONNOT01	1444072F6 (THYRNNOT03), 1649584T6 (PROSTUT09), 1720770X15C1 (BLADNOT06), 2204612F6 (SPLNFTET02), 3576329H1 (BRONNOT01), SAFC01083F1	
63	129	3805550	BLADTUT03	1416364F6 (BRAINOT12), 1553473H1 (BLADTUT04), 3232384H1 (COLNUCT03), 3287257H1 (HEAQNOT05), 3539473H1 (SEMVNOT04), 3805550H1 (BLADTUT03)	

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
64	130	4546403	COLXTDT01	1687704F6 (PROSTIT01), 1962744R6 (BRSTNOT04), 2674742F6 (KIDNNNOT19), 4546403H1 (COLXTDT01), 4632828T6 (GBLADIT02)
65	131	4767318	BRAINT02	134566R1 (BMARNOT02), 549352R1 (BEPINOT01), 1819757T6 (GBLATUT01), 2863295H1 (KIDNNNOT20), 4767318H1 (BRATNOT02), SBLA03778F1, g3737930
66	132	4834527	BRAWNNOT01	859906X38C1 (BRAITUT03), 1231225H1 (BRAITUT01), 1393681T6 (THYRNNOT03), 1416996F6 (BRAINOT12), 2422475H1 (SCORNNO02), 3999137R6 (HNT2AZS07), 4834527F6 (BRAWNOT01), 4834527H1 (BRAWNOT01), 5691642H1 (BRAUNOT02)

Table 2

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
1 269	S59 T71 T146 T211 T73 S127 T133 S216	S59 N12		GTP-binding protein: D79-M234, Y80-C239 ATP/GTP binding site (P-loop): G102-S109	GTP-binding protein: Cgpa [Caulobacter crescentus] g3820578	BLAST-Genbank BLAST-DOMO MOTIFS
2 428	S59 S188 S200 S284 S367 S381 T399 T29 T193 T288 T354 S419			Beta transducin family, G-beta repeats: T269-L315, F261-D293 L280-V294, V185-V199 Signal peptide: M1-A35	Ras inhibitor [Homo sapiens] g190895	ProfileScan MOTIFS BLIMPS-PRINTS HHMER-PFAM SPScan
3 562	S151 S152 T443 T444 S33 S104 S126 S127 S135 S216 S239 T350 T383 S450 T481 S146 T223 S287 S356 T434 T470 Y501	S151 N125 N354	N145			BLAST-Genbank
4 229	T108 S153 S9 S160 S215 T219 T142 S180	N111 N140	N198	ATP/GTP-binding site: G28-S35 Ras family: K23-T219 Ras transforming protein: V22-M43, A63-S85, P124-A137, L156-A178, D102-S145, K150-S180	Small GTP binding protein [Saccharomyces cerevisiae] g1171484	BLAST-Genbank MOTIFS HHMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-DOMO
5 360	T108 S360 S115 T217 T264 S295 S296 S35 S52 S160 S174 T206 T249	N149 N287 N327 N351		WD domain, G-beta repeats: M1-T64, M27-K41, F274-K306	Similar to WD domain, G-beta repeat protein [C. elegans] g3880929	BLAST-Genbank HHMER-PFAM ProfileScan BLIMPS-PRINTS
6 460	T18 T107 T123 S149 S199 S280 S336 S369 S71 T106 S387 Y302 Y400	N270 N350		Signal peptide: M1-A57	Rabin3 [Rattus norvegicus] g624225	BLAST-Genbank SPScan

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
7 239	S234 S25 T47 T52 S98 T1190 T206 S236 S223	N188	Phosducin: L20-I179, E30-D239	Phosducin-like protein [Homo sapiens] q4104075	BLAST-Genbank BLAST-PRODOM BLAST-DOMO	
8 334	T225 T235 S260 T4 S45 S63 S133 S162 S193 T279 T308		ATP/GTP-binding site (P-loop) : G150-S157 GTP1/OBG family: L75-D89, I146-Q166 G-protein, alpha subunit: I79-L87	GTP-binding protein homolog [L. brasiliensis] g2570231	BLAST-Genbank MOTIFS BLIMPS-BLOCKS BLIMPS-PRINTS	
9 341	S91 T122 S185 T199 T228 S65 T85 S323		Signal peptide: M1-A61 WD domain, G-beta repeats: L164-D196, C173-P217, V183-L197, S185-W195	Putative WD-40 repeat protein [Arabidopsis thaliana] 94191773	SPScan BLAST-Genbank MOTIFS ProfileScan HHMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS	
10 513	T29 T72 T109 S124 S136 S215 T341 T481 T501 S65 T245 T330 S338 T372 T386 S437 S451 T473 Y228 Y254		N242 N417	Beta-transducin family, G-beta repeats: F345-N377, K210-N242, E303-G335, S366-W376, N353-V400, L229-F243, I364-M378	Similar to WD domain G-beta repeats protein [C. elegans] g3875246	BLAST-Genbank MOTIFS HHMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS ProfileScan
11 186	T61 S80 S107 S163 S31 T66 S183	N64 N148	ARF-family: N6-S186, P51-S90, M95-L149 GTP-binding, SAR1 protein: F78-K103, I123-I144 ATP/GTP binding site (P-loop): G27-T34	Similar to ADP-ribosylation factor [C. elegans] q3881189	BLAST-Genbank HHMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS MOTIFS	

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Motifs, and Domains	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
12	204	S184 S203 S34 S152 T14 T20 T25 T62 S86		Ras family: K5-M189 Ras transforming protein: M1-E150, V4-T25, V113-L126 ATP/GTP binding site (P-loop): G10-S17	Ras-like protein, [Mus musculus] g1656005	BLAST-Genbank HMMER-PFAM BLIMPS-PRINTS BLAST-DOMO MOTIFS	
13	100	S31 S46 T52 T61 S84 S4 S26 S27 T86		Beta-transducin, WD repeats: L81-M95, V70-S100, M1-S100	Similar to beta-transducin [C. elegans] g3875373; Alzheimer's disease protein [Homo sapiens] GeneSeq W21578	BLAST-Genbank MOTIFS BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS BLAST-PRODOM	
14	795	T569 S776 S54 S188 S201 T248 T249 T298 S306 S368 T422 S466 T561 S586 S625 S678 T731 S777 S13 T42 S120 T134 T174 S213 S254 T266 S391 S415 S588 S620 S694 T742	N52 N421 N559 N585 N708	WD domain, G-beta repeats: L108-L139, L147-K179, T168-W178, Y227-K259, L126-N140, M166-A180	Phospholipase A2-activating protein [Rattus Norvegicus] g1017706	BLAST-Genbank BLAST-PRODOM BLAST-DOMO HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS	
15	393	S48 S61 T143 T334 T148 T200 S208 T212 T245 S266 S325	N182 N197	WD domain, G-beta repeats: L121-A153, L357-R389, P322-F369, L140-S154	[Arabidopsis thaliana] g4263521	Putative WD-repeat protein [Arabidopsis thaliana] g4263521	
16	485	S31 S108 S222 S321 S346 S357 T84 T125 T137 T151 T187 S227 T268 S395 T403 S409 T437 Y92 Y261		Beta-transducin, WD repeats: L129-L143, V219-T233, S262-W272, V387-G401, L429-V443, L452-G468	Notchless protein [Xenopus laevis] g3687833	BLAST-Genbank MOTIFS HMMER-PFAM ProfileScan BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-DOMO BLAST-PRODOM	

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homo logous Sequences	Analytical Methods & Databases
17 199	T32 T91 S177 T56 S153 S186 Y149			ATP/GTP-binding site (P-loop): G15-T22 Transforming protein, p21: L9-H30, T32-K48, I50-S72, Q115-L128, Y149-A171	Rab7 [Mus musculus] g1050551	BLAST-Genbank MOTIFS BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO
18 163	T18 T46 S120 S55 T151 T83 S125		N81 N159		Rhotekin [Mus musculus] g1293145	BLAST-Genbank
19 290	S56 S84 T234 S41 T91 T132 T234 T11 T47 T80 T194		N89 N188	Beta-transducin, WD-repeats: S41-W51, F195-D227, L238-N270, L214-I228, L257-M271, T203-S249	Similar to beta-transducin, [C. elegans] g3875373; Alzheimer's disease protein [Homo sapiens] GeneSeq W21578	BLAST-Genbank MOTIFS HHMMER-PFAM BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS BLAST-PRODOM
20 705	T277 T364 S393 S448 S479 S483 T554 T568 S586 S239 S250 T374 S379 T398 S485 T528		N274	Beta-transducin, WD-repeats: L390-L404, L370-D403, I413-R445	Similar to WD-domain G-beta repeat prot. [C. elegans] g3880340; 70kD tumor-specific antigen [R. norvegicus] g2505957	BLAST-Genbank HHMMER-PFAM BLAST-PRODOM BLAST-DOMO BLIMPS-BLOCKS BLIMPS-PRINTS MOTIFS
21 454	T426 S451 S28 S51 T81 T89 T166 S214 T241 S264 T305 S343 S185 T193 S421		N58	ATP/GRP-binding site (P-loop): G73-S80 Cell division control protein: V47-P240	Similar to Drosophila melanogaster septin (sep2) [Homo sapiens] g1503988	BLAST-Genbank BLAST-PRODOM BLAST-DOMO MOTIFS
22 433	S169 T239 T292 S309 S382 S129 S297 Y60 Y101 Y315		N338	Protein GTPase activating protein: L8-S169 PH domain: Y138-Q355, Q191-I351, P210-E375	RhoGAP protein [Homo sapiens] g312212	BLAST-Genbank BLAST-PRODOM BLAST-DOMO

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
23	406	T83 S143 T75 T115 T216 T315 Y247	S303 N184 N401 N402		Rab 9 effector, P40 [Homo sapiens] g2217970	BLAST-Genbank
24	229	S7 S127 T50 S178		ATP/GTP-binding site (P-loop): G40-T47 Ras family: K35-L217 Transforming protein, p21: F34-A55, R57-R73, V75-K97, N139-L152	Rab GTPase, Rab33B [Mus musculus] g2516239	BLAST-Genbank MOTIFS HMMER-PFAM BLIMPS-PRINTS BLAST-DOMO
25	670	T28 T45 S69 S3 S108 T277 S406 S6 T52 T82 S91 S102 S126 S609 S158 S197 T213 S217 T281 S323 S416 T419 T428 T474 S496 T540 S624 T664	S53 N343	G-beta WD repeat domain: F386-D424, L411-T425, Y429-D465, L469-D504, L510-D545, L549-D585, K589-S629, M633-T669 Beta-transducin Trp-Asp repeats signature: C401-I447	Beta transducin-like protein [Podospora anserina] g607003	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS ProfileScan
26	445	T17 T48 T126 T160 T293 T364 T97 T132 S201 S217 S305 T322 S357 S434 Y339	N46 N95 N355	G-beta WD repeat domain: L62-N95, V82-L96, F124-M138, F297-V311 Beta-transducin Trp-Asp repeats signature: S316-A356 SOF1 protein, WD repeat: D129-V277, F309-V444	Beta-transducin [Schizosaccharomyces pombe] g3393019	BLAST-GenBank BLAST-DOMO BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS
27	236	S24 S60 S86 T181 S117 S140		GYP7, GTPase activating protein: M1-I155	GTPase activating protein [Yarrowia lipolytica] c2370595	BLAST-GenBank BLAST-PRODOM MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
28	498	S97 T158 S247 S281 S425 S468 S494 T84 S176 T355 T474 Y239		G-beta WD repeat domain: L188-Q220, I446-G479, M466-P480 Beta-transducin Trp-Asp repeats signature: F200-A245	Similarity to guanine nucleotide binding protein [Caenorhabditis elegans] g3878300	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS ProfileScan
29	334	S63 S104 S148 S189 T208 S276 S50 T110 S118 T124 S152 T160 T237 T326	N265	G-beta WD repeat domain: L41-G73, I83-D115, L102-V116, L125-D157, L167-D199, I210-D242 Beta-transducin Trp-Asp repeats signature: S49-A308 Signal peptide: M1-A47	Similar to guanine nucleotide binding protein [Caenorhabditis elegans] g3874290	BLAST-GenBank BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS ProfileScan SPScan
30	292	S102 T145 S188 S52 T89 S204 S222 S283	N209	Protein with WD repeat: P7-W129 Signal peptide: M1-S68	F-box protein FBX16 [Mus musculus] g6456114	BLAST-PRODOM BLAST-GenBank MOTIFS SPScan
31	588	T184 T76 T137 S139 T161 T174 T183 S285 T351 T375 S432 T473 S488 S213 T265 S389 S394 T412 T546	N159	G-beta WD repeat domain: A293-E331, C337-T375, Y379-D417, I404-L418, E460-D497, T506-S543, G547-A586 Beta-transducin Trp-Asp repeats signature: A308-E354, I393-Q441	TipD (sequence similarity to Beta-transducin family) [Dictyostelium discoideum] g2407788	BLAST-GenBank BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS ProfileScan
32	326	T50 T84 S98 S142 T261 T65 T148 T178 T189 T221	N187	G-beta WD repeat domain: L120-N153, I140-L154		BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS
33	453	T157 T218 T248 S320 S347 S412 S7 T236 S290 T396 T406 Y63	N59 N225	G-beta WD repeat domain: D180-E211, A198-V212		BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
34	161	T137 T18 T102 Y96		DMR-N9 protein: K93-S148	DMR-N9 (homology to WD repeat sequences) [Mus musculus] g817954	BLAST-GenBank BLAST-PRODOM MOTIFS
35	684	T173 S25 S43 S74 S83 S127 S152 S154 S182 T316 T331 T341 S372 T535 T606 S623 T138 T151 S168 S238 S299 T336 T422 S476 T506 T530 T628 T647	N526 N621	ATP/GTP-binding site motif A (P-loop): G267 Elongation factor 1 alpha protein (GTP-binding) domain: D485-E684 Elongation factor Tu domain: K258-D658, N262-K273, M343-G374, R664-G677 GTP-binding elongation factors signature: A249-E420, N262-T275, K294-P346, T341-F351, T357-V368, L401-Q410, P443-I682 RAS transforming protein: K258-V439	eRFs (related to eukaryotic release factor 3) [Mus musculus] g4566435	BLAST-GenBank BLAST-DOMO BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS ProfileScan
36	366	S342 T52 S71 T102 T119 T224 T324 T66 S195 S271 T353 Y225	N32	G-beta WD repeat domain: V146-L160, L284-I298 Signal Peptide: M1-T56	BLIMPS-PRINTS MOTIFS SPScan	
37	339	S152 S183 T107 T115		Beta-transducin Trp-Asp repeats signature: N101-L162 Trp-Asp repeats-containing protein: R54-A172 Transmembrane domain: A300-I323	Hypothetical trp-asp repeats containing protein [schizosaccharomyces pombe] g3850059	BLAST-GenBank BLAST-DOMO BLAST-PRODOM HMMER MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signtature Sequences, Motifs, and Domains	Homo logous Sequences	Analytical Methods & Databases
38	213	T29 T134 S153 T181 S200 T92 T129 S207		ATP/GTP-binding site motif A (P-loop): G15 Grp-binding protein signature (Arf1, Ran): W5-E179 Ras family signature: R10-C213 Transforming protein p21: F9-E30, R32-R48, E51-S73, Y114-L127, Y149-I171 Signal peptide: M1-V19	Rab-related GTP-binding protein [Homo sapiens] g1491714	BLAST-GenBank BLAST-DOMO BLAST-PRODOM BLIMPS-PRINTS HMMER-PFAM MOTIFS SPScan
39	393	S209 T363 S60 S99 S119 S135 T144 T147 S174 S210 T350 S359 S370 T371		G-beta WD repeat domain: G33-D69, K73-D110 L97-A111, W114-N152, L236-K276, I263-L277 Signal peptide: M1-T43	Similar to beta-transducin [Caenorhabditis elegans] g860695	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS SPScan
40	399	S86 T191 S219 S224 S254 S275 S308 S59 S72 T96 S373 S385 T394	N88 N106 N321 N322	ATP/GTP-binding site motif A (P-loop): G68 G-protein alpha subunit: R63-Q78 GTP-binding protein GTR1: A57-D294 Ras transforming protein: K61-L203	Gtr2 homolog, novel small GTPase subfamily [Schizosaccharomyces pombe] g3560242	BLAST-GenBank BLAST-DOMO BLAST-PRODOM BLIMPS-PRINTS MOTIFS SPScan
41	412	T106 S337 S391 S29 S30 S41 S130 S154 S207 S231 S326 S82 S97 T212 S220	N367	G-beta WD repeat domain: C184-E217, L204-Y218 Signal peptide: M1-G18	Putative transcriptional regulation protein, trp-asp repeat containing [Schizosaccharomyces pombe] q3766375	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS SPScan

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
42 163		S15 S17 S71 T114 Y49			Arf-like 2 binding protein BARF1 [Homo sapiens] g4426962	BLAST-GenBank MOTIFS
43 514	S113 T174 S263 S297 S441 S484 S510 T100 S192 T371 T490 Y255			G-beta WD repeat domain: L204-Q236, L462-G495, M482-P496 Beta-transducin Trp-Asp repeats signature: F216-A261	Similarity to guanine nucleotide binding protein [Caenorhabditis elegans] g3878300	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS ProfileScan
44 67	T30 S15 Y18			G-protein gamma subunit: E2-L67, M9-R24, K10-P57, D45-G62 Prenyl group binding site (CAAX box): V64	G gamma protein [Mus musculus] g7259257	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS ProfileScan
45 315	T148 S162 S209 S244 S252 S45 T48 S132 S140 S158 T214 S244		N79	WD40 domains/G-beta repeats: Q15-N53, G57-N95, G99-D137, P143-D179, G223-D263 WD/G-beta profiles: L71-Q116, T114-V161 WD/G-beta repeat signature: V250-L264	Contains similarity to G beta repeats (PROSITE:PS00670) of the beta-transducin family [Caenorhabditis elegans] g1086900	BLAST-GenBank MOTIFS ProfileScan HMMER-PFAM
46 504	T268 T99 T193 S323 S324 T409 T493 T91 T98 T133 T185 T234 T259 T264 T287 T337 S415 S498		N37 N295	WD40 domains/G-beta repeats: A211-D250, E254-S292, A296-A331, G338-D378, R382-D420 WD/G-beta profiles: T396-I442, T268-A316, C355-F400 WD/G-beta signatures: L407-L421, V279-V293 WD repeat protein-like region: I4-A226	Similar to S. cerevisiae PRP19 protein; similar to G-beta repeat region of guanine nucleotide binding protein [Caenorhabditis elegans] g727450	BLAST-GenBank BLAST-PRODOM MOTIFS ProfileScan HMMER-PFAM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
47	522	S84 S315 S510 T20 S50 S57 S74 S116 S122 S128 S161 S185 T274 T300 S339 S345 S357 S367 T373 S459 T474 S136 S143 T174 S200 T300 S315 S356 S385 S420 T492	N226 N355	SAPK (stress activated protein kinase) interacting protein (similar to ras inhibitor) [Gallus gallus] g429812	SAPK (stress activated protein kinase)	BLAST-GenBank MOTIFs
48	316	T109 S27 S86 S188 S7 S8 S82 T96 T105	N29 N136 N186	Pleckstrin homology (PH) domains: S3-N45, I59-Q301 RhoGAP domain: P140-N291 GTPase protein-like region: G125-L307	Beta2-Chimaerin [Homo sapiens] g457230	BLAST-GenBank BLAST-PRODOM BLAST-DOMO HMMER-PFAM MOTIFs BLIMPS-PRINTS BLIMPS-PRODOM
49	387	S97 S199 T249 S342 S369 S382 T54 T182 T381		ATP/GTP-binding site motif (P-loop): G155-S162 GTP1/OBC GTP-binding protein family signatures: V151-A171, K172-I190, V200-G215, G217-D225 GTP-binding protein-like region: F15-P173 RAS transforming protein-like region: L145-I296	GTP-binding protein [Aequifex aeolicus] g2984292	BLAST-GenBank BLAST-PRODOM BLAST-DOMO BLIMPS-BLOCKS BLIMPS-PRINTS MOTIFs

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
50	334	T228 S91 T224 T228 T262 S34 S81 T224 T262 S286 T324	N108 N257 N322	ATP/GTP-binding site motif (P-loop): G149-S156 Ras domain: R144-M334 p21/ras-related transforming protein signatures: Y143-S164, N166-L182, H248-D261, F282-K304 Ras transforming protein-like region: I140-E284	NOEY2 putative tumor suppressor [Homo sapiens] g4100355	BLAST-GenBank BLAST-PRODOM BLAST-DOMO HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS MOTIFS
51	551	T199 S38 T62 S85 T116 S169 S351 T379 S421 S422 S456 S12 S22 S150 T366 S383 T482 Y404 Y449	N1133 N148 N1179 N293 N296	Regulator of chromosome condensation (RCC1) / guanine nucleotide dissociation stimulator domains: E117-S169, D170-D222, T223-D274, E275-G292, G328-G339 RCC1 signatures: V157-L167, V262-L272	UVB-resistance protein UVR8 [Arabidopsis thaliana] g5478530	BLAST-GenBank BLAST-PRODOM HMMER-PFAM PROFILESCAN BLIMPS-PRINTS MOTIFS
52	308	S152 T230 S266 S299 S19 S22 S240	N76	WD40 domains/G-beta repeats: Q33-R73, W79-T119, W126-K181, W188-T230, P241-K276, S11-A50 Sec13 related/WD repeat protein-like region: R73-I177 WD/G-beta profile: G11-A50	Sec13-related protein [Arabidopsis thaliana] g3150415	BLAST-GenBank HMMER-PFAM PROFILESCAN BLIMPS-PRINTS BLAST-PRODOM MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
53	949	S206 S514 T22 S216 T226 S273 T315 S663 T745 T908 T155 S232 S258 T350 S359 S472 S609 S776 S837 S913 Y682 Y862	N114	WD40 domains/G-beta repeats: V199-K237, V248-S284, G287-H326 Drosophila lethal(2) giant larvae tumor suppressor protein signature: K221-P244, A353-E377		HHMER-PFAM BLIMPS-PRINTS MOTIFs
54	227	S11 T113 S173 T155 S173	N38	ATP/GTP-binding site motif (P-loop): G37-T44 Ras family domain: K32-C227 p21/ras-related transforming protein signatures: F31-D52, S54-K70, V72-T94, D134-M147, F169-I191 Ras transforming protein-like region: F27-T172	GTP-binding protein [Bos taurus] g162764	BLAST-GenBank HHMER-PFAM BLIMPS-PRINTS BLAST-DOOMO BLAST-PRODOM MOTIFs
55	474	T430 S98 S118 S309 S450 S463 T66 S130 T141 S241 S289 S309 S389 S450	N179 N185	WD40 domains/G-beta repeats: D70-Q109, T120-N159, E164-D202 G-beta repeat signature: L146-V160 WD repeat/coronin protein-like region: I208-Q467	Coronin-2 [Mus musculus] g4895039	BLAST-GenBank HHMER-PFAM BLAST-DOOMO BLAST-PRODOM MOTIFs
56	547	S16 T77 S85 S90 S112 S114 T132 S160 T166 T225 S248 S438 S491 S526 S125 S267 T299 T305 S504	N101 N110 N147 N297	WD40 domains/G-beta repeats: G159-N197, C312-A353, G357-D396 WD40/G-beta signatures: V245-A259 I428-T442	Guanine nucleotide-binding protein beta 5 [Mesocricetus auratus] g1001939	BLAST-GenBank HHMER-PFAM BLIMPS-PRINTS MOTIFs

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
57 686	T331 S431 T637 S34 S169 S554 S28 S124 S192 S273 S341 T366 S426 S449 S470	N26 N44 N271 N424 N628	G-beta profile: S106-S152	Beta-transducin-like protein [Podospora anserina] g607003	BLAST-GenBank PROFILESCAN HMMER-PFAM	
58 93	S15 T2 S3 T24			HP protein (RhoGAP ortholog) [Homo sapiens] g2559002	BLAST-GenBank MOTIFS	
59 521	S63 S223 T64 T117 S147 S159 S195 S200 T214 S271 S401 S448 T49 S110 S195 T235 T280 T439	N71 N108 N381	Amino acyl tRNA ligase motif: P173-T183	GTPase activating protein [Schizosaccharomyces pombe] g3150248	BLAST-GenBank MOTIFS	
60 751	T287 S543 T61 S275 S345 T430 T474 T565 T676 S705 S726 T727 S57 T63 T70 T287 S345 T389 T432 S458 T479 T518 T538	N344 N640	GTP binding elongation factor Tu family domain: E44-T530	Elongation factor G C-terminus domain: L556-T727	BLAST-GenBank HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS ProfileScan BLAST-PRODOM BLAST-DOMO MOTIFS	
61 666	T492 S615 S619 T35 S142 T177 T212 S224 S270 T353 S403 T456 T471 T500 T550 S560 S572 T378 S403 S496 T509 T608 T611 T625	N75 N582	GTP binding elongation factor signatures: N48-T61, Q97-A105, N117-F127, R133-V144, F169-R178	Elongation factor G [Rattus norvegicus] g310102	Rho target rhophilin [Mus musculus] g1176422	BLAST-GenBank MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homo logous Sequences	Analytical Methods & Databases
62	746	S22 T98 S571 T46 S53 S61 S66 S70 S71 T97 S14 S126 S127 T165 T184 T190 S249 S279 S323 S430 S519 S680 S736 S115 T190 T237 S349 S436 T444 S567 S598 S601 T613 S652 T741		WD40 domains/G-beta repeats: T403-E441, R570-H606, Q610-D648, T653-H691, L704-T746, C418-A461 G-beta repeat signature: L428-V442 Trp-Asp repeat protein-like region: S22-L407	Bop1 growth control protein [Mus musculus] g1679772	BLAST-GenBank BLAST-PRODOM BLAST-DOMO MOTIFS BLIMPS-PRINTS ProfileScan HMMER-PFAM
63	212	S105 S142 S148 S162 S167 S44 T56 T101 S162 S190	N131	ATP/GRP-binding site motif (P-loop): G25-T32 Ras family domain: K20-C212 ADP-ribosylation factor family domain: P6-R183 p21/ras-related transforming protein signatures: F19-T40, A42-K58, L60-T82, S122-L135, A158-L180 Ras transforming protein-like region: Y15-I155	Rab19 [Mus musculus] g2598565	BLAST-GenBank HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-DOMO BLAST-PRODOM MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
64	307	T275 S276 T15 S25 T99 S164 S201 S6 S270 T293	N196 N291	WD40 domains/G-beta repeats: M1-I49, L60-D98, E102-Q140 Sterile alpha motif (SAM) : E161-R225 WD/G-beta signatures: L36-V50, I127-F141 G-beta profile: L74-P122	Hypothetical trp-asp repeats [C. elegans] SwissProt Q93847	BLAST- SwissProt HMMER-PFAM BLIMPS-PRINTS ProfileScan MOTIFS
65	378	S137 T167 T193 S202 S237 S276 S290 S310 S362 S82 T150 T158 T199 S362 T368		WD40 domains/G-beta repeats: H72-L110, L116-D155, L241-D279 G-beta profiles: S137-C175, S87-C133, I255-S312	WD repeat protein [Schizosaccharomyces pombe] 95701965	BLAST-GenBank HMMER-PFAM ProfileScan MOTIFS
66	466	S6 T24 S69 T209 S246 S357 T450 S181 S236 S242 T322 T407 T450	N448	RasGEF domain: V197-E397 Guanine nucleotide releasing protein-like region: P201-S432	Putative guanine-nucleotide releasing factor [Drosophila affinis] Q2981229	BLAST-GenBank HMMER-PFAM BLAST-PRODOM BLAST-DOMO

Table 3

Nucleotide SEQ ID No :	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
67	434-478	Cardiovascular (0.238) Reproductive (0.238) Hematopoietic / Immune (0.190)	Cancer (0.429) Inflammation/Trauma (0.524) Cell Proliferation (0.095)	pINCY
68	380-424 551-595	Nervous (0.185) Reproductive (0.167) Gastrointestinal (0.148)	Cancer (0.444) Cell Proliferation (0.315) Inflammation/Trauma (0.278)	pINCY
69	433-477	Reproductive (0.429) Nervous (0.142) Hematopoietic / Immune (0.142)	Cancer (0.714) Inflammation/Trauma (0.142)	pINCY
70	684-728	Reproductive (0.333) Nervous (0.178) Cardiovascular (0.111)	Cancer (0.467) Cell Proliferation (0.244) Inflammation/Trauma (0.267)	pINCY
71	219-263	Hematopoietic / Immune (0.257) Reproductive (0.229) Gastrointestinal (0.143)	Cell Proliferation (0.400) Inflammation/Trauma (0.429)	pINCY
72	865-912	Gastrointestinal (0.286) Reproductive (0.286) Cardiovascular (0.238)	Cancer (0.667) Cell Proliferation (0.143) Inflammation/Trauma (0.238)	pINCY
73	900-944	Reproductive (0.229) Hematopoietic / Immune (0.157) Nervous (0.157)	Cancer (0.422) Inflammation/Trauma (0.349) Cell Proliferation (0.205)	pINCY
74	109-153 919-963	Reproductive (0.270) Gastrointestinal (0.162) Cardiovascular (0.135)	Cancer (0.405) Cell Proliferation (0.270) Inflammation/Trauma (0.324)	pINCY
75	1352-1396	Reproductive (0.296) Gastrointestinal (0.167) Nervous (0.167)	Cancer (0.509) Inflammation/Trauma (0.269) Cell Proliferation (0.157)	pINCY
76	541-585 1189-1233	Reproductive (0.238) Cardiovascular (0.190) Gastrointestinal (0.190)	Cancer (0.524) Inflammation/Trauma (0.310) Cell Proliferation (0.143)	PBLUESCRIPT
77	110-154	Reproductive (0.250) Nervous (0.224) Hematopoietic / Immune (0.132) Gastrointestinal (0.132)	Cancer (0.355) Inflammation/Trauma (0.342) Cell Proliferation (0.211)	PSPORT1
78	218-262	Reproductive (0.375) Nervous (0.188) Urologic (0.188)	Cancer (0.562) Inflammation/Trauma (0.250)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
79	380-424	Hematopoietic/Immune (0.227) Nervous (0.227) Reproductive (0.227)	Inflammation/Trauma (0.636) Cancer (0.364)	PSPORT1
80	217-261	Reproductive (0.275) Gastrointestinal (0.196) Nervous (0.196)	Cancer (0.431) Inflammation/Trauma (0.451) Cell Proliferation (0.196)	PSPORT1
81	488-532 812-856	Reproductive (0.301) Nervous (0.151) Gastrointestinal (0.130)	Cancer (0.466) Inflammation/Trauma (0.288) Cell Proliferation (0.151)	pINCY
82	595-639	Reproductive (0.333) Developmental (0.148) Gastrointestinal (0.148)	Cancer (0.444) Cell Proliferation (0.370) Inflammation/Trauma (0.333)	pINCY
83	219-263	Hematopoietic/Immune (0.400) Gastrointestinal (0.200) Cardiovascular (0.100)	Inflammation/Trauma (0.429) Cell Proliferation (0.357) Cancer (0.286)	pINCY
84	164-208	Cardiovascular (0.667) Nervous (0.222)	Cancer (0.556) Cell Proliferation (0.111)	PBLUESCRIPT
85	487-531 757-801	Reproductive (0.182) Cardiovascular (0.091)	Cancer (0.308) Cell Proliferation (0.231) Inflammation/Trauma (0.154)	pINCY
86	325-369 811-855	Hematopoietic/Immune (0.288) Reproductive (0.197) Cardiovascular (0.136)	Inflammation (0.394) Cancer (0.318) Cell Proliferation (0.212)	pINCY
87	163-207	Reproductive (0.218) Nervous (0.172) Gastrointestinal (0.138)	Cancer (0.448) Cell Proliferation (0.218) Inflammation (0.207)	pINCY
88	362-406 758-802	Reproductive (0.273) Gastrointestinal (0.227) Cardiovascular (0.136) Musculoskeletal (0.136)	Cancer (0.681) Cell Proliferation (0.182) Inflammation/Trauma (0.318)	pINCY
89	272-316	Reproductive (0.229) Gastrointestinal (0.193) Nervous (0.193)	Cancer (0.404) Inflammation (0.220) Cell Proliferation (0.165)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
90	98-142	Nervous (0.400) Cardiovascular (0.200) Developmental (0.200) Gastrointestinal (0.200)	Cell Proliferation (0.400) Inflammation (0.400) Cancer (0.200)	pINCY
91	384-428	Reproductive (0.221) Gastrointestinal (0.156) Hematopoietic/Immune (0.143)	Cancer (0.468) Inflammation/Trauma (0.325) Cell Proliferation (0.273)	PBLUESCRIPT
92	80-124 731-775	Reproductive (0.286) Hematopoietic/Immune (0.143)	Cancer (0.469) Inflammation/Trauma (0.326) Cell Proliferation (0.306)	PBLUESCRIPT
93	437-481 641-685	Reproductive (0.250) Nervous (0.200) Cardiovascular (0.183)	Cancer (0.550) Inflammation/Trauma (0.284) Cell Proliferation (0.150)	PBLUESCRIPT
94	397-441 1036-1080	Reproductive (0.291) Hematopoietic/Immune (0.228)	Inflammation/Trauma (0.468) Cancer (0.392) Cell Proliferation (0.165)	pINCY
95	247-291	Reproductive (0.242) Hematopoietic/Immune (0.121)	Cancer (0.455) Inflammation/Trauma (0.333)	pINCY
96	453-497 858-902	Nervous (0.600) Reproductive (0.400)	Cell Proliferation (0.273) Cancer (0.400) Inflammation/Trauma (0.200) Neurological (0.200)	pINCY
97	224-268 770-814 1211-1255	Gastrointestinal (0.262) Reproductive (0.215) Nervous (0.169)	Cancer (0.462) Inflammation/Trauma (0.339) Cell Proliferation (0.231)	pINCY
98	3-47 1086-1130	Reproductive (0.211) Gastrointestinal (0.211) Hematopoietic/Immune (0.158)	Cancer (0.553) Cell Proliferation (0.368) Inflammation/Trauma (0.342)	pINCY
99	388-432 874-918	Reproductive (0.268) Nervous (0.146) Cardiovascular (0.146)	Cancer (0.390) Inflammation/Trauma (0.390) Cell Proliferation (0.220)	pINCY
100	26-70	Gastrointestinal (0.238) Cardiovascular (0.190)	Cancer (0.429) Inflammation/Trauma (0.381) Cell Proliferation (0.190)	pINCY
		Hematopoietic/Immune (0.143) Nervous (0.143) Endocrine (0.143)		

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
101	226-270 2062-2106	Nervous (0.234) Hematopoietic/Immune (0.170) Reproductive (0.149)	Inflammation/Trauma (0.383) Cancer (0.362) Cell Proliferation (0.213)	PINCY
102	487-531	Reproductive (0.276) Nervous (0.161) Gastrointestinal (0.138) Cardiovascular (0.138)	Cancer (0.494) Cell Proliferation (0.310) Inflammation/Trauma (0.264)	PINCY
103	561-605	Reproductive (0.274) Gastrointestinal (0.194) Cardiovascular (0.129)	Cancer (0.452) Inflammation/Trauma (0.339) Cell Proliferation (0.258)	PINCY
104	287-331 806-850	Gastrointestinal (0.500) Reproductive (0.250) Musculoskeletal (0.250)	Cancer (0.500) Inflammation/Trauma (0.250)	PINCY
105	154-198 505-549 757-801	Gastrointestinal (0.233) Reproductive (0.209) Hematopoietic/Immune (0.163) Nervous (0.163)	Cancer (0.465) Inflammation/Trauma (0.326) Cell Proliferation (0.209)	PINCY
106	174-218 1182-1226	Reproductive (0.185) Hematopoietic/Immune (0.185) Nervous (0.185)	Inflammation/Trauma (0.352) Cell Proliferation (0.333) Cancer (0.315)	PINCY
107	120-164 489-533	Reproductive (0.231) Hematopoietic/Immune (0.231) Nervous (0.154) Cardiovascular (0.154)	Cell Proliferation (0.462) Inflammation/Trauma (0.385) Cancer (0.231)	PINCY
108	64-108 1738-1782	Nervous (0.277) Reproductive (0.255) Cardiovascular (0.160)	Cancer (0.362) Inflammation/Trauma (0.362) Cell Proliferation (0.149)	PINCY
109	415-459 1027-1071 1549-1593	Reproductive (0.274) Hematopoietic/Immune (0.226) Nervous (0.167)	Inflammation/Trauma (0.476) Cancer (0.393) Cell Proliferation (0.179)	PINCY
110	242-286	Reproductive (0.500) Nervous (0.500)	Cancer (1.000)	PINCY
111	488-541 1028-1081	Reproductive (0.270) Nervous (0.191) Gastrointestinal (0.126)	Cancer (0.507) Inflammation/Trauma (0.284) Cell Proliferation (0.172)	FSPORT1

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
112	273-326	Reproductive (0.312)	Cancer (0.469)	pINCY
	867-920	Nervous (0.281)	Inflammation/Trauma (0.328)	
	1299-1352	Gastrointestinal (0.094)	Cell Proliferation (0.172)	
113	866-1135	Reproductive (0.245)	Cancer (0.445)	pINCY
		Gastrointestinal (0.136)	Cell Proliferation (0.227)	
		Nervous (0.136)	Inflammation/Trauma (0.327)	
114	155-325	Nervous (0.314)	Cancer (0.471)	pINCY
	812-1105	Reproductive (0.275)	Inflammation/Trauma (0.118)	
		Gastrointestinal (0.098)		
115	14-298	Gastrointestinal (0.190)	Cancer (0.476)	pINCY
		Nervous (0.190)	Cell Proliferation (0.190)	
		Reproductive (0.190)	Inflammation/Trauma (0.238)	
116	41-235	Reproductive (0.400)	Cancer (0.600)	pSPORT1
		Nervous (0.267)	Inflammation/Trauma (0.334)	
		Musculoskeletal (0.133)	Cell Proliferation (0.067)	
117	379-432	Reproductive (0.327)	Cancer (0.531)	pINCY
	973-1026	Nervous (0.184)	Cell Proliferation (0.224)	
	1297-1350	Urologic (0.102)	Inflammation/Trauma (0.265)	
118	974-1465	Reproductive (0.231)	Cancer (0.446)	pINCY
		Nervous (0.190)	Inflammation/Trauma (0.343)	
		Gastrointestinal (0.169)	Cell Proliferation (0.226)	
119	543-1028	Reproductive (0.292)	Cancer (0.517)	pSPORT1
		Nervous (0.163)	Cell Proliferation (0.167)	
		Gastrointestinal (0.139)	Inflammation/Trauma (0.235)	
120	385-552	Nervous (0.571)	Cancer (0.429)	pINCY
		Cardiovascular (0.143)	Inflammation/Trauma (0.572)	
		Developmental (0.143)	Cell Proliferation (0.143)	
121	685-864	Nervous (0.300)	Cancer (0.340)	pINCY
		Hematopoietic/Immune (0.200)	Inflammation/Trauma (0.440)	
		Cardiovascular (0.140)	Cell Proliferation (0.200)	
122	703-1026	Reproductive (0.400)	Cancer (0.680)	pINCY
		Cardiovascular (0.160)	Cell Proliferation (0.120)	
		Nervous (0.160)	Inflammation/Trauma (0.160)	
123	830-1351	Reproductive (0.200)	Cancer (0.415)	pINCY
		Cardiovascular (0.154)	Cell Proliferation (0.277)	
		Hematopoietic/Immune (0.154)	Inflammation/Trauma (0.354)	

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
124	272-325	Cardiovascular (0.250) Gastrointestinal (0.250) Musculoskeletal (0.250)	Inflammation/Trauma (0.750)	pINCY
125	130-972	Reproductive (0.180) Cardiovascular (0.160) Hematopoietic/Immune (0.160)	Cancer (0.440) Inflammation/Trauma (0.340) Cell Proliferation (0.220)	pINCY
126	434-973	Reproductive (0.188) Cardiovascular (0.156) Gastrointestinal (0.156)	Cancer (0.422) Inflammation/Trauma (0.328) Cell Proliferation (0.203)	pINCY
127	489-899	Gastrointestinal (0.333) Reproductive (0.333) Nervous (0.125)	Cancer (0.625) Inflammation/Trauma (0.208) Cell Proliferation (0.042)	pINCY
128	19-1242	Reproductive (0.354) Nervous (0.188)	Cancer (0.562) Cell Proliferation (0.250)	pINCY
129	217-270 541-594	Gastrointestinal (0.146) Reproductive (0.364) Cardiovascular (0.182) Gastrointestinal (0.182)	Inflammation/Trauma (0.250) Cancer (0.636) Inflammation/Trauma (0.364)	pINCY
130	115-864	Gastrointestinal (0.250) Hematopoietic/Immune (0.208)	Cancer (0.500) Inflammation/Trauma (0.292)	pINCY
131	255-308	Nervous (0.208) Reproductive (0.265)	Cancer (0.482) Cell Proliferation (0.349)	pINCY
132	23-541	Nervous (0.909) Endocrine (0.091)	Inflammation/Trauma (0.253) Cancer (0.636) Cell Proliferation (0.091)	pINCY

Table 4

SEQ ID NO:	Library	Library Comment
67	LATRTUT02	Library was constructed using RNA isolated from a myxoma removed from the left atrium of a 43-year-old caucasian male during annuloplasty. Pathology indicated atrial myxoma. Patient history included pulmonary insufficiency, acute myocardial infarction, atherosclerotic coronary artery disease, and hyperlipidemia. Family history included benign hypertension, acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
68	PENITUT01	Library was constructed using RNA isolated from tumor tissue removed from the penis of a 64-year-old caucasian male during penile amputation. Pathology indicated a fungating invasive grade 4 squamous cell carcinoma involving the inner wall of the foreskin and extending onto the glans penis. Patient history included benign neoplasm of the large bowel, atherosclerotic coronary artery disease, angina pectoris, gout, and obesity. Family history included malignant pharyngeal neoplasm, chronic lymphocytic leukemia, and chronic liver disease.
69	BLADTUT04	Library was constructed using RNA isolated from bladder tumor tissue removed from a 60-year-old caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology indicated grade 3 transitional cell carcinoma in the left bladder wall. Carcinoma in-situ was identified in the dome and trigone. Family history included type I diabetes, a malignant neoplasm of the stomach, atherosclerotic coronary artery disease, and an acute myocardial infarction.
70	BLADTUT06	Library was constructed using RNA isolated from bladder tumor tissue removed from the posterior bladder wall of a 58-year-old caucasian male during a radical cystectomy, radical prostatectomy, and gastrostomy. Pathology indicated grade 3 transitional cell carcinoma in the left lateral bladder wall. The remaining bladder showed marked cystitis with scattered microscopic foci of transitional cell carcinoma in situ. Patient history included angina and emphysema. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
71	ADRENOT07	Library was constructed using RNA isolated from adrenal tissue removed from a 61-year-old female during a bilateral adrenalectomy. Patient history included an unspecified disorder of the adrenal glands.
72	BRSTNOT19	Library was constructed using RNA isolated from breast tissue removed from a 67-year-old caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated residual invasive lobular carcinoma. Patient history included depressive disorder, benign large bowel neoplasm, and hemorrhoids. Family history included cerebrovascular and cardiovascular disease and lung cancer.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
73	SPLMN0T12	Library was constructed using RNA isolated from spleen tissue removed from a 65-year-old female. Pathology indicated the spleen was negative for metastasis. Pathology for the associated tumor tissue indicated well-differentiated neuroendocrine carcinoma (islet cell tumor), nuclear grade 1, forming a dominant mass in the distal pancreas. Multiple smaller tumor nodules were immediately adjacent to the main mass. The liver showed metastatic grade 1 islet cell tumor, forming multiple nodules. Multiple (4) peritoneal lymph nodes contained metastatic grade 1 islet cell tumor.
74	MONOTXT02	Library was constructed using RNA isolated from treated monocytes from peripheral blood removed from a 42-year-old female. The cells were treated with interleukin-10 (IL-10) and lipopolysaccharide (LPS). IL-10 was added at time 0 at 10 ng/ml, LPS was added at 1 hour at 5 ng/ml. The monocytes were isolated from buffy coat by adherence to plastic. Incubation time was 24 hours.
75	FIBPFEN06	Library was constructed from 1.56 million independent clones from a prostate stromal fibroblast tissue library. Starting RNA was made from fibroblasts of prostate stroma removed from a male fetus who died after 26 weeks' gestation. The libraries were normalized in two rounds using conditions adapted from Soares et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228 and Bonaldo et al. (1996) Genome Research 6:791, except that a significantly longer (48-hours/round) reannealing hybridization was used.
76	HUVESTB01	Library was constructed using RNA isolated from shear-stressed HUV-EC-C (ATCC CRL 1730) cells. Before RNA isolation, the cells were subjected to a shear stress of 10 dynes/cm.
77	SYNOOAT01	Library was constructed using RNA isolated from the knee synovial membrane tissue of an 82-year-old female with osteoarthritis.
78	UTRSNOT05	Library was constructed using RNA isolated from the uterine tissue of a 45-year-old Caucasian female during a total abdominal hysterectomy and total colectomy. Pathology for the associated tumor tissue indicated multiple leiomyomas of the myometrium and a grade 2 colonic adenocarcinoma of the cecum. Patient history included multiple sclerosis and mitral valve disorder. Family history included type I diabetes, cerebrovascular disease, atherosclerotic coronary artery disease, malignant skin neoplasm, hypertension, and malignant neoplasm of the colon.
79	HIPONON01	Library was constructed from 1.13 million independent clones from a hippocampus library. RNA was isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from an intracranial bleed. Patient history included nose cancer, hypertension, and arthritis. The normalization and hybridization conditions were adapted from Soares et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228.

Table 4 (cont.)

SEQ ID NO.	Library	Library Comment
80	BRSTTUT03	Library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant, and three separate nodules were found in the lower outer quadrant of the left breast. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular disease, coronary artery aneurysm, breast cancer, prostate cancer, atherosclerotic coronary artery disease, and type I diabetes.
81	SININOT01	Library was constructed using RNA isolated from ileum tissue obtained from the small intestine of a 4-year-old Caucasian female, who died from a closed head injury. Patient history included jaundice. Previous surgeries included a double hernia repair.
82	SINTFET03	Library was constructed using RNA isolated from small intestine tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation.
83	HNT3AZT01	Library was constructed using RNA isolated from the hnr2 cell line (derived from a human teratocarcinoma that exhibited properties characteristic of a committed neuronal precursor). Cells were treated for three days with 0.35 micromolar 5-aza-2'-deoxycytidine (AZ).
84	ENDANOT01	Library was constructed using RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.
85	LUNGTT08	Library was constructed using RNA isolated from lung tumor tissue removed from a 63-year-old Caucasian male during a right upper lobectomy with fiberoptic bronchoscopy. Pathology indicated a grade 3 adenocarcinoma. Patient history included atherosclerotic coronary artery disease, an acute myocardial infarction, rectal cancer, an asymptomatic abdominal aortic aneurysm, tobacco abuse, and cardiac dysrhythmia. Family history included congestive heart failure, stomach cancer, and lung cancer, type II diabetes, atherosclerotic coronary artery disease, and an acute myocardial infarction.
86	OVARTTUT10	Library was constructed using RNA isolated from ovarian tumor tissue removed from the left ovary of a 58-year-old Caucasian female during a total abdominal hysterectomy, removal of a solitary ovary, and repair of inguinal hernia. Pathology indicated a metastatic grade 3 adenocarcinoma of colonic origin, forming a partially cystic and necrotic tumor mass in the left ovary, and an adenocarcinoma of colonic origin forming a nodule in the left mesovarium. A single intramural leiomyoma was identified in the myometrium. The cervix showed mild chronic cystic cervicitis. Patient history included benign hypertension, follicular cyst of the ovary, colon cancer, benign colon neoplasm, and osteoarthritis. Family history included emphysema, myocardial infarction, atherosclerotic coronary artery disease, benign hypertension, and hyperlipidemia.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
87	BRSTNOT13	Library was constructed using RNA isolated from breast tissue removed from a 36-year-old Caucasian female during bilateral simple mastectomy. Patient history included a breast neoplasm, depressive disorder, hyperlipidemia, and a chronic stomach ulcer. Family history included cardiovascular and cerebrovascular disease; hyperlipidemia; skin, breast, esophageal, bladder, and bone cancer; and Hodgkin's lymphoma.
88	UTRSNOR01	Library was constructed using RNA isolated from uterine endometrium tissue removed from a 29-year-old Caucasian female during a vaginal hysterectomy and cystocele repair. Pathology indicated the endometrium was secretory, and the cervix showed mild chronic cervicitis with focal squamous metaplasia. Pathology for the associated tumor tissue indicated intramural uterine leiomyoma. Patient history included hypothyroidism, pelvic floor relaxation, and paraplegia. Family history included benign hypertension, type II diabetes, and hyperlipidemia.
89	BRSTMIMT02	Library was constructed using RNA isolated from diseased right breast tissue removed from a 46-year-old Caucasian female during a unilateral extended simple mastectomy and open breast biopsy. Pathology indicated mildly proliferative fibrocytic change, including intraductal duct ectasia, papilloma formation, and ductal hyperplasia. Pathology for the associated tumor tissue indicated multifocal ductal carcinoma <i>in situ</i> , both comedo and non-comedo types, nuclear grade 2 with extensive intraductal calcifications. Patient history included deficiency anemia, normal delivery, chronic sinusitis, extrinsic asthma, and kidney infection. Family history included type II diabetes, benign hypertension, cerebrovascular disease, skin cancer, and hyperlipidemia.
90	LIVRDIR01	Library was constructed using RNA isolated from diseased liver tissue removed from a 63-year-old Caucasian female during a liver transplant. Patient history included primary biliary cirrhosis. Serology was positive for anti-mitochondrial antibody.
91	HUVENOB01	Library was constructed using RNA isolated from HUV-EC-C (ATCC CRL 1730) cells.
92	TESTNOT03	Library was constructed using RNA isolated from testicular tissue removed from a 37-year-old Caucasian male, who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure.
93	LUNGNOT02	Library was constructed using RNA isolated from the lung tissue of a 47-year-old Caucasian male, who died of a subarachnoid hemorrhage.
94	LUNGFET03	Library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation.
95	PANCNOT07	Library was constructed using RNA isolated from the pancreatic tissue of a Caucasian male fetus, who died at 23 weeks' gestation.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
96	BRAINOT12	Library was constructed using RNA isolated from brain tissue removed from the right frontal lobe of a 5-year-old Caucasian male during a hemisphereectomy. Pathology indicated extensive polymicrogyria and mild to moderate gliosis (predominantly subpial and subcortical), which are consistent with chronic seizure disorder. Family history included a cervical neoplasm.
97	LIVRTUT01	Library was constructed using RNA isolated from liver tumor tissue removed from a 51-year-old Caucasian female during a hepatic lobectomy. Pathology indicated metastatic grade 3 adenocarcinoma consistent with colon cancer. Family history included a malignant neoplasm of the liver.
98	GBLATUT01	Library was constructed using RNA isolated from gall bladder tumor tissue removed from a 78-year-old Caucasian female during a cholecystectomy. Pathology indicated invasive grade 2 squamous cell carcinoma, forming a mass in the gall bladder. Patient history included diverticulitis of the colon, palpitations, benign hypertension, and hyperlipidemia. Family history included a cholecystectomy, atherosclerotic coronary artery disease, hyperlipidemia, and benign hypertension.
99	LEUKNOT02	Library was constructed using RNA isolated from white blood cells of a 45-year-old female with blood type O+. The donor tested positive for cytomegalovirus (CMV).
100	LUNGNOT22	Library was constructed using RNA isolated from lung tissue removed from a 58-year-old Caucasian female. The tissue sample used to construct this library was found to have tumor contaminant upon microscopic examination. Pathology for the associated tumor tissue indicated a caseating granuloma. Family history included congestive heart failure, breast cancer, secondary bone cancer, acute myocardial infarction and atherosclerotic coronary artery disease.
101	ADRETUT06	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.
102	ADRETUT06	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.
103	THYRNNOT10	Library was constructed using RNA isolated from diseased left thyroid tissue removed from a 30-year-old Caucasian female during a unilateral thyroid lobectomy and parathyroid reimplantation. Pathology indicated lymphocytic thyroiditis.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
104	CONNUTU05	Library was constructed using RNA isolated from tumorous skull soft tissue removed from a 34-year-old caucasian female during skull lesion excision. Pathology indicated grade 3 ependymoma forming an implant in the dermis and subcutis associated with dense fibrosis. Patient history included seizures, bone cancer, and brain cancer. Surgeries included cranioplasty and cerebral meninges lesion excision, and treatment included whole brain radiation. Family history included anxiety and depression.
105	HEZANOT01	Library was constructed using RNA isolated from right coronary and right circumflex coronary artery tissue removed from the explanted heart of a 46-year-old caucasian male during a heart transplantation. Patient history included myocardial infarction from total occlusion of the left anterior descending coronary artery, atherosclerotic coronary artery disease, hyperlipidemia, myocardial ischemia, dilated cardiomyopathy, left ventricular dysfunction, and tobacco abuse. Family history included atherosclerotic coronary artery disease.
106	UTTRMTM01	Library was constructed using RNA isolated from myometrial tissue removed from a 45-year-old Caucasian female during vaginal hysterectomy and bilateral salpingo-oophorectomy. Pathology indicated the myometrium was negative for tumor. Pathology for the associated tumor tissue indicated multiple (23) subserosal, intramural, and submucosal leiomyomata. The endometrium was in proliferative phase. The right ovary contained an old corpus luteum. The cervix, left ovary, and right and left fallopian tubes were unremarkable. The patient presented with stress incontinence. Patient history included extrinsic asthma without status asthmaticus and normal delivery. Patient medications included Motrin, iron sulfate, Premarin, prednisone, Tylenol #3, and colace. Family history included cerebrovascular disease, depression, and atherosclerotic coronary artery disease.
107	FIBPPEN06	This normalized library was constructed from 1.56 million independent clones from a prostate stromal fibroblast library. RNA was isolated from a male fetus, who died after 26 weeks' gestation. The normalization and hybridization conditions were adapted from Soares et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
108	BRAINOT19	Library was constructed using RNA isolated from diseased brain tissue removed from the left frontal lobe of a 27-year-old Caucasian male during a brain lobectomy. Pathology indicated a focal deep white matter lesion, characterized by marked gliosis, calcifications, and hemosiderin-laden macrophages, consistent with a remote perinatal injury. This tissue also showed mild to moderate generalized gliosis, predominantly subpial and subcortical, consistent with chronic seizure disorder. The left temporal lobe, including the mesial temporal structures, showed focal, marked pyramidal cell loss and gliosis in hippocampal sector CA1, consistent with mesial temporal sclerosis. GFAP was positive for astrocytes. Patient presented with intractable epilepsy, focal epilepsy, hemiplegia, and an unspecified brain injury. Patient history included cerebral palsy, abnormality of gait, and depressive disorder. Family history included brain cancer.
109	COLCDIT03	Library was constructed using RNA isolated from diseased colon polyp tissue removed from the cecum of a 67-year-old female. Pathology indicated a benign cecum polyp. Pathology for the associated tumor tissue indicated invasive grade 3 adenocarcinoma that arose in tubulovillous adenoma forming a fungating mass in the cecum.
110	BRAXNOT03	Library was constructed using RNA isolated from sensory-motor cortex tissue removed from the brain of a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarctions of the cerebral neocortex. The cerebral hemisphere revealed moderate fibrosis of the leptomeninges with focal calcifications. There was evidence of shrunken and slightly eosinophilic pyramidal neurons throughout the cerebral hemispheres. There were also multiple small microscopic areas of cavitation with surrounding gliosis, scattered throughout the cerebral cortex. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly and an enlarged spleen and liver. Patient medications included Simethicone, Lasix, Digoxin, Colace, Zantac, Captopril, and Vasotec.
111	BRAITUT02	Library was constructed using RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Family history included a malignant neoplasm of the kidney.
112	PROSNOT11	Library was constructed using RNA isolated from the prostate tissue of a 28-year-old Caucasian male, who died from a self-inflicted gunshot wound.
113	LIVRTUT01	Library was constructed using RNA isolated from liver tumor tissue removed from a 51-year-old Caucasian female during a hepatic lobectomy. Pathology indicated metastatic grade 3 adenocarcinoma consistent with colon cancer. Family history included a malignant neoplasm of the liver.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
114	PANCTUT02	Library was constructed using RNA isolated from pancreatic tumor tissue removed from a 45-year-old Caucasian female during radical pancreaticoduodenectomy. Pathology indicated a grade 4 anaplastic carcinoma. Family history included benign hypertension, hyperlipidemia and atherosclerotic coronary artery disease.
115	LIVRFET02	Library was constructed using RNA isolated from liver tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation. Family history included seven days of erythromycin treatment for bronchitis in the mother during the first trimester.
116	BRAITUT03	Library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe a 17-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a grade 4 fibrillary giant and small-cell astrocytoma. Family history included benign hypertension and cerebrovascular disease.
117	BRSTNOT07	Library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocytic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, cardiovascular disease, and type II diabetes.
118	SMCANOT01	Library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.
119	THP1AZS08	Library was constructed using 5.76 million clones from a 5-aza-2'-deoxycytidine (AZ) treated THP-1 promonocyte cell line library. Starting RNA was made from THP-1 promonocyte cells treated for three days with 0.8 micromolar AZ. The hybridization probe for subtraction was derived from a similarly constructed library, made from 1 microgram of polyA RNA isolated from untreated THP-1 cells. 5.76 million clones from the AZ-treated THP-1 cell library were then subjected to two rounds of subtractive hybridization with 5 million clones from the untreated THP-1 cell library. Subtractive hybridization conditions were based on the methodologies of Swaroop et al. (1991) Nucleic Acids Res. 19:1954, and Bonaldo et al. (1996) Genome Research 6:791. THP-1 (ATCC TIB 202) is a human promonocyte line derived from peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).
120	ADRETUT06	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.

Table 4 (cont.)

SEQ ID NO:	Library ID		Library Comment
121	SININOT03	Library was constructed using RNA isolated from ileum tissue obtained from an 8-year-old Caucasian female, who died from head trauma. Serology was positive for cytomegalovirus (CMV).	
122	SININOT03	Library was constructed using RNA isolated from ileum tissue obtained from an 8-year-old Caucasian female, who died from head trauma. Serology was positive for cytomegalovirus (CMV).	
123	TLYMNNOT06	Library was constructed using RNA isolated from activated Th2 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-4 in the presence of anti-IL-12 antibodies and B7-transfected COS cells, and then activated for six hours with anti-CD3 and anti-CD28 antibodies.	
124	HEAANOT01	Library was constructed using RNA isolated from right coronary and right circumflex coronary artery tissue removed from the explanted heart of a 46-year-old Caucasian male during a heart transplantation. Patient history included myocardial infarction from total occlusion of the left anterior descending coronary artery, atherosclerotic coronary artery disease, hyperlipidemia, myocardial ischemia, dilated cardiomyopathy, left ventricular dysfunction, and tobacco abuse. Previous surgeries included cardiac catheterization. Family history included atherosclerotic coronary artery disease.	
125	TYJINT01	Library was constructed using RNA isolated from a Jurkat cell line derived from the T cells of a male. The cells were treated for 18 hours with 50 ng/ml phorbol ester (PMA) and 1 micromolar calcium ionophore. Patient history included acute T-cell leukemia.	
126	BRAITUT24	Library was constructed using RNA isolated from right frontal brain tumor tissue removed from a 50-year-old Caucasian male during a cerebral meninges lesion excision. Pathology indicated meningioma. Family history included colon cancer and cerebrovascular disease.	
127	PROSTUT16	Library was constructed using RNA isolated from prostate tumor tissue removed from a 55-year-old Caucasian male. Pathology indicated adenocarcinoma, Gleason grade 5+4. Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Patient history included calculus of the kidney. Family history included lung cancer and breast cancer.	
128	BRONNOT01	Library was constructed using RNA isolated from bronchial tissue removed from a 15-year-old Caucasian male.	

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
129	BLADTUT03	Library was constructed using RNA isolated from bladder tumor tissue removed from a 58-year-old Caucasian male during a radical cystectomy, radical prostatectomy, regional lymph node excision, and urinary diversion to bowel. Pathology indicated invasive grade 3 transitional cell carcinoma. Patient history included a benign colon neoplasm. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
130	COLXTDT01	Library was constructed using RNA isolated from colon tissue removed from the appendix of a 37-year-old Black female during myomectomy, dilation and curettage, right fimbrial region biopsy, and incidental appendectomy. Pathology indicated an unremarkable appendix. Pathology for the associated tumor tissue indicated multiple (12) uterine leiomyomata. Patient history included premenopausal menorrhagia and sarcoidosis of the lung. Family history included acute myocardial infarction and atherosclerotic coronary artery disease.
131	BRATNOT02	Library was constructed using RNA isolated from superior temporal cortex tissue removed from the brain of a 35-year-old Caucasian male. No neuropathology was found. Patient history included dilated cardiomyopathy, congestive heart failure, and an enlarged spleen and liver.
132	BRAWNOT01	Library was constructed using RNA isolated from dentate nucleus tissue removed from the brain of a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarctions of the cerebral neocortex. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly, and an enlarged spleen and liver.

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score $\geq$ GCC-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	Score= 120 or greater; Match length= 56 or greater
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	Score=3.5 or greater
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
  - 5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66,
  - b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66,
  - c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66,

NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66, and

d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66.

2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

30

4. An isolated polynucleotide encoding a polypeptide of claim 2.

5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID

NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID 5 NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:132.

10 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. A cell transformed with a recombinant polynucleotide of claim 6.

15 8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

9. A method for producing a polypeptide of claim 1, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide 20 comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.

25

11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID 30 NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, 35 SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119,

SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:132,

- b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a  
5 polynucleotide sequence selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ 10 ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID 15 NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:132,  
c) a polynucleotide sequence complementary to a),  
d) a polynucleotide sequence complementary to b), and  
e) an RNA equivalent of a)-d).

20

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

13. A method for detecting a target polynucleotide in a sample, said target polynucleotide 25 having a sequence of a polynucleotide of claim 11, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and  
30 b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

35 15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

5

16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:132.

18. A method for treating a disease or condition associated with decreased expression of functional GBAP, comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

35 21. A method for treating a disease or condition associated with decreased expression of functional GBAP, comprising administering to a patient in need of such treatment a pharmaceutical

composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- 5        a) exposing a sample comprising a polypeptide of claim 1 to a compound, and  
b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

10

24. A method for treating a disease or condition associated with overexpression of functional GBAP, comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 23.

15        25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and  
b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a 20 compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- 25        a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,  
b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and  
c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change 30 in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method 35 comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, and

- b) detecting altered expression of the target polynucleotide.
28. A method for assessing toxicity of a test compound, said method comprising:
- a) treating a biological sample containing nucleic acids with the test compound;
  - 5 b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
  - 10 c) quantifying the amount of hybridization complex; and
  - d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

## SEQUENCE LISTING

<110> INCYTE GENOMICS, INC.  
YUE, Henry  
TANG, Y. Tom  
BANDMAN, Olga  
HILLMAN, Jennifer L.  
LAL, Preeti  
AU-YOUNG, Janice  
REDDY, Roopa  
YANG, Junming  
BAUGHN, Mariah R.  
LU, Dyung Aina M.  
AZIMZAI, Yalda  
PATTERSON, Chandra

<120> GTP-BINDING ASSOCIATED PROTEINS

<130> PF-0714 PCT

<140> To Be Assigned  
<141> Herewith

<150> 60/144,595; 60/150,460; 60/159,849  
<151> 1999-07-19; 1999-08-23; 1999-10-15

<160> 132  
<170> PERL Program

<210> 1  
<211> 269  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1405545CD1

<400> 1  
Met Pro Ala Val Leu Glu Arg Leu Ser Arg Tyr Asn Ser Thr Ser  
1 5 10 15  
Gln Ala Phe Ala Glu Val Leu Arg Leu Pro Lys Gln Gln Leu Arg  
20 25 30  
Lys Leu Leu Tyr Pro Leu Gln Glu Val Glu Arg Phe Leu Ala Pro  
35 40 45  
Tyr Gly Arg Gln Asp Leu His Leu Arg Ile Phe Asp Pro Ser Pro  
50 55 60  
Glu Asp Ile Ala Arg Ala Asp Asn Ile Phe Thr Ala Thr Glu Arg  
65 70 75  
Asn Arg Ile Asp Tyr Val Ser Ser Ala Val Arg Ile Asp His Ala  
80 85 90  
Pro Asp Leu Pro Arg Pro Glu Val Cys Phe Ile Gly Arg Ser Asn  
95 100 105  
Val Gly Lys Ser Ser Leu Ile Lys Ala Leu Phe Ser Leu Ala Pro  
110 115 120  
Glu Val Glu Val Arg Val Ser Lys Lys Pro Gly His Thr Lys Lys  
125 130 135  
Met Asn Phe Phe Lys Val Gly Lys His Phe Thr Val Val Asp Met  
140 145 150  
Pro Gly Tyr Gly Phe Arg Ala Pro Glu Asp Phe Val Asp Met Val  
155 160 165  
Glu Thr Tyr Leu Lys Glu Arg Arg Asn Leu Lys Arg Thr Phe Leu

Leu	Val	Asp	Ser	Val	Val	Gly	Ile	Gln	Lys	Thr	Asp	Asn	Ile	Ala
170														180
185									190					195
Ile	Glu	Met	Cys	Glu	Glu	Phe	Ala	Leu	Pro	Tyr	Val	Ile	Val	Leu
200									205					210
Thr	Lys	Ile	Asp	Lys	Ser	Ser	Lys	Gly	His	Leu	Leu	Lys	Gln	Val
215									220					225
Leu	Gln	Ile	Gln	Lys	Phe	Val	Asn	Met	Lys	Thr	Gln	Gly	Cys	Phe
230									235					240
Pro	Gln	Leu	Phe	Pro	Val	Ser	Ala	Val	Thr	Phe	Ser	Gly	Ile	His
245									250					255
Leu	Leu	Arg	Cys	Phe	Ile	Ala	Ser	Val	Thr	Gly	Ser	Leu	Asp	
260									265					

<210> 2  
<211> 428  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1451265CD1

<400> 2

Met	Glu	Val	Ala	Val	Cys	Thr	Asp	Ser	Ala	Ala	Pro	Met	Trp	Ser
1					5				10					15
Cys	Ile	Val	Trp	Glu	Leu	His	Ser	Gly	Ala	Asn	Leu	Leu	Thr	Tyr
					20				25					30
Arg	Gly	Gly	Gln	Ala	Gly	Pro	Arg	Gly	Leu	Ala	Leu	Leu	Asn	Gly
					35				40					45
Glu	Tyr	Leu	Leu	Ala	Ala	Gln	Leu	Gly	Lys	Asn	Tyr	Ile	Ser	Ala
					50				55					60
Trp	Glu	Leu	Gln	Arg	Lys	Asp	Gln	Leu	Gln	Gln	Lys	Ile	Met	Cys
					65				70					75
Pro	Gly	Pro	Val	Thr	Cys	Leu	Thr	Ala	Ser	Pro	Asn	Gly	Leu	Tyr
					80				85					90
Val	Leu	Ala	Gly	Val	Ala	Glu	Ser	Ile	His	Leu	Trp	Glu	Val	Ser
					95				100					105
Thr	Gly	Asn	Leu	Leu	Val	Ile	Leu	Ser	Arg	His	Tyr	Gln	Asp	Val
					110				115					120
Ser	Cys	Leu	Gln	Phe	Thr	Gly	Asp	Ser	Ser	His	Phe	Ile	Ser	Gly
					125				130					135
Gly	Lys	Asp	Cys	Leu	Val	Leu	Val	Trp	Ser	Leu	Cys	Ser	Val	Leu
					140				145					150
Gln	Ala	Asp	Pro	Ser	Arg	Ile	Pro	Ala	Pro	Arg	His	Val	Trp	Ser
					155				160					165
His	His	Thr	Leu	Pro	Ile	Thr	Asp	Leu	His	Cys	Gly	Phe	Gly	
					170				175					180
Pro	Leu	Ala	Arg	Val	Ala	Thr	Ser	Ser	Leu	Asp	Gln	Thr	Val	Lys
					185				190					195
Leu	Trp	Glu	Val	Ser	Ser	Gly	Glu	Leu	Leu	Ser	Val	Leu	Phe	
					200				205					210
Asp	Val	Ser	Ile	Met	Ala	Val	Thr	Met	Asp	Leu	Ala	Glu	His	
					215				220					225
Met	Phe	Cys	Gly	Gly	Ser	Glu	Gly	Ser	Ile	Phe	Gln	Val	Asp	Leu
					230				235					240
Phe	Thr	Trp	Pro	Gly	Gln	Arg	Glu	Arg	Ser	Phe	His	Pro	Glu	Gln
					245				250					255
Asp	Ala	Gly	Lys	Val	Phe	Lys	Gly	His	Arg	Asn	Gln	Val	Thr	Cys
					260				265					270
Leu	Ser	Val	Ser	Thr	Asp	Gly	Ser	Val	Leu	Leu	Ser	Gly	Ser	His
					275				280					285
Asp	Glu	Thr	Val	Arg	Leu	Trp	Asp	Val	Gln	Ser	Lys	Gln	Cys	Ile
					290				295					300

Arg Thr Val Ala Leu Lys Gly Pro Val Thr Asn Ala Ala Ile Leu  
     305                         310                         315  
 Leu Ala Pro Val Ser Met Leu Ser Ser Asp Phe Arg Pro Ser Leu  
     320                         325                         330  
 Pro Leu Pro His Phe Asn Lys His Leu Leu Gly Ala Glu His Gly  
     335                         340                         345  
 Asp Glu Pro Arg His Gly Gly Leu Thr Leu Arg Leu Gly Leu His  
     350                         355                         360  
 Gln Gln Gly Ser Glu Pro Ser Tyr Leu Asp Arg Thr Glu Gln Leu  
     365                         370                         375  
 Gln Ala Val Leu Cys Ser Thr Met Glu Lys Ser Val Leu Gly Gly  
     380                         385                         390  
 Gln Asp Gln Leu Arg Val Arg Val Thr Glu Leu Glu Asp Glu Val  
     395                         400                         405  
 Arg Asn Leu Arg Lys Ile Asn Arg Asp Leu Phe Asp Phe Ser Thr  
     410                         415                         420  
 Arg Phe Ile Thr Arg Pro Ala Lys  
     425

&lt;210&gt; 3

&lt;211&gt; 562

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1556311CD1

&lt;400&gt; 3

Met Pro Glu Thr Val Asn His Asn Lys His Gly Asn Val Ala Leu  
     1                         5                             10                         15  
 Pro Gly Thr Lys Pro Thr Pro Ile Pro Pro Pro Arg Leu Lys Lys  
     20                         25                             30  
 Gln Ala Ser Phe Leu Glu Ala Glu Gly Gly Ala Lys Thr Leu Ser  
     35                         40                             45  
 Gly Gly Arg Pro Gly Ala Gly Pro Glu Leu Glu Leu Gly Thr Ala  
     50                         55                             60  
 Gly Ser Pro Gly Gly Ala Pro Pro Glu Ala Ala Pro Gly Asp Cys  
     65                         70                             75  
 Thr Arg Ala Pro Pro Pro Ser Ser Glu Ser Arg Pro Pro Cys His  
     80                         85                             90  
 Gly Gly Arg Gln Arg Leu Ser Asp Met Ser Ile Ser Thr Ser Ser  
     95                         100                          105  
 Ser Asp Ser Leu Glu Phe Asp Arg Ser Met Pro Leu Phe Gly Tyr  
   110                         115                          120  
 Glu Ala Asp Thr Asn Ser Ser Leu Glu Asp Tyr Glu Gly Glu Ser  
   125                         130                          135  
 Asp Gln Glu Thr Met Ala Pro Pro Ile Lys Ser Lys Lys Lys Arg  
   140                         145                          150  
 Ser Ser Ser Phe Val Leu Pro Lys Leu Val Lys Ser Gln Leu Gln  
   155                         160                          165  
 Lys Val Ser Gly Val Phe Ser Ser Phe Met Thr Pro Glu Lys Arg  
   170                         175                          180  
 Met Val Arg Arg Ile Ala Glu Leu Ser Arg Asp Lys Cys Thr Tyr  
   185                         190                          195  
 Phe Gly Cys Leu Val Gln Asp Tyr Val Ser Phe Leu Gln Glu Asn  
   200                         205                          210  
 Lys Glu Cys His Val Ser Ser Thr Asp Met Leu Gln Thr Ile Arg  
   215                         220                          225  
 Gln Phe Met Thr Gln Val Lys Asn Tyr Leu Ser Gln Ser Ser Glu  
   230                         235                          240  
 Leu Asp Pro Pro Ile Glu Ser Leu Ile Pro Glu Asp Gln Ile Asp  
   245                         250                          255  
 Val Val Leu Glu Lys Ala Met His Lys Cys Ile Leu Lys Pro Leu

260	265	270
Lys Gly His Val Glu Ala Met Leu Lys Asp Phe His Met Ala Asp		
275	280	285
Gly Ser Trp Lys Gln Leu Lys Glu Asn Leu Gln Leu Val Arg Gln		
290	295	300
Arg Asn Pro Gln Glu Leu Gly Val Phe Ala Pro Thr Pro Asp Phe		
305	310	315
Val Asp Val Glu Lys Ile Lys Val Lys Phe Met Thr Met Gln Lys		
320	325	330
Met Tyr Ser Pro Glu Lys Lys Val Met Leu Leu Arg Val Cys		
335	340	345
Lys Leu Ile Tyr Thr Val Met Glu Asn Asn Ser Gly Arg Met Tyr		
350	355	360
Gly Ala Asp Asp Phe Leu Pro Val Leu Thr Tyr Val Ile Ala Gln		
365	370	375
Cys Asp Met Leu Glu Leu Asp Thr Glu Ile Glu Tyr Met Met Glu		
380	385	390
Leu Leu Asp Pro Ser Leu Leu His Gly Glu Gly Gly Tyr Tyr Leu		
395	400	405
Thr Ser Ala Tyr Gly Ala Leu Ser Leu Ile Lys Asn Phe Gln Glu		
410	415	420
Glu Gln Ala Ala Arg Leu Leu Ser Ser Glu Thr Arg Asp Thr Leu		
425	430	435
Arg Gln Trp His Lys Arg Arg Thr Thr Asn Arg Thr Ile Pro Ser		
440	445	450
Val Asp Asp Phe Gln Asn Tyr Leu Arg Val Ala Phe Gln Glu Val		
455	460	465
Asn Ser Gly Cys Thr Gly Lys Thr Leu Leu Val Arg Pro Tyr Ile		
470	475	480
Thr Thr Glu Asp Val Cys Gln Ile Cys Ala Glu Lys Phe Lys Val		
485	490	495
Gly Asp Pro Glu Glu Tyr Ser Leu Phe Leu Phe Val Asp Glu Thr		
500	505	510
Trp Gln Gln Leu Ala Glu Asp Thr Tyr Pro Gln Lys Ile Lys Ala		
515	520	525
Glu Leu His Ser Arg Pro Gln Pro His Ile Phe His Phe Val Tyr		
530	535	540
Lys Arg Ile Lys Asn Asp Pro Tyr Gly Ile Ile Phe Gln Asn Gly		
545	550	555
Glu Glu Asp Leu Thr Thr Ser		
560		

&lt;210&gt; 4

&lt;211&gt; 229

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1901373CD1

&lt;400&gt; 4

Met Ala Glu Asp Lys Thr Lys Pro Ser Glu Leu Asp Gln Gly Lys			
1	5	10	15
Tyr Asp Ala Asp Asp Asn Val Lys Ile Ile Cys Leu Gly Asp Ser			
20	25	30	
Ala Val Gly Lys Ser Lys Leu Met Glu Arg Phe Leu Met Asp Gly			
35	40	45	
Phe Gln Pro Gln Gln Leu Ser Thr Tyr Ala Leu Thr Leu Tyr Lys			
50	55	60	
His Thr Ala Thr Val Asp Gly Arg Thr Ile Leu Val Asp Phe Trp			
65	70	75	
Asp Thr Ala Gly Gln Glu Arg Phe Gln Ser Met His Ala Ser Tyr			
80	85	90	

Tyr His Lys Ala His Ala Cys Ile Met Val Phe Asp Val Gln Arg  
     95                         100                         105  
 Lys Val Thr Tyr Arg Asn Leu Ser Thr Trp Tyr Thr Glu Leu Arg  
     110                         115                         120  
 Glu Phe Arg Pro Glu Ile Pro Cys Ile Val Val Ala Asn Lys Ile  
     125                         130                         135  
 Asp Ala Asp Ile Asn Val Thr Gln Lys Ser Phe Asn Phe Ala Lys  
     140                         145                         150  
 Lys Phe Ser Leu Pro Leu Tyr Phe Val Ser Ala Ala Asp Gly Thr  
     155                         160                         165  
 Asn Val Val Lys Leu Phe Asn Asp Ala Ile Arg Leu Ala Val Ser  
     170                         175                         180  
 Tyr Lys Gln Asn Ser Gln Asp Phe Met Asp Glu Ile Phe Gln Glu  
     185                         190                         195  
 Leu Glu Asn Phe Ser Leu Glu Gln Glu Glu Glu Asp Val Pro Asp  
     200                         205                         210  
 Gln Glu Gln Ser Ser Ser Ile Glu Thr Pro Ser Glu Glu Val Ala  
     215                         220                         225  
 Ser Pro His Ser

<210> 5  
<211> 360  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2367767CD1

<400> 5  
 Met Phe Val Ala Arg Ser Ile Ala Ala Asp His Lys Asp Leu Ile  
     1                         5                             10                         15  
 His Asp Val Ser Phe Asp Phe His Gly Arg Arg Met Ala Thr Cys  
     20                         25                             30  
 Ser Ser Asp Gln Ser Val Lys Val Trp Asp Lys Ser Glu Ser Gly  
     35                         40                             45  
 Asp Trp His Cys Thr Ala Ser Trp Lys Thr His Ser Gly Ser Val  
     50                         55                             60  
 Trp Arg Val Thr Trp Ala His Pro Glu Phe Gly Gln Val Leu Ala  
     65                         70                             75  
 Ser Cys Ser Phe Asp Arg Thr Ala Ala Val Trp Glu Glu Ile Val  
     80                         85                             90  
 Gly Glu Ser Asn Asp Lys Leu Arg Gly Gln Ser His Trp Val Lys  
     95                         100                             105  
 Arg Thr Thr Leu Val Asp Ser Arg Thr Ser Val Thr Asp Val Lys  
     110                         115                             120  
 Phe Ala Pro Lys His Met Gly Leu Met Leu Ala Thr Cys Ser Ala  
     125                         130                             135  
 Asp Gly Ile Val Arg Ile Tyr Glu Ala Pro Asp Val Met Asn Leu  
     140                         145                             150  
 Ser Gln Trp Ser Leu Gln His Glu Ile Ser Cys Lys Leu Ser Cys  
     155                         160                             165  
 Ser Cys Ile Ser Trp Asn Pro Ser Ser Ser Arg Ala His Ser Pro  
     170                         175                             180  
 Met Ile Ala Val Gly Ser Asp Asp Ser Ser Pro Asn Ala Met Ala  
     185                         190                             195  
 Lys Val Gln Ile Phe Glu Tyr Asn Glu Asn Thr Arg Lys Tyr Ala  
     200                         205                             210  
 Lys Ala Glu Thr Leu Met Thr Val Thr Asp Pro Val His Asp Ile  
     215                         220                             225  
 Ala Phe Ala Pro Asn Leu Gly Arg Ser Phe His Ile Leu Ala Ile  
     230                         235                             240  
 Ala Thr Lys Asp Val Arg Ile Phe Thr Leu Lys Pro Val Arg Lys

245	250	255
Glu Leu Thr Ser Ser Gly Gly Pro Thr Lys	Phe Glu Ile His	Ile
260	265	270
Val Ala Gln Phe Asp Asn His Asn Ser Gln	Val Trp Arg Val	Ser
275	280	285
Trp Asn Ile Thr Gly Thr Val Leu Ala Ser	Ser Gly Asp Asp	Gly
290	295	300
Cys Val Arg Leu Trp Lys Ala Asn Tyr Met	Asp Asn Trp Lys	Cys
305	310	315
Thr Gly Ile Leu Lys Gly Asn Gly Ser Pro	Val Asn Gly Ser	Ser
320	325	330
Gln Gln Gly Thr Ser Asn Pro Ser Leu Gly	Ser Asn Ile Pro	Ser
335	340	345
Leu Gln Asn Ser Leu Asn Gly Ser Ser Ala	Gly Arg Lys His	Ser
350	355	360

<210> 6  
<211> 460  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3090433CD1

<400> 6

Met Ala Asn Asp Pro Leu Glu Gly Phe His	Glu Val Asn Leu Ala	
1 5	10 15	
Ser Pro Thr Ser Pro Asp Leu Leu Gly Val	Tyr Glu Ser Gly Thr	
20 25	30	
Gln Glu Gln Thr Thr Ser Pro Ser Val Ile	Tyr Arg Pro His Pro	
35 40	45	
Ser Ala Leu Ser Ser Val Pro Ile Gln Ala	Asn Ala Leu Asp Val	
50 55	60	
Ser Glu Leu Pro Thr Gln Pro Val Tyr Ser	Ser Pro Arg Arg Leu	
65 70	75	
Asn Cys Ala Glu Ile Ser Ser Ile Ser Phe	His Val Thr Asp Pro	
80 85	90	
Ala Pro Cys Ser Thr Ser Gly Val Thr Ala	Gly Leu Thr Lys Leu	
95 100	105	
Thr Thr Arg Lys Asp Asn Tyr Asn Ala	Glu Arg Glu Phe Leu	Gln
110 115	120	
Gly Ala Thr Ile Thr Glu Ala Cys Asp	Gly Ser Asp Asp Ile	Phe
125 130	135	
Gly Leu Ser Thr Asp Ser Leu Ser Arg	Leu Arg Ser Pro Ser	Val
140 145	150	
Leu Glu Val Arg Glu Lys Gly Tyr Glu	Arg Leu Lys Glu Glu	Leu
155 160	165	
Ala Lys Ala Gln Arg Glu Leu Lys Leu	Lys Asp Glu Glu Cys	Glu
170 175	180	
Arg Leu Ser Lys Val Arg Asp Gln Leu	Gly Gln Glu Leu Glu	Glu
185 190	195	
Leu Thr Ala Ser Leu Phe Glu Ala His	Lys Met Val Arg	Glu
200 205	210	
Ala Asn Ile Lys Gln Ala Thr Ala Glu	Lys Gln Leu Lys Glu	Ala
215 220	225	
Gln Gly Lys Ile Asp Val Leu Gln Ala	Glu Val Ala Ala Leu	Lys
230 235	240	
Thr Leu Val Leu Ser Ser Ser Pro Thr	Ser Pro Thr Gln Glu	Pro
245 250	255	
Leu Pro Gly Gly Lys Thr Pro Phe Lys	Lys Gly His Thr Arg	Asn
260 265	270	
Lys Ser Thr Ser Ser Ala Met Ser Gly	Ser His Gln Asp Leu	Ser

	275	280	285
Val Ile Gln Pro Ile Val Lys Asp Cys	Lys	Glu Ala Asp Leu	Ser
290	295	300	
Leu Tyr Asn Glu Phe Arg Leu Trp Lys	Asp	Glu Pro Thr Met	Asp
305	310	315	
Arg Thr Cys Pro Phe Leu Asp Lys Ile	Tyr	Gln Glu Asp Ile	Phe
320	325	330	
Pro Cys Leu Thr Phe Ser Lys Ser Glu	Leu	Ala Ser Ala Val	Leu
335	340	345	
Glu Ala Val Glu Asn Asn Thr Leu Ser	Ile	Glu Pro Val Gly	Leu
350	355	360	
Gln Pro Ile Arg Phe Val Lys Ala Ser	Ala	Val Glu Cys Gly	Gly
365	370	375	
Pro Lys Lys Cys Ala Leu Thr Gly Gln	Ser	Lys Ser Cys Lys His	
380	385	390	
Arg Ile Lys Leu Gly Asp Ser Ser Asn	Tyr	Tyr Tyr Ile Ser	Pro
395	400	405	
Phe Cys Arg Tyr Arg Ile Thr Ser Val	Cys	Asn Phe Phe Thr	Tyr
410	415	420	
Ile Arg Tyr Ile Gln Gln Gly Leu Val	Lys	Gln Gln Asp Val	Asp
425	430	435	
Gln Met Phe Trp Glu Val Met Gln Leu	Arg	Lys Glu Met Ser	Leu
440	445	450	
Ala Lys Leu Gly Tyr Phe Lys Glu Glu	Leu		
	455	460	

&lt;210&gt; 7

&lt;211&gt; 239

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3800591CD1

&lt;400&gt; 7

Met Gln Asp Pro Asn Ala Asp Thr Glu Trp Asn Asp Ile Leu Arg			
1	5	10	15
Lys Lys Gly Ile Leu Pro Pro Lys Glu Ser Leu Lys Glu Leu Glu			
20	25	30	
Glu Glu Ala Glu Glu Glu Gln Arg Ile Leu Gln Gln Ser Val Val			
35	40	45	
Lys Thr Tyr Glu Asp Met Thr Leu Glu Glu Leu Glu Asp His Glu			
,50	55	60	
Asp Glu Phe Asn Glu Glu Asp Glu Arg Ala Ile Glu Met Tyr Arg			
65	70	75	
Arg Arg Arg Leu Ala Glu Trp Lys Ala Thr Lys Leu Lys Asn Lys			
80	85	90	
Phe Gly Glu Val Leu Glu Ile Ser Gly Lys Asp Tyr Val Gln Glu			
95	100	105	
Val Thr Lys Ala Gly Glu Gly Leu Trp Val Ile Leu His Leu Tyr			
110	115	120	
Lys Gln Gly Ile Pro Leu Cys Ala Leu Ile Asn Gln His Leu Ser			
125	130	135	
Gly Leu Ala Arg Lys Phe Pro Asp Val Lys Phe Ile Lys Ala Ile			
140	145	150	
Ser Thr Thr Cys Ile Pro Asn Tyr Pro Asp Arg Asn Leu Pro Thr			
155	160	165	
Ile Phe Val Tyr Leu Glu Gly Asp Ile Lys Ala Gln Phe Ile Gly			
170	175	180	
Pro Leu Val Phe Gly Gly Met Asn Leu Thr Arg Asp Glu Leu Glu			
185	190	195	
Trp Lys Leu Ser Glu Ser Gly Ala Ile Met Thr Asp Leu Glu Glu			
200	205	210	

Asn Pro Lys Lys Pro Ile Glu Asp Val Leu Leu Ser Ser Val Arg  
                   215                  220                  225  
 Arg Ser Val Leu Met Lys Arg Asp Ser Asp Ser Glu Gly Asp  
                   230                  235  
 <210> 8  
 <211> 334  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> misc\_feature  
 <223> Incyte ID No: 5308471CD1  
  
 <400> 8  
 Met Arg Leu Thr Pro Arg Ala Leu Cys Ser Ala Ala Gln Ala Ala  
     1              5                  10                  15  
 Trp Arg Glu Asn Phe Pro Leu Cys Gly Arg Asp Val Ala Arg Trp  
     20                  25                  30  
 Phe Pro Gly His Met Ala Lys Gly Leu Lys Lys Met Gln Ser Ser  
     35                  40                  45  
 Leu Lys Leu Val Asp Cys Ile Ile Glu Val His Asp Ala Arg Ile  
     50                  55                  60  
 Pro Leu Ser Gly Arg Asn Pro Leu Phe Gln Glu Thr Leu Gly Leu  
     65                  70                  75  
 Lys Pro His Leu Leu Val Leu Asn Lys Met Asp Leu Ala Asp Leu  
     80                  85                  90  
 Thr Glu Gln Gln Lys Ile Met Gln His Leu Glu Gly Glu Gly Leu  
     95                  100                105  
 Lys Asn Val Ile Phe Thr Asn Cys Val Lys Asp Glu Asn Val Lys  
 110                  115                120  
 Gln Ile Ile Pro Met Val Thr Glu Leu Ile Gly Arg Ser His Arg  
 125                  130                135  
 Tyr His Arg Lys Glu Asn Leu Glu Tyr Cys Ile Met Val Ile Gly  
 140                  145                150  
 Val Pro Asn Val Gly Lys Ser Ser Leu Ile Asn Ser Leu Arg Arg  
 155                  160                165  
 Gln His Leu Arg Lys Gly Lys Ala Thr Arg Val Gly Gly Glu Pro  
 170                  175                180  
 Gly Ile Thr Arg Ala Val Met Ser Lys Ile Gln Val Ser Glu Arg  
 185                  190                195  
 Pro Leu Met Phe Leu Leu Asp Thr Pro Gly Val Leu Ala Pro Arg  
 200                  205                210  
 Ile Glu Ser Val Glu Thr Gly Leu Lys Leu Ala Leu Cys Gly Thr  
 215                  220                225  
 Val Leu Asp His Leu Val Gly Glu Glu Thr Met Ala Asp Tyr Leu  
 230                  235                240  
 Leu Tyr Thr Leu Asn Lys His Gln Arg Phe Gly Tyr Val Gln His  
 245                  250                255  
 Tyr Gly Leu Gly Ser Ala Cys Asp Asn Val Glu Arg Val Leu Lys  
 260                  265                270  
 Ser Val Ala Val Lys Leu Gly Lys Thr Gln Lys Val Lys Val Leu  
 275                  280                285  
 Thr Gly Thr Gly Asn Val Asn Val Ile Gln Pro Asn Tyr Pro Ala  
 290                  295                300  
 Ala Ala Arg Asp Phe Leu Gln Thr Phe Arg Arg Gly Leu Leu Gly  
 305                  310                315  
 Ser Val Met Leu Asp Leu Asp Val Leu Arg Gly His Pro Pro Ala  
 320                  325                330  
 Glu Thr Leu Pro

<210> 9  
 <211> 341  
 <212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 5324322CD1

<400> 9

Met Glu Arg Ala Val Pro Leu Ala Val Pro Leu Gly Gln Thr Glu  
1 5 10 15  
Val Phe Gln Ala Leu Gln Arg Leu His Met Thr Ile Phe Ser Gln  
20 25 30  
Ser Val Ser Pro Cys Gly Lys Phe Leu Ala Ala Gly Asn Asn Tyr  
35 40 45  
Gly Gln Ile Ala Ile Phe Ser Leu Ser Ser Ala Leu Ser Ser Glu  
50 55 60  
Ala Lys Glu Glu Ser Lys Lys Pro Val Val Thr Phe Gln Ala His  
65 70 75  
Asp Gly Pro Val Tyr Ser Met Val Ser Thr Asp Arg His Leu Leu  
80 85 90  
Ser Ala Gly Asp Gly Glu Val Lys Ala Trp Leu Trp Ala Glu Met  
95 100 105  
Leu Lys Lys Gly Cys Lys Glu Leu Trp Arg Arg Gln Pro Pro Tyr  
110 115 120  
Arg Thr Ser Leu Glu Val Pro Glu Ile Asn Ala Leu Leu Leu Val  
125 130 135  
Pro Lys Glu Asn Ser Leu Ile Leu Ala Gly Gly Asp Cys Gln Leu  
140 145 150  
His Thr Met Asp Leu Glu Thr Gly Thr Phe Thr Arg Val Leu Arg  
155 160 165  
Gly His Thr Asp Tyr Ile His Cys Leu Ala Leu Arg Glu Arg Ser  
170 175 180  
Pro Glu Val Leu Ser Gly Gly Glu Asp Gly Ala Val Arg Leu Trp  
185 190 195  
Asp Leu Arg Thr Ala Lys Glu Val Gln Thr Ile Glu Val Tyr Lys  
200 205 210  
His Glu Glu Cys Ser Arg Pro His Asn Gly Arg Trp Ile Gly Cys  
215 220 225  
Leu Ala Thr Asp Ser Asp Trp Met Val Cys Gly Gly Pro Ala  
230 235 240  
Leu Thr Leu Trp His Leu Arg Ser Ser Thr Pro Thr Thr Ile Phe  
245 250 255  
Pro Ile Arg Ala Pro Gln Lys His Val Thr Phe Tyr Gln Asp Leu  
260 265 270  
Ile Leu Ser Ala Gly Gln Gly Arg Cys Val Asn Gln Trp Gln Leu  
275 280 285  
Ser Gly Glu Leu Lys Ala Gln Val Pro Gly Ser Ser Pro Gly Leu  
290 295 300  
Leu Ser Leu Ser Leu Asn Gln Gln Pro Ala Ala Pro Glu Cys Lys  
305 310 315  
Val Leu Thr Ala Ala Gly Asn Ser Cys Arg Val Asp Val Phe Thr  
320 325 330  
Asn Leu Gly Tyr Arg Ala Phe Ser Leu Ser Phe  
335 340

<210> 10

<211> 513

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 067184CD1

<400> 10

Met Ser Ile Glu Ile Glu Ser Ser Asp Val Ile Arg Leu Ile Met  
 1 5 10 15  
 Gln Tyr Leu Lys Glu Asn Ser Leu His Arg Ala Leu Ala Thr Leu  
 20 25 30  
 Gln Glu Glu Thr Thr Val Ser Leu Asn Thr Val Asp Ser Ile Glu  
 35 40 45  
 Ser Phe Val Ala Asp Ile Asn Ser Gly His Trp Asp Thr Val Leu  
 50 55 60  
 Gln Ala Ile Gln Ser Leu Lys Leu Pro Asp Lys Thr Leu Ile Asp  
 65 70 75  
 Leu Tyr Glu Gln Val Val Leu Glu Leu Ile Glu Leu Arg Glu Leu  
 80 85 90  
 Gly Ala Ala Arg Ser Leu Leu Arg Gln Thr Asp Pro Met Ile Met  
 95 100 105  
 Leu Lys Gln Thr Gln Pro Glu Arg Tyr Ile His Leu Glu Asn Leu  
 110 115 120  
 Leu Ala Arg Ser Tyr Phe Asp Pro Arg Glu Ala Tyr Pro Asp Gly  
 125 130 135  
 Ser Ser Lys Glu Lys Arg Arg Ala Ala Ile Ala Gln Ala Leu Ala  
 140 145 150  
 Gly Glu Val Ser Val Val Pro Pro Ser Arg Leu Met Ala Leu Leu  
 155 160 165  
 Gly Gln Ala Leu Lys Trp Gln Gln His Gln Gly Leu Leu Pro Pro  
 170 175 180  
 Gly Met Thr Ile Asp Leu Phe Arg Gly Lys Ala Ala Val Lys Asp  
 185 190 195  
 Val Glu Glu Glu Lys Phe Pro Thr Gln Leu Ser Arg His Ile Lys  
 200 205 210  
 Phe Gly Gln Lys Ser His Val Glu Cys Ala Arg Phe Ser Pro Asp  
 215 220 225  
 Gly Gln Tyr Leu Val Thr Gly Ser Val Asp Gly Phe Ile Glu Val  
 230 235 240  
 Trp Asn Phe Thr Thr Gly Lys Ile Arg Lys Asp Leu Lys Tyr Gln  
 245 250 255  
 Ala Gln Asp Asn Phe Met Met Met Asp Asp Ala Val Leu Cys Met  
 260 265 270  
 Cys Phe Ser Arg Asp Thr Glu Met Leu Ala Thr Gly Ala Gln Asp  
 275 280 285  
 Gly Lys Ile Lys Val Trp Lys Ile Gln Ser Gly Gln Cys Leu Arg  
 290 295 300  
 Arg Phe Glu Arg Ala His Ser Lys Gly Val Thr Cys Leu Ser Phe  
 305 310 315  
 Ser Lys Asp Ser Ser Gln Ile Leu Ser Ala Ser Phe Asp Gln Thr  
 320 325 330  
 Ile Arg Ile His Gly Leu Lys Ser Gly Lys Thr Leu Lys Glu Phe  
 335 340 345  
 Arg Gly His Ser Ser Phe Val Asn Glu Ala Thr Phe Thr Gln Asp  
 350 355 360  
 Gly His Tyr Ile Ile Ser Ala Ser Ser Asp Gly Thr Val Lys Ile  
 365 370 375  
 Trp Asn Met Lys Thr Thr Glu Cys Ser Asn Thr Phe Lys Ser Leu  
 380 385 390  
 Gly Ser Thr Ala Gly Thr Asp Ile Thr Val Asn Ser Val Ile Leu  
 395 400 405  
 Leu Pro Lys Asn Pro Glu His Phe Val Val Cys Asn Arg Ser Asn  
 410 415 420  
 Thr Val Val Ile Met Asn Met Gln Gly Gln Ile Val Arg Ser Phe  
 425 430 435  
 Ser Ser Gly Lys Arg Glu Gly Gly Asp Phe Val Cys Cys Ala Leu  
 440 445 450  
 Ser Pro Arg Gly Glu Trp Ile Tyr Cys Val Gly Glu Asp Phe Val  
 455 460 465  
 Leu Tyr Cys Phe Ser Thr Val Thr Gly Lys Leu Glu Arg Thr Leu

470	475	480
Thr Val His Glu Lys Asp Val Ile Gly Ile Ala His His Pro His		
485	490	495
Gln Asn Leu Ile Ala Thr Tyr Ser Glu Asp Gly Leu Leu Lys Leu		
500	505	510

Trp Lys Pro

<210> 11  
<211> 186  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 722896CD1

<400> 11

Met Ile Ala Leu Phe Asn Lys Leu Leu Asp Trp Phe Lys Ala Leu			
1	5	10	15
Phe Trp Lys Glu Glu Met Glu Leu Thr Leu Val Gly Leu Gln Tyr			
20	25	30	
Ser Gly Lys Thr Thr Phe Val Asn Val Ile Ala Ser Gly Gln Phe			
35	40	45	
Asn Glu Asp Met Ile Pro Thr Val Gly Phe Asn Met Arg Lys Ile			
50	55	60	
Thr Lys Gly Asn Val Thr Ile Lys Leu Trp Asp Ile Gly Gly Gln			
65	70	75	
Pro Arg Phe Arg Ser Met Trp Glu Arg Tyr Cys Arg Gly Val Ser			
80	85	90	
Ala Ile Val Tyr Met Val Asp Ala Ala Asp Gln Glu Lys Ile Glu			
95	100	105	
Ala Ser Lys Asn Glu Leu His Asn Leu Leu Asp Lys Pro Gln Leu			
110	115	120	
Gln Gly Ile Pro Val Leu Val Leu Gly Asn Lys Arg Asp Leu Pro			
125	130	135	
Gly Ala Leu Asp Glu Lys Glu Leu Ile Glu Lys Met Asn Leu Ser			
140	145	150	
Ala Ile Gln Asp Arg Glu Ile Cys Cys Tyr Ser Ile Ser Cys Lys			
155	160	165	
Glu Lys Asp Asn Ile Asp Ile Thr Leu Gln Trp Leu Ile Gln His			
170	175	180	
Ser Lys Ser Arg Arg Ser			
185			

<210> 12  
<211> 204  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1571739CD1

<400> 12

Met Asn Asp Val Lys Leu Ala Val Leu Gly Gly Glu Gly Thr Gly			
1	5	10	15
Lys Ser Ala Leu Thr Val Arg Phe Leu Thr Lys Arg Phe Ile Gly			
20	25	30	
Glu Tyr Ala Ser Asn Phe Glu Ser Ile Tyr Lys Lys His Leu Cys			
35	40	45	
Leu Glu Arg Lys Gln Leu Asn Leu Glu Ile Tyr Asp Pro Cys Ser			
50	55	60	
Gln Thr Gln Lys Ala Lys Phe Ser Leu Thr Ser Glu Leu His Trp			
65	70	75	

Ala Asp Gly Phe Val Ile Val Tyr Asp Ile Ser Asp Arg Ser Ser  
                   80                  85                  90  
 Phe Ala Phe Ala Lys Ala Leu Ile Tyr Arg Ile Arg Glu Pro Gln  
                   95                  100                  105  
 Thr Ser His Cys Lys Arg Ala Val Glu Ser Ala Val Phe Leu Val  
                   110                  115                  120  
 Gly Asn Lys Arg Asp Leu Cys His Val Arg Glu Val Gly Trp Glu  
                   125                  130                  135  
 Glu Gly Gln Lys Leu Ala Leu Glu Asn Arg Cys Gln Phe Cys Glu  
                   140                  145                  150  
 Leu Ser Ala Ala Glu Gln Ser Leu Glu Val Glu Met Met Phe Ile  
                   155                  160                  165  
 Arg Ile Ile Lys Asp Ile Leu Ile Asn Phe Lys Leu Lys Glu Lys  
                   170                  175                  180  
 Arg Arg Pro Ser Gly Ser Lys Ser Met Ala Lys Leu Ile Asn Asn  
                   185                  190                  195  
 Val Phe Gly Lys Arg Arg Lys Ser Val  
                   200

<210> 13  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1739479CD1

<400> 13

Met	Trp	Asp	Ser	Lys	Lys	Ile	Gly	Leu	Arg	Gln	His	His	Cys	Arg
1				5				10					15	
Lys	Cys	Gly	Lys	Ala	Val	Cys	Gly	Lys	Cys	Ser	Ser	Lys	Arg	Ser
				20				25					30	
Ser	Ile	Pro	Leu	Met	Gly	Phe	Glu	Phe	Glu	Val	Arg	Val	Cys	Asp
				35				40					45	
Ser	Cys	His	Glu	Ala	Ile	Thr	Asp	Glu	Glu	Arg	Ala	Pro	Thr	Ala
				50				55					60	
Thr	Phe	His	Asp	Ser	Lys	His	Asn	Ile	Val	His	Val	His	Phe	Asp
	65				70				75					
Ala	Thr	Arg	Gly	Trp	Leu	Leu	Thr	Ser	Gly	Thr	Asp	Lys	Val	Ile
				80				85					90	
Lys	Leu	Trp	Asp	Met	Thr	Pro	Val	Val	Ser					
				95				100						

<210> 14  
 <211> 795  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1999147CD1

<400> 14

Met	Thr	Ser	Gly	Ala	Thr	Arg	Tyr	Arg	Leu	Ser	Cys	Ser	Leu	Arg
1				5					10					15
Gly	His	Glu	Leu	Asp	Val	Arg	Gly	Leu	Val	Cys	Cys	Ala	Tyr	Pro
				20				25					30	
Pro	Gly	Ala	Phe	Val	Ser	Val	Ser	Arg	Asp	Arg	Thr	Thr	Arg	Leu
				35				40					45	
Trp	Ala	Pro	Asp	Ser	Pro	Asn	Arg	Ser	Phe	Thr	Glu	Met	His	Cys
				50				55					60	
Met	Ser	Gly	His	Ser	Asn	Phe	Val	Ser	Cys	Val	Cys	Ile	Ile	Pro
				65				70					75	
Ser	Ser	Asp	Ile	Tyr	Pro	His	Gly	Leu	Ile	Ala	Thr	Gly	Gly	Asn

	80	85	90
Asp His Asn Ile Cys	Ile Phe Ser Leu Asp	Ser Pro Met Pro	Leu
95	100	105	
Tyr Ile Leu Lys Gly	His Lys Asn Thr Val	Cys Ser Leu Ser	Ser
110	115	120	
Gly Lys Phe Gly	Thr Leu Leu Ser Gly	Ser Trp Asp Thr Thr	Ala
125	130	135	
Lys Val Trp Leu Asn	Asp Lys Cys Met	Met Thr Leu Gln Gly	His
140	145	150	
Thr Ala Ala Val Trp	Ala Val Lys Ile Leu	Pro Glu Gln Gly	Leu
155	160	165	
Met Leu Thr Gly Ser	Ala Asp Lys Thr Val	Lys Leu Trp Lys	Ala
170	175	180	
Gly Arg Cys Glu Arg	Thr Phe Ser Gly His	Glu Asp Cys Val	Arg
185	190	195	
Gly Leu Ala Ile Leu	Ser Glu Thr Glu Phe	Leu Ser Cys Ala	Asn
200	205	210	
Asp Ala Ser Ile Arg	Arg Trp Gln Ile Thr	Gly Glu Cys Leu	Glu
215	220	225	
Val Tyr Tyr Gly His	Thr Asn Tyr Ile Tyr	Ser Ile Ser Val	Phe
230	235	240	
Pro Asn Cys Arg Asp	Phe Val Thr Thr Ala	Glu Asp Arg Ser	Leu
245	250	255	
Arg Ile Trp Lys His	Gly Glu Cys Ala Gln	Thr Ile Arg Leu	Pro
260	265	270	
Ala Gln Ser Ile Trp	Cys Cys Val Leu	Asp Asn Gly Asp	Ile
275	280	285	
Val Val Gly Ala Ser	Asp Gly Ile Ile Arg	Val Phe Thr Glu	Ser
290	295	300	
Glu Asp Arg Thr Ala	Ser Ala Glu Glu Ile	Lys Ala Phe Glu	Lys
305	310	315	
Glu Leu Ser His Ala	Thr Ile Asp Ser Lys	Thr Gly Asp Leu	Gly
320	325	330	
Asp Ile Asn Ala Glu	Gln Leu Pro Gly Arg	Glu His Leu Asn	Glu
335	340	345	
Pro Gly Thr Arg Glu	Gly Gln Thr Arg Leu	Ile Arg Asp Gly	Glu
350	355	360	
Lys Val Glu Ala Tyr	Gln Trp Ser Val	Ser Glu Gly Arg Trp	Ile
365	370	375	
Lys Ile Gly Asp Val	Val Gly Ser Ser Gly	Ala Asn Gln Gln	Thr
380	385	390	
Ser Gly Lys Val Leu	Tyr Glu Gly Lys Glu	Phe Asp Tyr Val	Phe
395	400	405	
Ser Ile Asp Val Asn	Glu Gly Pro Ser	Tyr Lys Leu Pro	Tyr
410	415	420	
Asn Thr Ser Asp Asp	Pro Trp Leu Thr Ala	Tyr Asn Phe Leu	Gln
425	430	435	
Lys Asn Asp Leu Asn	Pro Met Phe Leu Asp	Gln Val Ala Lys	Phe
440	445	450	
Ile Ile Asp Asn Thr	Lys Gly Gln Met	Leu Gly Leu Gly	Asn Pro
455	460	465	
Ser Phe Ser Asp Pro	Phe Thr Gly Gly	Gly Arg Tyr Val Pro	Gly
470	475	480	
Ser Ser Gly Ser Ser	Asn Thr Leu Pro	Thr Ala Asp Pro Phe	Thr
485	490	495	
Gly Ala Gly Arg Tyr	Val Pro Gly Ser Ala	Ser Met Gly Thr	Thr
500	505	510	
Met Ala Gly Val Asp	Pro Phe Thr Gly Asn	Ser Ala Tyr Arg	Ser
515	520	525	
Ala Ala Ser Lys Thr	Met Asn Ile Tyr Phe	Pro Lys Lys Glu	Ala
530	535	540	
Val Thr Phe Asp Gln	Ala Asn Pro Thr Gln	Ile Leu Gly Lys	Leu
545	550	555	

Lys Glu Leu Asn Gly Thr Ala Pro Glu Glu Lys Lys Leu Thr Glu  
     560                         565                         570  
 Asp Asp Leu Ile Leu Leu Glu Lys Ile Leu Ser Leu Ile Cys Asn  
     575                         580                         585  
 Ser Ser Ser Glu Lys Pro Thr Val Gln Gln Leu Gln Ile Leu Trp  
     590                         595                         600  
 Lys Ala Ile Asn Cys Pro Glu Asp Ile Val Phe Pro Ala Leu Asp  
     605                         610                         615  
 Ile Leu Arg Leu Ser Ile Lys His Pro Ser Val Asn Glu Asn Phe  
     620                         625                         630  
 Cys Asn Glu Lys Glu Gly Ala Gln Phe Ser Ser His Leu Ile Asn  
     635                         640                         645  
 Leu Leu Asn Pro Lys Gly Lys Pro Ala Asn Gln Leu Leu Ala Leu  
     650                         655                         660  
 Arg Thr Phe Cys Asn Cys Phe Val Gly Gln Ala Gly Gln Lys Leu  
     665                         670                         675  
 Met Met Ser Gln Arg Glu Ser Leu Met Ser His Ala Ile Glu Leu  
     680                         685                         690  
 Lys Ser Gly Ser Asn Lys Asn Ile His Ile Ala Leu Ala Thr Leu  
     695                         700                         705  
 Ala Leu Asn Tyr Ser Val Cys Phe His Lys Asp His Asn Ile Glu  
     710                         715                         720  
 Gly Lys Ala Gln Cys Leu Ser Leu Ile Ser Thr Ile Leu Glu Val  
     725                         730                         735  
 Val Gln Asp Leu Glu Ala Thr Phe Arg Leu Leu Val Ala Leu Gly  
     740                         745                         750  
 Thr Leu Ile Ser Asp Asp Ser Asn Ala Val Gln Leu Ala Lys Ser  
     755                         760                         765  
 Leu Gly Val Asp Ser Gln Ile Lys Lys Tyr Ser Ser Val Ser Glu  
     770                         775                         780  
 Pro Ala Lys Val Ser Glu Cys Cys Arg Phe Ile Leu Asn Leu Leu  
     785                         790                         795

<210> 15  
 <211> 393  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2182085CD1

<400> 15  
 Met Glu Asp Phe Glu Asp Asp Pro Arg Ala Leu Gly Ala Arg Gly  
     1                 5                         10                 15  
 His Arg Arg Ser Val Ser Arg Gly Ser Tyr Gln Leu Gln Ala Gln  
     20                         25                         30  
 Met Asn Arg Ala Val Tyr Glu Asp Arg Pro Pro Gly Ser Val Val  
     35                         40                         45  
 Pro Thr Ser Ala Ala Glu Ala Ser Arg Ala Met Ala Gly Asp Thr  
     50                         55                         60  
 Ser Leu Ser Glu Asn Tyr Ala Phe Ala Gly Met Tyr His Val Phe  
     65                         70                         75  
 Asp Gln His Val Asp Glu Ala Val Pro Arg Val Arg Phe Ala Asn  
     80                         85                         90  
 Asp Asp Arg His Arg Leu Ala Cys Cys Ser Leu Asp Gly Ser Ile  
     95                         100                         105  
 Ser Leu Cys Gln Leu Val Pro Ala Pro Pro Thr Val Leu Arg Val  
     110                         115                         120  
 Leu Arg Gly His Thr Arg Gly Val Ser Asp Phe Ala Trp Ser Leu  
     125                         130                         135  
 Ser Asn Asp Ile Leu Val Ser Thr Ser Leu Asp Ala Thr Met Arg  
     140                         145                         150

Ile Trp Ala Ser Glu Asp Gly Arg Cys Ile Arg Glu Ile Pro Asp  
                  155                         160                         165  
 Pro Asp Ser Ala Glu Leu Leu Cys Cys Thr Phe Gln Pro Val Asn  
                  170                         175                         180  
 Asn Asn Leu Thr Val Val Gly Asn Ala Lys His Asn Val His Val  
                  185                         190                         195  
 Met Asn Ile Ser Thr Gly Lys Lys Val Lys Gly Gly Ser Ser Lys  
                  200                         205                         210  
 Leu Thr Gly Arg Val Leu Ala Leu Ser Phe Asp Ala Pro Gly Arg  
                  215                         220                         225  
 Leu Leu Trp Ala Gly Asp Asp Arg Gly Ser Val Phe Ser Phe Leu  
                  230                         235                         240  
 Phe Asp Met Ala Thr Gly Lys Leu Thr Lys Ala Lys Arg Leu Val  
                  245                         250                         255  
 Val His Glu Gly Ser Pro Val Thr Ser Ile Ser Ala Arg Ser Trp  
                  260                         265                         270  
 Val Ser Arg Glu Ala Arg Asp Pro Ser Leu Leu Ile Asn Ala Cys  
                  275                         280                         285  
 Leu Asn Lys Leu Leu Tyr Arg Val Val Asp Asn Glu Gly Thr  
                  290                         295                         300  
 Leu Gln Leu Lys Arg Ser Phe Pro Ile Glu Gln Ser Ser His Pro  
                  305                         310                         315  
 Val Arg Ser Ile Phe Cys Pro Leu Met Ser Phe Arg Gln Gly Ala  
                  320                         325                         330  
 Cys Val Val Thr Gly Ser Glu Asp Met Cys Val His Phe Phe Asp  
                  335                         340                         345  
 Val Glu Arg Ala Ala Lys Ala Ala Val Asn Lys Leu Gln Gly His  
                  350                         355                         360  
 Ser Ala Pro Val Leu Asp Val Ser Phe Asn Cys Asp Glu Ser Leu  
                  365                         370                         375  
 Leu Ala Ser Ser Asp Ala Ser Gly Met Val Ile Val Trp Arg Arg  
                  380                         385                         390  
 Glu Gln Lys

<210> 16  
<211> 485  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2216640CD1

<400> 16  
 Met Ala Ala Ala Val Ala Asp Glu Ala Val Ala Arg Asp Val Gln  
     1                 5                         10                         15  
 Arg Leu Leu Val Gln Phe Gln Asp Glu Gly Gly Gln Leu Leu Gly  
     20                         25                         30  
 Ser Pro Phe Asp Val Pro Val Asp Ile Thr Pro Asp Arg Leu Gln  
     35                         40                         45  
 Leu Val Cys Asn Ala Leu Leu Ala Gln Glu Asp Pro Leu Pro Leu  
     50                         55                         60  
 Ala Phe Phe Val His Asp Ala Glu Ile Val Ser Ser Leu Gly Lys  
     65                         70                         75  
 Thr Leu Glu Ser Gln Ala Val Glu Thr Glu Lys Val Leu Asp Ile  
     80                         85                         90  
 Ile Tyr Gln Pro Gln Ala Ile Phe Arg Val Arg Ala Val Thr Arg  
     95                         100                         105  
 Cys Thr Ser Ser Leu Glu Gly His Ser Glu Ala Val Ile Ser Val  
   110                         115                         120  
 Ala Phe Ser Pro Thr Gly Lys Tyr Leu Ala Ser Gly Ser Gly Asp  
   125                         130                         135  
 Thr Thr Val Arg Phe Trp Asp Leu Ser Thr Glu Thr Pro His Phe

	140	145	150
Thr Cys Lys Gly His Arg His Trp Val Leu Ser Ile Ser Trp Ser	155	160	165
Pro Asp Gly Lys Lys Leu Ala Ser Gly Cys Lys Asn Gly Gln Ile	170	175	180
Leu Leu Trp Asp Pro Ser Thr Gly Lys Gln Val Gly Arg Thr Leu	185	190	195
Ala Gly His Ser Lys Trp Ile Thr Gly Leu Ser Trp Glu Pro Leu	200	205	210
His Ala Asn Pro Glu Cys Arg Tyr Val Ala Ser Ser Ser Lys Asp	215	220	225
Gly Ser Val Arg Ile Trp Asp Thr Thr Ala Gly Arg Cys Glu Arg	230	235	240
Ile Leu Thr Gly His Thr Gln Ser Val Thr Cys Leu Arg Trp Gly	245	250	255
Gly Asp Gly Leu Leu Tyr Ser Ala Ser Gln Asp Arg Thr Ile Lys	260	265	270
Val Trp Arg Ala His Asp Gly Val Leu Cys Arg Thr Leu Gln Gly	275	280	285
His Gly His Trp Val Asn Thr Met Ala Leu Ser Thr Asp Tyr Ala	290	295	300
Leu Arg Thr Gly Ala Phe Glu Pro Ala Glu Ala Ser Val Asn Pro	305	310	315
Gln Asp Leu Gln Gly Ser Leu Gln Glu Leu Lys Glu Arg Ala Leu	320	325	330
Ser Arg Tyr Asn Leu Val Arg Gly Gln Gly Pro Glu Arg Leu Val	335	340	345
Ser Gly Ser Asp Asp Phe Thr Leu Phe Leu Trp Ser Pro Ala Glu	350	355	360
Asp Lys Lys Pro Leu Thr Arg Met Thr Gly His Gln Ala Leu Ile	365	370	375
Asn Gln Val Leu Phe Ser Pro Asp Ser Arg Ile Val Ala Ser Ala	380	385	390
Ser Phe Asp Lys Ser Ile Lys Leu Trp Asp Gly Arg Thr Gly Lys	395	400	405
Tyr Leu Ala Ser Leu Arg Gly His Val Ala Ala Val Tyr Gln Ile	410	415	420
Ala Trp Ser Ala Asp Ser Arg Leu Leu Val Ser Gly Ser Ser Asp	425	430	435
Ser Thr Leu Lys Val Trp Asp Val Lys Ala Gln Lys Leu Ala Met	440	445	450
Asp Leu Pro Gly His Ala Asp Glu Val Tyr Ala Val Asp Trp Ser	455	460	465
Pro Asp Gly Gln Arg Val Ala Ser Gly Gly Lys Asp Lys Cys Leu	470	475	480
Arg Ile Trp Arg Arg	485		

&lt;210&gt; 17

&lt;211&gt; 199

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2417361CD1

&lt;400&gt; 17

Met Asn Pro Arg Lys Lys Val Asp Leu Lys Leu Ile Ile Val Gly	1	5	10	15
Ala Ile Gly Val Gly Lys Thr Ser Leu Leu His Gln Tyr Val His	20	25	30	
Lys Thr Phe Tyr Glu Glu Tyr Gln Thr Thr Leu Gly Ala Ser Ile	35	40	45	

Leu Ser Lys Ile Ile Leu Gly Asp Thr Thr Leu Lys Leu Gln  
       50                   55                   60  
 Ile Trp Asp Thr Gly Gly Gln Glu Arg Phe Arg Ser Met Val Ser  
       65                   70                   75  
 Thr Phe Tyr Lys Gly Ser Asp Gly Cys Ile Leu Ala Phe Asp Val  
       80                   85                   90  
 Thr Asp Leu Glu Ser Phe Glu Ala Leu Asp Ile Trp Arg Gly Asp  
       95                   100                  105  
 Val Leu Ala Lys Ile Val Pro Met Glu Gln Ser Tyr Pro Met Val  
       110                  115                  120  
 Leu Leu Gly Asn Lys Ile Asp Leu Ala Asp Arg Lys Val Pro Gln  
       125                  130                  135  
 Glu Val Ala Gln Gly Trp Cys Arg Glu Lys Asp Ile Pro Tyr Phe  
       140                  145                  150  
 Glu Val Ser Ala Lys Asn Asp Ile Asn Val Val Gln Ala Phe Glu  
       155                  160                  165  
 Met Leu Ala Ser Arg Ala Leu Ser Arg Tyr Gln Ser Ile Leu Glu  
       170                  175                  180  
 Asn His Leu Thr Glu Ser Ile Lys Leu Ser Pro Asp Gln Ser Arg  
       185                  190                  195  
 Ser Arg Cys Cys

<210> 18  
 <211> 163  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2454384CD1

<400> 18  
 Met Glu Gly Pro Ser Leu Arg Gly Pro Ala Leu Arg Leu Ala Gly  
   1            5            10            15  
 Leu Pro Thr Gln Gln Asp Cys Asn Ile Gln Glu Lys Ile Asp Leu  
   20            25            30  
 Glu Ile Arg Met Arg Glu Gly Ile Trp Lys Leu Leu Ser Leu Ser  
   35            40            45  
 Thr Gln Lys Asp Gln Val Leu His Ala Val Lys Asn Leu Met Val  
   50            55            60  
 Cys Asn Ala Arg Leu Met Ala Tyr Thr Ser Glu Leu Gln Lys Leu  
   65            70            75  
 Glu Glu Gln Ile Ala Asn Gln Thr Gly Arg Cys Asp Val Lys Phe  
   80            85            90  
 Glu Ser Lys Glu Arg Thr Ala Cys Lys Gly Lys Ile Ala Ile Ser  
   95            100          105  
 Asp Ile Arg Ile Pro Leu Met Trp Lys Asp Ser Asp His Phe Ser  
   110           115          120  
 Asn Lys Glu Arg Ser Arg Arg Tyr Ala Ile Phe Cys Leu Phe Lys  
   125           130          135  
 Met Gly Ala Asn Val Phe Asp Thr Asp Val Val Asn Val Asp Lys  
   140           145          150  
 Thr Ile Thr Asp Ile Cys Phe Glu Asn Val Thr Ile Leu  
   155           160

<210> 19  
 <211> 290  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2610262CD1

<400> 19  
 Met Ala Ala Glu Ile Gln Pro Lys Pro Leu Thr Arg Lys Pro Ile  
   1               5               10               15  
 Leu Leu Gln Arg Met Glu Gly Ser Gln Glu Val Val Asn Met Ala  
   20               25               30  
 Val Ile Val Pro Lys Glu Glu Gly Val Ile Ser Val Ser Glu Asp  
   35               40               45  
 Arg Thr Val Arg Val Trp Leu Lys Arg Asp Ser Gly Gln Tyr Trp  
   50               55               60  
 Pro Ser Val Tyr His Ala Met Pro Ser Pro Cys Ser Cys Met Ser  
   65               70               75  
 Phe Asn Pro Glu Thr Arg Arg Leu Ser Ile Gly Leu Asp Asn Gly  
   80               85               90  
 Thr Ile Ser Glu Phe Ile Leu Ser Glu Asp Tyr Asn Lys Met Thr  
   95               100              105  
 Pro Val Lys Asn Tyr Gln Ala His Gln Ser Arg Val Thr Met Ile  
 110               115              120  
 Leu Phe Val Leu Glu Leu Glu Trp Val Leu Ser Thr Gly Gln Asp  
 125               130              135  
 Lys Gln Phe Ala Trp His Cys Ser Glu Ser Gly Gln Arg Leu Gly  
 140               145              150  
 Gly Tyr Arg Thr Ser Ala Val Ala Ser Gly Leu Gln Phe Asp Val  
 155               160              165  
 Glu Thr Arg His Val Phe Ile Gly Asp His Ser Gly Gln Val Thr  
 170               175              180  
 Ile Leu Lys Leu Glu Gln Glu Asn Cys Thr Leu Val Thr Thr Phe  
 185               190              195  
 Arg Gly His Thr Gly Gly Val Thr Ala Leu Cys Trp Asp Pro Val  
 200               205              210  
 Gln Arg Val Leu Phe Ser Gly Ser Ser Asp His Ser Val Ile Met  
 215               220              225  
 Trp Asp Ile Gly Gly Arg Lys Gly Thr Ala Ile Glu Leu Gln Gly  
 230               235              240  
 His Asn Asp Arg Val Gln Ala Leu Ser Tyr Ala Gln His Thr Arg  
 245               250              255  
 Gln Leu Ile Ser Cys Gly Gly Asp Gly Gly Ile Val Val Trp Asn  
 260               265              270  
 Met Asp Val Glu Arg Gln Glu Pro Leu Trp Ser Cys Phe Val Val  
 275               280              285  
 Met Ile Ser Ala Val  
 290

<210> 20  
<211> 705  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2700075CD1

<400> 20  
 Met Gly Thr Trp Glu His Leu Val Ser Thr Gly Phe Asn Gln Met  
   1               5               10               15  
 Arg Glu Arg Glu Val Lys Leu Trp Asp Thr Arg Phe Phe Ser Ser  
   20               25               30  
 Ala Leu Ala Ser Leu Thr Leu Asp Thr Ser Leu Gly Cys Leu Val  
   35               40               45  
 Pro Leu Leu Asp Pro Asp Ser Gly Leu Leu Val Leu Ala Gly Lys  
   50               55               60  
 Gly Glu Arg Gln Leu Tyr Cys Tyr Glu Val Val Pro Gln Gln Pro  
   65               70               75  
 Ala Leu Ser Pro Val Thr Gln Cys Val Leu Glu Ser Val Leu Arg  
   80               85               90

Gly	Ala	Ala	Leu	Val	Pro	Arg	Gln	Ala	Leu	Ala	Val	Met	Ser	Cys
				95					100					105
Glu	Val	Leu	Arg	Val	Leu	Gln	Leu	Ser	Asp	Thr	Ala	Ile	Val	Pro
				110					115					120
Ile	Gly	Tyr	His	Val	Pro	Arg	Lys	Ala	Val	Glu	Phe	His	Glu	Asp
				125					130					135
Leu	Phe	Pro	Asp	Thr	Ala	Gly	Cys	Val	Pro	Ala	Thr	Asp	Pro	His
				140					145					150
Ser	Trp	Trp	Ala	Gly	Asp	Asn	Gln	Gln	Val	Gln	Lys	Val	Ser	Leu
				155					160					165
Asn	Pro	Ala	Cys	Arg	Pro	His	Pro	Ser	Phe	Thr	Ser	Cys	Leu	Val
				170					175					180
Pro	Pro	Ala	Glu	Pro	Leu	Pro	Asp	Thr	Ala	Gln	Pro	Ala	Val	Met
				185					190					195
Glu	Thr	Pro	Val	Gly	Asp	Ala	Asp	Ala	Ser	Glu	Gly	Phe	Ser	Ser
				200					205					210
Pro	Pro	Ser	Ser	Leu	Thr	Ser	Pro	Ser	Thr	Pro	Ser	Ser	Leu	Gly
				215					220					225
Pro	Ser	Leu	Ser	Ser	Thr	Ser	Gly	Ile	Gly	Thr	Ser	Pro	Ser	Leu
				230					235					240
Arg	Ser	Leu	Gln	Ser	Leu	Leu	Gly	Pro	Ser	Ser	Lys	Phe	Arg	His
				245					250					255
Ala	Gln	Gly	Thr	Val	Leu	His	Arg	Asp	Ser	His	Ile	Thr	Asn	Leu
				260					265					270
Lys	Gly	Leu	Asn	Leu	Thr	Thr	Pro	Gly	Glu	Ser	Asp	Gly	Phe	Cys
				275					280					285
Ala	Asn	Lys	Leu	Arg	Val	Ala	Val	Pro	Leu	Leu	Ser	Ser	Gly	Gly
				290					295					300
Gln	Val	Ala	Val	Leu	Glu	Leu	Arg	Lys	Pro	Gly	Arg	Leu	Pro	Asp
				305					310					315
Thr	Ala	Leu	Pro	Thr	Leu	Gln	Asn	Gly	Ala	Ala	Val	Thr	Asp	Leu
				320					325					330
Ala	Trp	Asp	Pro	Phe	Asp	Pro	His	Arg	Leu	Ala	Val	Ala	Gly	Glu
				335					340					345
Asp	Ala	Arg	Ile	Arg	Leu	Trp	Arg	Val	Pro	Ala	Glu	Gly	Leu	Glu
				350					355					360
Glu	Val	Leu	Thr	Thr	Pro	Glu	Thr	Val	Leu	Thr	Gly	His	Thr	Glu
				365					370					375
Lys	Ile	Cys	Ser	Leu	Arg	Phe	His	Pro	Leu	Ala	Ala	Asn	Val	Leu
				380					385					390
Ala	Ser	Ser	Ser	Tyr	Asp	Leu	Thr	Val	Arg	Ile	Trp	Asp	Leu	Gln
				395					400					405
Ala	Gly	Ala	Asp	Arg	Leu	Lys	Leu	Gln	Gly	His	Gln	Asp	Gln	Ile
				410					415					420
Phe	Ser	Leu	Ala	Trp	Ser	Pro	Asp	Gly	Gln	Gln	Leu	Ala	Thr	Val
				425					430					435
Cys	Lys	Asp	Gly	Arg	Val	Arg	Val	Tyr	Arg	Pro	Arg	Ser	Gly	Pro
				440					445					450
Glu	Pro	Leu	Gln	Glu	Gly	Pro	Gly	Pro	Lys	Gly	Gly	Arg	Gly	Ala
				455					460					465
Arg	Ile	Val	Trp	Val	Cys	Asp	Gly	Arg	Cys	Leu	Leu	Val	Ser	Gly
				470					475					480
Phe	Asp	Ser	Gln	Ser	Glu	Arg	Gln	Leu	Leu	Leu	Tyr	Glu	Ala	Glu
				485					490					495
Ala	Leu	Ala	Gly	Gly	Pro	Leu	Ala	Val	Leu	Gly	Leu	Asp	Val	Ala
				500					505					510
Pro	Ser	Thr	Leu	Leu	Pro	Ser	Tyr	Asp	Pro	Asp	Thr	Gly	Leu	Val
				515					520					525
Leu	Leu	Thr	Gly	Lys	Gly	Asp	Thr	Arg	Val	Phe	Leu	Tyr	Glu	Leu
				530					535					540
Leu	Pro	Glu	Ser	Pro	Phe	Phe	Leu	Glu	Cys	Asn	Ser	Phe	Thr	Ser
				545					550					555
Pro	Asp	Pro	His	Lys	Gly	Leu	Val	Leu	Leu	Pro	Lys	Thr	Glu	Cys

560	565	570
Asp Val Arg Glu Val Glu Leu Met Arg Cys	Leu Arg Leu Arg Gln	
575	580	585
Ser Ser Leu Glu Pro Val Ala Phe Arg Leu	Pro Arg Val Arg Lys	
590	595	600
Glu Phe Phe Gln Asp Asp Val Phe Pro Asp	Thr Ala Val Ile Trp	
605	610	615
Glu Pro Val Leu Ser Ala Glu Ala Trp Leu	Gln Gly Ala Asn Gly	
620	625	630
Gln Pro Trp Leu Leu Ser Leu Gln Pro Pro	Asp Met Ser Pro Val	
635	640	645
Ser Gln Ala Pro Arg Glu Ala Pro Ala Arg	Arg Ala Pro Ser Ser	
650	655	660
Ala Gln Tyr Leu Glu Glu Lys Ser Asp Gln	Gln Lys Lys Glu Glu	
665	670	675
Leu Leu Asn Ala Met Val Ala Lys Leu Gly	Asn Arg Glu Asp Pro	
680	685	690
Leu Pro Gln Asp Ser Phe Glu Gly Val Asp	Glu Asp Glu Trp Asp	
695	700	705

<210> 21  
<211> 454  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2786701CD1

<400> 21  
Met Ala Ser Ser Glu Val Ala Arg His Leu Leu Phe Gln Ser His  
1 5 10 15  
Met Ala Thr Lys Thr Thr Cys Met Ser Ser Gln Gly Ser Asp Asp  
20 25 30  
Glu Gln Ile Lys Arg Glu Asn Ile Arg Ser Leu Thr Met Ser Gly  
35 40 45  
His Val Gly Phe Glu Ser Leu Pro Asp Gln Leu Val Asn Arg Ser  
50 55 60  
Ile Gln Gln Gly Phe Cys Phe Asn Ile Leu Cys Val Gly Glu Thr  
65 70 75  
Gly Ile Gly Lys Ser Thr Leu Ile Asp Thr Leu Phe Asn Thr Asn  
80 85 90  
Phe Glu Asp Tyr Glu Ser Ser His Phe Cys Pro Asn Val Lys Leu  
95 100 105  
Lys Ala Gln Thr Tyr Glu Leu Gln Glu Ser Asn Val Gln Leu Lys  
110 115 120  
Leu Thr Ile Val Asn Thr Val Gly Phe Gly Asp Gln Ile Asn Lys  
125 130 135  
Glu Glu Ser Tyr Gln Pro Ile Val Asp Tyr Ile Asp Ala Gln Phe  
140 145 150  
Glu Ala Tyr Leu Gln Glu Glu Leu Lys Ile Lys Arg Ser Leu Phe  
155 160 165  
Thr Tyr His Asp Ser Arg Ile His Val Cys Leu Tyr Phe Ile Ser  
170 175 180  
Pro Thr Gly His Ser Leu Lys Thr Leu Asp Leu Leu Thr Met Lys  
185 190 195  
Asn Leu Asp Ser Lys Val Asn Ile Ile Pro Val Ile Ala Lys Ala  
200 205 210  
Asp Thr Val Ser Lys Thr Glu Leu Gln Lys Phe Lys Ile Lys Leu  
215 220 225  
Met Ser Glu Leu Val Ser Asn Gly Val Gln Ile Tyr Gln Phe Pro  
230 235 240  
Thr Asp Asp Asp Thr Ile Ala Lys Val Asn Ala Ala Met Asn Gly

245	250	255
Gln Leu Pro Phe Ala Val Val Gly Ser Met Asp Glu Val Lys Val		
260	265	270
Gly Asn Lys Met Val Lys Ala Arg Gln Tyr Pro Trp Gly Val Val		
275	280	285
Gln Val Glu Asn Glu Asn His Cys Asp Phe Val Lys Leu Arg Glu		
290	295	300
Met Leu Ile Cys Thr Asn Met Glu Asp Leu Arg Glu Gln Thr His		
305	310	315
Thr Arg His Tyr Glu Leu Tyr Arg Arg Cys Lys Leu Glu Glu Met		
320	325	330
Gly Phe Thr Asp Val Gly Pro Glu Asn Lys Pro Val Ser Val Gln		
335	340	345
Glu Thr Tyr Glu Ala Lys Arg His Glu Phe His Gly Glu Arg Gln		
350	355	360
Arg Lys Glu Glu Glu Met Lys Gln Met Phe Val Gln Arg Val Lys		
365	370	375
Glu Lys Glu Ala Ile Leu Lys Glu Ala Glu Arg Glu Leu Gln Ala		
380	385	390
Lys Phe Glu His Leu Lys Arg Leu His Gln Glu Glu Arg Met Lys		
395	400	405
Leu Glu Glu Lys Arg Arg Leu Leu Glu Glu Glu Ile Ile Ala Phe		
410	415	420
Ser Lys Lys Lys Ala Thr Ser Glu Ile Phe His Ser Gln Ser Phe		
425	430	435
Leu Ala Thr Gly Ser Asn Leu Arg Lys Asp Lys Asp Arg Lys Asn		
440	445	450
Ser Asn Phe Leu		

<210> 22  
<211> 433  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3068538CD1

<400> 22		
Met Ala Gly Gln Asp Pro Ala Leu Ser Thr Ser His Pro Phe Tyr		
1 5 10 15		
Asp Val Ala Arg His Gly Ile Leu Gln Val Ala Gly Asp Asp Arg		
20 25 30		
Phe Gly Arg Arg Val Val Thr Phe Ser Cys Cys Arg Met Pro Pro		
35 40 45		
Ser His Glu Leu Asp His Gln Arg Leu Leu Glu Tyr Leu Lys Tyr		
50 55 60		
Thr Leu Asp Gln Tyr Val Glu Asn Asp Tyr Thr Ile Val Tyr Phe		
65 70 75		
His Tyr Gly Leu Asn Ser Arg Asn Lys Pro Ser Leu Gly Trp Leu		
80 85 90		
Gln Ser Ala Tyr Lys Glu Phe Asp Arg Lys Tyr Lys Lys Asn Leu		
95 100 105		
Lys Ala Leu Tyr Val Val His Pro Thr Ser Phe Ile Lys Val Leu		
110 115 120		
Trp Asn Ile Leu Lys Pro Leu Ile Ser His Lys Phe Gly Lys Lys		
125 130 135		
Val Ile Tyr Phe Asn Tyr Leu Ser Glu Leu His Glu His Leu Lys		
140 145 150		
Tyr Asp Gln Leu Val Ile Pro Pro Glu Val Leu Arg Tyr Asp Glu		
155 160 165		
Lys Leu Gln Ser Leu His Glu Gly Arg Thr Pro Pro Pro Thr Lys		
170 175 180		

Thr Pro Pro Pro Arg Pro Pro Leu Pro Thr Gln Gln Phe Gly Val  
     185                         190                         195  
 Ser Leu Gln Tyr Leu Lys Asp Lys Asn Gln Gly Glu Leu Ile Pro  
     200                         205                         210  
 Pro Val Leu Arg Phe Thr Val Thr Tyr Leu Arg Glu Lys Gly Leu  
     215                         220                         225  
 Arg Thr Glu Gly Leu Phe Arg Arg Ser Ala Ser Val Gln Thr Val  
     230                         235                         240  
 Arg Glu Ile Gln Arg Leu Tyr Asn Gln Gly Lys Pro Val Asn Phe  
     245                         250                         255  
 Asp Asp Tyr Gly Asp Ile His Ile Pro Ala Val Ile Leu Lys Thr  
     260                         265                         270  
 Phe Leu Arg Glu Leu Pro Gln Pro Leu Leu Thr Phe Gln Ala Tyr  
     275                         280                         285  
 Glu Gln Ile Leu Gly Ile Thr Cys Val Glu Ser Ser Leu Arg Val  
     290                         295                         300  
 Thr Gly Cys Arg Gln Ile Leu Arg Ser Leu Pro Glu His Asn Tyr  
     305                         310                         315  
 Val Val Leu Arg Tyr Leu Met Gly Phe Leu His Ala Val Ser Arg  
     320                         325                         330  
 Glu Ser Ile Phe Asn Lys Met Asn Ser Ser Asn Leu Ala Cys Val  
     335                         340                         345  
 Phe Gly Leu Asn Leu Ile Trp Pro Ser Gln Gly Val Ser Ser Leu  
     350                         355                         360  
 Ser Ala Leu Val Pro Leu Asn Met Phe Thr Glu Leu Leu Ile Glu  
     365                         370                         375  
 Tyr Tyr Glu Lys Ile Phe Ser Thr Pro Glu Ala Pro Gly Glu His  
     380                         385                         390  
 Gly Leu Ala Pro Trp Glu Gln Gly Ser Arg Ala Ala Pro Leu Gln  
     395                         400                         405  
 Glu Ala Val Pro Arg Thr Gln Ala Thr Gly Leu Thr Lys Pro Thr  
     410                         415                         420  
 Leu Pro Pro Ser Pro Leu Met Ala Ala Arg Arg Arg Leu  
     425                         430

&lt;210&gt; 23

&lt;211&gt; 406

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 5159072CD1

&lt;400&gt; 23

Met Ala Asp Gly Asn Glu Asp Leu Arg Ala Asp Asp Leu Pro Gly  
     1                         5                         10                         15  
 Pro Ala Phe Glu Ser Tyr Glu Ser Met Glu Leu Ala Cys Pro Ala  
     20                         25                         30  
 Glu Arg Ser Gly His Val Ala Val Ser Asp Gly Arg His Met Phe  
     35                         40                         45  
 Val Trp Gly Gly Tyr Lys Ser Asn Gln Val Arg Gly Leu Tyr Asp  
     50                         55                         60  
 Phe Tyr Leu Pro Arg Glu Glu Leu Trp Ile Tyr Asn Met Glu Thr  
     65                         70                         75  
 Gly Arg Trp Lys Lys Ile Asn Thr Glu Gly Asp Val Pro Pro Ser  
     80                         85                         90  
 Met Ser Gly Ser Cys Ala Val Cys Val Asp Arg Val Leu Tyr Leu  
     95                         100                         105  
 Phe Gly Gly His His Ser Arg Gly Asn Thr Asn Lys Phe Tyr Met  
   110                         115                         120  
 Leu Asp Ser Arg Ser Thr Asp Arg Val Leu Gln Trp Glu Arg Ile  
   125                         130                         135  
 Asp Cys Gln Gly Ile Pro Pro Ser Ser Lys Asp Lys Leu Gly Val

140	145	150
Trp Val Tyr Lys Asn Lys Leu Ile Phe	Phe Gly Gly Tyr Gly	Tyr
155	160	165
Leu Pro Glu Asp Lys Val Leu Gly Thr	Phe Glu Phe Asp. Glu	Thr
170	175	180
Ser Phe Trp Asn Ser Ser His Pro Arg	Gly Trp Asn Asp His	Val
185	190	195
His Ile Leu Asp Thr Glu Thr Phe Thr	Trp Ser Gln Pro Ile	Thr
200	205	210
Thr Gly Lys Ala Pro Ser Pro Arg Ala	Ala His Ala Cys Ala	Thr
215	220	225
Val Gly Asn Arg Gly Phe Val Phe Gly	Gly Arg Tyr Arg Asp	Ala
230	235	240
Arg Met Asn Asp Leu His Tyr Leu Asn	Leu Asp Thr Trp Glu	Trp
245	250	255
Asn Glu Leu Ile Pro Gln Gly Ile Cys	Pro Val Gly Arg Ser	Trp
260	265	270
His Ser Leu Thr Pro Val Ser Ser Asp	His Leu Phe Leu Phe	Gly
275	280	285
Gly Phe Thr Thr Asp Lys Gln Pro Leu	Ser Asp Ala Trp Thr	Tyr
290	295	300
Cys Ile Ser Lys Asn Glu Trp Ile Gln	Phe Asn His Pro Tyr	Thr
305	310	315
Glu Lys Pro Arg Leu Trp His Thr Ala	Cys Ala Ser Asp Glu	Gly
320	325	330
Glu Val Ile Val Phe Gly Gly Cys Ala	Asn Asn Leu Leu Val	His
335	340	345
His Arg Ala Ala His Ser Asn Glu Ile	Leu Ile Phe Ser Val	Gln
350	355	360
Pro Lys Ser Leu Val Arg Leu Ser Leu	Glu Ala Val Ile Cys	Phe
365	370	375
Lys Glu Met Leu Ala Asn Ser Trp Asn	Cys Leu Pro Lys His	Leu
380	385	390
Leu His Ser Val Asn Gln Arg Phe Gly	Ser Asn Asn Thr Ser	Gly
395	400	405

Ser

<210> 24  
<211> 229  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 5519057CD1

<400> 24

Met Ala Glu Glu Met Glu Ser Ser Leu Glu Ala Ser Phe Ser Ser		
1 5 10 15		
Ser Gly Ala Val Ser Gly Ala Ser Gly Phe Leu Pro Pro Ala Arg		
20 25 30		
Ser Arg Ile Phe Lys Ile Ile Val Ile Gly Asp Ser Asn Val Gly		
35 40 45		
Lys Thr Cys Leu Thr Tyr Arg Phe Cys Ala Gly Arg Phe Pro Asp		
50 55 60		
Arg Thr Glu Ala Thr Ile Gly Val Asp Phe Arg Glu Arg Ala Val		
65 70 75		
Glu Ile Asp Gly Glu Arg Ile Lys Ile Gln Leu Trp Asp Thr Ala		
80 85 90		
Gly Gln Glu Arg Phe Arg Lys Ser Met Val Gln His Tyr Tyr Arg		
95 100 105		
Asn Val His Ala Val Val Phe Val Tyr Asp Met Thr Asn Met Ala		
110 115 120		

Ser Phe His Ser Leu Pro Ser Trp Ile Glu Glu Cys Lys Gln His  
     125                         130                         135  
 Leu Leu Ala Asn Asp Ile Pro Arg Ile Leu Val Gly Asn Lys Cys  
     140                         145                         150  
 Asp Leu Arg Ser Ala Ile Gln Val Pro Thr Asp Leu Ala Gln Lys  
     155                         160                         165  
 Phe Ala Asp Thr His Ser Met Pro Leu Phe Glu Thr Ser Ala Lys  
     170                         175                         180  
 Asn Pro Asn Asp Asn Asp His Val Glu Ala Ile Phe Met Thr Leu  
     185                         190                         195  
 Ala His Lys Leu Lys Cys His Lys Pro Leu Met Leu Ser Gln Pro  
     200                         205                         210  
 Pro Asp Asn Gly Ile Ile Leu Lys Pro Glu Pro Lys Pro Ala Met  
     215                         220                         225  
 Thr Cys Trp Cys

<210> 25  
 <211> 670  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 035379CD1

<400> 25  
 Met Ser Ser Gly Lys Ser Ala Arg Tyr Asn Arg Phe Ser Gly Gly  
     1                         5                         10                         15  
 Pro Ser Asn Leu Pro Thr Pro Asp Val Thr Thr Gly Thr Arg Met  
     20                         25                         30  
 Glu Thr Thr Phe Gly Pro Ala Phe Ser Ala Val Thr Thr Ile Thr  
     35                         40                         45  
 Lys Ala Asp Gly Thr Ser Thr Tyr Lys Gln His Cys Arg Thr Pro  
     50                         55                         60  
 Ser Ser Ser Ser Thr Leu Ala Tyr Ser Pro Arg Asp Glu Glu Asp  
     65                         70                         75  
 Ser Met Pro Pro Ile Ser Thr Pro Arg Arg Ser Asp Ser Ala Ile  
     80                         85                         90  
 Ser Val Arg Ser Leu His Ser Glu Ser Ser Met Ser Leu Arg Ser  
     95                         100                         105  
 Thr Phe Ser Leu Pro Glu Glu Glu Glu Pro Glu Pro Leu Val  
     110                         115                         120  
 Phe Ala Glu Gln Pro Ser Val Lys Leu Cys Cys Gln Leu Cys Cys  
     125                         130                         135  
 Ser Val Phe Lys Asp Pro Val Ile Thr Thr Cys Gly His Thr Phe  
     140                         145                         150  
 Cys Arg Arg Cys Ala Leu Lys Ser Glu Lys Cys Pro Val Asp Asn  
     155                         160                         165  
 Val Lys Leu Thr Val Val Val Asn Asn Ile Ala Val Ala Glu Gln  
     170                         175                         180  
 Ile Gly Glu Leu Phe Ile His Cys Arg His Gly Cys Arg Val Ala  
     185                         190                         195  
 Gly Ser Gly Lys Pro Pro Ile Phe Glu Val Asp Pro Arg Gly Cys  
     200                         205                         210  
 Pro Phe Thr Ile Lys Leu Ser Ala Arg Lys Asp His Glu Gly Ser  
     215                         220                         225  
 Cys Asp Tyr Arg Pro Val Arg Cys Pro Asn Asn Pro Ser Cys Pro  
     230                         235                         240  
 Pro Leu Leu Arg Met Asn Leu Glu Ala His Leu Lys Glu Cys Glu  
     245                         250                         255  
 His Ile Lys Cys Pro His Ser Lys Tyr Gly Cys Thr Phe Ile Gly  
     260                         265                         270  
 Asn Gln Asp Thr Tyr Glu Thr His Leu Glu Thr Cys Arg Phe Glu

	275	280	285
Gly Leu Lys Glu Phe Leu Gln Gln Thr Asp Asp Arg Phe His Glu			
290	295	300	
Met His Val Ala Leu Ala Gln Lys Asp Gln Glu Ile Ala Phe Leu			
305	310	315	
Arg Ser Met Leu Gly Lys Leu Ser Glu Lys Ile Asp Gln Leu Glu			
320	325	330	
Lys Ser Leu Glu Leu Lys Phe Asp Val Leu Asp Glu Asn Gln Ser			
335	340	345	
Lys Leu Ser Glu Asp Leu Met Glu Phe Arg Arg Asp Ala Ser Met			
350	355	360	
Leu Asn Asp Glu Leu Ser His Ile Asn Ala Arg Leu Asn Met Gly			
365	370	375	
Ile Leu Gly Ser Tyr Asp Pro Gln Gln Ile Phe Lys Cys Lys Gly			
380	385	390	
Thr Phe Val Gly His Gln Gly Pro Val Trp Cys Leu Cys Val Tyr			
395	400	405	
Ser Met Gly Asp Leu Leu Phe Ser Gly Ser Ser Asp Lys Thr Ile			
410	415	420	
Lys Val Trp Asp Thr Cys Thr Tyr Lys Cys Gln Lys Thr Leu			
425	430	435	
Glu Gly His Asp Gly Ile Val Leu Ala Leu Cys Ile Gln Gly Cys			
440	445	450	
Lys Leu Tyr Ser Gly Ser Ala Asp Cys Thr Ile Ile Val Trp Asp			
455	460	465	
Ile Gln Asn Leu Gln Lys Val Asn Thr Ile Arg Ala His Asp Asn			
470	475	480	
Pro Val Cys Thr Leu Val Ser Ser His Asn Val Leu Phe Ser Gly			
485	490	495	
Ser Leu Lys Ala Ile Lys Val Trp Asp Ile Val Gly Thr Glu Leu			
500	505	510	
Lys Leu Lys Lys Glu Leu Thr Gly Leu Asn His Trp Val Arg Ala			
515	520	525	
Leu Val Ala Ala Gln Ser Tyr Leu Tyr Ser Gly Ser Tyr Gln Thr			
530	535	540	
Ile Lys Ile Trp Asp Ile Arg Thr Leu Asp Cys Ile His Val Leu			
545	550	555	
Gln Thr Ser Gly Gly Ser Val Tyr Ser Ile Ala Val Thr Asn His			
560	565	570	
His Ile Val Cys Gly Thr Tyr Glu Asn Leu Ile His Val Trp Asp			
575	580	585	
Ile Glu Ser Lys Glu Gln Val Arg Thr Leu Thr Gly His Val Gly			
590	595	600	
Thr Val Tyr Ala Leu Ala Val Ile Ser Thr Pro Asp Gln Thr Lys			
605	610	615	
Val Phe Ser Ala Ser Tyr Asp Arg Ser Leu Arg Val Trp Ser Met			
620	625	630	
Asp Asn Met Ile Cys Thr Gln Thr Leu Leu Arg His Gln Ser Ser			
635	640	645	
Val Thr Ala Leu Ala Val Ser Arg Gly Arg Leu Phe Ser Gly Ala			
650	655	660	
Val Asp Ser Thr Val Lys Val Trp Thr Cys			
665	670		

&lt;210&gt; 26

&lt;211&gt; 445

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 275354CD1

&lt;400&gt; 26

Met Lys Val Lys Met Leu Ser Arg Asn Pro Asp Asn Tyr Val Arg  
   1               5               10               15  
 Glu Thr Lys Leu Asp Leu Gln Arg Val Pro Arg Asn Tyr Asp Pro  
   20               25               30  
 Ala Leu His Pro Phe Glu Val Pro Arg Glu Tyr Val Arg Ala Leu  
   35               40               45  
 Asn Ala Thr Lys Leu Glu Arg Val Phe Ala Lys Pro Phe Leu Ala  
   50               55               60  
 Ser Leu Asp Gly His Arg Asp Gly Val Asn Cys Leu Ala Lys His  
   65               70               75  
 Pro Glu Lys Leu Ala Thr Val Leu Ser Gly Ala Cys Asp Gly Glu  
   80               85               90  
 Val Arg Ile Trp Asn Leu Thr Gln Arg Asn Cys Ile Arg Thr Ile  
   95               100              105  
 Gln Ala His Glu Gly Phe Val Arg Gly Ile Cys Thr Arg Phe Cys  
   110              115              120  
 Gly Thr Ser Phe Phe Thr Val Gly Asp Asp Lys Thr Val Lys Gln  
   125              130              135  
 Trp Lys Met Asp Gly Pro Gly Tyr Gly Asp Glu Glu Glu Pro Leu  
   140              145              150  
 His Thr Ile Leu Gly Lys Thr Val Tyr Thr Gly Ile Asp His His  
   155              160              165  
 Trp Lys Glu Ala Val Phe Ala Thr Cys Gly Gln Gln Val Asp Ile  
   170              175              180  
 Trp Asp Glu Gln Arg Thr Asn Pro Ile Cys Ser Met Thr Trp Gly  
   185              190              195  
 Phe Asp Ser Ile Ser Ser Val Lys Phe Asn Pro Ile Glu Thr Phe  
   200              205              210  
 Leu Leu Gly Ser Cys Ala Ser Asp Arg Asn Ile Val Leu Tyr Asp  
   215              220              225  
 Met Arg Gln Ala Thr Pro Leu Lys Lys Val Ile Leu Asp Met Arg  
   230              235              240  
 Thr Asn Thr Ile Cys Trp Asn Pro Met Glu Ala Phe Ile Phe Thr  
   245              250              255  
 Ala Ala Asn Glu Asp Tyr Asn Leu Tyr Thr Phe Asp Met Arg Ala  
   260              265              270  
 Leu Asp Thr Pro Val Met Val His Met Asp His Val Ser Ala Val  
   275              280              285  
 Leu Asp Val Asp Tyr Ser Pro Thr Gly Lys Glu Phe Val Ser Ala  
   290              295              300  
 Ser Phe Asp Lys Ser Ile Arg Ile Phe Pro Val Asp Lys Ser Arg  
   305              310              315  
 Ser Arg Glu Val Tyr His Thr Lys Arg Met Gln His Val Ile Cys  
   320              325              330  
 Val Lys Trp Thr Ser Asp Ser Lys Tyr Ile Met Cys Gly Ser Asp  
   335              340              345  
 Glu Met Asn Ile Arg Leu Trp Lys Ala Asn Ala Ser Glu Lys Leu  
   350              355              360  
 Gly Val Leu Thr Ser Arg Glu Lys Ala Ala Lys Asp Tyr Asn Gln  
   365              370              375  
 Lys Leu Lys Glu Lys Phe Gln His Tyr Pro His Ile Lys Arg Ile  
   380              385              390  
 Ala Arg His Arg His Leu Pro Lys Ser Ile Tyr Ser Gln Ile Gln  
   395              400              405  
 Glu Gln Arg Ile Met Lys Glu Ala Arg Arg Arg Lys Glu Val Asn  
   410              415              420  
 Arg Ile Lys His Ser Lys Pro Gly Ser Val Pro Leu Val Ser Glu  
   425              430              435  
 Lys Lys Lys His Val Val Ala Val Val Lys  
   440              445

<210> 27  
 <211> 236  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 311658CD1

&lt;400&gt; 27

Met	Ser	Asp	Leu	Leu	Ser	Pro	Leu	Leu	Tyr	Val	Met	Glu	Asn	Glu
1														15
Val	Asp	Ala	Phe	Trp	Cys	Phe	Ala	Ser	Tyr	Met	Asp	Gln	Met	His
														30
Gln	Asn	Phe	Glu	Glu	Gln	Met	Gln	Gly	Met	Lys	Thr	Gln	Leu	Ile
														45
Gln	Leu	Ser	Thr	Leu	Leu	Arg	Leu	Leu	Asp	Ser	Gly	Phe	Cys	Ser
														60
Tyr	Leu	Glu	Ser	Gln	Asp	Ser	Gly	Tyr	Leu	Tyr	Phe	Cys	Phe	Arg
														75
Trp	Leu	Leu	Ile	Arg	Phe	Lys	Arg	Glu	Phe	Ser	Phe	Leu	Asp	Ile
														90
Leu	Arg	Leu	Trp	Glu	Val	Met	Trp	Thr	Glu	Leu	Pro	Cys	Thr	Asn
														105
Phe	His	Leu	Leu	Leu	Cys	Cys	Ala	Ile	Leu	Glu	Ser	Glu	Lys	Gln
														120
Gln	Ile	Met	Glu	Lys	His	Tyr	Gly	Phe	Asn	Glu	Ile	Leu	Lys	His
														135
Ile	Asn	Glu	Leu	Ser	Met	Lys	Ile	Asp	Val	Glu	Asp	Ile	Leu	Cys
														150
Lys	Ala	Glu	Ala	Ile	Ser	Leu	Gln	Met	Val	Lys	Cys	Lys	Glu	Leu
														165
Pro	Gln	Ala	Val	Cys	Glu	Ile	Leu	Gly	Leu	Gln	Gly	Ser	Glu	Val
														180
Thr	Thr	Pro	Asp	Ser	Asp	Val	Gly	Glu	Asp	Glu	Asn	Val	Val	Met
														195
Thr	Pro	Cys	Pro	Thr	Ser	Ala	Phe	Gln	Ser	Asn	Ala	Leu	Pro	Thr
														210
Leu	Ser	Ala	Ser	Gly	Ala	Arg	Asn	Asp	Ser	Pro	Thr	Gln	Ile	Pro
														225
Val	Ser	Ser	Asp	Val	Cys	Arg	Leu	Thr	Pro	Ala				
														235

&lt;210&gt; 28

&lt;211&gt; 498

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1251632CD1

&lt;400&gt; 28

Met	Gln	Glu	Ser	Gly	Cys	Arg	Leu	Glu	His	Pro	Ser	Ala	Thr	Lys
1														15
Phe	Arg	Asn	His	Val	Met	Glu	Gly	Asp	Trp	Asp	Lys	Ala	Glu	Asn
														30
Asp	Leu	Asn	Glu	Leu	Lys	Pro	Leu	Val	His	Ser	Pro	His	Ala	Ile
														45
Val	Arg	Met	Lys	Phe	Leu	Leu	Leu	Gln	Gln	Lys	Tyr	Leu	Glu	Tyr
														60
Leu	Glu	Asp	Gly	Lys	Val	Leu	Glu	Ala	Leu	Gln	Val	Leu	Arg	Cys
														75
Glu	Leu	Thr	Pro	Leu	Lys	Tyr	Asn	Thr	Glu	Arg	Ile	His	Val	Leu
														90
Ser	Gly	Tyr	Leu	Met	Cys	Ser	His	Ala	Glu	Asp	Leu	Arg	Ala	Lys
														105
95														

Ala Glu Trp Glu Gly Lys Gly Thr Ala Ser Arg Ser Lys Leu Leu  
 110 115 120  
 Asp Lys Leu Gln Thr Tyr Leu Pro Pro Ser Val Met Leu Pro Pro  
 125 130 135  
 Arg Arg Leu Gln Thr Leu Leu Arg Gln Ala Val Glu Leu Gln Arg  
 140 145 150  
 Asp Arg Cys Leu Tyr His Asn Thr Lys Leu Asp Asn Asn Leu Asp  
 155 160 165  
 Ser Val Ser Leu Leu Ile Asp His Val Cys Ser Arg Arg Gln Phe  
 170 175 180  
 Pro Cys Tyr Thr Gln Gln Ile Leu Thr Glu His Cys Asn Glu Val  
 185 190 195  
 Trp Phe Cys Lys Phe Ser Asn Asp Gly Thr Lys Leu Ala Thr Gly  
 200 205 210  
 Ser Lys Asp Thr Thr Val Ile Ile Trp Gln Val Asp Pro Asp Thr  
 215 220 225  
 His Leu Leu Lys Leu Leu Lys Thr Leu Glu Gly His Ala Tyr Gly  
 230 235 240  
 Val Ser Tyr Ile Ala Trp Ser Pro Asp Asp Asn Tyr Leu Val Ala  
 245 250 255  
 Cys Gly Pro Asp Asp Cys Ser Glu Leu Trp Leu Trp Asn Val Gln  
 260 265 270  
 Thr Gly Glu Leu Arg Thr Lys Met Ser Gln Ser His Glu Asp Ser  
 275 280 285  
 Leu Thr Ser Val Ala Trp Asn Pro Asp Gly Lys Arg Phe Val Thr  
 290 295 300  
 Gly Gly Gln Arg Gly Gln Phe Tyr Gln Cys Asp Leu Asp Gly Asn  
 305 310 315  
 Leu Leu Asp Ser Trp Glu Gly Val Arg Val Gln Cys Leu Trp Cys  
 320 325 330  
 Leu Ser Asp Gly Lys Thr Val Leu Ala Ser Asp Thr His Gln Arg  
 335 340 345  
 Ile Arg Gly Tyr Asn Phe Glu Asp Leu Thr Asp Arg Asn Ile Val  
 350 355 360  
 Gln Glu Asp His Pro Ile Met Ser Phe Thr Ile Ser Lys Asn Gly  
 365 370 375  
 Arg Leu Ala Leu Leu Asn Val Ala Thr Gln Gly Val His Leu Trp  
 380 385 390  
 Asp Leu Gln Asp Arg Val Leu Val Arg Lys Tyr Gln Gly Val Thr  
 395 400 405  
 Gln Gly Phe Tyr Thr Ile His Ser Cys Phe Gly Gly His Asn Glu  
 410 415 420  
 Asp Phe Ile Ala Ser Gly Ser Glu Asp His Lys Val Tyr Ile Trp  
 425 430 435  
 His Lys Arg Ser Glu Leu Pro Ile Ala Glu Leu Thr Gly His Thr  
 440 445 450  
 Arg Thr Val Asn Cys Val Ser Trp Asn Pro Gln Ile Pro Ser Met  
 455 460 465  
 Met Ala Ser Ala Ser Asp Asp Gly Thr Val Arg Ile Trp Gly Pro  
 470 475 480  
 Ala Pro Phe Ile Asp His Gln Asn Ile Glu Glu Glu Cys Ser Ser  
 485 490 495

Met Asp Ser

<210> 29  
 <211> 334  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1331955CD1

&lt;400&gt; 29

Met	Ala	Thr	Glu	Glu	Lys	Lys	Pro	Glu	Thr	Glu	Ala	Ala	Arg	Ala
1			5					10					15	
Gln	Pro	Thr	Pro	Ser	Ser	Ser	Ala	Thr	Gln	Ser	Lys	Pro	Thr	Pro
								20					25	30
Val	Lys	Pro	Asn	Tyr	Ala	Leu	Lys	Phe	Thr	Leu	Ala	Gly	His	Thr
								35					40	45
Lys	Ala	Val	Ser	Ser	Val	Lys	Phe	Ser	Pro	Asn	Gly	Glu	Trp	Leu
								50					55	60
Ala	Ser	Ser	Ser	Ala	Asp	Lys	Leu	Ile	Lys	Ile	Trp	Gly	Ala	Tyr
								65					70	75
Asp	Gly	Lys	Phe	Glu	Lys	Thr	Ile	Ser	Gly	His	Lys	Leu	Gly	Ile
								80					85	90
Ser	Asp	Val	Ala	Trp	Ser	Ser	Asp	Ser	Asn	Leu	Leu	Val	Ser	Ala
								95					100	105
Ser	Asp	Asp	Lys	Thr	Leu	Lys	Ile	Trp	Asp	Val	Ser	Ser	Gly	Lys
								110					115	120
Cys	Leu	Lys	Thr	Leu	Lys	Gly	His	Ser	Asn	Tyr	Val	Phe	Cys	Cys
								125					130	135
Asn	Phe	Asn	Pro	Gln	Ser	Asn	Leu	Ile	Val	Ser	Gly	Ser	Phe	Asp
								140					145	150
Glu	Ser	Val	Arg	Ile	Trp	Asp	Val	Lys	Thr	Gly	Lys	Cys	Leu	Lys
								155					160	165
Thr	Leu	Pro	Ala	His	Ser	Asp	Pro	Val	Ser	Ala	Val	His	Phe	Asn
								170					175	180
Arg	Asp	Gly	Ser	Leu	Ile	Val	Ser	Ser	Ser	Tyr	Asp	Gly	Leu	Cys
								185					190	195
Arg	Ile	Trp	Asp	Thr	Ala	Ser	Gly	Gln	Cys	Leu	Lys	Thr	Leu	Ile
								200					205	210
Asp	Asp	Asp	Asn	Pro	Pro	Val	Ser	Phe	Val	Lys	Phe	Ser	Pro	Asn
								215					220	225
Gly	Lys	Tyr	Ile	Leu	Ala	Ala	Thr	Leu	Asp	Asn	Thr	Leu	Lys	Leu
								230					235	240
Trp	Asp	Tyr	Ser	Lys	Gly	Lys	Cys	Leu	Lys	Thr	Tyr	Thr	Gly	His
								245					250	255
Lys	Asn	Glu	Lys	Tyr	Cys	Ile	Phe	Ala	Asn	Phe	Ser	Val	Thr	Gly
								260					265	270
Gly	Lys	Trp	Ile	Val	Ser	Gly	Ser	Glu	Asp	Asn	Leu	Val	Tyr	Ile
								275					280	285
Trp	Asn	Leu	Gln	Thr	Lys	Glu	Ile	Val	Gln	Lys	Leu	Gln	Gly	His
								290					295	300
Thr	Asp	Val	Val	Ile	Ser	Thr	Ala	Cys	His	Pro	Thr	Glu	Asn	Ile
								305					310	315
Ile	Ala	Ser	Ala	Ala	Leu	Glu	Asn	Asp	Lys	Thr	Ile	Lys	Leu	Trp
								320					325	330
Lys	Ser	Asp	Cys											

&lt;210&gt; 30

&lt;211&gt; 292

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1412614CD1

&lt;400&gt; 30

Met	Met	Ala	Phe	Ala	Pro	Pro	Lys	Asn	Thr	Asp	Gly	Pro	Lys	Met
1			5						10					15
Gln	Thr	Lys	Met	Ser	Thr	Trp	Thr	Pro	Leu	Asn	His	Gln	Leu	Leu
									20					25
Asn	Asp	Arg	Val	Phe	Glu	Glu	Arg	Arg	Ala	Leu	Leu	Gly	Lys	Trp
									35					40
														45

Phe Asp Lys Trp Thr Asp Ser Gln Arg Arg Arg Ile Leu Thr Gly  
 50 55 60  
 Leu Leu Glu Arg Cys Ser Leu Ser Gln Gln Lys Phe Cys Cys Arg  
 65 70 75  
 Lys Leu Gln Glu Lys Ile Pro Ala Glu Ala Leu Asp Phe Thr Thr  
 80 85 90  
 Lys Leu Pro Arg Val Leu Ser Leu Tyr Ile Phe Ser Phe Leu Asp  
 95 100 105  
 Pro Arg Ser Leu Cys Arg Cys Ala Gln Val Cys Trp His Trp Lys  
 110 115 120  
 Asn Leu Ala Glu Leu Asp Gln Leu Trp Met Leu Lys Cys Leu Arg  
 125 130 135  
 Phe Asn Trp Tyr Ile Asn Phe Ser Pro Thr Pro Phe Glu Gln Gly  
 140 145 150  
 Ile Trp Lys Lys His Tyr Ile Gln Met Val Lys Glu Leu His Ile  
 155 160 165  
 Thr Lys Pro Lys Thr Pro Pro Lys Asp Gly Phe Val Ile Ala Asp  
 170 175 180  
 Val Gln Leu Val Thr Ser Asn Ser Pro Glu Glu Lys Gln Ser Pro  
 185 190 195  
 Leu Ser Ala Phe Arg Ser Ser Ser Ser Leu Arg Lys Lys Asn Asn  
 200 205 210  
 Ser Gly Glu Lys Ala Leu Pro Pro Trp Arg Ser Ser Asp Lys His  
 215 220 225  
 Pro Thr Asp Ile Ile Arg Phe Asn Tyr Leu Asp Asn Arg Asp Pro  
 230 235 240  
 Met Glu Thr Val Gln Gln Gly Arg Arg Lys Arg Asn Gln Ile Thr  
 245 250 255  
 Pro Asp Phe Ser Arg Gln Ser His Asp Lys Lys Asn Lys Leu Gln  
 260 265 270  
 Asp Arg Thr Arg Leu Arg Lys Ala Gln Ser Met Met Ser Arg Arg  
 275 280 285  
 Asn Pro Phe Pro Leu Cys Pro  
 290

<210> 31  
<211> 588  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1750781CD1

<400> 31  
 Met Ser Ser Gly Leu Arg Ala Ala Asp Phe Pro Arg Trp Lys Arg  
 1 5 10 15  
 His Ile Ser Glu Gln Leu Arg Arg Arg Asp Arg Leu Gln Arg Gln  
 20 25 30  
 Ala Phe Glu Glu Ile Ile Leu Gln Tyr Asn Lys Leu Leu Glu Lys  
 35 40 45  
 Ser Asp Leu His Ser Val Leu Ala Gln Lys Leu Gln Ala Glu Lys  
 50 55 60  
 His Asp Val Pro Asn Arg His Glu Ile Ser Pro Gly His Asp Gly  
 65 70 75  
 Thr Trp Asn Asp Asn Gln Leu Gln Glu Met Ala Gln Leu Arg Ile  
 80 85 90  
 Lys His Gln Glu Glu Leu Thr Glu Leu His Lys Lys Arg Gly Glu  
 95 100 105  
 Leu Ala Gln Leu Val Ile Asp Leu Asn Asn Gln Met Gln Arg Lys  
 110 115 120  
 Asp Arg Glu Met Gln Met Asn Glu Ala Lys Ile Ala Glu Cys Leu  
 125 130 135  
 Gln Thr Ile Ser Asp Leu Glu Thr Glu Cys Leu Asp Leu Arg Thr

	140	145	150
Lys Leu Cys Asp	Leu Glu Arg Ala Asn	Gln Thr Leu Lys Asp	Glu
155	160	165	
Tyr Asp Ala Leu	Gln Ile Thr Phe Thr	Ala Leu Glu Gly Lys	Leu
170	175	180	
Arg Lys Thr Thr	Glu Glu Asn Gln Glu	Leu Val Thr Arg Trp	Met
185	190	195	
Ala Glu Lys Ala	Gln Glu Ala Asn Arg	Leu Asn Ala Glu Asn	Glu
200	205	210	
Lys Asp Ser Arg	Arg Arg Gln Ala Arg	Leu Gln Lys Glu Leu	Ala
215	220	225	
Glu Ala Ala Lys	Glu Pro Leu Pro Val	Glu Gln Asp Asp Asp	Ile
230	235	240	
Glu Val Ile Val	Asp Glu Thr Ser Asp	His Thr Glu Glu Thr	Ser
245	250	255	
Pro Val Arg Ala	Ile Ser Arg Ala Ala	Thr Arg Arg Ser Val	Ser
260	265	270	
Ser Phe Pro Val	Pro Gln Asp Asn Val	Asp Thr His Pro Gly	Ser
275	280	285	
Gly Lys Glu Val	Arg Val Pro Ala Thr	Ala Leu Cys Val Phe	Asp
290	295	300	
Ala His Asp Gly	Glu Val Asn Ala Val	Gln Phe Ser Pro Gly	Ser
305	310	315	
Arg Leu Leu Ala	Thr Gly Gly Met Asp	Arg Arg Val Lys Leu	Trp
320	325	330	
Glu Val Phe Gly	Glu Lys Cys Glu Phe	Lys Gly Ser Leu Ser	Gly
335	340	345	
Ser Asn Ala Gly	Ile Thr Ser Ile Glu	Phe Asp Ser Ala Gly	Ser
350	355	360	
Tyr Leu Leu Ala	Ala Ser Asn Asp Phe	Ala Ser Arg Ile Trp	Thr
365	370	375	
Val Asp Asp Tyr	Arg Leu Arg His Thr	Leu Thr Gly His Ser	Gly
380	385	390	
Lys Val Leu Ser	Ala Lys Phe Leu Leu	Asp Asn Ala Arg Ile	Val
395	400	405	
Ser Gly Ser His	Asp Arg Thr Leu Lys	Leu Trp Asp Leu Arg	Ser
410	415	420	
Lys Val Cys Ile	Lys Thr Val Phe Ala	Gly Ser Ser Cys Asn	Asp
425	430	435	
Ile Val Cys Thr	Glu Gln Cys Val Met	Ser Gly His Phe Asp	Lys
440	445	450	
Lys Ile Arg Phe	Trp Asp Ile Arg Ser	Glu Ser Ile Val Arg	Glu
455	460	465	
Met Glu Leu Leu	Gly Lys Ile Thr Ala	Leu Asp Leu Asn Pro	Glu
470	475	480	
Arg Thr Glu Leu	Leu Ser Cys Ser Arg	Asp Asp Leu Leu Lys	Val
485	490	495	
Ile Asp Leu Arg	Thr Asn Ala Ile Lys	Gln Thr Phe Ser Ala	Pro
500	505	510	
Gly Phe Lys Cys	Gly Ser Asp Trp Thr	Arg Val Val Phe Ser	Pro
515	520	525	
Asp Gly Ser Tyr	Val Ala Ala Gly Ser	Ala Glu Gly Ser Leu	Tyr
530	535	540	
Ile Trp Ser Val	Leu Thr Gly Lys Val	Glu Lys Val Leu Ser	Lys
545	550	555	
Gln His Ser Ser	Ser Ile Asn Ala Val	Ala Trp Ser Pro Ser	Gly
560	565	570	
Ser His Val Val	Ser Val Asp Lys Gly	Cys Lys Ala Val Leu	Trp
575	580	585	
Ala Gln Tyr			

<210> 32  
<211> 326

<212> PRT  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1821658CD1

<210> 33  
<211> 453  
<212> PRT  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1872574CD1

<400> 33 Met Ala Arg Lys Val Val Ser Arg Lys Arg Lys Ala Pro Ala Ser

1	5	10	15												
Pro	Gly	Ala	Gly	Ser	Asp	Ala	Gln	Gly	Pro	Gln	Phe	Gly	Trp	Asp	
		20							25					30	
His	Ser	Leu	His	Lys	Arg	Lys	Arg	Leu	Pro	Pro	Val	Lys	Arg	Ser	
				35					40					45	
Leu	Val	Tyr	Tyr	Leu	Lys	Asn	Arg	Glu	Val	Arg	Leu	Gln	Asn	Glu	
				50					55					60	
Thr	Ser	Tyr	Ser	Arg	Val	Leu	His	Gly	Tyr	Ala	Ala	Gln	Gln	Leu	
				65					70					75	
Pro	Ser	Leu	Leu	Lys	Glu	Arg	Glu	Phe	His	Leu	Gly	Thr	Leu	Asn	
				80					85					90	
Lys	Val	Phe	Ala	Ser	Gln	Trp	Leu	Asn	His	Arg	Gln	Val	Val	Cys	
				95					100					105	
Gly	Thr	Lys	Cys	Asn	Thr	Leu	Phe	Val	Val	Asp	Val	Gln	Thr	Ser	
				110					115					120	
Gln	Ile	Thr	Lys	Ile	Pro	Ile	Leu	Lys	Asp	Arg	Glu	Pro	Gly	Gly	
				125					130					135	
Val	Thr	Gln	Gln	Gly	Cys	Gly	Ile	His	Ala	Ile	Glu	Leu	Asn	Pro	
				140					145					150	
Ser	Arg	Thr	Leu	Leu	Ala	Thr	Gly	Gly	Asp	Asn	Pro	Asn	Ser	Leu	
				155					160					165	
Ala	Ile	Tyr	Arg	Leu	Pro	Thr	Leu	Asp	Pro	Val	Cys	Val	Gly	Asp	
				170					175					180	
Asp	Gly	His	Lys	Asp	Trp	Ile	Phe	Ser	Ile	Ala	Trp	Ile	Ser	Asp	
				185					190					195	
Thr	Met	Ala	Val	Ser	Gly	Ser	Arg	Asp	Gly	Ser	Met	Gly	Leu	Trp	
				200					205					210	
Glu	Val	Thr	Asp	Asp	Val	Leu	Thr	Lys	Ser	Asp	Ala	Arg	His	Asn	
				215					220					225	
Val	Ser	Arg	Val	Pro	Val	Tyr	Ala	His	Ile	Thr	His	Lys	Ala	Leu	
				230					235					240	
Lys	Asp	Ile	Pro	Lys	Glu	Asp	Thr	Asn	Pro	Asp	Asn	Cys	Lys	Val	
				245					250					255	
Arg	Ala	Leu	Ala	Phe	Asn	Asn	Lys	Asn	Lys	Glu	Leu	Gly	Ala	Val	
				260					265					270	
Ser	Leu	Asp	Gly	Tyr	Phe	His	Leu	Trp	Lys	Ala	Glu	Asn	Thr	Leu	
				275					280					285	
Ser	Lys	Leu	Leu	Ser	Thr	Lys	Leu	Pro	Tyr	Cys	Arg	Glu	Asn	Val	
				290					295					300	
Cys	Leu	Ala	Tyr	Gly	Ser	Glu	Trp	Ser	Val	Tyr	Ala	Val	Gly	Ser	
				305					310					315	
Gln	Ala	His	Val	Ser	Phe	Leu	Asp	Pro	Arg	Gln	Pro	Ser	Tyr	Asn	
				320					325					330	
Val	Lys	Ser	Val	Cys	Ser	Arg	Glu	Arg	Gly	Ser	Gly	Ile	Arg	Ser	
				335					340					345	
Val	Ser	Phe	Tyr	Glu	His	Ile	Ile	Thr	Val	Gly	Thr	Gly	Gln	Gly	
				350					355					360	
Ser	Leu	Leu	Phe	Tyr	Asp	Ile	Arg	Ala	Gln	Arg	Phe	Leu	Glu	Glu	
				365					370					375	
Arg	Leu	Ser	Ala	Cys	Tyr	Gly	Ser	Lys	Pro	Arg	Leu	Ala	Gly	Glu	
				380					385					390	
Asn	Leu	Lys	Leu	Thr	Thr	Gly	Lys	Gly	Trp	Leu	Asn	His	Asp	Glu	
				395					400					405	
Thr	Trp	Arg	Asn	Tyr	Phe	Ser	Asp	Ile	Asp	Phe	Phe	Pro	Asn	Ala	
				410					415					420	
Val	Tyr	Thr	His	Cys	Tyr	Asp	Ser	Ser	Gly	Thr	Lys	Leu	Phe	Val	
				425					430					435	
Ala	Gly	Gly	Pro	Leu	Pro	Ser	Gly	Leu	His	Gly	Asn	Tyr	Ala	Gly	
				440					445					450	
Leu Trp Ser															
<210> 34															
<211> 161															

<212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2590967CD1

<400> 34  
 Met Ala Thr Glu Gly Gly Lys Glu Met Asn Glu Ile Lys Thr  
 1 5 10 15  
 Gln Phe Thr Thr Arg Glu Gly Leu Tyr Lys Leu Leu Pro His Ser  
 20 25 30  
 Glu Tyr Ser Arg Pro Asn Arg Val Pro Phe Asn Ser Gln Gly Ser  
 35 40 45  
 Asn Pro Val Arg Val Ser Phe Val Asn Leu Asn Asp Gln Ser Gly  
 50 55 60  
 Asn Gly Asp Arg Leu Cys Phe Asn Val Gly Arg Glu Leu Tyr Phe  
 65 70 75  
 Tyr Ile Tyr Lys Gly Val Arg Lys Ala Ala Asp Leu Ser Lys Pro  
 80 85 90  
 Ile Asp Lys Arg Ile Tyr Lys Gly Thr Gln Pro Thr Cys His Asp  
 95 100 105  
 Phe Asn His Leu Thr Ala Thr Ala Glu Ser Val Ser Leu Leu Val  
 110 115 120  
 Gly Phe Ser Ala Gly Gln Val Gln Leu Ile Asp Pro Ile Lys Lys  
 125 130 135  
 Glu Thr Ser Lys Leu Phe Asn Glu Glu Gly Ser Leu Ser Ser Pro  
 140 145 150  
 Ser Gln Ala Ser Ser Pro Gly Gly Thr Val Val  
 155 160

<210> 35  
 <211> 684  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2824491CD1

<400> 35  
 Met Ala Arg His Arg Asn Val Arg Gly Tyr Asn Tyr Asp Glu Asp  
 1 5 10 15  
 Phe Glu Asp Asp Asp Leu Tyr Gly Gln Ser Val Glu Asp Asp Tyr  
 20 25 30  
 Cys Ile Ser Pro Ser Thr Ala Ala Gln Phe Ile Tyr Ser Arg Arg  
 35 40 45  
 Asp Lys Pro Ser Val Glu Pro Val Glu Glu Tyr Asp Tyr Glu Asp  
 50 55 60  
 Leu Lys Glu Ser Ser Asn Ser Val Ser Asn His Gln Leu Ser Gly  
 65 70 75  
 Phe Asp Gln Ala Arg Leu Tyr Ser Cys Leu Asp His Met Arg Glu  
 80 85 90  
 Val Leu Gly Asp Ala Val Pro Asp Glu Ile Leu Ile Glu Ala Val  
 95 100 105  
 Leu Lys Asn Lys Phe Asp Val Gln Lys Ala Leu Ser Gly Val Leu  
 110 115 120  
 Glu Gln Asp Arg Val Gln Ser Leu Lys Asp Lys Asn Glu Ala Thr  
 125 130 135  
 Val Ser Thr Gly Lys Ile Ala Lys Gly Lys Pro Val Asp Ser Gln  
 140 145 150  
 Thr Ser Arg Ser Glu Ser Glu Ile Val Pro Lys Val Ala Lys Met  
 155 160 165  
 Thr Val Ser Gly Lys Lys Gln Thr Met Gly Phe Glu Val Pro Gly

	170		175		180
Val Ser Ser Glu	Glu Asn Gly His Ser	Phe His Thr Pro Gln	Lys		
185		190		195	
Gly Pro Pro Ile	Glu Asp Ala Ile Ala	Ser Ser Asp Val	Leu Glu		
200		205		210	
Thr Ala Ser Lys	Ser Ala Asn Pro Pro	His Thr Ile Gln Ala	Ser		
215		220		225	
Glu Glu Gln Ser	Ser Thr Pro Ala Pro	Val Lys Lys Ser Gly	Lys		
230		235		240	
Leu Arg Gln Gln	Ile Asp Val Lys Ala	Glu Leu Glu Lys Arg	Gln		
245		250		255	
Gly Gly Lys Gln	Leu Leu Asn Leu Val	Val Ile Gly His Val	Asp		
260		265		270	
Ala Gly Lys Ser	Thr Leu Met Gly His	Met Leu Tyr Leu Leu	Gly		
275		280		285	
Asn Ile Asn Lys	Arg Thr Met His Lys	Tyr Glu Gln Glu Ser	Lys		
290		295		300	
Lys Ala Gly Lys	Ala Ser Phe Ala Tyr	Ala Trp Val Leu Asp	Glu		
305		310		315	
Thr Gly Glu Glu	Arg Glu Arg Gly Val	Thr Met Asp Val Gly	Met		
320		325		330	
Thr Lys Phe Glu	Thr Thr Thr Lys Val	Ile Thr Leu Met Asp	Ala		
335		340		345	
Pro Gly His Lys	Asp Phe Ile Pro Asn	Met Ile Thr Gly Ala	Ala		
350		355		360	
Gln Ala Asp Val	Ala Val Leu Val Val	Asp Ala Ser Arg Gly	Glu		
365		370		375	
Phe Glu Ala Gly	Phe Glu Thr Gly Gly	Gln Thr Arg Glu His	Gly		
380		385		390	
Leu Leu Val Arg	Ser Leu Gly Val Thr	Gln Leu Ala Val Ala	Val		
395		400		405	
Asn Lys Met Asp	Gln Val Asn Trp Gln	Gln Glu Arg Phe Gln	Glu		
410		415		420	
Ile Thr Gly Lys	Leu Gly His Phe Leu	Lys Gln Ala Gly Phe	Lys		
425		430		435	
Glu Ser Asp Val	Gly Phe Ile Pro Thr	Ser Gly Leu Ser Gly	Glu		
440		445		450	
Asn Leu Ile Thr	Arg Ser Gln Ser Ser	Glu Leu Thr Lys Trp	Tyr		
455		460		465	
Lys Gly Leu Cys	Leu Leu Glu Gln Ile	Asp Ser Phe Lys Pro	Pro		
470		475		480	
Gln Arg Ser Ile	Asp Lys Pro Phe Arg	Leu Cys Val Ser Asp	Val		
485		490		495	
Phe Lys Asp Gln	Gly Ser Gly Phe Cys	Ile Thr Gly Lys Ile	Glu		
500		505		510	
Ala Gly Tyr Ile	Gln Thr Gly Asp Arg	Leu Leu Ala Met Pro	Pro		
515		520		525	
Asn Glu Thr Cys	Thr Val Lys Gly Ile	Thr Leu His Asp Glu	Pro		
530		535		540	
Val Asp Trp Ala	Ala Ala Gly Asp His	Val Ser Leu Thr Leu	Val		
545		550		555	
Gly Met Asp Ile	Ile Lys Ile Asn Val	Gly Cys Ile Phe Cys	Gly		
560		565		570	
Pro Lys Val Pro	Ile Lys Ala Cys Thr	Arg Phe Arg Ala Arg	Ile		
575		580		585	
Leu Ile Phe Asn	Ile Glu Ile Pro Ile	Thr Lys Gly Phe Pro	Val		
590		595		600	
Leu Leu His Tyr	Gln Thr Val Ser Glu	Pro Ala Val Ile Lys	Arg		
605		610		615	
Leu Ile Ser Val	Leu Asn Lys Ser Thr	Gly Glu Val Thr Lys	Lys		
620		625		630	
Lys Pro Lys Phe	Leu Thr Lys Gly Gln	Asn Ala Leu Val Glu	Leu		
635		640		645	

Gln Thr Gln Arg Pro Ile Ala Leu Glu Leu Tyr Lys Asp Phe Lys  
 650 655 660  
 Glu Leu Gly Arg Phe Met Leu Arg Tyr Gly Gly Ser Thr Ile Ala  
 665 670 675  
 Ala Gly Val Val Thr Glu Ile Lys Glu  
 680  
 <210> 36  
 <211> 366  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2825460CD1  
  
 <400> 36  
 Met Ala Ala Ala Ala Ala Arg Trp Asn His Val Trp Val Gly Thr  
 1 5 10 15  
 Glu Thr Gly Ile Leu Lys Gly Val Asn Leu Gln Arg Lys Gln Ala  
 20 25 30  
 Ala Asn Phe Thr Ala Gly Gly Gln Pro Arg Arg Glu Glu Ala Val  
 35 40 45  
 Ser Ala Leu Cys Trp Gly Thr Gly Gly Glu Thr Gln Met Leu Val  
 50 55 60  
 Gly Cys Ala Asp Arg Thr Val Lys His Phe Ser Thr Glu Asp Gly  
 65 70 75  
 Ile Phe Gln Gly Gln Arg His Cys Pro Gly Gly Glu Met Phe  
 80 85 90  
 Arg Gly Leu Ala Gln Ala Asp Gly Thr Leu Ile Thr Cys Val Asp  
 95 100 105  
 Ser Gly Ile Leu Arg Val Trp His Asp Lys Asp Lys Asp Thr Ser  
 110 115 120  
 Ser Asp Pro Leu Leu Glu Leu Arg Val Gly Pro Gly Val Cys Arg  
 125 130 135  
 Met Arg Gln Asp Pro Ala His Pro His Val Val Ala Thr Gly Gly  
 140 145 150  
 Lys Glu Asn Ala Leu Lys Ile Trp Asp Leu Gln Gly Ser Glu Glu  
 155 160 165  
 Pro Val Phe Arg Ala Lys Asn Val Arg Asn Asp Trp Leu Asp Leu  
 170 175 180  
 Arg Val Pro Ile Trp Asp Gln Asp Ile Gln Phe Leu Pro Gly Ser  
 185 190 195  
 Gln Lys Leu Val Thr Cys Thr Gly Tyr His Gln Val Arg Val Tyr  
 200 205 210  
 Asp Pro Ala Ser Pro Gln Arg Arg Pro Val Leu Glu Thr Thr Tyr  
 215 220 225  
 Gly Glu Tyr Pro Leu Thr Ala Met Thr Leu Thr Pro Gly Gly Asn  
 230 235 240  
 Ser Val Ile Val Gly Asn Thr His Gly Gln Leu Ala Glu Ile Asp  
 245 250 255  
 Leu Arg Gln Gly Arg Leu Leu Gly Cys Leu Lys Gly Leu Ala Gly  
 260 265 270  
 Ser Val Arg Gly Leu Gln Cys His Pro Ser Lys Pro Leu Leu Ala  
 275 280 285  
 Ser Cys Gly Leu Asp Arg Val Leu Arg Ile His Arg Ile Gln Asn  
 290 295 300  
 Pro Arg Gly Leu Glu His Lys Asp Glu Pro Gln Glu Pro Gln Glu  
 305 310 315  
 Pro Asn Lys Val Pro Leu Glu Asp Thr Glu Thr Asp Glu Leu Trp  
 320 325 330  
 Ala Ser Leu Glu Ala Ala Ala Lys Arg Lys Leu Ser Gly Leu Glu  
 335 340 345  
 Gln Pro Gln Gly Ala Leu Gln Thr Arg Arg Arg Lys Lys Lys Arg

	350	355	360
Pro Gly Ser Thr Ser Pro			
365			
<210> 37			
<211> 339			
<212> PRT			
<213> Homo sapiens			
<220>			
<221> misc_feature			
<223> Incyte ID No: 2871116CD1			
<400> 37			
Met Ala Thr Glu Ile Gly Ser Pro Pro Arg Phe Phe His Met Pro			
1 5 10 15			
Arg Phe Gln His Gln Ala Pro Arg Gln Leu Phe Tyr Lys Arg Pro			
20 25 30			
Asp Phe Ala Gln Gln Ala Met Gln Gln Leu Thr Phe Asp Gly			
35 40 45			
Lys Arg Met Arg Lys Ala Val Asn Arg Lys Thr Ile Asp Tyr Asn			
50 55 60			
Pro Ser Val Ile Lys Tyr Leu Glu Asn Arg Ile Trp Gln Arg Asp			
65 70 75			
Gln Arg Asp Met Arg Ala Ile Gln Pro Asp Ala Gly,Tyr Tyr Asn			
80 85 90			
Asp Leu Val Pro Pro Ile Gly Met Leu Asn Asn Pro Met Asn Ala			
95 100 105			
Val Thr Thr Lys Phe Val Arg Thr Ser Thr Asn Lys Val Lys Cys			
110 115 120			
Pro Val Phe Val Val Arg Leu Gln Glu Glu Phe Glu Ser Leu Ser			
125 130 135			
Val Leu Lys Ser Trp Thr Pro Glu Gly Arg Arg Leu Val Thr Gly			
140 145 150			
Ala Ser Ser Gly Glu Phe Thr Leu Trp Asn Gly Leu Thr Phe Asn			
155 160 165			
Phe Glu Thr Ile Leu Gln Ala His Asp Ser Pro Val Arg Ala Met			
170 175 180			
Thr Trp Ser His Asn Asp Met Trp Met Leu Thr Ala Asp His Gly			
185 190 195			
Gly Tyr Val Lys Tyr Trp Gln Ser Asn Met Asn Asn Val Lys Met			
200 205 210			
Phe Gln Ala His Lys Glu Ala Ile Arg Glu Ala Arg Phe Ile His			
215 220 225			
Asn Ile Pro Phe Ser Val Val Pro Ile Val Met Val Lys Leu Phe			
230 235 240			
Ser Lys Cys Ile Leu Gly Ala Glu Met His Gly Leu Cys Gln Phe			
245 250 255			
Leu Gly Asn Phe Leu His Pro Ile Asn Thr Ile Phe Phe Phe Val			
260 265 270			
Phe Thr His Ser Pro Phe Cys Trp His Leu Ser Glu Val Val Leu			
275 280 285			
Ser Arg Tyr Gln Pro Leu Gln Tyr Val Arg Asp Val Leu Ser Ala			
290 295 300			
Ala Phe Cys Thr Gly Phe Leu Phe Ser Phe Met Ile Asn Asn Val			
305 310 315			
Tyr Thr Leu Phe Leu Phe Ile Ile Tyr Cys Val Arg Gln Glu Tyr			
320 325 330			
Phe Ile Pro Asn Lys Glu Phe Ser Leu			
335			
<210> 38			
<211> 213			
<212> PRT			
<213> Homo sapiens			

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2942212CD1

<400> 38  
 Met Glu Ala Ile Trp Leu Tyr Gln Phe Arg Leu Ile Val Ile Gly  
 1 5 10 15  
 Asp Ser Thr Val Gly Lys Ser Cys Leu Ile Arg Arg Phe Thr Glu  
 20 25 30  
 Gly Arg Phe Ala Gln Val Ser Asp Pro Thr Val Gly Val Asp Phe  
 35 40 45  
 Phe Ser Arg Leu Val Glu Ile Glu Pro Gly Lys Arg Ile Lys Leu  
 50 55 60  
 Gln Ile Trp Asp Thr Ala Gly Gln Glu Arg Phe Arg Ser Ile Thr  
 65 70 75  
 Arg Ala Tyr Tyr Arg Asn Ser Val Gly Gly Leu Leu Leu Phe Ala  
 80 85 90  
 Ile Thr Asn Arg Arg Ser Phe Gln Asn Val His Glu Trp Leu Glu  
 95 100 105  
 Glu Thr Lys Val His Val Gln Pro Tyr Gln Ile Val Phe Val Leu  
 110 115 120  
 Val Gly His Lys Cys Asp Leu Asp Thr Gln Arg Gln Val Thr Arg  
 125 130 135  
 His Glu Ala Glu Lys Leu Ala Ala Ala Tyr Gly Met Lys Tyr Ile  
 140 145 150  
 Glu Thr Ser Ala Arg Asp Ala Ile Asn Val Glu Lys Ala Phe Thr  
 155 160 165  
 Asp Leu Thr Arg Asp Ile Tyr Glu Leu Val Lys Arg Gly Glu Ile  
 170 175 180  
 Thr Ile Gln Glu Gly Trp Glu Gly Val Lys Ser Gly Phe Val Pro  
 185 190 195  
 Asn Val Val His Ser Ser Glu Glu Val Val Lys Ser Glu Arg Arg  
 200 205 210

Cys Leu Cys

<210> 39  
 <211> 393  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3685151CD1

<400> 39  
 Met Glu Leu Val Ala Gly Cys Tyr Glu Gln Val Leu Phe Gly Phe  
 1 5 10 15  
 Ala Val His Pro Glu Pro Glu Ala Cys Gly Asp His Glu Gln Gln  
 20 25 30  
 Trp Thr Leu Val Ala Asp Phe Thr His His Ala His Thr Ala Ser  
 35 40 45  
 Leu Ser Ala Val Ala Val Asn Ser Arg Phe Val Val Thr Gly Ser  
 50 55 60  
 Lys Asp Glu Thr Ile His Ile Tyr Asp Met Lys Lys Lys Ile Glu  
 65 70 75  
 His Gly Ala Leu Val His His Ser Gly Thr Ile Thr Cys Leu Thr  
 80 85 90  
 Phe Tyr Gly Asn Arg His Leu Ile Ser Gly Ala Glu Asp Gly Leu  
 95 100 105  
 Ile Cys Ile Trp Asp Ala Lys Lys Trp Glu Ser Leu Thr Ser Ile  
 110 115 120  
 Lys Ala His Lys Gly Gln Val Thr Phe Leu Ser Ile His Pro Ser  
 125 130 135

Gly Lys Leu Ala Leu Ser Val Gly Thr Asp Lys Thr Leu Arg Thr  
     140                         145                         150  
 Trp Asn Leu Val Glu Gly Arg Ser Ala Phe Ile Lys Asn Ile Lys  
     155                         160                         165  
 Gln Asn Ala His Ile Val Glu Trp Ser Pro Arg Gly Glu Gln Tyr  
     170                         175                         180  
 Val Val Ile Ile Gln Asn Lys Ile Asp Ile Tyr Gln Leu Asp Thr  
     185                         190                         195  
 Ala Ser Ile Ser Gly Thr Ile Thr Asn Glu Lys Arg Ile Ser Ser  
     200                         205                         210  
 Val Lys Phe Leu Ser Glu Ser Val Leu Ala Val Ala Gly Asp Glu  
     215                         220                         225  
 Glu Val Ile Arg Phe Phe Asp Cys Asp Ser Leu Val Cys Leu Cys  
     230                         235                         240  
 Glu Phe Lys Ala His Glu Asn Arg Val Lys Asp Met Phe Ser Phe  
     245                         250                         255  
 Glu Ile Pro Glu His His Val Ile Val Ser Ala Ser Ser Asp Gly  
     260                         265                         270  
 Phe Ile Lys Met Trp Lys Leu Lys Gln Asp Lys Lys Val Pro Pro  
     275                         280                         285  
 Ser Leu Leu Cys Glu Ile Asn Thr Asn Ala Arg Leu Thr Cys Leu  
     290                         295                         300  
 Gly Val Trp Leu Asp Lys Val Ala Asp Met Lys Glu Ser Leu Pro  
     305                         310                         315  
 Pro Ala Ala Glu Pro Ser Pro Val Ser Lys Glu Gln Ser Lys Ile  
     320                         325                         330  
 Gly Lys Lys Glu Pro Gly Asp Thr Val His Lys Glu Glu Lys Arg  
     335                         340                         345  
 Ser Lys Pro Asn Thr Lys Lys Arg Gly Leu Thr Gly Asp Ser Lys  
     350                         355                         360  
 Lys Ala Thr Lys Glu Ser Gly Leu Ile Ser Thr Lys Lys Arg Lys  
     365                         370                         375  
 Met Val Glu Met Leu Glu Lys Lys Arg Lys Lys Lys Lys Ile Lys  
     380                         385                         390

Thr Met Gln

<210> 40  
 <211> 399  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 4881515CD1

<400> 40  
 Met Ser Leu Gln Tyr Gly Ala Glu Glu Thr Pro Leu Ala Gly Ser  
     1                         5                         10                         15  
 Tyr Gly Ala Ala Asp Ser Phe Pro Lys Asp Phe Gly Tyr Gly Val  
     20                         25                         30  
 Glu Glu Glu Glu Glu Ala Ala Ala Ala Gly Gly Gly Val Gly  
     35                         40                         45  
 Ala Gly Ala Gly Gly Cys Gly Pro Gly Gly Ala Asp Ser Ser  
     50                         55                         60  
 Lys Pro Arg Ile Leu Leu Met Gly Leu Arg Arg Ser Gly Lys Ser  
     65                         70                         75  
 Ser Ile Gln Lys Val Val Phe His Lys Met Ser Pro Asn Glu Thr  
     80                         85                         90  
 Leu Phe Leu Glu Ser Thr Asn Lys Ile Tyr Lys Asp Asp Ile Ser  
     95                         100                         105  
 Asn Ser Ser Phe Val Asn Phe Gln Ile Trp Asp Phe Pro Gly Gln  
   110                         115                         120  
 Met Asp Phe Phe Asp Pro Thr Phe Asp Tyr Glu Met Ile Phe Arg

	125	130	135
Gly Thr Gly Ala	Leu Ile Tyr Val Ile Asp	Ala Gln Asp Asp	Tyr
	140	145	150
Met Glu Ala Leu	Thr Arg Leu His Ile	Thr Val Ser Lys Ala	Tyr
	155	160	165
Lys Val Asn Pro	Asp Met Asn Phe Glu	Val Phe Ile His Lys	Val
	170	175	180
Asp Gly Leu Ser	Asp Asp His Lys Ile	Glu Thr Gln Arg Asp	Ile
	185	190	195
His Gln Arg Ala	Asn Asp Asp Leu Ala	Asp Ala Gly Leu Glu	Lys
	200	205	210
Leu His Leu Ser	Phe Tyr Leu Thr Ser	Ile Tyr Asp His Ser	Ile
	215	220	225
Phe Glu Ala Phe	Ser Lys Val Val Gln	Lys Leu Ile Pro Gln	Leu
	230	235	240
Pro Thr Leu Glu	Asn Leu Leu Asn Ile	Phe Ile Ser Asn Ser	Gly
	245	250	255
Ile Glu Lys Ala	Phe Leu Phe Asp Val	Val Ser Lys Ile Tyr	Ile
	260	265	270
Ala Thr Asp Ser	Ser Pro Val Asp Met	Gln Ser Tyr Glu Leu	Cys
	275	280	285
Cys Asp Met Ile	Asp Val Val Ile Asp	Val Ser Cys Ile Tyr	Gly
	290	295	300
Leu Lys Glu Asp	Gly Ser Gly Ser Ala	Tyr Asp Lys Glu Ser	Met
	305	310	315
Ala Ile Ile Lys	Leu Asn Asn Thr Thr	Val Leu Tyr Leu Lys	Glu
	320	325	330
Val Thr Lys Phe	Leu Ala Leu Val Cys	Ile Leu Arg Glu Glu	Ser
	335	340	345
Phe Glu Arg Lys	Gly Leu Ile Asp Tyr	Asn Phe His Cys Phe	Arg
	350	355	360
Lys Ala Ile His	Glu Val Phe Glu Val	Gly Val Thr Ser His	Arg
	365	370	375
Ser Cys Gly His	Gln Thr Ser Ala Ser	Ser Leu Lys Ala Leu	Thr
	380	385	390
His Asn Gly Thr	Pro Arg Asn Ala Ile		
	395		

&lt;210&gt; 41

&lt;211&gt; 412

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 5324681CD1

&lt;400&gt; 41

Met Ala Gly Ser Val	Gly Leu Ala Leu Cys	Gly Gln Thr Leu Val	
1	5	10	15
Val Arg Gly Gly Ser	Arg Phe Leu Ala Thr	Ser Ile Ala Ser Ser	
	20	25	30
Asp Asp Asp Ser	Leu Phe Ile Tyr Asp	Cys Ser Ala Ala Glu Lys	
	35	40	45
Lys Ser Gln Glu Asn	Lys Gly Glu Asp Ala	Pro Leu Asp Gln Gly	
	50	55	60
Ser Gly Ala Ile Leu	Ala Ser Thr Phe Ser	Lys Ser Gly Ser Tyr	
	65	70	75
Phe Ala Leu Thr Asp	Asp Ser Lys Arg Leu	Ile Leu Phe Arg Thr	
	80	85	90
Lys Pro Trp Gln Cys	Leu Ser Val Arg Thr	Val Ala Arg Arg Cys	
	95	100	105
Thr Ala Leu Thr	Phe Ile Ala Ser Glu	Glu Lys Val Leu Val Ala	
	110	115	120

<210> 42  
<211> 163  
<212> PRT  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 5387651CD1

```

<400> 42
Met Asp Ala Leu Glu Gly Glu Ser Phe Ala Leu Ser Phe Ser Ser
      1           5           10          15
Ala Ser Asp Ala Glu Phe Asp Ala Val Val Gly Tyr Leu Glu Asp
      20          25          30
Ile Ile Met Asp Asp Glu Phe Gln Leu Leu Gln Arg Asn Phe Met
      35          40          45
Asp Lys Tyr Tyr Leu Glu Phe Glu Asp Thr Glu Glu Asn Lys Leu
      50          55          60
Ile Tyr Thr Pro Ile Phe Asn Glu Tyr Ile Ser Leu Val Glu Lys
      65          70          75
Tyr Ile Glu Glu Gln Leu Leu Gln Arg Ile Pro Glu Phe Asn Met
      80          85          90
Ala Ala Phe Thr Thr Leu Gln His His Lys Asp Glu Val Ala

```

	95	100	105
Gly Asp Ile Phe Asp Met Leu Leu Thr Phe Thr Asp Phe Leu Ala			
110	115	120	
Phe Lys Glu Met Phe Leu Asp Tyr Arg Ala Glu Lys Glu Gly Arg			
125	130	135	
Gly Leu Asp Leu Ser Ser Gly Leu Val Val Thr Ser Leu Cys Lys			
140	145	150	
Ser Ser Ser Leu Pro Ala Ser Gln Asn Asn Leu Arg His			
155	160		

&lt;210&gt; 43

&lt;211&gt; 514

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 5595679CD1

&lt;400&gt; 43

Met Gln Glu Ser Gly Cys Arg Leu Glu His Pro Ser Ala Thr Lys			
1	5	10	15
Phe Arg Asn His Val Met Glu Gly Asp Trp Asp Lys Ala Glu Asn			
20	25	30	
Asp Leu Asn Glu Leu Lys Pro Leu Val His Ser Pro His. Ala Ile			
35	40	45	
Val Val Arg Gly Ala Leu Glu Ile Ser Gln Thr Leu Leu Gly Ile			
50	55	60	
Ile Val Arg Met Lys Phe Leu Leu Leu Gln Gln Lys Tyr Leu Glu			
65	70	75	
Tyr Leu Glu Asp Gly Lys Val Leu Glu Ala Leu Gln Val Leu Arg			
80	85	90	
Cys Glu Leu Thr Pro Leu Lys Tyr Asn Thr Glu Arg Ile His Val			
95	100	105	
Leu Ser Gly Tyr Leu Met Cys Ser His Ala Glu Asp Leu Arg Ala			
110	115	120	
Lys Ala Glu Trp Glu Gly Lys Gly Thr Ala Ser Arg Ser Lys Leu			
125	130	135	
Leu Asp Lys Leu Gln Thr Tyr Leu Pro Pro Ser Val Met Leu Pro			
140	145	150	
Pro Arg Arg Leu Gln Thr Leu Leu Arg Gln Ala Val Glu Leu Gln			
155	160	165	
Arg Asp Arg Cys Leu Tyr His Asn Thr Lys Leu Asp Asn Asn Leu			
170	175	180	
Asp Ser Val Ser Leu Leu Ile Asp His Val Cys Ser Arg Arg Gln			
185	190	195	
Phe Pro Cys Tyr Thr Gln Gln Ile Leu Thr Glu His Cys Asn Glu			
200	205	210	
Val Trp Phe Cys Lys Phe Ser Asn Asp Gly Thr Lys Leu Ala Thr			
215	220	225	
Gly Ser Lys Asp Thr Thr Val Ile Ile Trp Gln Val Asp Pro Asp			
230	235	240	
Thr His Leu Leu Lys Leu Leu Lys Thr Leu Glu Gly His Ala Tyr			
245	250	255	
Gly Val Ser Tyr Ile Ala Trp Ser Pro Asp Asp Asn Tyr Leu Val			
260	265	270	
Ala Cys Gly Pro Asp Asp Cys Ser Glu Leu Trp Leu Trp Asn Val			
275	280	285	
Gln Thr Gly Glu Leu Arg Thr Lys Met Ser Gln Ser His Glu Asp			
290	295	300	
Ser Leu Thr Ser Val Ala Trp Asn Pro Asp Gly Lys Arg Phe Val			
305	310	315	
Thr Gly Gly Gln Arg Gly Gln Phe Tyr Gln Cys Asp Leu Asp Gly			
320	325	330	

Asn Leu Leu Asp Ser Trp Glu Gly Val Arg Val Gln Cys Leu Trp  
     335                         340                         345  
 Cys Leu Ser Asp Gly Lys Thr Val Leu Ala Ser Asp Thr His Gln  
     350                         355                         360  
 Arg Ile Arg Gly Tyr Asn Phe Glu Asp Leu Thr Asp Arg Asn Ile  
     365                         370                         375  
 Val Gln Glu Asp His Pro Ile Met Ser Phe Thr Ile Ser Lys Asn  
     380                         385                         390  
 Gly Arg Leu Ala Leu Leu Asn Val Ala Thr Gln Gly Val His Leu  
     395                         400                         405  
 Trp Asp Leu Gln Asp Arg Val Leu Val Arg Lys Tyr Gln Gly Val  
     410                         415                         420  
 Thr Gln Gly Phe Tyr Thr Ile His Ser Cys Phe Gly Gly His Asn  
     425                         430                         435  
 Glu Asp Phe Ile Ala Ser Gly Ser Glu Asp His Lys Val Tyr Ile  
     440                         445                         450  
 Trp His Lys Arg Ser Glu Leu Pro Ile Ala Glu Leu Thr Gly His  
     455                         460                         465  
 Thr Arg Thr Val Asn Cys Val Ser Trp Asn Pro Gln Ile Pro Ser  
     470                         475                         480  
 Met Met Ala Ser Ala Ser Asp Asp Gly Thr Val Arg Ile Trp Gly  
     485                         490                         495  
 Pro Ala Pro Phe Ile Asp His Gln Asn Ile Glu Glu Glu Cys Ser  
     500                         505                         510  
 Ser Met Asp Ser

<210> 44  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 5782457CD1

<400> 44  
 Met Glu Glu Trp Asp Val Pro Gln Met Lys Lys Glu Val Glu Ser  
     1                         5                         10                         15  
 Leu Lys Tyr Gln Leu Ala Phe Gln Arg Glu Met Ala Ser Lys Thr  
     20                         25                         30  
 Ile Pro Glu Leu Leu Lys Trp Ile Glu Asp Gly Ile Pro Lys Asp  
     35                         40                         45  
 Pro Phe Leu Asn Pro Asp Leu Met Lys Asn Asn Pro Trp Val Glu  
     50                         55                         60  
 Lys Gly Lys Cys Thr Ile Leu  
     65

<210> 45  
 <211> 315  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 760677CD1

<400> 45  
 Met Ala Phe Pro Glu Pro Lys Pro Arg Pro Pro Glu Leu Pro Gln  
     1                         5                         10                         15  
 Lys Arg Leu Lys Thr Leu Asp Cys Gly Gln Gly Ala Val Arg Ala  
     20                         25                         30  
 Val Arg Phe Asn Val Asp Gly Asn Tyr Cys Leu Thr Cys Gly Ser  
     35                         40                         45  
 Asp Lys Thr Leu Lys Leu Trp Asn Pro Leu Arg Gly Thr Leu Leu

	50	55	60
Arg Thr Tyr Ser Gly His Gly Tyr Glu Val Leu Asp Ala Ala Gly			
65	70	75	
Ser Phe Asp Asn Ser Ser Leu Cys Ser Gly Gly Gly Asp Lys Ala			
80	85	90	
Val Val Leu Trp Asn Val Ala Ser Gly Gln Val Val Arg Lys Phe			
95	100	105	
Arg Gly His Ala Gly Lys Val Asn Thr Val Gln Phe Ser Glu Glu			
110	115	120	
Ala Thr Val Ile Leu Ser Gly Ser Ile Asp Ser Ser Ile Arg Cys			
125	130	135	
Trp Asp Cys Arg Ser Arg Arg Pro Glu Pro Val Gln Thr Leu Asp			
140	145	150	
Glu Ala Arg Asp Gly Val Ser Ser Val Lys Val Ser Asp His Glu			
155	160	165	
Ile Leu Ala Gly Ser Val Asp Gly Arg Val Arg Arg Tyr Asp Leu			
170	175	180	
Arg Met Gly Gln Leu Phe Ser Asp Tyr Val Gly Ser Pro Ile Thr			
185	190	195	
Cys Thr Cys Phe Ser Arg Asp Gly Gln Cys Thr Leu Val Ser Ser			
200	205	210	
Leu Asp Ser Thr Leu Arg Leu Leu Asp Lys Asp Thr Gly Glu Leu			
215	220	225	
Leu Gly Glu Tyr Lys Gly His Lys Asn Gln Glu Tyr Lys Leu Asp			
230	235	240	
Cys Cys Leu Ser Glu Arg Asp Thr His Val Val Ser Cys Ser Glu			
245	250	255	
Asp Gly Lys Val Phe Phe Trp Asp Leu Val Glu Gly Ala Leu Ala			
260	265	270	
Leu Ala Leu Pro Val Gly Ser Gly Val Val Gln Ser Leu Asp Tyr			
275	280	285	
His Pro Thr Glu Pro Cys Leu Leu Thr Ala Met Gly Gly Ser Val			
290	295	300	
Gln Cys Trp Arg Glu Glu Ala Tyr Glu Ala Glu Asp Gly Ala Gly			
305	310	315	

<210> 46  
<211> 504  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1348567CD1

<400> 46

Met Ser Leu Ile Cys Ser Ile Ser Asn Glu Val Pro Glu His Pro			
1	5	10	15
Cys Val Ser Pro Val Ser Asn His Val Tyr Glu Arg Arg Leu Ile			
20	25	30	
Glu Lys Tyr Ile Ala Glu Asn Gly Thr Asp Pro Ile Asn Asn Gln			
35	40	45	
Pro Leu Ser Glu Glu Gln Leu Ile Asp Ile Lys Val Ala His Pro			
50	55	60	
Ile Arg Pro Lys Pro Pro Ser Ala Thr Ser Ile Pro Ala Ile Leu			
65	70	75	
Lys Ala Leu Gln Asp Glu Trp Asp Ala Val Met Pro His Ser Phe			
80	85	90	
Thr Leu Arg Gln Gln Leu Gln Thr Thr Arg Gln Glu Leu Ser His			
95	100	105	
Ala Leu Tyr Gln His Asp Ala Ala Cys Arg Val Ile Ala Arg Leu			
110	115	120	
Thr Lys Glu Val Thr Ala Ala Arg Glu Ala Leu Ala Thr Leu Lys			

	125	130	135
Pro Gln Ala Gly	Leu Ile Val Pro Gln	Ala Val Pro Ser Ser	Gln
	140	145	150
Pro Ser Val Val	Gly Ala Gly Glu Pro	Met Asp Leu Gly Glu	Leu
	155	160	165
Val Gly Met Thr	Pro Glu Ile Ile Gln	Lys Leu Gln Asp Lys	Ala
	170	175	180
Thr Val Leu Thr	Thr Glu Arg Lys Lys	Arg Gly Lys Thr Val	Pro
	185	190	195
Glu Glu Leu Val	Lys Pro Glu Glu Leu	Ser Lys Tyr Arg Gln	Val
	200	205	210
Ala Ser His Val	Gly Leu His Ser Ala	Ser Ile Pro Gly Ile	Leu
	215	220	225
Ala Leu Asp Leu	Cys Pro Ser Asp Thr	Asn Lys Ile Leu Thr	Gly
	230	235	240
Gly Ala Asp Lys	Asn Val Val Val Phe	Asp Lys Ser Ser Glu	Gln
	245	250	255
Ile Leu Ala Thr	Leu Lys Gly His Thr	Lys Lys Val Thr Ser	Val
	260	265	270
Val Phe His Pro	Ser Gln Asp Leu Val	Phe Ser Ala Ser Pro	Asp
	275	280	285
Ala Thr Ile Arg	Ile Trp Ser Val Pro	Asn Ala Ser Cys Val	Gln
	290	295	300
Val Val Arg Ala	His Glu Ser Ala Val	Thr Gly Leu Ser Leu	His
	305	310	315
Ala Thr Gly Asp	Tyr Leu Leu Ser Ser	Ser Asp Asp Gln Tyr	Trp
	320	325	330
Ala Phe Ser Asp	Ile Gln Thr Gly Arg	Val Leu Thr Lys Val	Thr
	335	340	345
Asp Glu Thr Ser	Gly Cys Ser Leu Thr	Cys Ala Gln Phe His	Pro
	350	355	360
Asp Gly Leu Ile	Phe Gly Thr Gly Thr	Met Asp Ser Gln Ile	Lys
	365	370	375
Ile Trp Asp Leu	Lys Glu Arg Thr Asn	Val Ala Asn Phe Pro	Gly
	380	385	390
His Ser Gly Pro	Ile Thr Ser Ile Ala	Phe Ser Glu Asn Gly	Tyr
	395	400	405
Tyr Leu Ala Thr	Ala Ala Asp Asp Ser	Ser Val Lys Leu Trp	Asp
	410	415	420
Leu Arg Lys Leu	Lys Asn Phe Lys Thr	Leu Gln Leu Asp Asn	Asn
	425	430	435
Phe Glu Val Lys	Ser Leu Ile Phe Asp	Gln Ser Gly Thr Tyr	Leu
	440	445	450
Ala Leu Gly Gly	Thr Asp Val Gln Ile	Tyr Ile Cys Lys Gln	Trp
	455	460	465
Thr Glu Ile Leu	His Phe Thr Glu His	Ser Gly Leu Thr Thr	Gly
	470	475	480
Val Ala Phe Gly	His His Ala Lys Phe	Ile Ala Ser Thr Gly	Met
	485	490	495
Asp Arg Ser Leu	Lys Phe Tyr Ser Leu		
	500		

&lt;210&gt; 47

&lt;211&gt; 522

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1751354CD1

&lt;400&gt; 47

Met Ala Phe Leu Asp Asn Pro Thr Ile Ile Leu Ala His Ile Arg  
1 5 10 15

Gln	Ser	His	Val	Thr	Ser	Asp	Asp	Thr	Gly	Met	Cys	Glu	Met	Val
				20				25					30	
Leu	Ile	Asp	His	Asp	Val	Asp	Leu	Glu	Lys	Ile	His	Pro	Pro	Ser
				35				40					45	
Met	Pro	Gly	Asp	Ser	Gly	Ser	Glu	Ile	Gln	Gly	Ser	Asn	Gly	Glu
				50				55					60	
Thr	Gln	Gly	Tyr	Val	Tyr	Ala	Gln	Ser	Val	Asp	Ile	Thr	Ser	Ser
				65				70					75	
Trp	Asp	Phe	Gly	Ile	Arg	Arg	Arg	Ser	Asn	Thr	Ala	Gln	Arg	Leu
				80				85					90	
Glu	Arg	Leu	Arg	Lys	Glu	Arg	Gln	Asn	Gln	Ile	Lys	Cys	Lys	Asn
				95				100					105	
Ile	Gln	Trp	Lys	Glu	Arg	Asn	Ser	Lys	Gln	Ser	Ala	Gln	Glu	Leu
				110				115					120	
Lys	Ser	Leu	Phe	Glu	Lys	Lys	Ser	Leu	Lys	Glu	Lys	Pro	Pro	Ile
				125				130					135	
Ser	Gly	Lys	Gln	Ser	Ile	Leu	Ser	Val	Arg	Leu	Glu	Gln	Cys	Pro
				140				145					150	
Leu	Gln	Leu	Asn	Asn	Pro	Phe	Asn	Glu	Tyr	Ser	Lys	Phe	Asp	Gly
				155				160					165	
Lys	Gly	His	Val	Gly	Thr	Thr	Ala	Thr	Lys	Lys	Ile	Asp	Val	Tyr
				170				175					180	
Leu	Pro	Leu	His	Ser	Ser	Gln	Asp	Arg	Leu	Leu	Pro	Met	Thr	Val
				185				190					195	
Val	Thr	Met	Ala	Ser	Ala	Arg	Val	Gln	Asp	Leu	Ile	Gly	Leu	Ile
				200				205					210	
Cys	Trp	Gln	Tyr	Thr	Ser	Glu	Gly	Arg	Glu	Pro	Lys	Leu	Asn	Asp
				215				220					225	
Asn	Val	Ser	Ala	Tyr	Cys	Leu	His	Ile	Ala	Glu	Asp	Asp	Gly	Glu
				230				235					240	
Val	Asp	Thr	Asp	Phe	Pro	Pro	Leu	Asp	Ser	Asn	Glu	Pro	Ile	His
				245				250					255	
Lys	Phe	Gly	Phe	Ser	Thr	Leu	Ala	Leu	Val	Glu	Lys	Tyr	Ser	Ser
				260				265					270	
Pro	Gly	Leu	Thr	Ser	Lys	Glu	Ser	Leu	Phe	Val	Arg	Ile	Asn	Ala
				275				280					285	
Ala	His	Gly	Phe	Ser	Leu	Ile	Gln	Val	Asp	Asn	Thr	Lys	Val	Thr
				290				295					300	
Met	Lys	Glu	Ile	Leu	Leu	Lys	Ala	Val	Lys	Arg	Arg	Lys	Gly	Ser
				305				310					315	
Gln	Lys	Val	Ser	Gly	Pro	Gln	Tyr	Arg	Leu	Glu	Lys	Gln	Ser	Glu
				320				325					330	
Pro	Asn	Val	Ala	Val	Asp	Leu	Asp	Ser	Thr	Leu	Glu	Ser	Gln	Ser
				335				340					345	
Ala	Trp	Glu	Phe	Cys	Leu	Val	Arg	Glu	Asn	Ser	Ser	Arg	Ala	Asp
				350				355					360	
Gly	Val	Phe	Glu	Glu	Asp	Ser	Gln	Ile	Asp	Ile	Ala	Thr	Val	Gln
				365				370					375	
Asp	Met	Leu	Ser	Ser	His	His	Tyr	Lys	Ser	Phe	Lys	Val	Ser	Met
				380				385					390	
Ile	His	Arg	Leu	Arg	Phe	Thr	Thr	Asp	Val	Gln	Leu	Gly	Ile	Ser
				395				400					405	
Gly	Asp	Lys	Val	Glu	Ile	Asp	Pro	Val	Thr	Asn	Gln	Lys	Ala	Ser
				410				415					420	
Thr	Lys	Phe	Trp	Ile	Lys	Gln	Lys	Pro	Ile	Ser	Ile	Asp	Ser	Asp
				425				430					435	
Leu	Leu	Cys	Ala	Cys	Asp	Leu	Ala	Glu	Glu	Lys	Ser	Pro	Ser	His
				440				445					450	
Ala	Ile	Phe	Lys	Leu	Thr	Tyr	Leu	Ser	Asn	His	Asp	Tyr	Lys	His
				455				460					465	
Leu	Tyr	Phe	Glu	Ser	Asp	Ala	Ala	Thr	Val	Asn	Glu	Ile	Val	Leu
				470				475					480	
Lys	Val	Asn	Tyr	Ile	Leu	Glu	Ser	Arg	Ala	Ser	Thr	Ala	Arg	Ala

	485	490	495
Asp Tyr Phe Ala Gln Lys Gln Arg Lys		Leu Asn Arg Arg Thr	Ser
500		505	510
Phe Ser Phe Gln Lys Glu Lys Lys Ser		Gly Gln Gln	
515		520	

<210> 48  
<211> 316  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1976780CD1

<400> 48			
Met Ala Ser Lys Asp Lys Ser Ser Lys Lys Asn Val Phe Glu Leu			
1	5	10	15
Lys Thr Arg Gln Gly Thr Glu Leu Leu Ile Gln Ser Asp Asn Asp			
20		25	30
Thr Val Ile Asn Asp Trp Phe Lys Val Leu Ser Ser Thr Ile Asn			
35		40	45
Asn Gln Ala Val Glu Thr Asp Glu Gly Ile Glu Glu Glu Ile Pro			
50		55	60
Asp Ser Pro Gly Ile Glu Lys His Asp Lys Glu Lys Glu Gln Lys			
65		70	75
Asp Pro Lys Lys Leu Arg Ser Phe Lys Val Ser Ser Ile Asp Ser			
80		85	90
Ser Glu Gln Lys Lys Thr Lys Lys Asn Leu Lys Lys Phe Leu Thr			
95		100	105
Arg Arg Pro Thr Leu Gln Ala Val Arg Glu Lys Gly Tyr Ile Lys			
110		115	120
Asp Gln Val Phe Gly Ser Asn Leu Ala Asn Leu Cys Gln Arg Glu			
125		130	135
Asn Gly Thr Val Pro Lys Phe Val Lys Leu Cys Ile Glu His Val			
140		145	150
Glu Glu His Gly Leu Asp Ile Asp Gly Ile Tyr Arg Val Ser Gly			
155		160	165
Asn Leu Ala Val Ile Gln Lys Leu Arg Phe Ala Val Asn His Asp			
170		175	180
Glu Lys Leu Asp Leu Asn Asp Ser Lys Trp Glu Asp Ile His Val			
185		190	195
Ile Thr Gly Ala Leu Lys Met Phe Phe Arg Glu Leu Pro Glu Pro			
200		205	210
Leu Phe Thr Phe Asn His Phe Asn Asp Phe Val Asn Ala Ile Lys			
215		220	225
Gln Glu Pro Arg Gln Arg Val Ala Ala Val Lys Asp Leu Ile Arg			
230		235	240
Gln Leu Pro Lys Pro Asn Gln Asp Thr Met Gln Ile Leu Phe Arg			
245		250	255
His Leu Arg Arg Val Ile Glu Asn Gly Glu Lys Asn Arg Met Thr			
260		265	270
Tyr Gln Ser Ile Ala Ile Val Phe Gly Pro Thr Leu Leu Lys Pro			
275		280	285
Glu Lys Glu Thr Gly Asn Ile Ala Val His Thr Val Tyr Gln Asn			
290		295	300
Gln Ile Val Glu Leu Ile Leu Leu Glu Leu Ser Ser Ile Phe Gly			
305		310	315

Arg

<210> 49  
<211> 387  
<212> PRT  
<213> Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2048234CD1

&lt;400&gt; 49

Met Val His Cys Ser Cys Val Leu Phe Arg Lys Tyr Gly Asn Phe  
1 5 10 15  
Ile Asp Lys Leu Arg Leu Phe Thr Arg Gly Gly Ser Gly Gly Met  
20 25 30  
Gly Tyr Pro Arg Leu Gly Gly Glu Gly Lys Gly Gly Asp Val  
35 40 45  
Trp Val Val Ala Gln Asn Arg Met Thr Leu Lys Gln Leu Lys Asp  
50 55 60  
Arg Tyr Pro Arg Lys Arg Phe Val Ala Gly Val Gly Ala Asn Ser  
65 70 75  
Lys Ile Ser Ala Leu Lys Gly Ser Lys Gly Lys Asp Trp Glu Ile  
80 85 90  
Pro Val Pro Val Gly Ile Ser Val Thr Asp Glu Asn Gly Lys Ile  
95 100 105  
Ile Gly Glu Leu Ser Lys Glu Asn Asp Arg Ile Leu Val Ala Gln  
110 115 120  
Gly Gly Leu Gly Gly Lys Leu Leu Thr Asn Phe Leu Pro Leu Lys  
125 130 135  
Gly Gln Lys Arg Ile Ile His Leu Asp Leu Lys Leu Ile Ala Asp  
140 145 150  
Val Gly Leu Val Gly Phe Pro Asn Ala Gly Lys Ser Ser Leu Leu  
155 160 165  
Ser Cys Val Ser His Ala Lys Pro Ala Ile Ala Asp Tyr Ala Phe  
170 175 180  
Thr Thr Leu Lys Leu Lys Leu Gly Lys Ile Met Tyr Ser Asp Phe  
185 190 195  
Lys Gln Ile Ser Val Ala Asp Leu Pro Gly Leu Ile Glu Gly Ala  
200 205 210  
His Met Asn Lys Gly Met Gly His Lys Phe Leu Lys His Ile Glu  
215 220 225  
Arg Thr Arg Gln Leu Leu Phe Val Val Asp Ile Ser Gly Phe Gln  
230 235 240  
Leu Ser Ser His Thr Gln Tyr Arg Thr Ala Phe Glu Thr Ile Ile  
245 250 255  
Leu Leu Thr Lys Glu Leu Glu Leu Tyr Lys Glu Glu Leu Gln Thr  
260 265 270  
Lys Pro Ala Leu Leu Ala Val Asn Lys Met Asp Leu Pro Asp Ala  
275 280 285  
Gln Asp Lys Phe His Glu Leu Met Ser Gln Leu Gln Asn Pro Lys  
290 295 300  
Asp Phe Leu His Leu Phe Glu Lys Asn Met Ile Pro Glu Arg Thr  
305 310 315  
Val Glu Phe Gln His Ile Ile Pro Ile Ser Ala Val Thr Gly Glu  
320 325 330  
Gly Ile Glu Glu Leu Lys Asn Cys Ile Arg Lys Ser Leu Asp Glu  
335 340 345  
Gln Ala Asn Gln Glu Asn Asp Ala Leu His Lys Lys Gln Leu Leu  
350 355 360  
Asn Leu Trp Ile Ser Asp Thr Met Ser Ser Thr Glu Pro Pro Ser  
365 370 375  
Lys His Ala Val Thr Thr Ser Lys Met Asp Ile Ile  
380 385

&lt;210&gt; 50

&lt;211&gt; 334

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> misc\_feature  
 <223> Incyte ID No: 2111754CD1

<400> 50  
 Met Pro Ser Gly Pro Arg Ala Ala Leu Arg Trp Ala Ser Pro Ser  
   1               5               10               15  
 Gln Leu Val Ser Tyr His Val Leu Arg Asn Gly Ile Tyr Ala Cys  
   20               25               30  
 Tyr Pro His Ser Leu Arg Pro Arg Thr Pro Leu Leu Cys Ala Ser  
   35               40               45  
 Arg Asn Ile Lys Pro Arg Arg Ser Glu Leu Leu Gly Cys Pro Val  
   50               55               60  
 Gly Cys Arg Gly Ser Leu Ser Glu Gln Arg Ile Cys Leu Leu Gly  
   65               70               75  
 Cys Leu Val Arg Ala Ser Glu Lys Gly Val Ser Cys Cys Gln Leu  
   80               85               90  
 Ser Val Gly Glu Leu Val His Val Ser Pro Leu Arg Ile Pro Thr  
   95               100              105  
 Met Gly Asn Ala Ser Phe Gly Ser Lys Glu Gln Lys Leu Leu Lys  
   110              115              120  
 Arg Leu Arg Leu Leu Pro Ala Leu Leu Ile Leu Arg Ala Phe Lys  
   125              130              135  
 Pro His Arg Lys Ile Arg Asp Tyr Arg Val Val Val Val Gly Thr  
   140              145              150  
 Ala Gly Val Gly Lys Ser Thr Leu Leu His Lys Trp Ala Ser Gly  
   155              160              165  
 Asn Phe Arg His Glu Tyr Leu Pro Thr Ile Glu Asn Thr Tyr Cys  
   170              175              180  
 Gln Leu Leu Gly Cys Ser His Gly Val Leu Ser Leu His Ile Thr  
   185              190              195  
 Asp Ser Lys Ser Gly Asp Gly Asn Arg Ala Leu Gln Arg His Val  
   200              205              210  
 Ile Ala Arg Gly His Ala Phe Val Leu Val Tyr Ser Val Thr Lys  
   215              220              225  
 Lys Glu Thr Leu Glu Glu Leu Lys Ala Phe Tyr Glu Leu Ile Cys  
   230              235              240  
 Lys Ile Lys Gly Asn Asn Leu His Lys Phe Pro Ile Val Leu Val  
   245              250              255  
 Gly Asn Lys Ser Asp Asp Thr His Arg Glu Val Ala Leu Asn Asp  
   260              265              270  
 Gly Ala Thr Cys Ala Met Glu Trp Asn Cys Ala Phe Met Glu Ile  
   275              280              285  
 Ser Ala Lys Thr Asp Val Asn Val Gln Glu Leu Phe His Met Leu  
   290              295              300  
 Leu Asn Tyr Lys Lys Lys Pro Thr Thr Gly Leu Gln Glu Pro Glu  
   305              310              315  
 Lys Lys Ser Gln Met Pro Asn Thr Thr Glu Lys Leu Leu Asp Lys  
   320              325              330  
 Cys Ile Ile Met

<210> 51  
 <211> 551  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2123286CD1

<400> 51  
 Met Glu Glu Glu Leu Pro Leu Phe Ser Gly Asp Ser Gly Lys Pro  
   1               5               10               15  
 Val Gln Ala Thr Leu Ser Ser Leu Lys Met Leu Asp Val Gly Lys

	20	25	30
Trp Pro Ile Phe Ser	Leu Cys Ser Glu	Glu Glu Leu Gln Leu	Ile
35	40	45	
Arg Gln Ala Cys Val	Phe Gly Ser Ala Gly Asn	Glu Val Leu	Tyr
50	55	60	
Thr Thr Val Asn Asp	Glu Ile Phe Val	Leu Gly Thr Asn Cys	Cys
65	70	75	
Gly Cys Leu Gly	Leu Gly Asp Val Gln	Ser Thr Ile Glu	Pro Arg
80	85	90	
Arg Leu Asp Ser	Leu Asn Gly Lys	Ile Ala Cys Leu	Ser Tyr
95	100	105	
Gly Ser Gly Pro His	Ile Val Leu Ala	Thr Thr Glu Gly	Glu Val
110	115	120	
Phe Thr Trp Gly His	Asn Ala Tyr Ser	Gln Leu Gly Asn	Gly Thr
125	130	135	
Thr Asn His Gly	Leu Val Pro Cys His	Ile Ser Thr Asn	Leu Ser
140	145	150	
Asn Lys Gln Val	Ile Glu Val Ala Cys	Gly Ser Tyr His	Ser Leu
155	160	165	
Val Leu Thr Ser Asp	Gly Glu Val Phe	Ala Trp Gly Tyr	Asn Asn
170	175	180	
Ser Gly Gln Val	Gly Ser Gly Ser Thr	Val Asn Gln Pro	Ile Pro
185	190	195	
Arg Arg Val Thr Gly	Cys Leu Gln Asn	Lys Val Val Val	Thr Ile
200	205	210	
Ala Cys Gly Gln Met	Cys Cys Met Ala	Val Val Asp Thr	Gly Glu
215	220	225	
Val Tyr Val Trp Gly	Tyr Asn Gly Asn	Gly Gln Leu Gly	Leu Gly
230	235	240	
Asn Ser Gly Asn Gln	Pro Thr Pro Cys	Arg Val Ala Ala	Leu Gln
245	250	255	
Gly Ile Arg Val Gln	Arg Val Ala Cys	Gly Tyr Ala His	Thr Leu
260	265	270	
Val Leu Thr Asp Glu	Gly Gln Val Tyr	Ala Trp Gly Ala	Asn Ser
275	280	285	
Tyr Gly Gln Leu	Gly Thr Gly Asn Lys	Ser Asn Gln Ser	Tyr Pro
290	295	300	
Thr Pro Val Thr Val	Glu Lys Asp Arg	Ile Ile Glu Ile	Ala Ala
305	310	315	
Cys His Ser Thr His	Thr Ser Ala Ala	Lys Thr Gln Gly	Gly His
320	325	330	
Val Tyr Met Trp Gly	Gln Cys Arg Gly	Gln Ser Val Ile	Leu Pro
335	340	345	
His Leu Thr His Phe	Ser Cys Thr Asp	Asp Val Phe	Ala Cys Phe
350	355	360	
Ala Thr Pro Ala Val	Thr Trp Arg Leu	Leu Ser Val Glu	Pro Asp
365	370	375	
Asp His Leu Thr Val	Ala Glu Ser Leu	Lys Arg Glu Phe	Asp Asn
380	385	390	
Pro Asp Thr Ala Asp	Leu Lys Phe Leu	Val Asp Gly Lys	Tyr Ile
395	400	405	
Tyr Ala His Lys Val	Leu Leu Lys Ile	Arg Cys Glu His	Phe Arg
410	415	420	
Ser Ser Leu Glu Asp	Asn Glu Asp Asp	Ile Val Glu Met	Ser Glu
425	430	435	
Phe Ser Tyr Pro Val	Tyr Arg Ala Phe	Leu Glu Tyr	Leu Tyr Thr
440	445	450	
Asp Ser Ile Ser Leu	Ser Pro Glu Glu	Ala Val Gly	Leu Leu Asp
455	460	465	
Leu Ala Thr Phe Tyr	Arg Glu Asn Arg	Leu Lys Lys	Leu Cys Gln
470	475	480	
Gln Thr Ile Lys Gln	Gly Ile Cys Glu	Asn Ala Ile	Ala Leu
485	490	495	

Leu Ser Ala Ala Val Lys Tyr Asp Ala Gln Asp Leu Glu Glu Phe  
       500                   505                   510  
 Cys Phe Arg Phe Cys Ile Asn His Leu Thr Val Val Thr Gln Thr  
       515                   520                   525  
 Ser Gly Phe Ala Glu Met Asp His Asp Leu Leu Lys Asn Phe Ile  
       530                   535                   540  
 Ser Lys Ala Ser Arg Val Gly Ala Phe Lys Asn  
       545                   550  
 <210> 52  
 <211> 308  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2477507CD1

<400> 52  
 Met Ile His Asp Ala Gln Met Asp Tyr Tyr Gly Thr Arg Leu Ala  
       1                5                10                15  
 Thr Cys Ser Ser Asp Arg Ser Val Lys Ile Phe Asp Val Arg Asn  
       20                25                30  
 Gly Gly Gln Ile Leu Ile Ala Asp Leu Arg Gly His Glu Gly Pro  
       35                40                45  
 Val Trp Gln Val Ala Trp Ala His Pro Met Tyr Gly Asn Ile Leu  
       50                55                60  
 Ala Ser Cys Ser Tyr Asp Arg Lys Val Ile Ile Trp Arg Glu Glu  
       65                70                75  
 Asn Gly Thr Trp Glu Lys Ser His Glu His Ala Gly His Asp Ser  
       80                85                90  
 Ser Val Asn Ser Val Cys Trp Ala Pro His Asp Tyr Gly Leu Ile  
       95                100              105  
 Leu Ala Cys Gly Ser Ser Asp Gly Ala Ile Ser Leu Leu Thr Tyr  
       110              115              120  
 Thr Gly Glu Gly Gln Trp Glu Val Lys Lys Ile Asn Asn Ala His  
       125              130              135  
 Thr Ile Gly Cys Asn Ala Val Ser Trp Ala Pro Ala Val Val Pro  
       140              145              150  
 Gly Ser Leu Ile Asp His Pro Ser Gly Gln Lys Pro Asn Tyr Ile  
       155              160              165  
 Lys Arg Phe Ala Ser Gly Gly Cys Asp Asn Leu Ile Lys Leu Trp  
       170              175              180  
 Lys Glu Glu Glu Asp Gly Gln Trp Lys Glu Glu Gln Lys Leu Glu  
       185              190              195  
 Ala His Ser Asp Trp Val Arg Asp Val Ala Trp Ala Pro Ser Ile  
       200              205              210  
 Gly Leu Pro Thr Ser Thr Ile Ala Ser Cys Ser Gln Asp Gly Arg  
       215              220              225  
 Val Phe Ile Trp Thr Cys Asp Asp Ala Ser Ser Asn Thr Trp Ser  
       230              235              240  
 Pro Lys Leu Leu His Lys Phe Asn Asp Val Val Trp His Val Ser  
       245              250              255  
 Trp Ser Ile Thr Ala Asn Ile Leu Ala Val Ser Gly Gly Asp Asn  
       260              265              270  
 Lys Val Thr Leu Trp Lys Glu Ser Val Asp Gly Gln Trp Val Cys  
       275              280              285  
 Ile Ser Asp Val Asn Lys Gly Gln Gly Ser Val Ser Ala Ser Val  
       290              295              300  
 Thr Glu Gly Gln Gln Asn Glu Gln  
       305

<210> 53  
 <211> 949  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2759119CD1

&lt;400&gt; 53

Met	Asp	Ala	Leu	Glu	Asp	Tyr	Val	Trp	Pro	Arg	Ala	Thr	Ser	Glu
1			5					10						15
Leu	Ile	Leu	Leu	Pro	Val	Thr	Gly	Leu	Glu	Cys	Val	Gly	Asp	Arg
			20					25						30
Leu	Leu	Ala	Gly	Glu	Gly	Pro	Asp	Val	Leu	Val	Tyr	Ser	Leu	Asp
			35					40						45
Phe	Gly	Gly	His	Leu	Arg	Met	Ile	Lys	Arg	Val	Gln	Asn	Leu	Leu
			50					55						60
Gly	His	Tyr	Leu	Ile	His	Gly	Phe	Arg	Val	Arg	Pro	Glu	Pro	Asn
			65					70						75
Gly	Asp	Asp	Leu	Asp	Leu	Glu	Ala	Met	Val	Ala	Val	Phe	Gly	Ser
			80					85						90
Gly	Leu	Arg	Val	Val	Lys	Ile	Ser	Trp	Gly	Gln	Gly	His	Phe	Trp
			95					100						105
Glu	Leu	Trp	Arg	Ser	Gly	Leu	Trp	Asn	Met	Ser	Asp	Trp	Ile	Trp
			110					115						120
Asp	Ala	Arg	Trp	Leu	Glu	Gly	Asn	Ile	Ala	Leu	Ala	Gly	His	
			125					130						135
Asn	Ser	Val	Val	Leu	Tyr	Asp	Pro	Val	Val	Gly	Cys	Ile	Leu	Gln
			140					145						150
Glu	Val	Pro	Cys	Thr	Asp	Arg	Cys	Thr	Leu	Ser	Ser	Ala	Cys	Leu
			155					160						165
Ile	Gly	Asp	Ala	Trp	Lys	Glu	Leu	Thr	Ile	Val	Ala	Gly	Ala	Val
			170					175						180
Ser	Asn	Gln	Leu	Leu	Val	Trp	Tyr	Pro	Ala	Thr	Ala	Leu	Ala	Asp
			185					190						195
Asn	Lys	Pro	Val	Ala	Pro	Asp	Arg	Arg	Ile	Ser	Gly	His	Val	Gly
			200					205						210
Ile	Ile	Phe	Ser	Met	Ser	Tyr	Leu	Glu	Ser	Lys	Gly	Leu	Leu	Ala
			215					220						225
Thr	Ala	Ser	Glu	Asp	Arg	Ser	Val	Arg	Ile	Trp	Lys	Val	Gly	Asp
			230					235						240
Leu	Arg	Val	Pro	Gly	Gly	Arg	Val	Gln	Asn	Ile	Gly	His	Cys	Phe
			245					250						255
Gly	His	Ser	Ala	Arg	Val	Trp	Gln	Val	Lys	Leu	Leu	Glu	Asn	Tyr
			260					265						270
Leu	Ile	Ser	Ala	Gly	Glu	Asp	Cys	Val	Cys	Leu	Val	Trp	Ser	His
			275					280						285
Glu	Gly	Glu	Ile	Leu	Gln	Ala	Phe	Arg	Gly	His	Gln	Gly	Arg	Gly
			290					295						300
Ile	Arg	Ala	Ile	Ala	Ala	His	Glu	Arg	Gln	Ala	Trp	Val	Ile	Thr
			305					310						315
Gly	Gly	Asp	Asp	Ser	Gly	Ile	Arg	Leu	Trp	His	Leu	Val	Gly	Arg
			320					325						330
Gly	Tyr	Arg	Gly	Leu	Gly	Val	Ser	Ala	Leu	Cys	Phe	Lys	Ser	Arg
			335					340						345
Ser	Arg	Pro	Gly	Thr	Leu	Lys	Ala	Val	Thr	Leu	Ala	Gly	Ser	Trp
			350					355						360
Arg	Leu	Leu	Ala	Val	Thr	Asp	Thr	Gly	Ala	Leu	Tyr	Leu	Tyr	Asp
			365					370						375
Val	Glu	Val	Lys	Cys	Trp	Glu	Gln	Leu	Leu	Glu	Asp	Lys	His	Phe
			380					385						390
Gln	Ser	Tyr	Cys	Leu	Leu	Glu	Ala	Ala	Pro	Gly	Pro	Glu	Gly	Phe
			395					400						405
Gly	Leu	Cys	Ala	Met	Ala	Asn	Gly	Glu	Gly	Arg	Val	Lys	Val	Val
			410					415						420

Pro Ile Asn Thr Pro Thr Ala Ala Val Asp Gln Thr Leu Phe Pro  
     425                          430                          435  
 Gly Lys Val His Ser Leu Ser Trp Ala Leu Arg Gly Tyr Glu Glu  
     440                          445                          450  
 Leu Leu Leu Ala Ser Gly Pro Gly Gly Val Val Ala Cys Leu  
     455                          460                          465  
 Glu Ile Ser Ala Ala Pro Ser Gly Lys Ala Ile Phe Val Lys Glu  
     470                          475                          480  
 Arg Cys Arg Tyr Leu Leu Pro Pro Ser Lys Gln Arg Trp His Thr  
     485                          490                          495  
 Cys Ser Ala Phe Leu Pro Pro Gly Asp Phe Leu Val Cys Gly Asp  
     500                          505                          510  
 Arg Arg Gly Ser Val Leu Leu Phe Pro Ser Arg Pro Gly Leu Leu  
     515                          520                          525  
 Lys Asp Pro Gly Val Gly Gly Lys Ala Arg Ala Gly Ala Gly Ala  
     530                          535                          540  
 Pro Val Val Gly Ser Gly Ser Ser Gly Gly Gly Asn Ala Phe Thr  
     545                          550                          555  
 Gly Leu Gly Pro Val Ser Thr Leu Pro Ser Leu His Gly Lys Gln  
     560                          565                          570  
 Gly Val Thr Ser Val Thr Cys His Gly Gly Tyr Val Tyr Thr Ile  
     575                          580                          585  
 Gly Arg Asp Gly Ala Tyr Tyr Gln Leu Phe Val Arg Asp Gly Gln  
     590                          595                          600  
 Leu Gln Pro Val Leu Arg Gln Lys Ser Cys Arg Gly Met Asn Trp  
     605                          610                          615  
 Leu Ala Gly Leu Arg Ile Val Pro Asp Gly Ser Met Val Ile Leu  
     620                          625                          630  
 Gly Phe His Ala Asn Glu Phe Val Val Trp Asn Pro Arg Ser His  
     635                          640                          645  
 Glu Lys Leu His Ile Val Asn Cys Gly Gly His Arg Ser Trp  
     650                          655                          660  
 Ala Phe Ser Asp Thr Glu Ala Ala Met Ala Phe Ala Tyr Leu Lys  
     665                          670                          675  
 Asp Gly Asp Val Met Leu Tyr Arg Ala Leu Gly Gly Cys Thr Arg  
     680                          685                          690  
 Pro His Val Ile Leu Arg Glu Gly Leu His Gly Arg Glu Ile Thr  
     695                          700                          705  
 Cys Val Lys Arg Val Gly Thr Ile Thr Leu Gly Pro Glu Tyr Gly  
     710                          715                          720  
 Val Pro Ser Phe Met Gln Pro Asp Asp Leu Glu Pro Gly Ser Glu  
     725                          730                          735  
 Gly Pro Asp Leu Thr Asp Ile Val Ile Thr Cys Ser Glu Asp Thr  
     740                          745                          750  
 Thr Val Cys Val Leu Ala Leu Pro Thr Thr Thr Gly Ser Ala His  
     755                          760                          765  
 Ala Leu Thr Ala Val Cys Asn His Ile Ser Ser Val Arg Ala Val  
     770                          775                          780  
 Ala Val Trp Gly Ile Gly Thr Pro Gly Gly Pro Gln Asp Pro Gln  
     785                          790                          795  
 Pro Gly Leu Thr Ala His Val Val Ser Ala Gly Gly Arg Ala Glu  
     800                          805                          810  
 Met His Cys Phe Ser Ile Met Val Thr Pro Asp Pro Ser Thr Pro  
     815                          820                          825  
 Ser Arg Leu Ala Cys His Val Met His Leu Ser Ser His Arg Leu  
     830                          835                          840  
 Asp Glu Tyr Trp Asp Arg Gln Arg Asn Arg His Arg Met Val Lys  
     845                          850                          855  
 Val Asp Pro Glu Thr Arg Tyr Met Ser Leu Ala Val Cys Glu Leu  
     860                          865                          870  
 Asp Gln Pro Gly Leu Gly Pro Leu Val Ala Ala Ala Cys Ser Asp  
     875                          880                          885  
 Gly Ala Val Ser Ser Phe Phe Cys Arg Ile Leu Gly Gly Phe Cys

Ser Ser Leu Leu Lys Pro Ser Thr Ile Ser Asp Val Ser Ser Arg	895	900
905	910	915
Ser Thr Pro Leu His Thr Arg His Pro Thr Arg Gly Gly Gly Ser	920	925
920	925	930
Ser Cys Ala Ala Gln Leu Leu Met Ala Ala Trp Leu Ser Gly Ile	935	940
		945

Ser Pro Pro Cys

<210> 54  
<211> 227  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2823818CD1

<400> 54

Met Arg His Glu Ala Pro Met Gln Met Ala Ser Ala Gln Asp Ala	1	5	10	15
Arg Tyr Gly Gln Lys Asp Ser Ser Asp Gln Asn Phe Asp Tyr Met	20	25	30	
Phe Lys Leu Leu Ile Ile Gly Asn Ser Ser Val Gly Lys Thr Ser	35	40	45	
Phe Leu Phe Arg Tyr Ala Asp Asp Ser Phe Thr Ser Ala Phe Val	50	55	60	
Ser Thr Val Gly Ile Asp Phe Lys Val Lys Thr Val Phe Lys Asn	65	70	75	
Val Lys Arg Ile Lys Leu Gln Ile Trp Asp Thr Ala Gly Gln Glu	80	85	90	
Arg Tyr Arg Thr Ile Thr Thr Ala Tyr Tyr Arg Gly Ala Met Gly	95	100	105	
Phe Ile Leu Met Tyr Asp Ile Thr Asn Glu Glu Ser Phe Asn Ala	110	115	120	
Val Gln Asp Trp Ser Thr Gln Ile Lys Thr Tyr Ser Trp Asp Asn	125	130	135	
Ala Gln Val Ile Leu Val Gly Asn Lys Cys Asp Met Glu Asp Glu	140	145	150	
Arg Val Ile Ser Thr Glu Arg Gly Gln His Leu Gly Glu Gln Leu	155	160	165	
Gly Phe Glu Phe Phe Glu Thr Ser Ala Lys Asp Asn Ile Asn Val	170	175	180	
Lys Gln Thr Phe Glu Arg Leu Val Asp Ile Ile Cys Asp Lys Met	185	190	195	
Ser Glu Ser Leu Glu Thr Asp Pro Ala Ile Thr Ala Ala Lys Gln	200	205	210	
Asn Thr Arg Leu Lys Glu Thr Pro Pro Pro Pro Gln Pro Asn Cys	215	220	225	

Ala Cys

<210> 55  
<211> 474  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2859730CD1

<400> 55

Met Arg Arg Val Val Arg Gln Ser Lys Phe Arg His Val Phe Gly	1	5	10	15
-------------------------------------------------------------	---	---	----	----

Gln Ala Val Lys Asn Asp Gln Cys Tyr Asp Asp Ile Arg Val Ser  
     20                         25                         30  
 Arg Val Thr Trp Asp Ser Ser Phe Cys Ala Val Asn Pro Arg Phe  
     35                         40                         45  
 Val Ala Ile Ile Ile Glu Ala Ser Gly Gly Ala Phe Leu Val  
     50                         55                         60  
 Leu Pro Leu Arg Lys Thr Gly Arg Ile Asp Lys Ser Tyr Pro Thr  
     65                         70                         75  
 Val Cys Gly His Thr Gly Pro Val Leu Asp Ile Asp Trp Cys Pro  
     80                         85                         90  
 His Asn Asp Gln Val Ile Ala Ser Gly Ser Glu Asp Cys Thr Val  
     95                         100                         105  
 Met Val Trp Gln Ile Pro Glu Asn Gly Leu Thr Leu Ser Leu Thr  
   110                         115                         120  
 Glu Pro Val Val Ile Leu Glu Gly His Ser Lys Arg Val Gly Ile  
   125                         130                         135  
 Val Ala Trp His Pro Thr Ala Arg Asn Val Leu Leu Ser Ala Gly  
   140                         145                         150  
 Cys Asp Asn Ala Ile Ile Trp Asn Val Gly Thr Gly Glu Ala  
   155                         160                         165  
 Leu Ile Asn Leu Asp Asp Met His Ser Asp Met Ile Tyr Asn Val  
   170                         175                         180  
 Ser Trp Asn Arg Asn Gly Ser Leu Ile Cys Thr Ala Ser Lys Asp  
   185                         190                         195  
 Lys Lys Val Arg Val Ile Asp Pro Arg Lys Gln Glu Ile Val Ala  
   200                         205                         210  
 Glu Lys Glu Lys Ala His Glu Gly Ala Arg Pro Met Arg Ala Ile  
   215                         220                         225  
 Phe Leu Ala Asp Gly Asn Val Phe Thr Thr Gly Phe Ser Arg Met  
   230                         235                         240  
 Ser Glu Arg Gln Leu Ala Leu Trp Asn Pro Lys Asn Met Gln Glu  
   245                         250                         255  
 Pro Ile Ala Leu His Glu Met Asp Thr Ser Asn Gly Val Leu Leu  
   260                         265                         270  
 Pro Phe Tyr Asp Pro Asp Thr Ser Ile Ile Tyr Leu Cys Gly Lys  
   275                         280                         285  
 Gly Asp Ser Ser Ile Arg Tyr Phe Glu Ile Thr Asp Glu Ser Pro  
   290                         295                         300  
 Tyr Val His Tyr Leu Asn Thr Phe Ser Ser Lys Glu Pro Gln Arg  
   305                         310                         315  
 Gly Met Gly Tyr Met Pro Lys Arg Gly Leu Asp Val Asn Lys Cys  
   320                         325                         330  
 Glu Ile Ala Arg Phe Phe Lys Leu His Glu Arg Lys Cys Glu Pro  
   335                         340                         345  
 Ile Ile Met Thr Val Pro Arg Lys Ser Asp Leu Phe Gln Asp Asp  
   350                         355                         360  
 Leu Tyr Pro Asp Thr Ala Gly Pro Glu Ala Ala Leu Glu Ala Glu  
   365                         370                         375  
 Glu Trp Phe Glu Gly Lys Asn Ala Asp Pro Ile Leu Ile Ser Leu  
   380                         385                         390  
 Lys His Gly Tyr Ile Pro Gly Lys Asn Arg Asp Leu Lys Val Val  
   395                         400                         405  
 Lys Lys Asn Ile Leu Asp Ser Lys Pro Thr Ala Asn Lys Lys Cys  
   410                         415                         420  
 Asp Leu Ile Ser Ile Pro Lys Lys Thr Thr Asp Thr Ala Ser Val  
   425                         430                         435  
 Gln Asn Glu Ala Lys Leu Asp Glu Ile Leu Lys Glu Ile Lys Ser  
   440                         445                         450  
 Ile Lys Asp Thr Ile Cys Asn Gln Asp Glu Arg Ile Ser Lys Leu  
   455                         460                         465  
 Glu Gln Gln Met Ala Lys Ile Ala Ala  
   470

&lt;210&gt; 56

<211> 547  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2861155CD1

<400> 56  
Met Lys Thr Leu Glu Thr Gln Pro Leu Ala Pro Asp Cys Cys Pro  
1 5 10 15  
Ser Asp Gln Asp Pro Ala Pro Ala His Pro Ser Pro His Ala Ser  
20 25 30  
Pro Met Asn Lys Asn Ala Asp Ser Glu Leu Met Pro Pro Pro Pro  
35 40 45  
Glu Arg Gly Asp Pro Pro Arg Leu Ser Pro Asp Pro Val Ala Gly  
50 55 60  
Ser Ala Val Ser Gln Glu Leu Arg Glu Gly Asp Pro Val Ser Leu  
65 70 75  
Ser Thr Pro Leu Glu Thr Glu Phe Gly Ser Pro Ser Glu Leu Ser  
80 85 90  
Pro Arg Ile Glu Glu Gln Glu Leu Ser Glu Asn Thr Ser Leu Pro  
95 100 105  
Ala Glu Glu Ala Asn Gly Ser Leu Ser Glu Glu Glu Ala Asn Gly  
110 115 120  
Pro Glu Leu Gly Ser Gly Lys Ala Met Glu Asp Thr Ser Gly Glu  
125 130 135  
Pro Ala Ala Glu Asp Glu Gly Asp Thr Ala Trp Asn Tyr Ser Phe  
140 145 150  
Ser Gln Leu Pro Arg Phe Leu Ser Gly Ser Trp Ser Glu Phe Ser  
155 160 165  
Thr Gln Pro Glu Asn Phe Leu Lys Gly Cys Lys Trp Ala Pro Asp  
170 175 180  
Gly Ser Cys Ile Leu Thr Asn Ser Ala Asp Asn Ile Leu Arg Ile  
185 190 195  
Tyr Asn Leu Pro Pro Glu Leu Tyr His Glu Gly Glu Gln Val Glu  
200 205 210  
Tyr Ala Glu Met Val Pro Val Leu Arg Met Val Glu Gly Asp Thr  
215 220 225  
Ile Tyr Asp Tyr Cys Trp Tyr Ser Leu Met Ser Ser Ala Gln Pro  
230 235 240  
Asp Thr Ser Tyr Val Ala Ser Ser Ser Arg Glu Asn Pro Ile His  
245 250 255  
Ile Trp Asp Ala Phe Thr Gly Glu Leu Arg Ala Ser Phe Arg Ala  
260 265 270  
Tyr Asn His Leu Asp Glu Leu Thr Ala Ala His Ser Leu Cys Phe  
275 280 285  
Ser Pro Asp Gly Ser Gln Leu Phe Cys Gly Phe Asn Arg Thr Val  
290 295 300  
Arg Val Phe Ser Thr Ala Arg Pro Gly Arg Asp Cys Glu Val Arg  
305 310 315  
Ala Thr Phe Ala Lys Lys Gln Gly Gln Ser Gly Ile Ile Ser Cys  
320 325 330  
Ile Ala Phe Ser Pro Ala Gln Pro Leu Tyr Ala Cys Gly Ser Tyr  
335 340 345  
Gly Arg Ser Leu Gly Leu Tyr Ala Trp Asp Asp Gly Ser Pro Leu  
350 355 360  
Ala Leu Leu Gly Gly His Gln Gly Gly Ile Thr His Leu Cys Phe  
365 370 375  
His Pro Asp Gly Asn Arg Phe Phe Ser Gly Ala Arg Lys Asp Ala  
380 385 390  
Glu Leu Leu Cys Trp Asp Leu Arg Gln Ser Gly Tyr Pro Leu Trp  
395 400 405

Ser Leu Gly Arg Glu Val Thr Thr Asn Gln Arg Ile Tyr Phe Asp  
     410                          415                          420  
 Leu Asp Pro Thr Gly Gln Phe Leu Val Ser Gly Ser Thr Ser Gly  
     425                          430                          435  
 Ala Val Ser Val Trp Asp Thr Asp Gly Pro Gly Asn Asp Gly Lys  
     440                          445                          450  
 Pro Glu Pro Val Leu Ser Phe Leu Pro Gln Lys Asp Cys Thr Asn  
     455                          460                          465  
 Gly Val Ser Leu His Pro Ser Leu Pro Leu Leu Ala Thr Ala Ser  
     470                          475                          480  
 Gly Gln Arg Val Phe Pro Glu Pro Thr Glu Ser Gly Asp Glu Gly  
     485                          490                          495  
 Glu Glu Leu Gly Leu Pro Leu Leu Ser Thr Arg His Val His Leu  
     500                          505                          510  
 Glu Cys Arg Leu Gln Leu Trp Trp Cys Gly Gly Gly Pro Asp Ser  
     515                          520                          525  
 Ser Ile Pro Asp Asp His Gln Gly Glu Lys Gly Gln Gly Gly Thr  
     530                          535                          540  
 Gly Gly Arg Ser Trp Gly Ala  
     545

&lt;210&gt; 57

&lt;211&gt; 686

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3002667CD1

<400> 57  
 Met Gly Glu Phe Lys Val His Arg Val Arg Phe Phe Asn Tyr Val  
     1                          5                          10                          15  
 Pro Ser Gly Ile Arg Cys Val Ala Tyr Asn Asn Gln Ser Asn Arg  
     20                          25                          30  
 Leu Ala Val Ser Arg Thr Asp Gly Thr Val Glu Ile Tyr Asn Leu  
     35                          40                          45  
 Ser Ala Asn Tyr Phe Gln Glu Lys Phe Phe Pro Gly His Glu Ser  
     50                          55                          60  
 Arg Ala Thr Glu Ala Leu Cys Trp Ala Glu Gly Gln Arg Leu Phe  
     65                          70                          75  
 Ser Ala Gly Leu Asn Gly Glu Ile Met Glu Tyr Asp Leu Gln Ala  
     80                          85                          90  
 Leu Asn Ile Lys Tyr Ala Met Asp Ala Phe Gly Gly Pro Ile Trp  
     95                          100                         105  
 Ser Met Ala Ala Ser Pro Ser Gly Ser Gln Leu Leu Val Gly Cys  
   110                          115                         120  
 Glu Asp Gly Ser Val Lys Leu Phe Gln Ile Thr Pro Asp Lys Ile  
   125                          130                         135  
 Gln Phe Glu Arg Asn Phe Asp Arg Gln Lys Ser Arg Ile Leu Ser  
   140                          145                         150  
 Leu Ser Trp His Pro Ser Gly Thr His Ile Ala Ala Gly Ser Ile  
   155                          160                         165  
 Asp Tyr Ile Ser Val Phe Asp Val Lys Ser Gly Ser Ala Val His  
   170                          175                         180  
 Lys Met Ile Val Asp Arg Gln Tyr Met Gly Val Ser Lys Arg Lys  
   185                          190                         195  
 Cys Ile Val Trp Gly Val Ala Phe Leu Ser Asp Gly Thr Ile Ile  
   200                          205                         210  
 Ser Val Asp Ser Ala Gly Lys Val Gln Phe Trp Asp Ser Ala Thr  
   215                          220                         225  
 Gly Thr Leu Val Lys Ser His Leu Ile Ala Asn Ala Asp Val Gln  
   230                          235                         240  
 Ser Ile Ala Val Ala Asp Gln Glu Asp Ser Phe Val Val Gly Thr

	245	250	255
Ala Glu Gly Thr Val Phe His Phe Gln Leu Val Pro Val Thr Ser	260	265	270
	275	280	285
Asn Ser Ser Glu Lys Gln Trp Val Arg Thr Lys Pro Phe Gln His	290	295	300
	305	310	315
His Thr His Asp Val Arg Thr Val Ala His Ser Pro Thr Ala Leu	320	325	330
	335	340	345
Ile Ser Gly Gly Thr Asp Thr His Leu Val Phe Arg Pro Leu Met	350	355	360
	365	370	375
Glu Lys Val Glu Val Lys Asn Tyr Asp Ala Ala Leu Arg Lys Ile	380	385	390
	395	400	405
Thr Phe Pro His Arg Cys Leu Ile Ser Cys Ser Lys Lys Arg Gln	410	415	420
	425	430	435
Leu Leu Leu Phe Gln Phe Ala His His Leu Glu Leu Trp Arg Leu	440	445	450
	455	460	465
Gly Ser Thr Val Ala Thr Gly Lys Asn Gly Asp Thr Leu Pro Leu	470	475	480
	485	490	495
Ser Lys Asn Ala Asp His Leu Leu His Leu Lys Thr Lys Gly Pro	500	505	510
	515	520	525
Glu Asn Ile Ile Cys Ser Cys Ile Ser Pro Cys Gly Ser Trp Ile	530	535	540
	545	550	555
Ala Tyr Ser Thr Val Ser Arg Phe Phe Leu Tyr Arg Leu Asn Tyr	560	565	570
	575	580	585
Phe Leu Arg Ser Ala Leu Gln Ile Leu Phe Ser Glu Asp Ser Thr	590	595	600
	605	610	615
Lys Leu Phe Val Ala Ser Asn Gln Gly Ala Leu His Ile Val Gln	620	625	630
	635	640	645
Leu Ser Gly Gly Ser Phe Lys His Leu His Ala Phe Gln Pro Gln	650	655	660
	665	670	675
Ser Gly Thr Val Glu Ala Met Cys Leu Leu Ala Val Ser Pro Asp	680	685	
<210> 58			
<211> 93			
<212> PRT			
<213> Homo sapiens			

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3043734CD1

<400> 58  
Met Thr Ser Lys Arg Lys Pro Cys Gln Thr Gln Leu Arg Arg Ser  
1 5 10 15  
Ile Ser Glu Gln Leu Arg Asp Ser Thr Ala Arg Ala Trp Asp Leu  
20 25 30  
Leu Trp Lys Asn Val Arg Glu Arg Arg Leu Ala Glu Ile Glu Ala  
35 40 45  
Lys Glu Ala Cys Asp Trp Leu Arg Ala Ala Gly Phe Pro Gln Tyr  
50 55 60  
Ala Gln Leu Tyr Glu Asp Ser Gln Phe Pro Ile Asn Ile Val Ala  
65 70 75  
Val Lys Asn Asp His Asp Phe Leu Glu Lys Asp Leu Val Glu Pro  
80 85 90  
Leu Cys Arg

<210> 59  
<211> 521  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3294893CD1

<400> 59  
Met Arg Arg Gly His Gly Gln Arg Arg Gly Gln Glu Ala Ile Leu  
1 5 10 15  
Glu Ala His Asn Ser Lys Leu Pro Gly Ser Ile Gln His Val Tyr  
20 25 30  
Gly Ala Gln His Pro Pro Phe Asp Pro Leu Leu His Gly Thr Leu  
35 40 45  
Leu Arg Ser Thr Ala Lys Met Pro Thr Thr Pro Val Lys Ala Lys  
50 55 60  
Arg Val Ser Thr Phe Gln Glu Phe Glu Ser Asn Thr Ser Asp Ala  
65 70 75  
Trp Asp Ala Gly Glu Asp Asp Asp Glu Leu Leu Ala Met Ala Ala  
80 85 90  
Glu Ser Leu Asn Ser Glu Val Val Met Glu Thr Ala Asn Arg Val  
95 100 105  
Leu Arg Asn His Ser Gln Arg Gln Gly Arg Pro Thr Leu Gln Glu  
110 115 120  
Gly Pro Gly Leu Gln Gln Lys Pro Arg Pro Glu Ala Glu Pro Pro  
125 130 135  
Ser Pro Pro Ser Gly Asp Leu Arg Leu Val Lys Ser Val Ser Glu  
140 145 150  
Ser His Thr Ser Cys Pro Ala Glu Ser Ala Ser Asp Ala Ala Pro  
155 160 165  
Leu Gln Arg Ser Gln Ser Leu Pro His Ser Ala Thr Val Thr Leu  
170 175 180  
Gly Gly Thr Ser Asp Pro Ser Thr Leu Ser Ser Ser Ala Leu Ser  
185 190 195  
Glu Arg Glu Ala Ser Arg Leu Asp Lys Phe Lys Gln Leu Leu Ala  
200 205 210  
Gly Pro Asn Thr Asp Leu Glu Glu Leu Arg Arg Leu Ser Trp Ser  
215 220 225  
Gly Ile Pro Lys Pro Val Arg Pro Met Thr Trp Lys Leu Leu Ser  
230 235 240  
Gly Tyr Leu Pro Ala Asn Val Asp Arg Arg Pro Ala Thr Leu Gln  
245 250 255

Arg Lys Gln Lys Glu Tyr Phe Ala Phe Ile Glu His Tyr Tyr Asp  
           260                         265                         270  
 Ser Arg Asn Asp Glu Val His Gln Asp Thr Tyr Arg Gln Ile His  
           275                         280                         285  
 Ile Asp Ile Pro Arg Met Ser Pro Glu Ala Leu Ile Leu Gln Pro  
           290                         295                         300  
 Lys Val Thr Glu Ile Phe Glu Arg Ile Leu Phe Ile Trp Ala Ile  
           305                         310                         315  
 Arg His Pro Ala Ser Gly Tyr Val Gln Gly Ile Asn Asp Leu Val  
           320                         325                         330  
 Thr Pro Phe Phe Val Val Phe Ile Cys Glu Tyr Ile Glu Ala Glu  
           335                         340                         345  
 Glu Val Asp Thr Val Asp Val Ser Gly Val Pro Ala Glu Val Leu  
           350                         355                         360  
 Cys Asn Ile Glu Ala Asp Thr Tyr Trp Cys Met Ser Lys Leu Leu  
           365                         370                         375  
 Asp Gly Ile Gln Asp Asn Tyr Thr Phe Ala Gln Pro Gly Ile Gln  
           380                         385                         390  
 Met Lys Val Lys Met Leu Glu Glu Leu Val Ser Arg Ile Asp Glu  
           395                         400                         405  
 Gln Val His Arg His Leu Asp Gln His Glu Val Arg Tyr Leu Gln  
           410                         415                         420  
 Phe Ala Phe Arg Trp Met Asn Asn Leu Leu Met Arg Glu Val Pro  
           425                         430                         435  
 Leu Arg Cys Thr Ile Arg Leu Trp Asp Thr Tyr Gln Ser Glu Pro  
           440                         445                         450  
 Asp Gly Phe Ser His Phe His Leu Tyr Val Cys Ala Ala Phe Leu  
           455                         460                         465  
 Val Arg Trp Arg Lys Glu Ile Leu Glu Glu Lys Asp Phe Gln Glu  
           470                         475                         480  
 Leu Leu Leu Phe Leu Gln Asn Leu Pro Thr Ala His Trp Asp Asp  
           485                         490                         495  
 Glu Asp Ile Ser Leu Leu Leu Ala Glu Ala Tyr Arg Leu Lys Phe  
           500                         505                         510  
 Ala Phe Ala Asp Ala Pro Asn His Tyr Lys Lys  
           515                         520

&lt;210&gt; 60

&lt;211&gt; 751

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3349052CD1

&lt;400&gt; 60

Met Arg Leu Leu Gly Ala Ala Ala Val Ala Ala Leu Gly Arg Gly  
     1                         5                         10                         15  
 Arg Ala Pro Ala Ser Leu Gly Trp Gln Arg Lys Gln Val Asn Trp  
     20                         25                         30  
 Lys Ala Cys Arg Trp Ser Ser Ser Gly Val Ile Pro Asn Glu Lys  
     35                         40                         45  
 Ile Arg Asn Ile Gly Ile Ser Ala His Ile Asp Ser Gly Lys Thr  
     50                         55                         60  
 Thr Leu Thr Glu Arg Val Leu Tyr Tyr Thr Gly Arg Ile Ala Lys  
     65                         70                         75  
 Met His Glu Val Lys Gly Lys Asp Gly Val Gly Ala Val Met Asp  
     80                         85                         90  
 Ser Met Glu Leu Glu Arg Gln Arg Gly Ile Thr Ile Gln Ser Ala  
     95                         100                         105  
 Ala Thr Tyr Thr Met Trp Lys Asp Val Asn Ile Asn Ile Ile Asp  
   110                         115                         120  
 Thr Pro Gly His Val Asp Phe Thr Ile Glu Val Glu Arg Ala Leu

	125	130	135
Arg Val Leu Asp Gly Ala Val Leu Val		Leu Cys Ala Val Gly	Gly
140	145	150	
Val Gln Cys Gln Thr Met Thr Val Asn Arg Gln Met Lys Arg Tyr			
155	160	165	
Asn Val Pro Phe Leu Thr Phe Ile Asn Lys Leu Asp Arg Met Gly			
170	175	180	
Ser Asn Pro Ala Arg Ala Leu Gln Gln Met Arg Ser Lys Leu Asn			
185	190	195	
His Asn Ala Ala Phe Met Gln Ile Pro Met Gly Leu Glu Gly Asn			
200	205	210	
Phe Lys Gly Ile Ile Asp Leu Ile Glu Glu Arg Ala Ile Tyr Phe			
215	220	225	
Asp Gly Asp Phe Gly Gln Ile Val Arg Tyr Gly Glu Ile Pro Ala			
230	235	240	
Glu Leu Arg Ala Ala Ala Thr Asp His Arg Gln Glu Leu Ile Glu			
245	250	255	
Cys Val Ala Asn Ser Asp Glu Gln Leu Gly Glu Met Phe Leu Glu			
260	265	270	
Glu Lys Ile Pro Ser Ile Ser Asp Leu Lys Leu Ala Ile Arg Arg			
275	280	285	
Ala Thr Leu Lys Arg Ser Phe Thr Pro Val Phe Leu Gly Ser Ala			
290	295	300	
Leu Lys Asn Lys Gly Val Gln Pro Leu Leu Asp Ala Val Leu Glu			
305	310	315	
Tyr Leu Pro Asn Pro Ser Glu Val Gln Asn Tyr Ala Ile Leu Asn			
320	325	330	
Lys Glu Asp Asp Ser Lys Glu Lys Thr Lys Ile Leu Met Asn Ser			
335	340	345	
Ser Arg Asp Asn Ser His Pro Phe Val Gly Leu Ala Phe Lys Leu			
350	355	360	
Glu Val Gly Arg Phe Gly Gln Leu Thr Tyr Val Arg Ser Tyr Gln			
365	370	375	
Gly Glu Leu Lys Lys Gly Asp Thr Ile Tyr Asn Thr Arg Thr Arg			
380	385	390	
Lys Lys Val Arg Leu Gln Arg Leu Ala Arg Met His Ala Asp Met			
395	400	405	
Met Glu Asp Val Glu Glu Val Tyr Ala Gly Asp Ile Cys Ala Leu			
410	415	420	
Phe Gly Ile Asp Cys Ala Ser Gly Asp Thr Phe Thr Asp Lys Ala			
425	430	435	
Asn Ser Gly Leu Ser Met Glu Ser Ile His Val Pro Asp Pro Val			
440	445	450	
Ile Ser Ile Ala Met Lys Pro Ser Asn Lys Asn Asp Leu Glu Lys			
455	460	465	
Phe Ser Lys Gly Ile Gly Arg Phe Thr Arg Glu Asp Pro Thr Phe			
470	475	480	
Lys Val Tyr Phe Asp Thr Glu Asn Lys Glu Thr Val Ile Ser Gly			
485	490	495	
Met Gly Glu Leu His Leu Glu Ile Tyr Ala Gln Arg Leu Glu Arg			
500	505	510	
Glu Tyr Gly Cys Pro Cys Ile Thr Gly Lys Pro Lys Val Ala Phe			
515	520	525	
Arg Glu Thr Ile Thr Ala Pro Val Pro Phe Asp Phe Thr His Lys			
530	535	540	
Lys Gln Ser Gly Gly Ala Gly Gln Tyr Gly Lys Val Ile Gly Val			
545	550	555	
Leu Glu Pro Leu Asp Pro Glu Asp Tyr Thr Lys Leu Glu Phe Ser			
560	565	570	
Asp Glu Thr Phe Gly Ser Asn Ile Pro Lys Gln Phe Val Pro Ala			
575	580	585	
Val Glu Lys Gly Phe Leu Asp Ala Cys Glu Lys Gly Pro Leu Ser			
590	595	600	

Gly His Lys Leu Ser Gly Leu Arg Phe Val Leu Gln Asp Gly Ala  
   605                         610                         615  
 His His Met Val Asp Ser Asn Glu Ile Ser Phe Ile Arg Ala Gly  
   620                         625                         630  
 Glu Gly Ala Leu Lys Gln Ala Leu Ala Asn Ala Thr Leu Cys Ile  
   635                         640                         645  
 Leu Glu Pro Ile Met Ala Val Glu Val Val Ala Pro Asn Glu Phe  
   650                         655                         660  
 Gln Gly Gln Val Ile Ala Gly Ile Asn Arg Arg His Gly Val Ile  
   665                         670                         675  
 Thr Gly Gln Asp Gly Val Glu Asp Tyr Phe Thr Leu Tyr Ala Asp  
   680                         685                         690  
 Val Pro Leu Asn Asp Met Phe Gly Tyr Ser Thr Glu Leu Arg Ser  
   695                         700                         705  
 Cys Thr Glu Gly Lys Gly Glu Tyr Thr Met Glu Tyr Ser Arg Tyr  
   710                         715                         720  
 Gln Pro Cys Leu Pro Ser Thr Gln Glu Asp Val Ile Asn Lys Tyr  
   725                         730                         735  
 Leu Glu Ala Thr Gly Gln Leu Pro Val Lys Lys Gly Lys Ala Lys  
   740                         745                         750

Asn

<210> 61  
<211> 666  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3357264CD1

<220>  
<221> unsure  
<222> 281  
<223> unknown or other

<400> 61  
 Met Cys Gly Ala Val Ile Pro Leu His Lys Pro Ala Gly Arg Lys  
   1                         5                         10                         15  
 Leu Gln Asn Gln Arg Ala Ala Leu Asn Gln Gln Ile Leu Lys Ala  
   20                         25                         30  
 Val Arg Met Arg Thr Gly Ala Glu Asn Leu Leu Lys Val Ala Thr  
   35                         40                         45  
 Asn Ser Lys Val Arg Glu Gln Val Arg Leu Glu Leu Ser Phe Val  
   50                         55                         60  
 Asn Ser Asp Leu Gln Met Leu Lys Glu Leu Glu Gly Leu Asn  
   65                         70                         75  
 Ile Ser Val Gly Val Tyr Gln Asn Thr Glu Glu Ala Phe Thr Ile  
   80                         85                         90  
 Pro Leu Ile Pro Leu Gly Leu Lys Glu Thr Lys Asp Val Asp Phe  
   95                         100                         105  
 Ala Val Val Leu Lys Asp Phe Ile Leu Glu His Tyr Ser Glu Asp  
 110                         115                         120  
 Gly Tyr Leu Tyr Glu Asp Glu Ile Ala Asp Leu Met Asp Leu Arg  
 125                         130                         135  
 Gln Ala Cys Arg Thr Pro Ser Arg Asp Glu Ala Gly Val Glu Leu  
 140                         145                         150  
 Leu Met Thr Tyr Phe Ile Gln Leu Gly Phe Val Glu Ser Arg Phe  
 155                         160                         165  
 Phe Pro Pro Thr Arg Gln Met Gly Leu Leu Phe Thr Trp Tyr Asp  
 170                         175                         180  
 Ser Leu Thr Gly Val Pro Val Ser Gln Gln Asn Leu Leu Leu Glu  
 185                         190                         195

Lys Ala Ser Val Leu Phe Asn Thr Gly Ala Leu Tyr Thr Gln Ile  
 200 205 210  
 Gly Thr Arg Cys Asp Arg Gln Thr Gln Ala Gly Leu Glu Ser Ala  
 215 220 225  
 Ile Asp Ala Phe Gln Arg Ala Ala Gly Val Leu Asn Tyr Leu Lys  
 230 235 240  
 Asp Thr Phe Thr His Thr Pro Ser Tyr Asp Met Ser Pro Ala Met  
 245 250 255  
 Leu Ser Val Leu Val Lys Met Met Leu Ala Gln Ala Gln Glu Ser  
 260 265 270  
 Val Phe Glu Lys Ile Ser Leu Pro Gly Ile Xaa Asn Glu Phe Phe  
 275 280 285  
 Met Leu Val Lys Val Ala Gln Glu Ala Ala Lys Val Gly Glu Val  
 290 295 300  
 Tyr Gln Gln Leu His Ala Ala Met Ser Gln Ala Pro Val Lys Glu  
 305 310 315  
 Asn Ile Pro Tyr Ser Trp Ala Ser Leu Ala Cys Val Lys Ala His  
 320 325 330  
 His Tyr Ala Ala Leu Ala His Tyr Phe Thr Ala Ile Leu Leu Ile  
 335 340 345  
 Asp His Gln Val Lys Pro Gly Thr Asp Leu Asp His Gln Glu Lys  
 350 355 360  
 Cys Leu Ser Gln Leu Tyr Asp His Met Pro Glu Gly Leu Thr Pro  
 365 370 375  
 Leu Ala Thr Leu Lys Asn Asp Gln Gln Arg Arg Gln Leu Gly Lys  
 380 385 390  
 Ser His Leu Arg Arg Ala Met Ala His His Glu Glu Ser Val Arg  
 395 400 405  
 Glu Ala Ser Leu Cys Lys Lys Leu Arg Thr Ile Glu Val Leu Gln  
 410 415 420  
 Lys Val Leu Cys Ala Ala Gln Glu Arg Ser Arg Leu Thr Tyr Ala  
 425 430 435  
 Gln His Gln Glu Glu Asp Asp Leu Leu Asn Leu Ile Asp Ala Pro  
 440 445 450  
 Ser Val Val Ala Lys Thr Glu Gln Glu Val Asp Ile Ile Leu Pro  
 455 460 465  
 Gln Phe Ser Lys Leu Thr Val Thr Asp Phe Phe Gln Lys Leu Gly  
 470 475 480  
 Pro Leu Ser Val Phe Ser Ala Asn Lys Arg Trp Thr Pro Pro Arg  
 485 490 495  
 Ser Ile Arg Phe Thr Ala Glu Glu Gly Asp Leu Gly Phe Thr Leu  
 500 505 510  
 Arg Gly Asn Ala Pro Val Gln Val His Phe Leu Asp Pro Tyr Cys  
 515 520 525  
 Ser Ala Ser Val Ala Gly Ala Arg Glu Gly Asp Tyr Ile Val Ser  
 530 535 540  
 Ile Gln Leu Val Asp Cys Lys Trp Leu Thr Leu Ser Glu Val Met  
 545 550 555  
 Lys Leu Leu Lys Ser Phe Gly Glu Asp Glu Ile Glu Met Lys Val  
 560 565 570  
 Val Ser Leu Leu Asp Ser Thr Ser Ser Met His Asn Lys Ser Ala  
 575 580 585  
 Thr Tyr Ser Val Gly Met Gln Lys Thr Tyr Ser Met Ile Cys Leu  
 590 595 600  
 Ala Ile Asp Asp Asp Asp Lys Thr Asp Lys Thr Lys Lys Ile Ser  
 605 610 615  
 Lys Lys Leu Ser Phe Leu Ser Trp Gly Thr Asn Lys Asn Arg Gln  
 620 625 630  
 Lys Ser Ala Ser Thr Leu Cys Leu Pro Ser Val Gly Ala Ala Arg  
 635 640 645  
 Pro Gln Val Lys Lys Leu Pro Ser Pro Phe Ser Leu Leu Asn  
 650 655 660  
 Ser Asp Ser Ser Trp Tyr

665

<210> 62  
<211> 746  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3576329CD1

<400> 62  
Met Ala Gly Ser Arg Gly Ala Gly Arg Thr Ala Ala Pro Ser Val  
1 5 10 15  
Arg Pro Glu Lys Arg Arg Ser Glu Pro Glu Leu Glu Pro Glu Pro  
20 25 30  
Glu Pro Glu Pro Pro Leu Leu Cys Thr Ser Pro Leu Ser His Ser  
35 40 45  
Thr Gly Ser Asp Ser Gly Val Ser Asp Ser Glu Glu Ser Val Phe  
50 55 60  
Ser Gly Leu Glu Asp Ser Gly Ser Asp Ser Ser Glu Asp Asp Asp  
65 70 75  
Glu Gly Asp Glu Gly Glu Asp Gly Ala Leu Asp Asp Glu Gly  
80 85 90  
His Ser Gly Ile Lys Lys Thr Thr Glu Glu Gln Val Gln Ala Ser  
95 100 105  
Thr Pro Cys Pro Arg Thr Glu Met Ala Ser Ala Arg Ile Gly Asp  
110 115 120  
Glu Tyr Ala Glu Asp Ser Ser Asp Glu Glu Asp Ile Arg Asn Thr  
125 130 135  
Val Gly Asn Val Pro Leu Glu Trp Tyr Asp Asp Phe Pro His Val  
140 145 150  
Gly Tyr Asp Leu Asp Gly Arg Arg Ile Tyr Lys Pro Leu Arg Thr  
155 160 165  
Arg Asp Glu Leu Asp Gln Phe Leu Asp Lys Met Asp Asp Pro Asp  
170 175 180  
Tyr Trp Arg Thr Val Gln Asp Pro Met Thr Gly Arg Asp Leu Arg  
185 190 195  
Leu Thr Asp Glu Gln Val Ala Leu Val Arg Arg Leu Gln Ser Gly  
200 205 210  
Gln Phe Gly Asp Val Gly Phe Asn Pro Tyr Glu Pro Ala Val Asp  
215 220 225  
Phe Phe Ser Gly Asp Val Met Ile His Pro Val Thr Asn Arg Pro  
230 235 240  
Ala Asp Lys Arg Ser Phe Ile Pro Ser Leu Val Glu Lys Glu Lys  
245 250 255  
Val Ser Arg Met Val His Ala Ile Lys Met Gly Trp Ile Gln Pro  
260 265 270  
Arg Arg Pro Arg Asp Pro Thr Pro Ser Phe Tyr Asp Leu Trp Ala  
275 280 285  
Gln Glu Asp Pro Asn Ala Val Leu Gly Arg His Lys Met His Val  
290 295 300  
Pro Ala Pro Lys Leu Ala Leu Pro Gly His Ala Glu Ser Tyr Asn  
305 310 315  
Pro Pro Pro Glu Tyr Leu Leu Ser Glu Glu Glu Arg Leu Ala Trp  
320 325 330  
Glu Gln Gln Glu Pro Gly Glu Arg Lys Leu Gly Phe Leu Pro Arg  
335 340 345  
Lys Phe Pro Ser Leu Arg Ala Val Pro Ala Tyr Gly Arg Phe Ile  
350 355 360  
Gln Glu Arg Phe Glu Arg Cys Leu Asp Leu Tyr Leu Cys Pro Arg  
365 370 375  
Gln Arg Lys Met Arg Val Asn Val Asp Pro Glu Asp Leu Ile Pro  
380 385 390

Lys Leu Pro Arg Pro Arg Asp Leu Gln Pro Phe Pro Thr Cys Gln  
 395 400 405  
 Ala Leu Val Tyr Arg Gly His Ser Asp Leu Val Arg Cys Leu Ser  
 410 415 420  
 val Ser Pro Gly Gly Gln Trp Leu Val Ser Gly Ser Asp Asp Gly  
 425 430 435  
 Ser Leu Arg Leu Trp Glu Val Ala Thr Ala Arg Cys Val Arg Thr  
 440 445 450  
 Val Pro Val Gly Gly Val Val Lys Ser Val Ala Trp Asn Pro Ser  
 455 460 465  
 Pro Ala Val Cys Leu Val Ala Ala Val Glu Asp Ser Val Leu  
 470 475 480  
 Leu Leu Asn Pro Ala Leu Gly Asp Arg Leu Val Ala Gly Ser Thr  
 485 490 495  
 Asp Gln Leu Leu Ser Ala Phe Val Pro Pro Glu Glu Pro Pro Leu  
 500 505 510  
 Gln Pro Ala Arg Trp Leu Glu Ala Ser Glu Glu Glu Arg Gln Val  
 515 520 525  
 Gly Leu Arg Leu Arg Ile Cys His Gly Lys Pro Val Thr Gln Val  
 530 535 540  
 Thr Trp His Gly Arg Gly Asp Tyr Leu Ala Val Val Leu Ala Thr  
 545 550 555  
 Gln Gly His Thr Gln Val Leu Ile His Gln Leu Ser Arg Arg Arg  
 560 565 570  
 Ser Gln Ser Pro Phe Arg Arg Ser His Gly Gln Val Gln Arg Val  
 575 580 585  
 Ala Phe His Pro Ala Arg Pro Phe Leu Leu Val Ala Ser Gln Arg  
 590 595 600  
 Ser Val Arg Leu Tyr His Leu Leu Arg Gln Glu Leu Thr Lys Lys  
 605 610 615  
 Leu Met Pro Asn Cys Lys Trp Val Ser Ser Leu Ala Val His Pro  
 620 625 630  
 Ala Gly Asp Asn Val Ile Cys Gly Ser Tyr Asp Ser Lys Leu Val  
 635 640 645  
 Trp Phe Asp Leu Asp Leu Ser Thr Lys Pro Tyr Arg Met Leu Arg  
 650 655 660  
 His His Lys Lys Ala Leu Arg Ala Val Ala Phe His Pro Arg Tyr  
 665 670 675  
 Pro Leu Phe Ala Ser Gly Ser Asp Asp Gly Ser Val Ile Val Cys  
 680 685 690  
 His Gly Met Val Tyr Asn Asp Leu Leu Gln Asn Pro Leu Leu Val  
 695 700 705  
 Pro Val Lys Val Leu Lys Gly His Val Leu Thr Arg Asp Leu Gly  
 710 715 720  
 Val Leu Asp Val Ile Phe His Pro Thr Gln Pro Trp Val Phe Ser  
 725 730 735  
 Ser Gly Ala Asp Gly Thr Val Arg Leu Phe Thr  
 740 745

&lt;210&gt; 63

&lt;211&gt; 212

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3805550CD1

&lt;400&gt; 63

Met Ala Gly Pro Gly Pro Gly Asp Pro Asp Glu Gln Tyr  
 1 5 10 15  
 Asp Phe Leu Phe Lys Leu Val Leu Val Gly Asp Ala Ser Val Gly  
 20 25 30  
 Lys Thr Cys Val Val Gln Arg Phe Lys Thr Gly Ala Phe Ser Glu

35	40	45
Arg Gln Gly Ser Thr Ile Gly Val Asp Phe Thr Met Lys Thr Leu		
50	55	60
Glu Ile Gln Gly Lys Arg Val Lys Leu Gln Ile Trp Asp Thr Ala		
65	70	75
Gly Gln Glu Arg Phe Arg Thr Ile Thr Gln Ser Tyr Tyr Arg Ser		
80	85	90
Ala Asn Gly Ala Ile Leu Ala Tyr Asp Ile Thr Lys Arg Ser Ser		
95	100	105
Phe Leu Ser Val Pro His Trp Ile Glu Asp Val Arg Lys Tyr Ala		
110	115	120
Gly Ser Asn Ile Val Gln Leu Ile Gly Asn Lys Ser Asp Leu		
125	130	135
Ser Glu Leu Arg Glu Val Ser Leu Ala Glu Ala Gln Ser Leu Ala		
140	145	150
Glu His Tyr Asp Ile Leu Cys Ala Ile Glu Thr Ser Ala Lys Asp		
155	160	165
Ser Ser Asn Val Glu Glu Ala Phe Leu Arg Val Ala Thr Glu Leu		
170	175	180
Ile Met Arg His Gly Gly Pro Leu Phe Ser Glu Lys Ser Pro Asp		
185	190	195
His Ile Gln Leu Asn Ser Lys Asp Ile Gly Glu Gly Trp Gly Cys		
200	205	210

Gly Cys

<210> 64  
<211> 307  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 4546403CD1

<400> 64			
Met Arg Cys Leu His Ser Glu Lys Ala His Asp Leu Gly Ile Thr			
1	5	10	15
Cys Cys Asp Phe Ser Ser Gln Pro Val Ser Asp Gly Glu Gln Gly			
20	25	30	
Leu Gln Phe Phe Arg Leu Ala Ser Cys Gly Gln Asp Cys Gln Val			
35	40	45	
Lys Ile Trp Ile Val Ser Phe Thr His Ile Leu Gly Phe Glu Leu			
50	55	60	
Lys Tyr Lys Ser Thr Leu Ser Gly His Cys Ala Pro Val Leu Ala			
65	70	75	
Cys Ala Phe Ser His Asp Gly Gln Met Leu Val Ser Gly Ser Val			
80	85	90	
Asp Lys Ser Val Ile Val Tyr Asp Thr Asn Thr Glu Asn Ile Leu			
95	100	105	
His Thr Leu Thr Gln His Thr Arg Tyr Val Thr Thr Cys Ala Phe			
110	115	120	
Ala Pro Asn Thr Leu Leu Leu Ala Thr Gly Ser Met Asp Lys Thr			
125	130	135	
Val Asn Ile Trp Gln Phe Asp Leu Glu Thr Leu Cys Gln Ala Arg			
140	145	150	
Ser Thr Glu His Gln Leu Lys Gln Phe Thr Glu Asp Trp Ser Glu			
155	160	165	
Glu Asp Val Ser Thr Trp Leu Cys Ala Gln Asp Leu Lys Asp Leu			
170	175	180	
Val Gly Ile Phe Lys Met Asn Asn Ile Asp Gly Lys Glu Leu Leu			
185	190	195	
Asn Leu Thr Lys Glu Ser Leu Ala Asp Asp Leu Lys Ile Glu Ser			
200	205	210	

Leu Gly Leu Arg Ser Lys Val Leu Arg Lys Ile Glu Glu Leu Arg  
 215 220 225  
 Thr Lys Val Lys Ser Leu Ser Ser Gly Ile Pro Asp Glu Phe Ile  
 230 235 240  
 Cys Pro Ile Thr Arg Glu Leu Met Lys Asp Pro Val Ile Ala Ser  
 245 250 255  
 Asp Gly Tyr Ser Tyr Glu Lys Glu Ala Met Glu Asn Trp Ile Ser  
 260 265 270  
 Lys Lys Lys Arg Thr Ser Pro Met Thr Asn Leu Val Leu Pro Ser  
 275 280 285  
 Ala Val Leu Thr Pro Asn Arg Thr Leu Lys Met Ala Ile Asn Arg  
 290 295 300  
 Trp Leu Glu Thr His Gln Lys  
 305  
 <210> 65  
 <211> 378  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> misc\_feature  
 <223> Incyte ID No: 4767318CD1  
  
 <400> 65  
 Met Arg Ala Ala Ala Ala Pro Gly Leu Thr Ala Pro Trp Arg Leu  
 1 5 10 15  
 Leu Gln Cys Cys Glu Leu Glu Ala Gly Glu Leu Gly Met Ala Val  
 20 25 30  
 Pro Ala Ala Ala Met Gly Pro Ser Ala Leu Gly Gln Ser Gly Pro  
 35 40 45  
 Gly Ser Met Ala Pro Trp Cys Ser Val Ser Ser Gly Pro Ser Arg  
 50 55 60  
 Tyr Val Leu Gly Met Gln Glu Leu Phe Arg Gly His Ser Lys Thr  
 65 70 75  
 Arg Glu Phe Leu Ala His Ser Ala Lys Val His Ser Val Ala Trp  
 80 85 90  
 Ser Cys Asp Gly Arg Arg Leu Ala Ser Gly Ser Phe Asp Lys Thr  
 95 100 105  
 Ala Ser Val Phe Leu Leu Glu Lys Asp Arg Leu Val Lys Glu Asn  
 110 115 120  
 Asn Tyr Arg Gly His Gly Asp Ser Val Asp Gln Leu Cys Trp His  
 125 130 135  
 Pro Ser Asn Pro Asp Leu Phe Val Thr Ala Ser Gly Asp Lys Thr  
 140 145 150  
 Ile Arg Ile Trp Asp Val Arg Thr Thr Lys Cys Ile Ala Thr Val  
 155 160 165  
 Asn Thr Lys Gly Glu Asn Ile Asn Ile Cys Trp Ser Pro Asp Gly  
 170 175 180  
 Gln Thr Ile Ala Val Gly Asn Lys Asp Asp Val Val Thr Phe Ile  
 185 190 195  
 Asp Ala Lys Thr His Arg Ser Lys Ala Glu Glu Gln Phe Lys Phe  
 200 205 210  
 Glu Val Asn Glu Ile Ser Trp Asn Asn Asp Asn Asn Met Phe Phe  
 215 220 225  
 Leu Thr Asn Gly Asn Gly Cys Ile Asn Ile Leu Ser Tyr Pro Glu  
 230 235 240  
 Leu Lys Pro Val Gln Ser Ile Asn Ala His Pro Ser Asn Cys Ile  
 245 250 255  
 Cys Ile Lys Phe Asp Pro Met Gly Lys Tyr Phe Ala Thr Gly Ser  
 260 265 270  
 Ala Asp Ala Leu Val Ser Leu Trp Asp Val Asp Glu Leu Val Cys  
 275 280 285  
 Val Arg Cys Phe Ser Arg Leu Asp Trp Pro Val Arg Thr Leu Ser

	290	295	300
Phe Ser His Asp Gly Lys Met Leu Ala Ser Ala Ser Glu Asp His	305	310	315
	320	325	330
Phe Ile Asp Ile Ala Glu Val Glu Thr Gly Asp Lys Leu Trp Glu	335	340	345
Val Gln Cys Glu Ser Pro Thr Phe Thr Val Ala Trp His Pro Lys	350	355	360
Arg Pro Leu Leu Ala Phe Ala Cys Asp Asp Lys Asp Gly Lys Tyr	365	370	375
Asp Ser Ser Arg Glu Ala Gly Thr Val Lys Leu Phe Gly Leu Pro			

Asn Asp Ser

<210> 66

<211> 466

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 4834527CD1

<400> 66

Met Pro Gln Thr Leu Ser Ala Ser Asp	1	5	10	15
Leu Ser Pro Pro Pro Thr Glu Pro Thr Asp	20	25	30	
Gln Pro Leu Leu Asp Gly Ala Pro Ser	35	40	45	
Ser Ala Ser Leu Glu Thr				
Leu Ile Gln His Leu Val Pro Thr Ala Asp	50	55	60	
Tyr Tyr Pro Glu Lys				
Ala Tyr Ile Phe Thr Phe Leu Leu Ser	65	70	75	
Ser Arg Leu Phe Ile Glu				
Pro Arg Glu Leu Leu Ala Arg Val Cys His	80	85	90	
Leu Cys Ile Glu Gln				
Gln Gln Leu Asp Lys Pro Val Leu Asp	95	100	105	
Lys Ala Arg Val Arg Lys				
Phe Gly Pro Lys Leu Leu Gln Leu Leu Ala	110	115	120	
Glu Trp Thr Glu Thr				
Phe Pro Arg Asp Phe Gln Glu Ser	125	130	135	
Thr Ile Gly His Leu Lys				
Asp Val Val Gly Arg Ile Ala Pro Cys Asp	140	145	150	
Glu Ala Tyr Arg Lys				
Arg Met His Gln Leu Leu Gln Ala Leu His	155	160	165	
Gln Lys Leu Ala Ala				
Leu Arg Gln Gly Pro Glu Gly Leu Val	170	175	180	
Gly Ala Asp Lys Pro Ile				
Ser Tyr Arg Thr Lys Pro Pro Ala Ser	185	190	195	
Ile His Arg Glu Leu Leu				
Gly Val Cys Ser Asp Pro Tyr Thr Leu Ala	200	205	210	
Gln Gln Leu Thr His				
Val Glu Leu Glu Arg Leu Arg His Ile	215	220	225	
Gly Pro Glu Glu Phe Val				
Gln Ala Phe Val Asn Lys Asp Pro Leu	230	235	240	
Ala Ser Thr Lys Pro Cys				
Phe Ser Asp Lys Thr Ser Asn Leu Glu Ala	245	250	255	
Tyr Val Lys Trp Phe				
Asn Arg Leu Cys Tyr Leu Val Ala Thr	260	265	270	
Glu Ile Cys Met Pro Ala				
Lys Lys Lys Gln Arg Ala Gln Val Ile	275	280	285	
Glu Phe Phe Ile Asp Val				
Ala Arg Glu Cys Phe Asn Ile Gly Asn Phe	290	295	300	

Ile Ile Ser Gly Met Asn Met Ser Pro Val Ser Arg Leu Lys Lys  
 305 310 315  
 Thr Trp Ala Lys Val Arg Thr Ala Lys Phe Phe Ile Leu Glu His  
 320 325 330  
 Gln Met Asp Pro Thr Gly Asn Phe Cys Asn Tyr Arg Thr Ala Leu  
 335 340 345  
 Arg Gly Ala Ala His Arg Ser Leu Thr Ala His Ser Ser Arg Glu  
 350 355 360  
 Lys Ile Val Ile Pro Phe Phe Ser Leu Leu Ile Lys Asp Ile Tyr  
 365 370 375  
 Phe Leu Asn Glu Gly Cys Ala Asn Arg Leu Pro Asn Gly His Val  
 380 385 390  
 Asn Phe Glu Lys Phe Leu Glu Leu Ala Lys Gln Val Gly Glu Phe  
 395 400 405  
 Ile Thr Trp Lys Gln Val Glu Cys Pro Phe Glu Gln Asp Ala Ser  
 410 415 420  
 Ile Thr His Tyr Leu Tyr Thr Ala Pro Ile Phe Ser Glu Asp Gly  
 425 430 435  
 Leu Tyr Leu Ala Ser Tyr Glu Ser Glu Ser Pro Glu Asn Gln Thr  
 440 445 450  
 Glu Lys Glu Arg Trp Lys Ala Leu Arg Ser Ser Ile Leu Gly Lys  
 455 460 465

Thr

<210> 67  
<211> 891  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1405545CB1

<400> 67  
ggagaatggc ggcgccgggc tgccggctggg agcgggaaga ctctttgaaa tgcctgcgggt 60  
gctagagcgca ctgagccgct ataatacgac gtcccaagct ttgtctgagg tgctgcggct 120  
gccgaaggcag cagctgagga agctgctgta cccgctgcag gaagtagagc ggttccctgc 180  
ccccctacggg aggcaagacc ttcacctgcg tatcttgac ccaagcccg aggacatagc 240  
cagggcggac aacatcttca cggccactga acggaaccgc atcgactacg tcagctccgc 300  
cgtcggatc gaccacgccc cggacacctcc gcccggcagag gtgtgtttta taggcagaag 360  
caatgttggaa aaatcatctc taatcaaggc ttatatttca ctggccctgtt aggttgaagt 420  
cagagtctcc aaaaaaccag gacacacaaa gaaaatgaat ttttcaag ttggaaaaca 480  
ttttacagtgt gtggacatgc caggttatgg ctttagagca cctgaagatt ttgttgacat 540  
ggttagagacc tatctaaaag aacgaaggaa ctgttggatc acattttat tagtgatag 600  
cgttgttggaa attcaaaaaa cagacaatat tgccatagaa atgtgtgaag aatttgcatt 660  
accttatgtt attgttattaa caaaaatttga caaatcttcc aaggggacatc ttttaaaaaca 720  
agtgcattcag atccagaaaat ttgttaacat gaaaactcaa ggatgtttc ctcagttgtt 780  
tcctgttaagt gctgtgactt ttcttggat ccacctgtt agatgctta tagccagtgt 840  
aacaggaagt cttgactaat gttcccggt ttagctgaag attcaaaaaa a 891

<210> 68  
<211> 1512  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1451265CB1

<400> 68  
gccccatggag gtggccgtgt gtacggactc ggccggccccc atgtggagct gcatcgtgt 60  
ggaacttcac tcggggcgcca acctgctcac ctaccgcggc ggccaggcgg gaccccgccg 120  
cctggcgctg ctcaatggcg agtatctgct ggccggcgcag ctgggcaaga attacatcag 180

<210> 69  
<211> 2536

<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1556311CB1

<400> 69

caactcttgt tgaagctttt aggcgctcgca gactttcat ttgtgagggc gacctctccc 60  
gaggggctct ttcacacaaa atatcccac ggcgtttc tcaccacaac tcttttcaac 120  
tcttgtctct cgcgacaatt ctcttgaag gcgaggcatt tgaccccaat ttgaaatttc atcgccccaa 180  
caacctggcg acaacaccca gagcttacat ctecttaggg ggaaaaaggc ctgtttaagg 240  
ggctttctt acactcaggg aactctcaca tcccttaggg cccctcggt gcggcaggact 300  
gccttgcaag gtttaccggg ttccggatt ttccggggg aaccataaca aacatggaa cgtagctctc 360  
gaaaccaggc cgagactcc agaaacatgc ccccggtcga agaagcaggc ttctttctg 420  
ccttggaaacg aaccaactcc catccctcca ccccggtcga cggggcaggc cccggagctg 480  
aaagcagagg gcggtgaaaa gaccttgago ggcggccggc cggggcaggc cccggagctg 540  
gagctggcga cagctggcag cccaggtggg gccccgcctg aggccgcccc gggggattgc 600  
acaaggggccc cgccgcccag ctctgaatca cggccccctg gccatggagg ccggcagcgg 660  
ctgagcgaca tgagcatttc tacttctcc tccgactcgc tggagttcga cccggagcatg 720  
cctctgtttg gctacgaggc ggacacccaac agcagctgg aggactacga gggggaaaagt 780  
gaccaagaga ccatggcgcc ccccatcaag tccaaaaaga aaaggagcag ctcccttcgtg 840  
ctgcccggcgc tcgtcaagtc ccagctcgac aagggtgagcg ggggtttcga ctcccttcatg 900  
accccgggaga agcggatgtt ccgcggatc ggcggatc cccggacaa atgcacctac 960  
ttcgggttgc tagtgcggg ctacgtgagc ttcttgaggc agaacaagga gtgccacgtg 1020  
tccagcaccg acatctgcg aaccatccgg cagttcatga cccaggtcaa gaactatttg 1080  
tctcagagct cggagcttgg ccccccattc gagtcgtga tccctgaaga ccaaataatgat 1140  
gtgggtctgg aaaaagccat gcacaagtgc atcttgaagc ccctcaaggg gcacgtggag 1200  
gccatgtga aggactttca catggccgtt ggctcatggc agcaactcaa ggagaacctg 1260  
cagttgtgc ggcagaggaa tccgcaggag ctgggggtct tcggcccgac ccctgttattt 1320  
gtggatgtgg agaaaaatcaa agtcaagttc atgaccatgc agaagatgtc ttccggaa 1380  
aagaaggctca tgctgtctgc gggggcttc aagctcattt acacggctcat ggagaacac 1440  
tcaggggaga tggatggcgc tgatgacttc ttggcgttcc tgacatgtt catagccccag 1500  
tgtgacatgc ttgaatttgc cactgaaatc gaggatcatgc tggagctctt agacccatcg 1560  
ctgttatcatg gagaaggagg ctattacttg acaagcgtt acatggagact ttctctgata 1620  
aagaatttcc aagaagaaca agcagcgcga ctgctcaactt cagaaaaccag agacacccctg 1680  
aggcagtggc acaaacggag aaccaccaac cggaccatcc cctctgttggc cgacttccag 1740

aattacctcc gagttgcatt tcaggaggc aacagtggtt gcacaggaaa gaccctcctt 1800  
 gtgagacatt acatcaccac tgaggatgt tgcagatct gcgctgagaa gttcaagggt 1860  
 ggggaccctg aggagtacag cctcttctc ttcggtgacg agacatggca gcagctggca 1920  
 gaggacactt accctcaaaa aatcaaggcg gagctgcaca gcccaccata 1980  
 ttccacttg tctacaaacg catcaagaac gatccttatg gcatattt ccagaacggg 2040  
 gaagaagacc tcaccaccc ctagaagaca ggcgggactt cccagtgggt catccaaagg 2100  
 ggagctggaa gccttcctt cccgcttcta catgctttag cttgaaaagg agtcaacctc 2160  
 tcggggaccc ctcagtgtag tgactaagcc atccacaggc caactcgcc aaggccaact 2220  
 tttagccacgc aaggtagctg aggttgtga aacagttagga ttcttcttgc gcaatggaga 2280  
 attgcattcg atggttcaag tgcctgaga ttgtttgcta cctacccca gtcaggtct 2340  
 aggttggctt acaggtagt atatgtcag aagaaacact taagatacaa gttctttga 2400  
 attcaacacgc agatgcttgc gatgcgtgc gtcaggtgtat tctcacttct gtggatggct 2460  
 tcatccctgc cttecccttct ttcttttcc ttgtgtgtt tttttttt ttttaaaaaaa 2520  
 gcettcgggt tttaaa 2536

<210> 70  
 <211> 1415  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1901373CB1

<400> 70  
 gcgaggacgc gggccgagcc ggaagtggag tgcgctgccc cgcgagctgg gcccggggc 60  
 gtgggtcgag agcgccgaga gtccagactg gcccggggc cccgactgac aataccctcc cctcccttgg 120  
 gtcctgtgc tctccagcccc tcactcgaa cccgactgac aataccctcc cctcccttgg 180  
 gctggacccc tctctacagc taggaccaa tggcagaaga aaaaacaaa ccgagtgagt 240  
 tgaccacagg aaatgtatgt gctgtatc acgtgaagat catctgcctg ggagacagcg 300  
 cagtggccaa atccaaactc atggagagat ttctcatggc tggcttcag ccacacgc 360  
 tgcacacgtt cggccctgacc ctgtacaagg acacagccac ggtagatgg aggaccatcc 420  
 ttgtggactt ttgggacacg gcaggccagg agcggttcca gaggatgtatgc gcctctact 480  
 accacaaggc ccacgcctgc atcatgtgtt ttgtatgtaca gaggaaagtc acctatagg 540  
 acctgagcac ctgtatatac gagcttcggg attcaggcc agagatccca tgcacgtgg 600  
 tggccataaa aattgtatgc gacataaaacg tgaccacaaa aagcttcaat ttggccaaa 660  
 agttctccctt gccccctgtt ttctgttcgg ctgtatgg taccatgtt gtgaagctct 720  
 tcaatgtatgc aattcgatata gctgtgttcc aaaaacagaa ctcccaggac ttcatggatg 780  
 agattttca ggagctcgag aacttcagct tggagcagga agaggaggac gtgccagacc 840  
 aggaacagag cagcagcatc gagaccccat gagaggaggt ggcctctccc cacagctgag 900  
 gggctggggc taggggtggg tggagccctt taaaatacc ctcccttca acaactctcc 960  
 agctctgaat ggagaaactc tctaggccat ccccttcttct acctctgtca acccaccat 1020  
 cctattagcc tcccacattc aaggccccgtg atacaggat gaggtcagca ccagcaaact 1080  
 ctggactgtt ggaagaatcc cccaccatgt ctcccttgcag cagaatttgg gatcagcatc 1140  
 attaacacctt tccccccccc tccccccgcag gcaacatgt aagagaatca gaaaacatga 1200  
 ttatgttca cttaatatac gggaaatggat gtgtttttt gtgtttttt tttttttt 1260  
 gttttcttcc caaagctcac ctggggaca attccttggg ctctcttgc ggtaatgatt 1320  
 taccctccca cccacagctg agtctgttag gccccatctt ttccctacgt tttctcccat 1380  
 ctttttctt cttcagtc tccatgtctt ggttt 1415

<210> 71  
 <211> 1902  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2367767CB1

<400> 71  
 gcgaggctcg gctaggctac gggccacgcg ccggccccc tggcccccactgtcctct 60  
 tcggaggcgc gggcccgacg gaaaccatgt ttgtggctcg cagcatcgcc gggaccaca 120  
 agatctcat ccacgatgtc tcttcgact tccacggcgcc gggatggca acctgtccca 180

gcgatcagag cgtaagggtc tgggataaaa gtgaaagtgg tgattggcat tgtactgcta 240  
 gcttgaagac acatagtgtc tctgtatggc gtgtgacatg gccccatcct gaattttggc 300  
 aggtttggc ttccctgttct tttgaccgaa cagctgctgt atgggaagaa atagtaggag 360  
 aatcaaatga taaactgcga ggacagagcc actgggttaa aaggacaact ctggtgata 420  
 gcagaacatc tgtaactgtat gtgaaggttt ctcccaagca catgggtttt atgttagcaa 480  
 cctgttcgc agatggtata gtaagaatct atgaggcacc agatgttatg aatctcagcc 540  
 agtggtctt gcagcatgag atctcatgtc agctaagctg tagttgtt tcttggaaacc 600  
 cttcaagctc tcgtgtcat tccccatga tcgcccgtagg aagtgtatc agtagcccc 660  
 acgcaatggc caaggttcag attttgaat ataatgaaaa caccaggaaa tatgcaaaag 720  
 ctgaaaactct tatgacatgc actgtatcctg ttcatgatat tgcatcgt ccaaatttgg 780  
 gaagatctt ccataattcta gcaatagcga cccaaagatgt gagaattttt acattaaagc 840  
 ctgtgaggaa agaactgact tcctctgggt gggcaacaaa gtttgaatc catatagtgg 900  
 ctcagttcga taatcataat tctcagggtt ggcgagttgag ttggatata acaggaacgg 960  
 tgcttagcata ttcaggagat gatgggtgtg taagattgtg gaaagctaat tataatggaca 1020  
 attggaaagtg tactggttt ttgaaaggta atgggagccc agtcaatggg agtttcagc 1080  
 agggaaaccttcc aaatccttcc ctaggttcaa atattccaag tcttcagaat tcattaaatg 1140  
 gatcttctgc tggcagaaag cacagctgag tacaagctaa ctggagtaac tttgctgttt 1200  
 tgctgcttgt tgcatgcaca caggaatggc aagcgagctc cttttccct tccccagcgc 1260  
 cggttgcacct cttccaagat acaccagcag cctgttact actaaacgcgca atccaaaagg 1320  
 cctttaaaaaa tacagtgtat atttttgtt cttagtcgtt tattgacact atttggaaact 1380  
 ttgttaatataaaat aaacggagag gctttctgtt gagacattgtt caccggaaa atttttgaa 1440  
 atgttcctgtt aactaatttgc ggtttaaaga tttttttttt tgtttaccatt cttatctgag 1500  
 tagtggggag gaggggaaa ccacttttttgc ttttttttttgc aatataagaca tattttttt 1560  
 gctttcttaaa aacagcttaa aatgtatggc ttttataatt ttaatttggaa gattgaataa 1620  
 atatttttta taaagattgt ttgagttgtt gatttttttttgc ttttttttttgc attttttttt 1680  
 tccatgatataat tcaatgttttgc ttttttttttgc ttttttttttgc atttttttttgc 1740  
 gagtgaattttaataaaatgtt aatgtatggc ttttttttttgc ttttttttttgc atttttttttgc 1800  
 cagggttaagc attttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc atttttttttgc 1860  
 ttataagttt ttaatttgcata gtttttttttgc ttttttttttgc ttttttttttgc atttttttttgc 1902

<210> 72  
 <211> 1681  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3090433CB1

<400> 72  
 gggcagggtt tgcttatggc taatgtatccc ttgaaaggct tccatgaagt aaaccttgc 60  
 tcacctactt ctccggaccc tcttgggtgt tatgaatcag gaactcaaga gcagactacc 120  
 tcacccaatgt tcatctaccg gccacaccct tcagctttat cctctgtacc tattcaggca 180  
 aatgcatttag atgtttctgtt acttccatca caaaccgtgtt attcatcccc cagacgttta 240  
 aattgtgcgg aaatatctgtt tattcatttttgc ttttttttttgc ttttttttttgc 300  
 tctgggttca cagctgttca aactaaatttttttgc ttttttttttgc ttttttttttgc 360  
 agagagttttt tacagggtgc tactataaca gaggcttgcg atggcagtgtt ttttttttttgc 420  
 ggggttggatc ctgatgttgc gtctcttttgc ttttttttttgc ttttttttttgc 480  
 aagggtctatg aacgatttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 540  
 gatgaagaat gtgaggggtt ttttttttttgc ttttttttttgc ttttttttttgc 600  
 ctcacagcttca gtcttatttttgc ttttttttttgc ttttttttttgc ttttttttttgc 660  
 gcaacacggc aaaaacacgtt aaaaaggatca gaaaaggatca ttttttttttgc ttttttttttgc 720  
 gtatgttgcatttca ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 780  
 ttggccagggtt gaaagacacc ttttttttttgc ttttttttttgc ttttttttttgc 840  
 gctatgtatgttca gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 900  
 gaggctgttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 960  
 aggacgtgttca ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 1020  
 tcaaaaaatgtt agttggcttc agctgttgc ttttttttttgc ttttttttttgc ttttttttttgc 1080  
 gaaccagggttca ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 1140  
 caaaaaaaaatgtt gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 1200  
 gactcaagca actattatttttgc ttttttttttgc ttttttttttgc ttttttttttgc 1260  
 aacttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 1320  
 cagatgtttt gggaggttca gtttttttttgc ttttttttttgc ttttttttttgc 1380

ttcaaagagg aactctgatg ctctgcgtgg gaccatgcct gaactccccg aataactgaa 1440  
 aaatggctga atattttat ggtaacttga tatttatttc caaggagtga gcctaagact 1500  
 ttttccct tttgcaaatt gctctaagaa gtaccatgt ttcttttaaa ctgatctatg 1560  
 ctgtgtttgc ttattctta gttgaacaca ctagaagaa ttccagggtgt actagtgaat 1620  
 gtaatttata gttgcaaaa aaaaaacaaa cctgaaataa ataaatgtta gattgaaaaa 1680  
 a 1681

<210> 73  
 <211> 1378  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3800591CB1

<400> 73  
 ggcagatcct atctggcgca tgcgaacgt tctgtgccga ttccttgaag agcaggcgca 60  
 gactcaaggc tggcgttcc gcccctactc ccccgctc gtccttggc ggggccaagg 120  
 ctggcgtgg ggaagaggcg tggcggcgct gtgcgcgtgc aaaaaagaga gctgaggggc 180  
 gggggcgctg cgccacagct ggtttgagca actgaactgg aaacaagatg caggaccctc 240  
 acgcagacac tgaatggat gacatcttac gcaaaaaaggg tatcttaccc cccaaaggaaa 300  
 gtctgaaaga atttggaaagag gaggcagaag aggagcagcg catcctccag cagtcaagtgg 360  
 tgaaaacata tgaagatatg acttttggaaag agctggagga tcatgaagac gagtttaatg 420  
 aggaggatga acgtgttattt gaaatgtaca gacggcgagg actggctgag tggaaagcaa 480  
 ctaaaactgaa gaataaaatc ggagaagttt tggagatctc agggaaaggat tatgttcaag 540  
 aagttaccaa agctggcgag ggcttgggg tcatcttgc cctttacaaa caaggaattt 600  
 ccctctgtgc cctgataat cagcacctca gtggacttgc cagaaaggat cctgatgtca 660  
 aatttatcaa agccatttca acaacactgca tacccttata tcctgatagg aatctgccc 720  
 cgatatttgtt tacctggaa ggagatatca aggttcagtt tatttggctt ctgggtttt 780  
 gcggcatgaa cctgacaaga gatgagttgg aatggaaact gtctgaatct ggagcaatta 840  
 tgacagacact ggaggaaaaac cctaagaagc cgattgaaga cgtgttgcgt tcctcagtgc 900  
 ggcgcctgtgt cctcatgaag agggacacgcg attccgggg tgactgaggg tacagttct 960  
 atcacatgcc gaactttttt gtgacaaattt gtctggattt ttaaaaaaaaag gaaaaagcaa 1020  
 gaatgaatcc ttgtgggat tagttttttaaaattatgt tcctaaatctt tacattttgg 1080  
 aaataatcat tgctggagat tctgttaaat attttggaaac tctttttttt taaaattata 1140  
 gtatccctc taaaaaaaaat taaaacccagc cattttgtatg gaaaaaaaaaaa aaaagataata 1200  
 tcaatattac aattcagggt tcctaattttt ctaaaaccta tgggaaattt ctaggatgga 1260  
 cgatctttagg aaggatact ttggctgtt gtgagaaaaca caaaaataatt ttattacact 1320  
 ttaaaaatgt ttgtcataa tttagttaat attaaccttg tttaacttta tagaaaga 1378

<210> 74  
 <211> 1444  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 5308471CB1

<400> 74  
 gcacgcgtg ccggaggccg cagccccggaa acctcagagg cgggtcgcag cggcgccagag 60  
 gaggtcagct gcccggagct ttccggggac ggtgcgcctca tgagattgac cccgcgcgc 120  
 ctgtgcagcg ccgcggcaggc cgcctggcg gagaacttcc ccctgtgcgg tcgcgcgtg 180  
 gcgcgtggcgt tccccggccca catggccaaag gggctgaaga agatgcagag cagctgaag 240  
 ctggtgact gtatcatcga ggtccacgt gcccggatcc cactttcagg ccgcacccct 300  
 ctgtttcagg aaacccttgg gcttaaggct cacttgcgtt tcctcaacaa gatggacttg 360  
 gggatctta cagagcagca gaaaattatg caacacttag aaggagaagg cctaaaaat 420  
 gtcattttta ccaactgtgt aaaggatgaa aatgtcaagc agatcatccc gatgttcaact 480  
 gaactgattt ggagaaggcca ccgcgttccac cggaaaggaga acctggatgta ctgtatcatg 540  
 gtcattttggg tcccccaacgt gggcaagtcc tcctcatca actccctccg gaggcagcac 600  
 ctcaggaaag gggaaaggccac cagggtgggtt ggcgagcctg ggatcaccag agctgtgatg 660  
 tccaaaatttca aggtctctga cggccccctg atgttccctgt tggacactcc tggcgtgctg 720

```

gctcctcgga ttgaaagtgt ggagacaggc ctgaagctgg ccctgtgtgg aacggtgctg 780
gaccacctgg tcggggagga gaccatggct gactaccgtc tgtacaccct caacaaacac 840
cagcgcttgc ggtacgtca gcactacggc ctgggcagtg cctgtgacaa cgttagagcgc 900
gtgtctaaga gtgtggctgt gaagctgggg aagacgcaga aggtgaaggt gctcacggc 960
acgggtaaacg tgaacgttat tcagcctaacc tatcctgcgg cagccgtga ctgcgtcag 1020
actttccgcc gttggctgtc gggttccgtg atgctggacc tcgcacgtct gcggggccac 1080
cccccggtg agactttgcc ctgaacttgt ccgggttaggg agggccggag gcatgtggcc 1140
tcccagacct cctgacactgg gtgggtgagg ctcaagacag ctcaccccggtt ccagaagctc 1200
catgtgtgc acttaggggtc tggtgtctct ggccccccac agcctggcca gctccaggga 1260
ccccagttgc agggcccaag cagggtggag tggacaccag gctttcccgat ggacgtccct 1320
gagcagctcc gcatgttgg ttctcccgga gtttcgtct caggcctt gagaatggaa 1380
tgctgtctca gaaggagttt aagctataac ctgttaacatt taaaatctca aaaaaaaaaaa 1440
aaaaa

```

<210> 75

<211> 2067

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 5324322CB1

<400> 75

<210> 76

<211> 2085

<212> DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 067184CB1

&lt;400&gt; 76

gtgttcgcgc actggccttg agggagagct ggggcctgct cccggagaga tacggctatg 60  
 tcgatcgaaa tcgaatctt ggatgtgatc cgccttatta tgcagtactt gaaggagaac 120  
 agtttacatc gggcgttagc cacctgcag gaggagacta ctgtgtctt gaatactgtg 180  
 gacagcattg agagtttgtt ggctgacatt aacagtggcc attgggatac tgtgttgcag 240  
 gctatacagt ctctgaaatt gccagacaaa accctcattt accttatga acagttgtt 300  
 ctggaattga tagagctccg tgaattgggt gctgccaggt cactttttag acagactgtat 360  
 cccatgtca tggtaaaaaca aacacgcca gagcgtatata ttcatcttga gaacctttt 420  
 gccaggctt atcttgatcc tcgtgaggca taccctagatg gaagtagcaa agaaaagaga 480  
 agagcagcaa ttgcccaggc cttagctggc gaagtcgtg tggcctcc atctcgtctc 540  
 atggcattgc tggcacaggc actgaagtgg cagcagcatc agggattgtc tcctcctgtt 600  
 atgaccatag atttggatc aggcaaggca gctgtcaaaat atgtggaaaga agaaaaagt 660  
 cctacacaac tgagcaggca tattaagttt ggtcagaaat cactatggta gtgtgtctga 720  
 ttttctccag atggtcgtt tttggtcaact ggtctgtt atggattcat tgaatgtgg 780  
 aactttacta ctggaaaaat cagaaaggat cttaaatgtt accggccaaga taactttatg 840  
 atgatggatc atgatgtctt ctgcattgtt ttccagcagag atacagaaat gttagcaact 900  
 ggggccaag atggaaaaat caagggtgtt aagattcaga gtggacaatg tttaggaga 960  
 tttgagaggg cacacagtaa ggggttcacc tttctaaatg tttctaaatg tagcagttag 1020  
 atccttagtgc ttcttttgc ccagacaatt agaattcatg gttttaaatc tggggaaaacc 1080  
 ctgaaggaat ttctgtggca ttccctctt gttaaacgaa caacattac acaagatgg 1140  
 cattacatta ttatgtcatc ctctgtatggc actgtaaagaat tcttggatat gaagaccaca 1200  
 gaatgttcaa atacatcaa atccccggc agacccggcag ggacagat taccgtcaac 1260  
 agtgtgattc tacttcttca aaacccttgcg cactttgtgg ttttcttcaactg atcaaacacg 1320  
 gtggcatca tgaatcatc tggcggcattt gtcagaagct tcagttctgg taaaagagaa 1380  
 ggtggggact ttgtttgtt tggccctctt cccctgtgtt aatggatcta ctgtgttaggg 1440  
 gaggactttg tggcttactg tttcgttaca gtcactggca aactggagag aactttgaca 1500  
 gtgcacgaga aggtgttgcg tggatttgc catcaccctc atcagaacctt gattgttacc 1560  
 tacagtgaag atggacttca aaagctctgg aaaccataat tcaactttt tttttaaatc 1620  
 agctcgaaag catgttactt aatgaagcat attcatgtt gttgtttttt tttttttttt 1680  
 gccagctttt ctaagcaat agattgttgc aattgttac agaataat tttttaat 1740  
 catgtttaag tagcaactac cttttttt ttttatattt tttttaat tttttaat 1800  
 tcttcttactt ggtgcgttca cttaatgttt tcattatct tcgaccttgg gaggtaata 1860  
 ctgtatatttca tagaaaaaaa ttcttacttctt ctgttattt gaaatgtt gggaaatgtc 1920  
 cctcccatatg taaaacttgtt aaataaggaa ctatatcata ttccatgtt gttgttctgtt 1980  
 ccattttttt tttttttt gagatggagt ttgttctgtt gcccaggctg gagtgcagcg 2040  
 gcacatctt ggttcaactgc aacccggccccc tcccttgc aagcg 2085

&lt;210&gt; 77

&lt;211&gt; 2061

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 722896CB1

&lt;400&gt; 77

cgagccgcgg gacccggggc gtaccgggaa ggggcgcgc cggggccgcag cgccaggggca 60  
 gcgaggggcg gcgccggactt ggcacccggc ggggcggcg gcagcggatca tgatcgctt 120  
 gttcaacaag ctgttgcact ggttcaaggc ctttattctgg aaggaggaga tggagctcac 180  
 gctggctggg cttcgttactt cggcaagac caccctcgat aacgtgtatcg cgtcaggaca 240  
 gttcaacgag gacatgttcc cccacgtggg ttccatgtt cggcaaaatca cccaaaggaa 300  
 tgtgtacttca aagctctggg acattggggg acagccgcgtt ttccgcggca tggggagcg 360  
 ctactgcggg ggagtggatcg ccattgttca catgggttgcgtt gttgttgcacc aggagaat 420  
 tgaggcctctt aagaacgagc tccacaaccc actggacaaa cctcagctgc agggcatccc 480  
 ggtttagtgc ctgggttaca agcgagaccc tccggggagca ttggatgtt gggatgtt 540  
 tgagaaaaatg aatctgttgc ccattccaggca ccggagatc tgctgtactt ccattctt 600

caaagaaaaag gacaacattg acatcacccct acagtggcctt attcaaacact cgaagtcacg 660  
gagaagctga gactccagcc ctctccctc agaccaggaa ccgtcatcat ctaaacctga 720  
agcccgagtc cccgccccacc ctgtcgctcc ccctaagccc accccctcctc acccagtgtg 780  
aggaggggcc tctggggacc ccagactcct gttctgcgtga gggttgaact cctgtttttt 840  
ttgtaaaata aattgcccccc cattctggtc ccctaacttc tcaccccttc ccgtgcctt 900  
tgtcccatca cccagccctg cctccctccccc agcagccctg ggcacagcc cccgcggccctg 960  
gctttttccc ggccccgtt tgtaatccccc ttttcaacac tctctgttat tgcctgtgt 1020  
gtacagtata tatatgtata tatattttaa tttttttaatt taagccaaaga ctaaaaatcaa 1080  
ccatgttgc ctgcaggggc ctttcaggat ctgggagggg gcagtcgttgc gagaaggagg 1140  
gagacgcagg tggacttggg gcaagttcag atcagaagag gtgcaggctg gcacccgtgg 1200  
caggtaaccg cctggcact ggtggccgccc tccctgtccc gtgtgtttcc accggcccaat 1260  
ctggcttgc ctggcagtgc ttgaatgcca caggctggca ggggcctctg gggggccctc 1320  
ccctcgaccc ccagccctgg tagagccacc agtacgcac accaggtaacc agaaaccacc 1380  
aggcacacccg ggcagaaaggc cagcgtccat gcccggcag ccccttcctg cctgttcctg 1440  
gctcccaagct cccggccctc ccaggggccc ccacccctccac ggcccacttc attttctgtt 1500  
ctcattttgc agagggtcac aaggagagaa ctcagcatgg ggggttgggtt ctttgggttc 1560  
tgggtttaat ttgtttaat ttaatgattt gtaaagtgtt gttcccttc cttttttaca 1620  
cttttcagct catatttaaac ctctgtttgg aaaatgatcc ttgttaactgtt acattttttt 1680  
gcttcctaaat aacaatgaca aaaaaaaaaaa taaatgacca gttttgtgtt ggggggggggt 1740  
tatggtgctg gttactttc cgcgcgttggc atgggttgc ctacaggcccccc acaggggccac 1800  
cagcacaccc cccgcacgtg ggccaccaaca gagccacggaa ggcgcacgcac atgccccccc 1860  
gggggagcaca atggcgctc aaaaaacggc ctcccaacgc tgcgtccagg ctcttgcgc 1920  
acccctctt cattttctt tcaagtttc atgttagtttcc agetttgagc cagcagctgc 1980  
cacttggggc tgcagcgctc tggttggggaa actggccagg gctgggtaga ggcagcaagg 2040  
ggacaggggct ggggtgtttt t 2061

<210> 78  
<211> 981  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1571739CB1

```

<400> 78
gtagttccag aaaataggac tgaccaagaa gcagaaaaagc aagatgaatg atgtgaagct 60
tgctgtctt ggtggtaag gaacaggcaa atctgcctt acatgtgggt ttcttactaa 120
gcgattcatt ggagaatatg cttctaatt tgaatctatc tataagaagc acttggttt 180
ggaaaaggaaa caactaaatc tagaaatata tgacccctgt tctcaaaacac aaaaagcaaa 240
atttccttc acaagtggc ttcaactggc agatgggtt gtatttgtt atgacatcag 300
tgataggct tcatttgtt ttgcaaaaagc gctgatctac agaatccggg agccacaac 360
tagtcattgt aaaagagctg tggaaatcagc agtgtttttg gttggcaaca aacgagatct 420
ttgtcatgt cgagagggtt gctggaaaga agggcaaaag ctggcaactgg aaaaccgatg 480
ccaattctgt gaactgtctg cagcagagca gtctctggag gtggaaatga tggatcatcag 540
aatttatcaag gacatcctga taaaacttcaa actcaaagaa aagagacgtc ccagtggatc 600
taaatcaatg gccaaattga tcaataatgt atttggaaaag agaaaggaaat ctgttttaga 660
gacaggttaat cctggagat ttccatatac agagagttc aaacattcag atgataatta 720
aactaacctt tgtatgcaat ttttttttgg taaaaaaat tcttctggag atatgaaatg 780
attgagttt aaccacagtt gtgttttcaa atatgttagtt tgcccttttg gttgtgtac 840
cctgtctact ctccttcaca cagaacctt catttattgt aacaacatcac actcaccctt 900
acctactggc ggacagcgat cccagttgc cttgccaat aaactctgtt tatgtgaatt 960
tattaaacqa caaaaaaaaa a 981

```

<210> 79  
<211> 1375  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1739479CB1

<400>	79	aattctgtgc ttctccctct tgggccttca cacacttagt cttatgtaaa taattattaa 60
tcataaaaa atgatggtgg agattcttat tcaccactac atcccatccc cagggcctgc 120		
cacagaatag gcattcgat aataattttt gaatgatgta ctgagaaaatc acaccctgt 180		
ttctttaaa cacatctga tagctccata agtttcatca gggfcagtgg tttccattgt 240		
cctgactgtg gggccacagt acctgttctg tgctttattt gacaagaccc ctgaatggtt 300		
ggacagtgtat tcctgcacaa agtgtgatca gcctttttc tggacttca agcaaattgtg 360		
ggacagtaag aaaattggtc taagacagca ccaactgcgc aagtgtggg aggccgtctg 420		
tggcaagtgc agctccaagc gctctccat cccccctgatg ggcttcgagt ttgaagtgag 480		
ggtctgtgac agctgccccg aggccatcac agatgaagaa cgtgcaccca cagccacatt 540		
ccatgacagt aaacataaca ttgtgcatgt gcatttcgat gcaacccaggag gatgggttact 600		
gactcttggaa actgacaagg ttataaaggt gtgggatatg accccagtgc tggcttgatg 660		
actctcccaag gaatcagaaaa gatagtattt actaaagaaaa cggttggttt aacccaaatc 720		
attaccagag tggtaaaagca gacatgtgag aagtaagaaaa gaaactaaag accctgtatg 780		
aatttgcaga ttaccatgt gcacagtggg gacccggcca gtgagcactc gcaaggggac 840		
tcttccaaact tgttcataaca atataaaaaga agctattttt ttaacaaatg gtttataacag 900		
tctggctgtg ctgcattgtt ttgagtgtac cgaaaaatct gtgtgggtg ttaattttt 960		
atactttca acacccatt ttatttggc ctttgcaga gaaataaggg aggtatctac 1020		
tcagagtatt tgggtcatta tactttctgt gtttacttca acatgttca cgtggccacg 1080		
ggctttttct tcttcctccct ctgcacccatc ctgcacccct tcgtcccttc ctggggggga 1140		
tgtattttat tattttatc ccagtgttcc tgcatttcatg tccttcctcag tggagagatt 1200		
tggaaactca tcatgtggat tcaccagcca gctgctgaa ttgcctgaag agcgatttgt 1260		
ttgttaatgtc tgccatc acgttcttat gaagtagaaaa agactgtgtt tctgcctcag 1320		
ttgcctctgt cttttccacca ttaaaaaaaaaaa aaatgctgtg agaaaaaaaaaaaa 1375		

<210> 80

<211> 2833

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 1999147CB1

<400> 80

cgggtgggac	gcacacactc	tgcgtcatgg	agggctgagg	ccgtatgtga	ttccggaggt	60
gcctgtcagg	cttgcgtgt	cactcgccc	gctcggcg	ccccctccca	gcgcggcc	120
cgtaccggct	ctcgggctct	tccggctccc	ggccggccct	tacctcgagg	ctcttc	180
gcccggggcc	ggcgcctctcc	gagtcgcccc	tgcggactgg	tctcgcacag	tgccctggca	240
ccggggcgcca	gacagacact	ggccatgacg	agggggcga	ccaggtaccg	gctgagctgc	300
tcgctccggg	gccacgagct	ggacgtacgg	ggcctgggt	gctgcgccta	tccgcccggga	360
gcctttgtgt	ccgtgtcccg	agaccgcacc	acccgcctct	gggccccaga	cagtccaaac	420
aggagctta	cagaatgca	ctgtatgagt	ggccatttca	attttgtatc	ttgtgtatgc	480
atcataccct	caagtgcacat	ctaccctcat	ggcctaattg	ccacccgggg	aatatgaccac	540
aatatatgca	ttttctca	ggacagtc	atggcactt	atattctaaa	aggccacaaaa	600
aatactgttt	gtatgtctatc	atctggaaaa	tttggacat	tacttagtgg	ttcatggac	660
accactgtca	aagtctggct	gaatcagaag	tgcatgtga	ccttgcaggg	tcatacagct	720
gcagtggtgg	cggtaaaagat	cttacctgaa	cagggctta	tgttactgg	atcagcagac	780
aagactgtta	aactgtggaa	ggctggaaaga	tgtgagagga	cttttcagg	gcatgaagac	840
tgtgtaaagag	gtttggcaat	tttgagtgaa	acagaattt	tttctgtgc	aatatgtatc	900
agtattagaa	ggtgcaaat	cactggcgag	tgtcttgaag	tatattatgg	acatacaaaa	960
tatatttata	gcatatccgt	ttttcccaaatt	tgttagagact	tgtgacaac	agcagagggac	1020
agatctctga	gaatctggaa	acatggggaa	tgtgctaaa	ctatccgcact	tccagctcg	1080
tctatatgtt	gtctgtgt	gctcgcaaat	ggtgacattt	tggtgtgtgc	gagtgtatgg	1140
attatttagag	tgtttacaga	atcagaagat	cgaacagca	gtgtcgaaga	aatcaaggct	1200
tttggaaaaag	aactgtctca	cgcaaccatt	gattctaaa	ctggcgattt	agggggacatc	1260
aatgctgagc	agcttcctgg	gagggaaacat	cttaatgaac	ctggtactag	agaaggacag	1320
actcgtctaa	tcagagatgg	ggagaaaagtc	gaagccatc	agtggagtgt	tagtgaaagg	1380
aggtgtggataa	aaatgtgtga	tgttgtggc	tcatctgtt	ctaattcaga	acatctggaa	1440
aaagtttat	atgaaggaa	agaatattgtat	tatgttttct	caattgtatg	caatgtaaagg	1500
ggaccatcat	ataaaatggcc	ataataacc	agtgtatgg	cttggtaac	tgcatataac	1560
ttcttacaga	agaatgattt	gaatcctatg	tttctggatc	aagtagctaa	atttattatt	1620
gataacacaa	aagggtcaaaat	gttgggactt	ggaaatccca	gcttttcaga	tccatttaca	1680

ggtgggtggc ggtatgttcc gggctttcg ggatcttcta acacactacc cacagcagat 1740  
 cctttacag gtgctggtc ttatgtacca ggttctgcaa gtatggaaac taccatggcc 1800  
 ggagttgatc catttacagg gaatagtgc taccgatcag ctgcataa aacaatgaat 1860  
 attattttcc ctaaaaaaga ggctgtcaca tttgaccaag caaacccctac acaaataattt 1920  
 ggtaaactga aggaacttaa tggaaactgca cctgaagaga agaagttaaac tgaggatgac 1980  
 ttgatacttc ttgagaagat actgtctca atatgtataa gttcttcaga aaaaccac 2040  
 gtcagcaac tttagtattt gtggaaagct attaactgtc ctgaagatat tgtcttcct 2100  
 gcacttgaca ttcttcgggt gtcaattaaa caccggcgtg tgaatgagaa cttctgcata 2160  
 gaaaaggaaag gggctcaggc cagcgtcat ctatcaatc ttctgaaccc taaaggaaag 2220  
 ccagcaaaacc agctgcttgc tctcaggact ttttgcattt gtttggcgg ccaggcagga 2280  
 caaaaactca ttagtgccca gagggaaatca ctgatgtccc atgcaataga actgaaatca 2340  
 gggagcaata agaacattca cattgtctg gctacattgg ccctgaaacta ttctgttgc 2400  
 tttcataaaag accataacat tgaaggaaa gcccaatgtt tgtcaactaat tagcacaatc 2460  
 ttgaaagttag tacaagacact ttttagactt ttgtggctt tggaaacactt 2520  
 atcagtatg atccaaatgc tgcataattt gccaagtctt tagtgttgc ttctcaaata 2580  
 aaaaagtattt cctcattgtc agaaccagct aaagtaagt aatgctgtat atttatccta 2640  
 aatttgctgt agcagtgggg aagaggacg gatattttt attgatttagt gttttttcc 2700  
 tcacatttga catgactgat aacagataat taaaaaaaaga gaatacgggt gattaagtaa 2760  
 aattttacat ttgtaaagt ggtggggagg ggaaacagaa ataaaatttt tgcactgctg 2820  
 aaaaaaaaaaaa aaa 2833

&lt;210&gt; 81

&lt;211&gt; 1752.

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2182085CB1

&lt;400&gt; 81

gcaggcagcc atcttgcctg gggcttgaga aaggggaggag agacagaagg aaccggcgcac 60  
 agtggctca gggccgctc gggggccctc aagaaccgga ggcagccccg gaggctgccg 120  
 cggccggaca cggccagagga ggaggccggg gaatggccgc ggtgtggcag caagtcttag 180  
 cagtggacgc gaggtacaac gcgtaccgc caccacgtt tccacagtgg cggacgcgt 240  
 atatccgcgc ggcgcagcgc tgctggggaa gaatggcaag gctgggcacc ccccacgcgt 300  
 gcgtcgccag tacctgaggc ttccggggca gctgtgggc cagcgtacg ggcacctctc 360  
 cgagccaggc agtgcgtctg cctatgcac cagcatgtc cgcagtagcc gcactactct 420  
 tgaccgcgtg gaggacttgc aggatgtcc tcggccctg gggggccctg ggcacccgtc 480  
 ttctgtcgc agaggctctt accagctgc ggcgcagatg aaccgtggc tctatgagga 540  
 caggccccctt ggcagcgtgg tgccccacgtc accagcagag gcaagtccgg ccatggccgg 600  
 ggacacgtca ctgagcggaga actatgcctt tgccggcatg tatcatgttt ttgaccagca 660  
 cgtggatgag gcagttccaa gggtgccgtt cggcaatgtat gaccgcaccc gcctggccctg 720  
 ctgctactc gacggcagca tctccctgtc ccagctgggt cctggccccc ccacagtgtct 780  
 tcgcgtctca cggggcccaac cccgtgtgt ctccgcattc gcctggtccc tctccaatga 840  
 catcctcggt tccacccatc tggatggccac catgcgtacatc tggccctctg aggatggcgt 900  
 ctgcacccgtt gagatccctt acccccgatag cgttgcactg ctctgtcga ccttccagcc 960  
 tgcataacaac aacccactgt tggtggggaa cggcaagcac aacgtgcatt tcatgaacat 1020  
 ctccacaggc aagaaaagtga agggggccctc cagcaagctg acaggccgtg tccttgcct 1080  
 gtcctttgtat gccccctggcc ggctgtctgt ggcgggtgtat gaccgtgcac gtgtcttc 1140  
 ttccctctttt gatatggca cagggaaagct gaccaaaagcc aagcgtttgg tggtgcattga 1200  
 ggggagccctt gtgaccacca ttcgcgtcc gtcctgggtc agccgcgagg cccggatcc 1260  
 ctcaactgtc atcaatgttt gctcaacaaa gtgtgtcgc tacagggtgg tagacaacga 1320  
 ggggaccctg cagctgaaga gaagcttccc catcgacgcg agctcacatc ctgtgcgcag 1380  
 catcttctgt cccctcatgt cttccggcca gggggccctgc gtggtgacgg gcagtggagga 1440  
 catgtgcgtt cacttcttg atgtggagcg ggccggcaag gctgtgtca acaagctgca 1500  
 gggccacagt gcacccgtgc ttgtatgtcatttcaactgc gacgagagcc tactggccctc 1560  
 cagtgcgtcc agcggcatgg tcatgtctg gagggggag cagaagtagg gtcctgtcgg 1620  
 ccctgtctgt gtcctccatc ccaccctct tactccagcc tcgtgttgc aataaagttt 1680  
 cgggtggcat gctgaggggcc ggctcccccacg ttcgtgggggg acggacaggg cagagggcag 1740  
 cggccagctg ca 1752

&lt;210&gt; 82

<211> 1854  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2216640CB1

<400> 82  
 cccacgcgtc cgccaggat ggccggcagca gtggcggacg aggccgtggc gcgcgatgtc 60  
 cagcggtgc tagtgcagg ccaggatgag ggcgggcagc tgctgggtc cccgttcgac 120  
 gtgcccgtag acatcacccc ggacaggctg cagctcgatgta gcaacgcgt actggcccg 180  
 gagatcccc tgccactgac ttctttgtc cacatgtctg agatcgatc ctcactgggg 240  
 aagacgttg agtcccgagc agtggagaca gagaaggatc tagacatcat ctaccagcca 300  
 cagctatct tcagatctc ggctgtact cgtgcacca gtccttggaa gggcacatgt 360  
 gaggcgtca ttctgtggc ttccagccct acggaaagt acctggccag tggctctgg 420  
 gacaccaccg tgccgttctg ggatctcgc acagagacac cacatttac atgcaaggga 480  
 cacagacact gggtcttag tatattctgg tctccagatg gcaagaagct ggcctcaggc 540  
 tgcagaatg gccagattt cctctggac ccaagcacag ggaagcagg gggcaggacc 600  
 ctcgctggcc acagcaagt gatcacaggc ctgagctggg agccccccta tgcaaccct 660  
 gagtgccgt atgtggccag cagcttcaag gatggcgtg tgccgatctg ggacacaact 720  
 gcaggcgtgt gtagcgtat ctcacccggg cacacccgt cggtcacctg tctccgggt 780  
 ggcttctata ctctgcctcc caggaccgca ccatcaaat ctggagagct 840  
 catgacgggtg tgctgtccg gactctgcaaa gggcacggcc actgggtgaa caccatggcc 900  
 ctcagactg actatgcct ggcacttggg gcctttaac ctgtcgaggc ctcagttat 960  
 ccccaagacc tccaaggatc ttgcaggag ttgaaggaga gggctctgag ccgatataac 1020  
 ctctgtcggg gccagggtcc agagaggctg gtgtctggc ccgacgactt cacccttattc 1080  
 ctgtggtccc cagcagagga caaaaagct ctcaactcgaa tgacaggaca ccaagctctc 1140  
 atcaaccagg tgcttcttc tcctgactcc cgcacatcggtt ctatgtccctc ctttgacaag 1200  
 tccatcaagc tggggatgg caggacggcc aatgtacctgg ctcccttacg cggccacgtg 1260  
 gctggcgtgt accagattgc tggttcagct gacagtccgc ttctggtcag cggcagcagt 1320  
 gacagcacac tgaaggatgtt ggtatgtaa gcccagaagc tggccatggaa cctgcccggc 1380  
 cacgcggatg aggtatatgc ttgtgactgg agtcccgatg gccagagat ggcaagtgg 1440  
 gggaggaca aatgcctccg gatatggagg agatgagacg gcccgaagtt ctctctgacc 1500  
 cccacctcga ctccggctt gccagctgc ttccctgcca gagaacaag gctgagatgg 1560  
 cagtgcacac accctccca ccagtgggg cctgagaatg cgttgccct gctgtccctc 1620  
 atagacccga atgggggttt cccacagat cccgcctgtg gcacacccca gagccagaaa 1680  
 tcgaaggatca caggaaatgtt tcaactaaat tgcccgtgt ctgctactt gtacccgt 1740  
 ggtacagaca ggggtgggtt gcagccaggc ttatgatgtt ggcccctgtt gtcagctctg 1800  
 tacagggtca gatcccaggat tctatgacca aataagtaac taaaaaaaaaaaaaaa 1854

<210> 83  
 <211> 862  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2417361CB1

<400> 83  
 ggcgtggctt caacagactt tcttttgcct gtctttgtcc cagaccctt tccctggccc 60  
 tgctgagacc actgctctaa gaagagacca ccagactgag agaggactcc cagctccct 120  
 cagacggag gcccggatgt gcacagccac agctgctctg aagccctcc atgaatcccc 180  
 ggaagaagggt ggacctgaaa ctcatatcg tcggagccat tgggtgtggaa aagacccccc 240  
 tccttcacca atatgtcaca aagacgtttt atgaggaata ccagaccaca ctgggggcca 300  
 gcatcctctc caagattatc atatgggtt acacaacttt gaagttacag atctgggaca 360  
 cgggcgggtca ggagcgggtc cgctccatgg tggccacgtt ctacaaggcc tccgatggct 420  
 gcatccttagc ttttgtgtc accgacactgg agtcttttga agccctgtat atctggcggg 480  
 gtgatgtctt ggccaaaggat gtcccatgg agcagtcata ccccatgtt tgggtgggg 540  
 acaagatcga tctggcagac cggaaaggatc cccaggaatg agctcaaggc tgggttagag 600  
 agaaagatcatc tccatgtt gaagtcagtg ccaagaatga catcaatgt gtcagctctg 660  
 ttgagatgtt ggccaggatgg gtcctgtcga ggtaccagag catcttagaa aatcacctca 720

cagaatccat caagctctcg ccagaccagt caaggaggcag atgctgctga cctccagacg 780  
 cctgctctgg aagcccagaa acagagcctg ccccgagcct ggtcacccca ggcttgagaa 840  
 caggtgacca tccccctcca gc 862

<210> 84  
 <211> 1406  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2454384CB1

<400> 84  
 ctagagcctg gggctctcgcc aacttccggc ggcggggagct gcagagcgca aggcccggcc 60  
 actgcgcgtg cgcttcggcc cggctctcc tcgcggcccg gcccctgcga ctgggacttg 120  
 gtacggccgg gcggttggcg tcctctgccc ctccctgccag gggcggggctt ttcaaatttt 180  
 ccctttaaag gagtggcgac ggccggaca gttcgcgtt gagatggagg ggccgagcct 240  
 gaggggtcct ggcgtccggc tggcggggct tcccacccag caggactgca acattcaaga 300  
 aaaaatagac ttagaaattt gaatgcgaga aggaatatgg aaactccctt ctctgagcac 360  
 tcagaaagat caagttttac atgcgtttaa gaatctcatg gtgtgcaatg ctcgactaat 420  
 ggcctataca tcggagctac agaaatttaga agaacagatt gcaaattcaga ctggaagatg 480  
 tgatgtgaaa ttggaaagta aagaacgaaac agcatgtaaa gaaagatgg ccatatcaga 540  
 tattcaataa ccaataatgt gaaagactc tgatcacttc agcaataaaag aacgatcacf 600  
 acgttatgcc attttttgtt tattcaaaat gggagctaat gtgtttgata ctgatgtgg 660  
 gaatgtggat aaaacaatca cagatataatg ttttggaaat gtaaccatat tgtaagtatt 720  
 ttttaatctt cagagaataa aaataatttta aaattcttct ttttggaaat aaagtctta 780  
 ttattggttc ttggattca tttatgtttt aaatgtttaa gtgatctta aatgtttat 840  
 atgattttaa aaattttttt gttcagaaga agtccatttc tctatctgca gttttctgat 900  
 gtgaaataaa aatggaaatc ttgttaattac tatttagcgtt aaatatttga ctattatag 960  
 atgaccattt tttaaattgt taataaaat attcgttta ttaacaaggc tatgcataca 1020  
 acagaatatc ctgtatgtt atttgatata gagagaattt aagcataaaaa caggattttt 1080  
 atctcatgtt gatatattgg ttgcagaaat actaaaatag tatagcact ttatttacaa 1140  
 gatagtcctg aagtacatgc tatataggaa ggcactttt aaattttggg gtgttctttt 1200  
 tcttatggtg cacttcttc atgtacttca aagcaataaa aaaaatggg tgatctcagg 1260  
 gctgtttta ttgtccctgc tcttttacag gtcattttt ttgtggcat aatacagaac 1320  
 aagaaggAAC tccttgggtt gccatagaaa tcatttttaa cttacatagt ttttctgcc 1380  
 ctccctcaaa ggttctatgt gcctaa 1406

<210> 85  
 <211> 1184  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2610262CB1

<400> 85  
 gcggttttgg tgcctgaagc agggagcgcg gagtcgttcc cgagagaggc ggccaggcta 60  
 tgctcgccgg tttccgggt tccgctccgg ccagccagag tctctgttc aacctgtgtc 120  
 cgtgtccctcag cagtctcctc agcccccggcc cgcggcgcgg ttggcggccg cccccaggc 180  
 ggcgcctccctc ctccgatggc ggcggagatc cggccaaagc ctctgaccgg caagccgatc 240  
 ctgtgcagc ggtgggggg gtcggaggat gttgttgcata tggccgtat cgtgcccgg 300  
 gaggaggccg tcatcagct ctcggaggac aggacagttt gtgtttggg aaagagagac 360  
 agtggacagt attggccaag cgtataccat gcaatgcctt ctccatgttc atgcatgtct 420  
 tttaaccggg aaacaagaag actgtccata ggtctagaca atggtacaat ctcagagttt 480  
 atattgttag aagattataa caagatgact cctgtgaaaa actatcaagc gcatcagagc 540  
 agagtgcga tgatcctgtt tgcctggag ctggagtggg tgctgagcac aggacaggac 600  
 aagcaatttg cctggcactg ctctgagat gggcagcggc ttggaggtta tcggaccagg 660  
 gctgtggctt caggcctgcata atttgcgtt gaaacccggc atgtgtttt cggtgaccac 720  
 tcaggccaaag taacaatctt caaactggag caagaaaact gcaccctgtt cacaacattc 780  
 agaggacaca caggtgggtt gaccgcgttc tggcggacc cagtcagcg ggtgttgg 840

tcaggcagtt cagatcactc tgtcatcatg tggcacatcg gtgggagaaa aggaacagcc 900  
 atcgagctcc aaggacacaa cgacagagtc cagccctct cctatgcaca gcacacgcga 960  
 caattgtatct cctgtggcggt tgatggtggg atttgtcgct ggaacatgga cgtggagagg 1020  
 cagagccctc tgtggagctg cttcgtggtt atgataaagt ctgtgtatg ctcaccttgg 1080  
 gaggtctcgcg acatatattg aagtcatctc taacctgaag tactgacaga ctttctggaa 1140  
 gaaaaggctt gtaggaggaa acttcagaat tctattaaat ggtg 1184

<210> 86  
 <211> 2965  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2700075CB1

<400> 86  
 ggcaccactg tgaaggctcg ggacgcagcc aagcagcagc ccctgacaga gctggcagcc 60  
 catggggacc tgggtgcagag cgccgtctgg accgcagatg gagccctgtt gggcacggcg 120  
 tgcaaggaca agcagctgcg gatcttgc cccagaacaa agccgcgggc ctctcagagc 180  
 acgcaggccc atgagaacag caggatagc cggtggcat ggtatgggcac ctgggagcac 240  
 cttgtgtcta ctggattcaa ccagatcggt gaggcgaag taaagctgtt ggacacgcgg 300  
 ttcttctcca ggcgcctgctc ctccctcacc ttggacacct cgcttgggtt tctctgtgcct 360  
 ctgtgtggacc ctgactctgg gctccctggc ctggcagggaa agggcgagag gcagctgtac 420  
 ttttacgagg tggtcccgca gcagccggcg ctgagcccgag tgaccctgtt tgccttggag 480  
 agcgtgtgc gtggggctgc ctttgcctcc cggcaggcgc tggccgtcat gagctgcgag 540  
 gtactcccgcg tcctacagct gaggcaca gcatgtgc ccatcggtt ccatgtgccc 600  
 cgcaggctg tggagttcca cgaggacatg ttcccgacca ctgcgggtt tgcctgtgcc 660  
 accgcaccccc atagctgtt ggctgggac aaccaggcagg tgcagaagg cagcccaac 720  
 cccgcctgcc ggcccaccc gagcttact tccctgtctgg tgcccccctgc ggagccccctc 780  
 cctgacacag cccagcctgc ggtatggag acaccctgg gtatgcaga cgcaagcggag 840  
 ggtttcttcc cccctccca gtcgttgcacc tcgccttcca cgcctccag cttggggccc 900  
 tcactctcca gcaccaggatgg catcggttcc acccccgatgg tgaggctgtt gcagaggctg 960  
 ctggggccca gttccaagg tccgcattgtt cagggtctgg tccctgcaccc agacagccac 1020  
 atcaccacacc tcaaggggctt caacccatcc accatgttgc agatgtacgg cttctgtgcc 1080  
 aacaagctgc gtgtggccgt gccgtgtctc accaggcccc gacagggttgc tttgttggag 1140  
 ctacggaaatc ctggccgttcc gcccacacg gactgtccca cgttgcagaa tggggcagct 1200  
 gtgactgtatcc tggccttggc ccccttgc cccatgc tccgtgttgc tggtgaggac 1260  
 gccaggatcc gactgtggcg ggttcccgca gagggtctgg aagagggtgtt caccacgcca 1320  
 gagactgtgc tcacaggcca cacggagaag atctgttccca tgccttcca cccactggca 1380  
 gcaatgtgc tggcctcgcc tcctatgttcc ctcactgttcc gcatctggaa ctttctaggct 1440  
 ggagctgtatcc ggctgttgc gcaaggccac caagaccaga tccctcaggctt ggcctggagt 1500  
 cctgtatggcc agcagctggc cactgtctgc aaggatgggg gtgtgcgggtt ctacaggcccc 1560  
 cggagctggcc ctgagccctt gcaaggaccc ccaaggccca agggaggacg cggagctcg 1620  
 attgtgttgc tatgtatggc tcgtgtctg ctgggtgtctg gctttgcaccc ccaaagttag 1680  
 cgcaggctgc tcctatatgg agctgtggcc ctggccggcg gacccttggc agtgttggc 1740  
 ctggacgttgc ctccctcaac cctgtgtccc agtacgttgc cagacactgg cctgtgtctc 1800  
 ctgacccggca agggcgacac ccgtgttattc ctgtacgttgc tgctccccca gtccttgcct 1860  
 ttcttggagt gcaacagctt cacgtgtccct gaccccccaca agggcctctg ctccttgcct 1920  
 aagacggatgt gcaacgttgc ggaagggtgg ctgtatgttgc gcttgcgttcc 1980  
 tccctggagc ctgtggccctt ccggctgttcc cggatccggaa aaggttctt ccaggatgtac 2040  
 gtgttcccgat acacggctgtt gatctggggat cctgtgttgc gtcggaggtt ctggctgca 2100  
 ggcgctaatgt ggcgcacccctt gcttgcaccc ctgcacccctc ctgacatgttgc cccagtgttgc 2160  
 caagccccccca gagaggcccccc tcgtgttgc gccccatctt cagecgatgtt cctggaaagaa 2220  
 aagtctgacc agcaaaaagaa ggaggatgtt ctgtatgttgc tggtggcaaa actggggaaac 2280  
 cgggaggacc cactccccca ggactctttt gaaggcgttgc acgaggacga gtgggacttag 2340  
 cctgcgcctcc cgtcacccctt acctcacatgt tgcgttgcact tcctagtgtca cacccacgg 2400  
 ctcatcttca agctggaaatc taccttctgtt gccccggcac atgttccccc tgcacttgc 2460  
 ctttccctgtt ggcacttcca catccttctgtt gcttgc gttccctagg actgttttca 2520  
 cctctgtgtt ctctggggatc agctgtgttgc catcgtgttgc cgcgttgc cggatgttgc 2580  
 gtgcagggtt gccccgggtt cggcaggatgtt ccttggcag gcccctggca ccctgttcc 2640  
 ctttgcctca ctgtgttgc gggctgttgc caggctgttgc tggcttccatc caggatctt 2700  
 ggtcacccca ctgtggccca tcttgcctgc tggtggcaaa ctggtcaagg gccttgggg 2760

ctggggcccc accaggcctt ctagagcgc accagtctca gggccctggg accagctgcc 2820  
 ctacttccca ggttgttagc caggagaagg gggcatcaca gagctgatgg tccaataagg 2880  
 ggggtgttag ccccgaggg actggcccgc acctgcctt gatgtttca gcaattaaac 2940  
 ttttaaaggc tgccaaaaaa aaaaaa 2965

 <210> 87  
 <211> 2823  
 <212> DNA  
 <213> Homo sapiens

 <220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2786701CB1

 <400> 87  
 cgaggaggcgc ctagcctcgc gccccggccg ttgcttctgc cctccggcc tccccggcc 60  
 gtccggggca ccagccgtc gggggggggc tgatacagcc gcttcaccgt gcccctgccc 120  
 gcgccatgg cctccctccga ggtggcgccg cacctgcctt ttcaagtctca catggcaacg 180  
 aaaacaacct gtatgtcttc acaaggatca gatgatgaac agataaaaag agaaaacatt 240  
 cgttcgttga ctatgtctgg ccatgttggt tttgagagtt tgccctgtca gctggtaac 300  
 agatccattc agcaagggtt ctgcttaat attctctgtg tggggaaac tggatttgg 360  
 aaatcaacac tgattgacac atgtttaat actaattttg aagactatga atccctcacat 420  
 ttttgcggaa atgtttaact taaagctca acatataa gtcaggaaag taatgttcaa 480  
 ttgaaattga ccattgtgaa tacatgtggg tttgggacc aaataataaa agaagagac 540  
 taccaaccaa tagttgacta catagatgtc cagtttgggg cctatcttca agagaactg 600  
 aagattaagg gtttcttctt tacctccat gattctcgca tccatgtgtg tctctacttc 660  
 atttcaccga caggccactc tctgaagaca cttgatctt taaccatgaa gaaccttgac 720  
 agcaaggtaa acattatacc agtggatgttcc aaagcagata cggttctaa aactgaatta 780  
 cagaagtttta agatcaagct catggatgttcc ttggtcagca atggcgttca gatataccag 840  
 ttcccaacgg atgatgacac tattgtcttgc gtcAACCGTGTG caatgaatgg acagttgcgg 900  
 tttgtgttgc tgggaagtat ggatgaggta aaagtccggaa acaagatgtt caaagctcgc 960  
 cagttccctt ggggtgttgc acaagtggaa aatggaaaacc actgttgcgtt tggaaaggct 1020  
 cggggaaatgc tcattttgtac aaatattggg gacctgcgg agcagacccca taccaggcac 1080  
 tatgatgtttt acaggcgctg ccaacttgggg gaaatgggtt ttacatgtt gggcccgaa 1140  
 aacaaggccag tcagtttca agagacatat gaagccaaaa gacatgatgtt ccatggtcaa 1200  
 cgtcagagga aggaagaaga aatgaaaacag atgtttgtc agcgagtaaa ggagaaagaa 1260  
 gccatattga aagaagctga gagagagcta caggccaaat ttgacccatc taagagactt 1320  
 caccaagaag agagaatgaa gcttgaagaa aagagaagac ttttggaaaga agaaaataatt 1380  
 gctttctcta aaaagaaaagc tacctccggg atattttcaca gccagtcctt tctggcaaca 1440  
 ggcagcaacc tgaggaagga caaggccgt aagaacttca attttttgtt aacacagaatg 1500  
 tccagagcac agaaggctat catcacaagc aaactttt aaaaaaaaaac tagaaggctg 1560  
 ctttgatttt gctgttattt gtttttatcc ttcttatattt ggtgaacagc cacagttaact 1620  
 gatataatgtt gaaaagtact ttcaagtaca aggtcaatac ataagccaga gtgaatgata 1680  
 ctacaagttt agcatctcta attcaaaaat ctgaaaatcca gaagcttcaa aatctgaatc 1740  
 ttttgagca ctgacttgac cccacaagt gaaaattccc caccggacac ctttgctt 1800  
 tgatgttca gtttaaacag attttggttc ttgcacaaaaa tttttgtata aattacttcc 1860  
 aggctatatg tataagggtgg atgtggaaaca tgaattatgt aatttagagtc gggcccggtt 1920  
 gtgtatatgc agatatttca aacctgaat cccaaacact tctggccctt agcattttgg 1980  
 ataagggttta ctcagttgtt accttatata tcatatataat tcaactgttgc tagaaatgtt 2040  
 taaggctgtg tttgtgtatg aatctaaatc tttttcttgc ctaccaagctt attgacttgc 2100  
 cagtgcattt taccaaagag cgaagtcaat gcccactgaaa atacagaacc cattaatatac 2160  
 gtggctatct gatttacattt atatttcaag atgaaccttt ttatataatg cttaaaatttt 2220  
 tggggaaatat gttttgggtt gtattatggc gctaaaactc taaccttta atagttttat 2280  
 agaactaaa aattttttat acaattacc aattgtgtat atgatcttac gctttgtgt 2340  
 cagattattt aatatgtat cttcatgcctt tattatgcct tattatggct gacgttattac 2400  
 tgtgggtggaa caaaaatatct tttaaaagtttta aaacatccag atatataaggc tattttttcc 2460  
 taaggataaa gtacctttca gcatggatgtt atcacagctt tcatttagggaa aacttttcat 2520  
 tacataactt gtttttttttgc tctttccagg gtaaaaaataa taagggtgg tcatttttat 2580  
 aaaaacttctt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 2640  
 ataatttccata ttttcagggtgg ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 2700  
 taatgttttc taacatttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 2760  
 aatatttctt aaaaaacttca ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 2820  
 aaaatatttctt aaaaaacttca ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 2823

<210> 88  
<211> 1549  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3068538CB1

<400> 88  
gcagacccgg cacgcagggtg gggccggcg gggtccgtgg ccagagctgc agagagacaa 60  
ggccggcggcg gctgctgtgc tgggtgcagt gaggaagagg ccctcggtgg tgcccatggc 120  
tggccaggat cctgcgtga gcacgagtca cccgttctac gacgtggcca gacatggcat 180  
tctgcagggt gcaggggatg accgttttg aagacgtgtt gtacacgttca gctgtgcgg 240  
gatgccacc ccccacgac tggaccacca gcccgtctg gagtatttga agtacacact 300  
ggaccaatac gttgagaacg attataccat cgtctatttc cactacgggc tgaacagccg 360  
gaacaaggct tccctgggt ggctccagag cgccatatacaag gagttcgata ggaagtacaaa 420  
gaagaacttg aaggccctct acgtgtgtca ccccaccagc ttcatcaagg tcctgtggaa 480  
catttgaag cccctcatca gtcacaagtt tggaaagaaa gtcatctatt tcaactacact 540  
gagttagtc cacgaacacc ttaaatatcga ccagctggtc atccctcccg aagtttgcg 600  
gtacatgtag aagctccaga gcctgcacga ggccggacg ccgcctccca ccaagacacc 660  
tccggcggc cccccgtctgc ccacacgac gtttggcgtc agtctgcaat acctcaaaga 720  
caaaaatcaa ggccaaactca tccccctgt gctgagggtt acagtgcgt acctgagaga 780  
gaaaggcctg cgccaccgagg gcctgttccg gagatccgccc agcgtgcaga ccgtccgcga 840  
gatccagagg ctctacaacc aagggaagcc cgtgaacttt gacgactacg gggacattca 900  
catccctgcc gtgatccgtga agaccccttgcgagactgtc ccccaagccgc ttctgaccc 960  
ccaggccctac gaggcagatc tcgggatcac ctgtgtggag agcagccgtc gtgtcaactgg 1020  
ctggcccccag atcttacgga gcctccaga gcacaactac gtctccctcc gctacccat 1080  
gggcttctgt catgcgggtt cccgggagag catcttcaac aaaatgaaca gctctaacct 1140  
ggcctgtgtc ttccggctga atttgcgtc gccatcccag ggggtctctt ccctgagtgc 1200  
ccttgcgtccc ctgaacatgt tcactgaact gctgatcgag tactataaaa agatttcag 1260  
cacccggag gcacccctggg agcaccggct ggcaccatgg gaacagggga gcaggcgcga 1320  
cccttgcag gaggctgtgc cacggacaca agccacgggc ctcaccaagc ctaccctacc 1380  
tccgagtccc ctgatggcag ccagaagacg tctctagttgt tgcaacact ctgtatattt 1440  
cgagctacct cccacacctg tctgtcact tttatgtttt ataaacttgg catctgtaaa 1500  
aataaccagc cattagatga attcagaacc ttctaatgaa aaaaaaaaaa 1549

<210> 89  
<211> 1722  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 5159072CB1

<400> 89  
gcaagaggga gccggcccgca cgccggaccgc ttccctgcag tgccccgagt cccggcccg 60  
cgccgcccgc gccccgtcc gctcgccgc cctctgtctg caggcgtgcc ccggccggcg 120  
cgagagccg tcctcgcccg aggaggctgg gaaacgcgag cgccaggccgc agagaggcc 180  
caacgcgcgc ccttcgcaca ccgccttttc ctgcctcgcc gccgctgtgc attttctcc 240  
ttttccatgtt ttttttggc ccctcgccggg tggggcatt gttggtagc aaaagtgcag 300  
cctcaagatg gctgatggca acgaggatct gccggctgtac gacttgctg ggccagcc 360  
cgagagctat gatgtccatgg agcttgcctg ccccgctgag cgccaggccgc acgtagccgt 420  
cagcgcacggg cgccacatgt tctgtctggg cgctacaag agtaatcaag tcagaggatt 480  
atatgactt tatctgccta gagaagaact atggatctac aacatggaga ctgaaagatg 540  
aaaaaaaatc aacactgaag gtgatgttcc tccttctatg tcaggaagct gtgtgtgtg 600  
tgttagacagg gtgtgtgtact tgggggaggg acaccattca agaggcaata ccaataagtt 660  
ctacatgctg gattcaaggt ctacagacag agtggttacag tggaaaagaa ttgattgcca 720  
aggaattctt ccatcatcaa aggacaaact tgggtgtctgg gtatataaaa acaagttat 780  
atttttggaa gggtatggat atttgcgtga agataaaagta ttggaaactt ttgattcga 840  
tggaaatcatct ttttggaaat caagtcatcc aagaggatgg aatgtcatg tacatatttt 900  
agataactgaa acatttacact ggagccagcc tataactact ggtaaagcac cttcaccc 960

```

tgctgccccat gcctgtgcaa ctgtcgaaaa tagaggcttc gtgtttggag gcagatatcg 1020
agatgtctaga atgaatgatc ttcaactatct taatctggat acatgggagt ggaatgaatt 1080
aattccacaa ggcataatgcc cagttggcg atcttggcac tcactaacac cagtttcttc 1140
agatcatctt tttctctttg gaggatttac cactgataaa cagccactaa gtgatgcctg 1200
gacttaactgc atcagtaaaa atgaatggat acaatttaat catccatata ccggaaaaacc 1260
aaggttatgg cacacagctt gtgcacagcgta tgaaggagaa gtaattgtttt tggttgatg 1320
tgccaacaac ttgcattgtcc atcacagac tgcacacagt aatgaaatac tataattttc 1380
agttcaacca aaatctcttg tacggctaaat cttagaagca gtcatttgct taaaagaaaat 1440
gttagccaaac tcatggtaact gccttccaaa acacttaactt cacaatgttta atcagaggtt 1500
tggtagtaac aacacttctg gatcttaagg cttcataaat aatgcctatg atcaccttgc 1560
atggacagca atccgtaaa catcacagag tggcatcatt tgtataatta tatgcattgt 1620
tgtagttgc acctgttggt ttaatgtgc atgtgaatgg cctagagaac ctatttttgt 1680
gtctaaagtt tacaataaat gtatTTAAC caaaaaaaaa aa 1722

```

<210> 90  
<211> 1264  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 5519057CB1

<400> 90  
agcgcgcgt cttgcgggtgg cgtaatctct cagccttct gtgttcctt tcctccgcct 60  
cagtttgggt cgggtcgccc gaatggctga ggagatggag tcgtcgctcg aggcaagctt 120  
ttcgccacg gggcagggt cagggggcctc agggtttttg cctctcgccc gctcccgcat 180  
cttcagaatg atcgtgatcg ggactccaa tggggcaag acatgcctga cctaccgctt 240  
ctgcgctggc cgctcccccg accgcacccga ggccacgata ggggtggatt tcggagaacg 300  
agcggtgag attgatgggg agcgcataa gatccagcta tgggacacag caggacaaga 360  
acgattcaga aagagcatgg ttccagacta ctacagaaat gtacatgctg ttgtcttcgt 420  
gtatgatatg accaacatgg cttagtttca tagcctacca tcttggatag aagaatgcaa 480  
acaacattt ctggccaatg atataccacg gattttgtt ggaataaat gtgacttgag 540  
aagtgcata caggatcccc cagacttggc aaaaaaaaattt gctgacacac acagtatgc 600  
tttgttggaa acgtctgtca aaaaccccaa tgataatgac catgtggaaag ctatatttat 660  
gaccctgtct cataagctta agtgcaccaa accattaatg cttagtcagc cccctgataa 720  
tggatttata ctgaagctgt aacccaaagcc tgcaatgacg tgctggtgct aaataacagt 780  
ctttattata ttatctaatt ttgactaaag aaataactttt gaagtatgac agtattaagt 840  
cataagattt aatctcaact ataatgggtc atcttgacac tttgtctgttt gtcattgtca 900  
cgcttttgta ttttgtatct acttaagtt gtcactgtga caacacagga aaagttgggt 960  
ttcagggtgag attgaaaatg aagcagaatg aggatgaatc tgaacatctc tccatctaga 1020  
gccccatgaa ggaagctca aatgagaaca tgatggaaatc agtaaccattt caatctttt 1080  
tccttaggatt gggaaaaaat gttaaagggt taggacacac ctaattagat gtcctttgaa 1140  
tgggaagggt tcttaatagg ataaaaactgt gtatccctt ctccccagag tacttttttg 1200  
ttttttccat agagacgggg tcttgctatg ttgtccaggc tggccttgag ctccctggct 1260  
caag 1264

<210> 91  
<211> 2640  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID.No: 035379CB1

```
<400> 91
cgggcgggg ggcatcatga agcgggctgg cggcgctgcg tcccgccgc gcgcgggg 60
gagggtgc ccaaggaccg tagatgc ctc tctagagcat gagtcaggc aagagtgc 120
gctacaacccg ctctccggg gggccccagca atcttcccac cccagacgtc accacaggga 180
ccagaatgg aacgacattc ggacccgc tttcaggcgt caccaccatc acaaaaagctg 240
acgggaccag cacctacaag cagcactgca ggacaccctc ctctccagc acccttg 300
actcccccg g gacaggagg gacagcatgc cccccatc g cactcccccg cgctccgact 360
```

ccggccatctc tgtccgctcc ctgcactcg agtccagcat gtctctgcgc tccacattct 420  
 cactgcccga ggaggaggag gagccggagc cactgggttt tgccggagcag ccctcggtga 480  
 agctgtgctg tcagctctgc tgcagcgtct tcaaagaccc cgtgatcacc acgtgtggc 540  
 acacgttctg taggagatgc gccttgaagt cagagaagtgc tcccgtggac aacgtcaaac 600  
 tgaccgttgtt ggtaaacaac atcgcgggtt cggacgat cggggagact ttcatccact 660  
 gcccccacgg ctggccggta gcgggcagcg ggaagcccccc catcttgag gtggaccccc 720  
 gaggggtgccc cttcaccatc aagctcagcg cccggaaaggaa ccacgagggc agctgtgact 780  
 acaggcctgt gccgtgtccc aacaacccca gctgcccccc gctgctcagg atgaacctgg 840  
 agggccaccc caaggagatgc gggcacatca aatgccccca ctccaagtagc gggtgacacgt 900  
 tcatacgaa ccaggacact tacgagaccc acctgtggagac ttgcggcttc gagggcctga 960  
 aggagttct gcagcagacg gatgaccgct tccacagat gCACGTGGCT ctggcccaaga 1020  
 aggaccagga gatgcgcctc ctgcgttcca tgctggaaa gCTCTCGGAG aagatcgacc 1080  
 agcttagagaa gagcctggag ctcaagttt acgttcttggaa cgaaaaccag agcaagctca 1140  
 gcgaggacct catggatgc cggggagac catccatgtt aaatgacgag ctgtcccaca 1200  
 tcaacgcgcg gctgaacatg ggcattcttag gctcctacga ccctcagcag atcttcaagt 1260  
 gcaaaaggac ctttggggc caccaggggc ctgtgtgggt tctctgcgtc tactccatgg 1320  
 gtgacctgtt cttcagtggc tcccttgaca agaccatcaa ggtgtggac acatgtacca 1380  
 cctacaagtg tcagaagaca ctggagggcc atgatggcat cgtgctggct ctctgcaccc 1440  
 aggggtgcaa actctacagc ggctctgcag actgcacccat cattgtgtt gacatccaga 1500  
 acctgcagaa ggtgaacacc atccggggcc atgacaacccc ggtgtgcac ctgggtctcc 1560  
 cacacaaacgt gcttccatc ggtcccttga agggccatcaa ggtctggac atcgtggca 1620  
 ctgagctgaa gttgaagaag gagctcagac gctctcaacca ctgggtggc gccctgggtt 1680  
 ctggccagag ctacatgtac agcggctcc accagacaaat caagatctgg gacatccgaa 1740  
 cccttgactg catccacgtc ctgcagacgt ctgggtggcag cgtctactcc attgtgtga 1800  
 caaatcacca cattgtctgt ggacacatcg agaaacccatcat ccacgtgtt gacatttgagt 1860  
 ccaaggagca ggtgcggacc ctcacggggc acgtggggcac cgtgtatgcc ctggcggtca 1920  
 tctcgacgcc agaccagacc aaagtcttca gtgcattctca cgacccgtcc ctcagggtct 1980  
 ggagtatgga caacatgtc tgcacgcaga cctgtgtcg ctcaggagc agtgtcaccg 2040  
 cgctggctgt gttccggggc cgactcttct cagggggtgtt ggatgtact gtgaagggtt 2100  
 ggacttgta acaggatcca ggccaggctg tggtttccccc tgaaccagcc ctggacccccc 2160  
 ctgagcaggc ctggccacat ggggtgttct cgggggtttct gcctgccccg tgggcatagg 2220  
 tggacaggct ctggcagccg ggcagtggcc tccctgtccc atgctcgccg agcctccctc 2280  
 tactcggcac tgccttgc gcccagcccc tctctgggtg ccaggtacga cgcttggccc 2340  
 gcccacccct ccatccccac cttccatccc cacccttagat ggagcgaggc cctttttact 2400  
 caccttttct accgttttta gactgtatgt agattggta ctcctgtt gaaataaatg 2460  
 ctccacagac tgcgtgttgc agtggggaca gtcctccggg acaaggggc tgcgtgtggc 2520  
 ctggaggtt gttgtcaacag gcaactggctg ctgtgatgg gggggcatgg ggcagtttcc 2580  
 ttgggtggac cccaggactt cggcccaactc cggggcctcc ctcctgtct aggaggtaac 2640

<210> 92  
 <211> 2071  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 275354CB1

<400> 92  
 gtgggcccggaa ctccctagccg acacccgtg gaggccggcc ggaagagcaa ccggagatgaa 60  
 ggtgaagatg ctgacccggaa atccggacaa ttatgtccgc gaaaccaagt tggacttaca 120  
 gagagttcca agaaactatcg atccctgtt acatccctttt gagggtccac gagaatatgt 180  
 aagagctta aatgtctacca aacttggaaacg agatatttgc aaaccatcc ttgcttcgtt 240  
 ggtatggtcac cgtgtatggg tcaattgtt gccaaggatcc ccaagagaacg tggctactgt 300  
 ctttctggg gcgtgtatgt gagggttag aatttggaaat ctaactcagc ggaattgtat 360  
 ccgtacaata caagcacatcg aaggctttgt acggagaata tgcgtgtt tttgtggac 420  
 ttcttttttc actgtttgtt atgacaaaac tgcgtgttgc tggaaaatgg atggggccagg 480  
 ctatggagac gaggaaagac cattacatcg aatatttaga aagacagtgt atactggat 540  
 tgcgtgttgc tggaaaagaag ctgttttgc cacatgtggc cagcaagtag acatttggaa 600  
 tggacaaaacta actaatccat tgcgtgttgc gacccggggta tttgtacgt taagttagt 660  
 taaatttaac ccaatttgaga cttttctt gggaaagttt gcatctgaca ggaatataatgt 720  
 actgtacatcg atgaggcaag ctactccctt gaaaaggatg atcttagata tgagaacaaa 780  
 tacaatctgt tggacccatcg tggacccatcg ctttttaca gcaatcgaa aagattataa 840

ctttatatact tttgatatgc gtgcactggc cactcctgtt atggccatc tggtatcatgt 900  
atctgcagtg cttgatgtgg attactctcc cactggaaag gagtttgcgt ctgctagtt 960  
cgataaaatct attcaaatct ttccgttaga caaaaatgtcg agcaggagg tatatcatac 1020  
aaagagaatg caacatgtta tctgtgtaaa atggacttct gacagcaagt atattatgtg 1080  
tggatctgtat gaaatgaaca ttgcgtgtg gaaagctaat gcttcgtaaa aattgggtgt 1140  
gccttacatca cgagaaaaag cagccaaaggat ttataaccag aaatgtaaagg agaaatttca 1200  
gcattatccat catataaaac gtatagctcg tcatcgacat ctacaaaat ctatctatag 1260  
ccagatttcg gaacacgcgc tcatgttggaa agtcgtcg cggaaaggaa tgaaatcgat 1320  
taaacacacgc aagcttggat ctgtgttggact tttgttcgat aagaaagaaac acgtatgtggc 1380  
agttgttaaa taatttgtat ttcttaacaat cctgtatgtat aattatgtt aattttgtat 1440  
tttgaaactc tacaaataaa agtgcgtgggat ctagattat tgcaaacatt ttagttat 1500  
gtgttagagct ttattgttac ttcttttagc taccctgaaa aatgtatccctt aaagggtggcc 1560  
tagtttgttta gactgttttta ttcttaatct gcattttctt ttcatgttag aatacagtat 1620  
ttgcaactca ttttttcttgg ttttttattac agatataactt actttcttctt tgatcttta 1680  
ttttagacac tatacattca aatttgacatt taagacccaa catctttat gttatcttta 1740  
atattatctt gaataatgtat tgcaatgtat ttcttcttgc tgatccaca taacattttag 1800  
aataatgtat tcaatttttt aacaatgtat ttatcttgcgt tgcgttactt atatttggct 1860  
ttttgactt tttaaaacaa tcagcgttgc ttttataac ttttataat aataatataa 1920  
tttgggttcaa gtttagat taaaaggatcc tttcagcatt gaaactttgg cctatcttttgc 1980  
gtaaataat ttcaatctca cttaaatccat aatagcttgc tgtaacatag gttttctt 2040  
ttttatcat aaacttaata aactttgtgg a 2071

<210> 93

<211> 2149

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 311658CB1

<400> 93

cattattttt	aaaatatta	cccactcttg	atagtgtatc	tgcactgaga	cacgtactgg	60
aagctatata	ttgttgaca	tcccaatcta	aaacaactca	tctttcttac	ttatgactag	120
agttccctct	cttcatttat	attttttctt	tggtaacat	cagtgtctac	caatttctaa	180
atgcaaagga	gaaagataca	attttaagcg	aaatgggtt	gatatgcaca	acttgcagaa	240
ggttacataa	aactgggtt	ttcagagatc	atttttctc	tcttttttag	gatatgttca	300
aggaatgagt	gatttacttt	ccccctcttt	atatgtgtatc	aaaaatgaag	tggatgcctt	360
tttgtgcctt	gccttataca	tggaccataat	gcatacgaat	tttgaagaac	aatgcagg	420
catgaagacc	cagctaattc	agctgagttac	cttacttcga	tttttagaca	ttggatttt	480
cagttactta	gaatctcagg	actctggata	cctttatTTT	tgcttcagg	ggctttaaat	540
cagattccaa	agggaaattta	gttttctaga	tattctcga	ttatgggggg	taatgtggac	600
cgaactacca	tgtacaaattt	tccatcttct	tctctgttgc	gctattctgg	aatcagaaaa	660
gcagcaataa	atggaaaagg	attatggctt	caatgaaata	cttaaagcata	tcataatgaa	720
gtccatggaa	attgtatgtgg	agatataact	ctgcaaggca	gaagcaattt	ctctacatgt	780
ggtaaaatgc	aggaaattgc	cacaaggcagt	ctgtgagatc	cttgggttcc	aaggcagtga	840
agttacaaca	ccagatttcag	acgttggtg	agacgaaaaat	gttgcata	ctccctgtcc	900
tacatctgca	tttcaaaagta	atgccttgcc	tacactctt	gccagtggag	ccagaaaatga	960
cagccccaaa	cagataccag	tgtcctcaga	tgtctgcaga	ttaacacctg	catgatact	1020
gttcttgctt	ttttgggaaag	agacactttt	ttgcaaccc	tttcaagta	cttggaaatgt	1080
gaaaatttga	aatcttggta	ttgtatcatgc	tttaaggtt	atgtaaagaa	agtgtactga	1140
tgttcttaca	ttaaagcttt	acaaaggattt	aaactaatta	ttttttgtgt	tacttctacc	1200
aaatagcctt	tcctttcga	taacattctt	cagtattttt	atagccaagt	acatttttt	1260
ttcttgctga	tgaactggaa	ttggataaaat	attgcagtg	gatgagttgg	aaattatgca	1320
cttggaaaaa	catttacttt	gtttaagctt	atgggttcc	agatttgatt	aaattaaatg	1380
tggaggcttt	ctatagcatt	ctaaagctgag	aagttagattt	ttacccagta	atgaaataaa	1440
aaataaaaaat	aaaaggattt	ttttctcttat	tgtttacgac	agtactcagc	ttaaattat	1500
atgctggtca	aatgtgattt	aaattggaca	ttttcatcaa	tgcagtctaa	tgtgttagata	1560
aatatttcaa	ccataataaag	tggatggca	gtatattttt	tacatttgcac	tttcttcac	1620
ttgtatataa	agatattataa	taagtactta	ttttagtata	taagaaagg	taggcattat	1680
ttcatttaact	gataaaaacg	cttgattttat	ataacctgg	ttatccaaat	ttaacatggc	1740
ttcagttatgt	gatcttttgc	aaaactattt	tcttaaacat	ttatccatgt	agattatgtt	1800
caacccctgtt	cctgggtgaa	ttttaaaattt	aattgttgc	aacctcaatt	tactaataat	1860

gttattatttc ttccctaata atgcattaac tgattaatca ggtgtttaaa tttttataaa 1920  
 atactcttgc aaaaagtta ttgaaaaat ttcttagatgg tctcatgagt ttcaaaataa 1980  
 taattttgt gtatgaacaa agcttgttt ttaccatgc agtattgcat gattttaaatg 2040  
 tatgtggaat taacataact gatTTTttt taattgtaaag ttgttaactc ctgtatataat 2100  
 cataaaata aatctgaagt tgaagtagt ttttagtta aattataact 2149

<210> 94  
 <211> 2332  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1251632CB1

<400> 94  
 gccaccccg aactgggcag cagcctcaag aagaagaagc ggctctccc gtcagatgag 60  
 gatgtcatta ggctaataagg acagcaactt aatggcttag ggctcaacca gactgttgat 120  
 ctccatgc aagagtcagg atgtcgttta gaacatccct ctgctaccaa attccggaaat 180  
 catgtcatgg aaggagactg ggataaggca gaaaatgacc tgaatgaact aaaggcttta 240  
 gtgcattctc ctcatgctat tgtgaggat aagttttgc tgctgcggca gaagttaccta 300  
 gaatctgg agatggccaa ggtcctggag gcacttcaag ttctacgcg tgaattgacg 360  
 ccgtctggaaat acaatacaga ggcattcat gtttttagt ggtatctgtat gtgttagccat 420  
 gcagaagacc tacgtgcaaa agcagaatgg gaaggccaaag ggacagcttc ccgatctaa 480  
 ctattggata aacttcagac ctatttacca ccatcgtga tgcttcccc acggcggtta 540  
 cagactctcc tgcggcaggc ggtgaaacta caaagggtac ggtgcctata tcacaataacc 600  
 aaacttgata ataatctaga ttctgtgtct ctgctttagat accatgttg tagtaggagg 660  
 cagttcccat ttatacgcg gcagatactt acggaggcat gtaatgaagt gtggttctgt 720  
 aaattctca atatggcac taaaactagca acaggatcaa aagataacaac agttatcata 780  
 tggcaagttg atccggatac acacctgcta aaactgctta aaacattaga aggacatgct 840  
 tatggcggtt ctttatattgc atggagtcca gatgacaact atctgttgc ttgtggccca 900  
 gatgactgtct gtagcttgc gctttggaaat gtacaaaacag gagaactaag gacaaaaatg 960  
 agccagtctc atgaagacag tttgacaagt gtggcttggaa atccagatgg gaagcgctt 1020  
 gtgactggag gtcagcgtgg gcagttctat cagtgtact tagatggtaa tctccgtac 1080  
 tcctggaaag gggtaaagat gcaatgcctt tggtgttgc gtgtggaaa gactgttctg 1140  
 gcatcagata cacccaggcg aattccgggc tataacttgc aggaccttac agataggac 1200  
 atagtacaag aagatcatcc tattatgtct ttactattt caaaaaaaaatgg ccgatttagct 1260  
 ttgttaaatg tagcaactca gggaggcat ttatggact tgcaagacag agtttttagta 1320  
 agaaaagtata aagggtttac acaagggttt tatacaattc attcatgtt tgaggccat 1380  
 aatgaagact tcatcgctag tggcagtgaa gatcacaagg ttatcatgtg gcacaaaacgt 1440  
 agtgaactgc caattgcgga gctgacaggg cacacacgtt cagtaaactg tggagactgg 1500  
 aaccacacaga ttccatccat gatggccagc gcctcagatg atggcactgt tagaatatgg 1560  
 ggaccagcac ctttttataga ccaccagaat attgaagagg aatgcgtatg catggatagt 1620  
 ttaggtgaa ttggagcag acgactctg ttaacttaa aattagtctg attttaatgg 1680  
 ctggggattt ggtgcaaaaca aacatgattt atagctggac agacatgtc gtcatgaaaa 1740  
 aagaaccatt tctgaagccc gattggggcc aacatattac accttgcgtt atagtaacca 1800  
 gtttagatgaa agcacgtctg tagaacgttg ttggacacca tggatattttt ttccccatc 1860  
 ggttgtgaag aactgtgcta cattcaggct taccctttaa actcgtatata tatattttt 1920  
 ttcccttcgt tttttgttgc ggcaggatatac cattttttgtt gctcttcgt gtaatgtaaatg 1980  
 ttaaatgtttt gttttggaaa ctttttttaa cagtttagaa ggcttgatag aaagagtgc 2040  
 tttagtctgaa ggtatataatc tggataggaa agaattttctt tctttttttt ctccaaatct 2100  
 ttccgcctta tttagttgttgc gatcttgcg gcttggttca tggatcttag ctttgcgg 2160  
 tgcgcgttat atactgtatcc agatgataaa ccagtgtact atgtcaaaag cactctaat 2220  
 attacatttg acaaaaaaggtt ttgtactttt cacatagctt gttggcccgtaaaaagggtta 2280  
 acagcacaat ttttttttttttaaaa taaattaaga agtattttataa gggaaaaaaa aa 2332

<210> 95  
 <211> 1751  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature

&lt;223&gt; Incyte ID No: 1331955CB1

<400> 95  
 gccccaatcg actccggaga caacgccggg cgacgcacc tcgcgcaggc ccggaggccc 60  
 ctgtgtctg tgcacgggc gtgtgtctg tgaaacgcg agggcacact agcacattcc 120  
 tggaaaggacc ccagaccac caagccactc agtcccttga cgagttcca ctcaccccg 180  
 ctgcctctgt caccgggtcc ctccaccctt gtctctgtg cggccagcgt cagaccatg 240  
 gcgacggagg agaagaagcc cgagaccgag gccggccagag cacagccaaac cccttcgtca 300  
 tccgcccactc agagcaagcc tacacctgtg aagccaaact atgctctaaa gttcacccctt 360  
 gctggccaca ccaaaggagt gtcctccgt aaattcagcc cgaatggaga gtggctggca 420  
 agttcatctg ctgataaaact tattaaaact tggggcgcgt atgatgggaa atttgagaaa 480  
 accatatctg gtcacaagct gggaaatccatc gatgttagct ggtcgtaaaaaatc ttctaaaccc 540  
 ctgtttctgt ctcagatgtg caaaacccctt aagatatggg acgtgagetc gggcaagtgt 600  
 ctgaaaaccc tgaaggggaca cagtaattat gtcttttgtc ccaaacttcaa tccccacttcc 660  
 aacatttttg ttcaggatc ctttgacgaa agcgtgagga tatgggatgt gaaaacagg 720  
 aagtgcctca agactttgcc agctcactcg gatccagtcg cggccgttca ttttaatctg 780  
 gatggatctt tgatagtttca aagtagctat gatggtctt gtcgcattcg ggacaccggcc 840  
 tcaggccagt gcctgaagac gtcatcgat gacgacaacc ccccccgtgtc ttttgtgaag 900  
 ttctccccga acggcaataa catccgtggc gccacgcgtgg acaaacactt gaagctctgg 960  
 gactacagca agggggaaatgt cctgaagacg tacactggcc acaagaatgt gaaataactgc 1020  
 atatttgcctt atttctctgt tactgtggg aagtggattt tgctgggtct agaggataac 1080  
 ctgttttaca tctggaaact tcagacgaaa gagattgtac agaaactaca aggccacaca 1140  
 gatgtcgta tctcaacacg ttgtcacccca acagaaaaca tcatcgccctc tgctgcgtca 1200  
 gaaaatgaca aaacaattaa actgtggaaag agtgactgtc aagtccctt gtcctgtccc 1260  
 gcgagagact gtcggaaatgt tgaccggat tgcaagaaaa caggggtgtct tggaggtgg 1320  
 ccccccagatc tgccctgtt ggtcaggaca gggcctgtt tgagccctt ctctgaagat 1380  
 gattggccg agcggaaatgt gtggaccacc gggaaatgttctaaatgtc tggtgacatt 1440  
 tcttgccaat tctaacaatc tcttagggaaag agttccatgt ctattgtttt ccaaacttgc 1500  
 caacaaaatgt ttttaattttt ttattacaga agggtaatgt tcaatttaac atgcgtgtg 1560  
 ttttttgcgtt aaacgttctg tatcttttg atattccatg acccagtgtca cgctgtggcc 1620  
 tgtcacccgccc accgtggccc cgccagctgg cctccccctt ggcccacggcc ggccggccccc 1680  
 attctctgtc gcttagatgc cctggcccaag ggcctgactc tccattccccg ccagtagggg 1740  
 taaccgagctc g 1751

&lt;210&gt; 96

&lt;211&gt; 1285

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1412614CB1

<400> 96  
 cggagaaaaaa gctgacctaa tgaaactgtg gcaacgtcag cgcttgaggc ttgaagaggg 60  
 agacaagctaa aagaggata tccagggtt tcatgtatggc atttgcacctt ccaaaaaaca 120  
 cagatggtcc caaaatgcag acaaagatgt gacacccgtggc acccctaaac catcagctat 180  
 tgaatgaccg ggtatgttggaa gaaagaagag ccctgtttgg caaatggttt gacaatgg 240  
 cagactctca aagaagaaga atccctcacag gctgtttggc ggcgtctcg ctgtcccagc 300  
 aaaagttctg ctgtcgaaag cttcaagaga aaattccagc agaaggccctg gactttacaa 360  
 ccaagcttcc aagggtgttata tctttttttt cctggacccctt cggagccctt 420  
 gtcgttgtgc acagggtgtc tggcattggaa agaaaccttgc tgagctgtgc cagctctgg 480  
 tgctgaaatgt ttacgttgc aactgttaca tcaattttctc tccaaactccc tttgagcagg 540  
 ggatctggaa gaagcactat attcaaatgg tggaaagaact tcatattacc aagccataaga 600  
 caccggccaaa ggatggattt gtaatcgctg acgttcaact agttacaacg aattctccag 660  
 aggaaaaaca gtcccttta tcaagggttttgc ggtcccttcc taagcacca acagatata 720  
 actcaggggaa gaaagcactt ccaccctggc gatcttctgtca taagcacca acagatata 780  
 ttcgttttaa ttaccttagac aaccgtgacc ccattggagac tgcgttgc ggaagaagaa 840  
 aaagaaaaacca aataacccttca gacttcagcc gacagtccaca tgataagaaa aataaatttc 900  
 aggacagaac taggctaaaga aaagcacaat caatgtatgtc gaggagaat ccctccac 960  
 tatgtccctta agtgccttgcgat cttccatggatccatgtc catctcgccctt ggcctccccc 1020  
 tgagtctgtg ggactcccttgc ccaactgtccac cacagctgaa attctcatgc agcatccctca 1080  
 caggcacccctt gggcccccacatgactcat ccaggttcca gagccaaatgt ggactgaaca 1140

tgggaagact tttattata tag aaatgacaag atgcttgca cagtggagag ctgaatttac 1200  
 ttggctccca ttagaaactc tttcagctta agtacttatt gtggtagtga gtcctacgg 1260  
 atttcagtaa aaaggaattc atggc 1285

<210> 97  
 <211> 3260  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1750781CB1

<400> 97  
 ccggaagacc gtcccggatg gcctcgaaaa ctgccagtgt gtggaggtga gctccggat 60  
 tgccggcatt cccgcttcgt ctgggtgctt catgtgcag gctgcggccg tcagccctcg 120  
 ctcgcattgg tggcgcttag gtgccccggc agcaagtgc acatgtcg ggctccgcgc 180  
 cgctgacttc ccccgcttgc agcgccacat ctggaggcaaa ctgaggcgcc gggaccggct 240  
 gcagagacag gcgttcgagg agatcatcct gcagtataac aaattgtcgaaa 300  
 tcttcattca gtgttggccc agaaactaca ggctgaaaag catgacgtac caaacaggca 360  
 cgagataagt cccggacatc atggcacatc gaatgacaaat cagctacaag aaatggccca 420  
 actgaggatt aagcaccatc aggaactgc tgaattacac aagaaacgtg gggagtttagc 480  
 tcaactggt attgacatcata accatcataat gcagcgaaag gacaggggaga tgcagatgaa 540  
 tgaagcaaaa attgcagaat gtttgcagac tatctctgac ctggagacgg agtgcttaga 600  
 cctgcgact aagctttgtg accttggaaag accaaccatc accctgaagg atgaatatga 660  
 tgccctgcag atcacttttca ctgccttgc gggaaaactg agggaaaacta cggaaagagaa 720  
 ccaggagctg gtcaccatc ggatgctga gaaagcccaag gaagccaaatc ggcttaatgc 780  
 agagaatgaa aaagactcca ggaggcgccca agcccggtgt cagaaagacg ttgcagaagc 840  
 agcaaaggaa cctctaccatc tcgaacacgaa tgatgacatt gaggttgcgggg tggatgaaac 900  
 ttctgtcac acagaagaga cctctctgt gcgagccatc acagagacg ccacgagacg 960  
 ctctgtctc tccttcccaatc tccccccggaa caatgtggat actcatctg gttctgttaa 1020  
 agaagtgagg gtaccatcata ctgccttgc tgcattcgat gcacatgatc gggaaagtcaa 1080  
 cgctgtgcag ttctgtccatc gttcccggtt actggccact ggaggcatgg accgcagggt 1140  
 taagctttgg gaagtatttg gagaaaaatg tgatgtcaag gtttccctat ctggcagtaa 1200  
 tgcaggaatt acaagcatc aatttgcattc tgctggatct tacctttag cagcttcaaa 1260  
 tgatttgcac acggcaatctc ggactgtggaa tgattatcga ttacggcaca cactcacggg 1320  
 acacagtggg aaagtgcgtt ctgctaaggatc cctgtctggac aatgcggcgg tttgttcagg 1380  
 aagtcaacgac cggactctca aactctggaa tctacgcagc aaagtctgc taaagacagt 1440  
 gtttgcggaa tccatgtca atgatattgt ctgcacagag caatgtgtaa tgagtggaca 1500  
 ttttgcacaa aaaaattcgtt tctggacatc tcgatcagag agcatatgtc gagagatgg 1560  
 gctgttggaa aagattactg ccctggactt aaacccagaa aggactgagc tcctgagctg 1620  
 ctcccgttatc gacttgttca aagtatttgc tctccgaaaca aatgtctatca agcagacatt 1680  
 cagtgacactt ggggtcaagt gcccgtctca ctggggcaggat gttgtcttca gcccgtatgg 1740  
 cagttacgtg gcccgtggct ctgtcgaggc ctctctgtat atctgtggatc tgctcacagg 1800  
 gaaagtggaa aagggttcttca aacggcggca cagctcatcc atcaatgcgg tggcggtgtc 1860  
 gcccctggc tccgcacgtt tcgatgtggaa caaaggatgc aaagctgtgc tttgtggcaca 1920  
 gtactgacgg ggctctcagg gctgggggaa ccccagtgtc ctccctcagaa gaagcacatg 1980  
 ggctctgcgca gcccctgtctt ggcagggtat gtgttgggtat tagcatggac ctcccagaga 2040  
 agctcaagct atgtggcaact gtagcttgc cgtaatggg atttctgttcaag atttactgtca 2100  
 ggtctctttt ggcctggaaag aataacactg aaaaaacactg acgctgtggt cacttagcag 2160  
 aggctcaggat tttgccttgc gggaaacacta ctgatctgtatc ccttccatc ctcaacttgg 2220  
 ggagcacagg gcccccgctgg gcctcttcac caacggcaggat gccaaatca gccccccat 2280  
 caagggtggc tttctctgtc tttctctgttgc ctttcccaatc tcgggttctgg cctaacgcac 2340  
 gtcccaacac ctgggttcaatc ttggccggat gaaatcttcaatc taagcatggg attaacggaa 2400  
 actcccaac tacagaccccc tccctgtgg gttgcatttgc tttgtctcat tactgtgttca 2460  
 atgtccctcac atcttccatc ctgttcttgc gagctttctg gctcttttc cccacaaaat 2520  
 tcgacacatt taaaatctc cgtgtggctt taaaatgg tttttgttt tttttgtttt 2580  
 ttgaggtggg agaggatgtt tgaaaatctt ttccaggggaa atgggttgc tgcagaggtt 2640  
 aggatgtgtt cctgtatcgt tctgcacaca cccagaaggat ggggtgcacac tgcattgtt 2700  
 ggggtggcaaa gggattcggag acctccaaaca tacttgcgt aagggtggat tttctggccat 2760  
 gccccctctg ccaaggctgt gtgcgttgc cttgggttgc tttgtcaaga agccttaggct 2820  
 cagaaggcaca gcagcgccat ctttccgtt cagggttgc tttgtcaaga agccttaggct 2880  
 atttatctt actatcttac ctacgtataa agttttgtt cattgggtgt gcgaaacacc 2940

cttttatca	ctttaaatt	tgcactttat	tttttttctt	ccatgttgt	tctctggaca	3000
tttggggatg	tgagtgttag	agctggtag	agaggagtca	ggcggcccttc	ccaccgatgg	3060
tcctggcctc	caccgcct	cttccctgt	cctgatcac	gttccat	ttggcccttc	3120
gagaactta	gtcaaggag	gttgaattc	acaggccagg	gcacatctt	tatatttttc	3180
attatgttgg	ccaacagaac	tttattgtaa	ataataataa	agaaatctgt	tatataacttt	3240
tcaaaaaaaaaaaaaaa	aaaaaaaaaaaaaaa					3260

<210> 98  
<211> 1276  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1821658CB1

```

<400> 98
gcggcacccc caaggaagac cagcctgcct ctggtcggtt cctggcgctc tgcgtttcgt 60
gacccgttcc agtagaaggc tatttaattt tcacaactgc ttgaattttg acatacaaga 120
tgaagcaaga tgccatcaaga aatgtgcctc acactgtggaa ttgtaaagat tatgtgcata 180
tggtagataa taatccccctt gaaatgggg attcaggaaaa cctaatttgcata tgggtggca 240
ataatattgt ggtcattggc acgtgtacgt ttcaggaaaga agaagcagac gttgaaggca 300
ttcagtataaa aacacttcga acatttcacc atggagtcag ggttgatggc atagcttgg 360
gcccgagac tagacttgat tcattgcctc cagtaatcaa attttgtact tcagctgctg 420
atatgaaaat tagattttt acttcagatc ttcaaggatata aaatgaatata aaggttttag 480
aggggccatac cgatttcatt aatggtttgg tggatcc caaagaaggc caagaaaattt 540
caagtgttag tgacgatcac acctgcagga ttggaaacctt ggaaggagtg cacaacgctc 600
attttgttct tcatttcctt ggcattgggt tggctggca tccctgggg actttttaagc 660
taatgggtgc agagaagaat gggaaacatcc gggtttatga tctttggcc caacaggctt 720
ttttatctct tgaatcagaaa caagtgcatt taatgtcagc acactgggtc taaaaaaaaca 780
ccttc当地 ctttcaaaatgt tggagccgtt gcaggaaatgt attggtaat ttggatatt actcgggtcca 840
gttatccca aaataagaga cctgttcaca tggatcgagc ctgttatttcc aggtgggtcca 900
caatttagtga aaatctgtt gcaaccactg gttatccctgg caaaatggca agccagttt 960
aaatttcatca tttaggacac cctcagccca tcctcatggg ttctgttagcc gttggatctg 1020
gactgtctgc gcatcgaact ctccctctgt gtgtaatgg aggagaccac aagctgttgt 1080
tttgggtgac tgaatgtt aatgtttttct gtacctttaga ttccaaaaact ttgttattttt 1140
agtacatatt ttgaagaattt tctatagtagc atattttggaa gaattttat atcaaataata 1200
ccgtataactt tagaaaaatgt ctcaatgtt gtttattaaat aaaatgttga tgggtttggaaa 1260
aaaaaaaaaaaaaaa 1276

```

<210> 99  
<211> 3608  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1872574CB1

```

<400> 99
gttttggttc tagccgctcg ccgtccttgc aggctctgcc gtccggaaagc cgctcatttc 60
cgcttccccct tcccttccc ggctcaagtc ctteccctct ctttccttcc ttccgccta 120
tctttttct gctggcgctc cgggtccggg ccattttccg ggccgggcgc actaagggtgc 180
ggggccccgg ggcccaagtat atgaccggcgc gtcctgtat ctttcgtttc ccccccggcc 240
tgtggctcg gggccgcggc ggccgtgtccc actatggccc ggaaaggtagt tagcaggaaag 300
cgaaaaaggcgcc cccgcctcgcc gggagctggg agcgacgcgc agggcccgca gtttggctgg 360
gatcactcgc ttcacaaaag gaaaagactt cttccctgtga agagatcctt agtataactac 420
ttgaagaacc gggaaagtca gctacagaat gaaaccagct acttcgtgt gtggcatgtt 480
tatgcagcac agcaacttcc cagtctccgt aaggagagag agttccacct tgggacccct 540
aataaaatgtt ttgcatctca gtgggttaat catagggaaag tgggtgttgg cacaatatgc 600
aacacgttat ttgtcgtaga tgtccagaca agccagatca ccaagatccc catttcgttggaa 660
gaccggggagc ctggagggtt gacccagca ggcgtgttggta tccatgccat cgagctgaat 720
ccttctagaa cactgcttagc cactggagga gacaacccca acagtcttgc catctatcga 780

```

<210> 100

<211> 1311

<212> DNA

<213> Homo sapiens

<220>

## <221> misc\_feature

<223> Incyte ID No: 2590967CB1

<400> 100

```
ggcaggatga acgctgcttt ccaagatggc gacggaggga ggagggaaagg agatgaacg 60  
gattaagacc caattcacca cccgggaaagg tctgtacaag ctgtgcgc actcgagta 120  
cagccggccc aaccgggtgc ccttcaactc gcaggatcc aaccctgtcc gcgttcctt 180  
cgtaaacctc aacgaccagt ctggcaacgg cgaccgcctc tgttcaatg tggccggga 240
```

gctgtacttc tataatctaca agggggtccg caaggctgct gacttgagta aaccaataga 300  
 taaaaggata tacaaaggaa cacagcctac ttgtcatgac ttcaaccacc taacagccac 360  
 agcagaaaagt gtctctctcc tagtgggctt ttccgcaggc caagtccagc ttatagaccc 420  
 aatcaaaaaa gaaaacttagca aacttttaa tgaggaaggc tcattgtcat ccccaagcca 480  
 gcccagtctc ccaggtggaa ctgtatgtgac gacgcacctc acgtctccc 540  
 gggacttggaa ctcgagggg tgacgaggag gagctccgag ctgcgcctga gccgtgccag 600  
 ccggcggacc tcaggcggtg gacgtccggt atagccgtgt ggacgggtgac cggctcaet 660  
 tgccgcgcgc tgctccgcgt gctcacccaa agaagttgtt tccattttaa accggctctt 720  
 tggggctgca gtaaaaaata agaaatggag tttcttgcgt ttttactcta aaattcaatg 780  
 taattaaatt tcataatataataata catatataca tagtgtaaaa taaaatgttt 840  
 cttggacaag aaatccccctg aaattcagct gtatagtgcc ttcaactgttt ttgcactgt 900  
 ttttctatac cttaggtggc cagaagacaa ccttgaatgc actcatagag aaaactgtta 960  
 ctttctgcacg taatgttaatt caggaagaca gacgctgcaa tcacagatt taaaaaattg 1020  
 tttgcactta aaaatagttt aatgtctgtt gaaagttact ttgcagatgg gtgttaaggac 1080  
 tcatggccct ctgaggtgcg gcgtgaatg gcccctttt cccgttgcgt tttatattac 1140  
 gtaaaaaataaa ctgttgtttc caatgcatac aactctgtat tatatgtata aatattgtaa 1200  
 ttctgcaatt gggggaaaata gttacttcac tagtaattt catcatttaa gagtgatatt 1260  
 tctaattcac aaaagttaat attaaaaacta tcttgaatataaaaaaaaaa a 1311

<210> 101  
 <211> 2839

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 2824491CB1

<400> 101

ggcctgcggg aagccaagat ggccatagg ggttctccag gctgcagttg ggccttatac 60  
 agtatctaag cggagtgttt tggaggagt taaggggctg tggcaaacgc cctctccgc 120  
 gtcatggccc ggcatacgaa tggcgggtc tataactacg atgaagattt tgaagatgt 180  
 gatctctacg gccagtcgtt agaggatgtt tattgtattt cgccgtcaac agtgcgtc 240  
 tttatattt caccggcgtt caaacccttc gttggcctg tggagaataa tgattatgaa 300  
 gatctgaaag aatcttccaa ttctgttca aaccatcagc tcagttggatt tgatcaagct 360  
 cgtctttttt catgccttgc tcacatgaga gaggtactt gatgtgtgtt ggcagatgaa 420  
 atattaattt aaggcgtttt gaaagacaag tttgtatgtc agaaggctt gtcaagggtt 480  
 ctgaaacaag atagagtgcg gatgttgaag gacaagaatg agcaacagt atctacagga 540  
 aagatagcaa aaggaaaacc agtagattcc cagacatcgc gaagtgaatc tggaaattgt 600  
 caaaaagttt cttaaatgac tggatcttgc aagaagcaaa ctatggatt tgaagtgcct 660  
 ggagtatctt ctgaaagaaa tggtcatagt ttccacacac ctcaaaaagg accgcccatt 720  
 gaagatgcca ttgcattttc cgatgttctt gagactgttt cttaaatctgc taatccaccc 780  
 cacacgattt aagcatcaga agacgacgt tcaaccccg caccgggtgaa aaagtctggc 840  
 aagctgaggc agcataataga tggtaaggcg gaactggaga agcggcaagg agggaaagcag 900  
 ctactcaact tagtggtcat tggtcatagtt gatgtctgggaa aagatactt gatggccat 960  
 atgttttattt ttctgggttt tataaacaataa agaactatgc ataagtatgtt acaggagttt 1020  
 aaaaaggctt gcaaaagctt gtttgcataat gcatgggtt tggatgaaac tggcaagaa 1080  
 aggaaaagggg gatgttccat gatgttggt atgacaaatgtt ttgaaaccac aaccaaaatgtt 1140  
 attacattaa tggatgttcc aggccataag gacttcattt caaatatgtt tacaggagca 1200  
 gcccaggccgg atgtatgtt tttagttgtt gatgcacca ggggagatgtt tgaagtgcga 1260  
 ttgagactg gaggacaac acgagagcat ggactcttgc tccgttctt gggagtgacg 1320  
 cagcttgcag ttgcattttt taaaatggat caggttattt ggcacacaaga aaggtttcaa 1380  
 gagattactg gaaaacttgg gcacttctt aagcaagcag gttttaaaggaa gatgtatgtt 1440  
 ggttttatttctt cttacatgtt gttcgttgc gaaaatctaa tcacaaatgtt tcagtcagg 1500  
 gaactcacaat aatggtataa aggactatgtt tatttagaac aaattgtatc cttaaaggctt 1560  
 ccccaaggcat ctattgacaa acctttttaga ttatgtgtt ccgtatgtttt caaagatcaa 1620  
 ggtatctggat tttgcataac tggtaaaaataa gaaatgggtt atatccaaac tggatgttcc 1680  
 ctactggcaa tgccttcttca tggaaacttgc accgtgaaag gaatcactt gcatgtatgtt 1740  
 cctgtcgact gggccggcagc aggcgatcat gtatgttca ttttgggtttt gatggatattt 1800  
 atcaaaaatca atgttggctg catatttgtt gggcccaaaatg taccatattaa agcttgcact 1860  
 cgtttcagag cccgaatctt cttatgttattt atgaaatttc ctatcaatggatggatctt 1920  
 gtgtgttac actacaaac tggatgttgc gggccggat taaaacgatt gattatgttgc 1980  
 ttaaacaacaaac gacgggtga agtcacaaag aaaaaggctt aatgttttgc taaaggccag 2040

aatgcattgg tagagctaca gacacaaaaga ccaatagctc ttgagctata taaagacttt 2100  
 aaagagctgg ggagggttcat gctacgttac ggtgggttcta caatagctgc tggtgttgc 2160  
 actgagataa aagaatgatg ggtcagaatt tctaccacgt ttctggatac agtgaaatag 2220  
 ctaacctctg tttcaagaat gcagttatta agtcaaagga acaatgtgca attgatatgt 2280  
 ttttagatga gagagaaaaaa ttaaagctaa aattagctgc aaagaagtat taataatcac 2340  
 ctctgcaaaaa attctaaggat gccaactggc aaagaaaagtc taatgttaaa aacaactttg 2400  
 ccttggaaac gttaaataat ggatttactt tgctaagatt tatggcaagt gtcaaaaata 2460  
 gtatctgaag atactgaatc atcatgaaat gaactctact tctggccaaa gcacaatgt 2520  
 tttgcagttt tctcttttga ttcaattata ctgcacatgt ttttaaggaaa agtaacttaa 2580  
 ttgggtttttt cagggcagttt atatttgacc taagctttttt tttttttttt tttttttttt 2640  
 tccagttaat gctaagaaaaa gatttggggaa aggttataat aaaagtattt tgtggtgacc 2700  
 ataagaatgt ccctccccaa acaagtaaac ttgtgaaagt ttaatttggaa attagtgaa 2760  
 gctgttcctt taaaagccaa gatatttattt aagttgtaaa gccagctaataaaatgcctt 2820  
 agttttagca taaaaaaaaaa 2839

<210> 102  
 <211> 1676  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2825460CB1

<400> 102  
 gggaggcgga gtttgagggtg agaggagatc gcgcattgc actccagct gggcaacaag 60  
 ggcgaagttc tctcaaaaaga aaaaaaaaaaa tcgtcggtt cctttccca tcttttttc 120  
 gtgacttata ttccagaacg aagccccaca catcattaaat gatttgaatc gtttctaaag 180  
 tttttcttaa atcggttttccaaatcgttttgc ttgtttttgc tctaacagtc cagaacacat 240  
 attacataat ggagccggga gacagactag ggctggctt atccggccac gcagttccagg 300  
 aaagggtctt ttccaaaaaaat gatcaatgtt ttcttcccgat ctacataaaac 360  
 aagcacctcc ttgttttattt ttcgtaaagc aaaacaagca tggaaagctt actgtttcgg 420  
 ctcttcaaac ttccagcaac tacactgcgc tgcatcgac tgcacgccc ctggtgacgc 480  
 acacgctcgcc cgccaaatgtt gaaatgtctg cctccaggct ttgtcatggc ggctgtgtct 540  
 gcacgctgga accatgtgtg ggtcggcacc gagactggga ttttggaaagg gttaaatctt 600  
 cagcgaaaac aggccggcggaa cttcacggcc ggaggacagc cgccgcgcga ggaggcagtg 660  
 agcgccctgt ttggggcacc cggcgccgag acccagatgc ttgggggtcg cgccggacagg 720  
 acggtaaaggc acttcagcgc cgaggatggc atattccagg gtcagagaca ctgccccggc 780  
 ggggaggggca ttgtccgtgg cctcgcccgac gccgacggca ccctcatcac atgtgtggat 840  
 tctggatttc tcaagatctg gcatgacaag gacaaggaca catcctctga cccactcctg 900  
 gaactgagag tggggccctgg ggtgtttagg atgcccaag acccagcaca ccccatgtg 960  
 gttgccacag gttggaaaga gaatgtttt aagatatggg acctgcagg ctctgaggaa 1020  
 cctgtgttca gggccaagaa cgtcggaat gactggctgg acttgcgggt tcccatctgg 1080  
 gaccaggaca tacagtttct cccagatca cagaagcttg tcacctgcac aggttaccac 1140  
 caggccgtg ttatgtatcc agcatcccccc cagcgcggc cagtcctaga gaccacctat 1200  
 ggagagtacc cactaacagc catgaccctc actccgggag gcaactcaat gattgtggaa 1260  
 aacactcatg ggcagctggc agaaattgac ctgcggcaag ggcgtctact gggctgtctg 1320  
 aaggggctgg caggcagttt gctgtgggtt cagtggccacc cttcaaagcc tctactagcc 1380  
 tcctgtggct tggacagatgt ctggaggata cacaggatcc agaatccacg gggcttgag 1440  
 cataaggatg agcccaaga gctcaagaa cccacaacagg tgcccctaga agacacagag 1500  
 acagatgaac ttgggcattt cttggaggca gctgccaagc ggaagcttc gggtttgag 1560  
 cagccccaaag gagctctcca aacgagacgg agaaaagaaga agcggcctgg gtccaccacg 1620  
 ccctgacgcc cctgtgccccca ctttgtaaat aaactgtgca acacccaaaa aaaaaaa 1676

<210> 103  
 <211> 3206  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2871116CB1

&lt;400&gt; 103

ccagagcgtg cgttcggtgg cccatagggg aagatggcgg ctgctcctt ggaggagcgg 60  
 gattgagagg atcgggggtgg ggagacaaaa caagagagac atttctggct ctgaaggcga 120  
 acgcttcgct gccatTTAG gagCTCTGCT caaAGCCAGA cgtatCCTAG aaggAAAACA 180  
 tcaccatggc tacAGAAATT ggttCTCCTC CTCGTTTTT ccatATGCCA aggtTCCAGC 240  
 accaggcacc tcgacAGCTG ttttATAAGC gaccTGATT tgcaCAACAG caAGCAATGC 300  
 aacagCTTAC ttttGATGGA aaACGAATGA gaaaAGCTGT gaACCgAAAA ACCATAGACT 360  
 acaatCCATC tGTAATTAAG tatttGGAGA acAGAAATATG GCAAAGAGAC cAGAGAGATA 420  
 tgcgggcaat tcAGCCTGAT gcAGGTTT ACAATGATCT GGTCCCACCT ATAGGAATGT 480  
 tgaataatcc tatGAATGCA gtaACACAA aATTGTTCG gACATCAACA aATAAAGTAA 540  
 agtGTCCTGT atttGTTGTT aggCTGcAGG aAGAGTTGCA aAGCCTCAGT gTCCTTAAAT 600  
 cgtggactcc aAGAGGAAGA CGCTTGTCA CTGGAGCTC TAGTGGGGAG TTTACCTGT 660  
 ggaatGGACT cacttcaat tttGAACAA tattACAGGC tcACGACAGC CCAGTgAGGG 720  
 ccatgacgtg gtcacataat gacATGTGGA tGTTGACAGC agACCACGGA ggATATGTGA 780  
 aatattggca gtcgaacatg aacaACGTCA agatGTTCCA ggcACATAAG gaggcGATTA 840  
 gagaggccag gtttatacac aatataccat ttTCTGTAGT CCCTATTGTC ATGGTTAAAT 900  
 tattCTCTAA gtgtattCTG ggtGcAGAGA TGCAtGGGTCt CTGTCAGTT CTGGGAAACT 960  
 ttctgcaccc tataAAACACA atatttttCT tttGTTTcAC ACATTCACCA ttttGCTGGC 1020  
 accttctga agtagtGTTG tcccGtATC AGCCTGtGC ATATGTTAGA gATGTAcTGT 1080  
 ctggcgcatt ttGcACTGTT ttTCTCTTTT CATTATGAT TAATAATGT tatacGTTat 1140  
 tccCTTTAT tATCTACTGT gtaAGACAAg AATATTCTAT TCCAATAAA GAATTcAGTC 1200  
 tttAATTATG caACTGAATA AAATCTAAAG CCTACAGAAA ACAACTTCAG AATTcACACA 1260  
 aagtggaaaa aggCTTAAGT gaAGACCTGG tGGCTTGGT tATGCCACGA CTTCCAAGG 1320  
 aaagtatagg actAAAACCC tcACAGATAA CTGGATGTGG CAAACATTA CGGAGTAATG 1380  
 aatgggttct tcaAGCTTg cAGCTGTAAG cAGATCATTG tcaAGAAAGAC TCTAGGACTT 1440  
 ttcttctgt tcactGTTGA taACATCACT tATGCAAATG tATACAATAA GTGGAGTTA 1500  
 aaatATTTc agtGAGTTGt atatttttAC acATCAGTGA gGTATGTGA gTAAAACtGG 1560  
 gggAAAAGT tccaAAATACA AGCCTGAAGA ATGCTGcAG cCTCAGAATAA aAGCTAAGCA 1620  
 gcattCTTA aggttGtGCC accCATGTGt gggAGGAGGT tgACATCTT ATGGAAACAT 1680  
 catCCACTGT agtCATTGt tcACATTTc AGAATCTAA CAGAAATTGT TGGATGAACA 1740  
 tgcttctgt ttGTagATTt tgCCTTAGtG tCATGCCAT ACATTGAGTT tacACAGCTG 1800  
 gtccttcata ggattccAAA gttcaAGGGA GTTTTAGAG ttagttGAGA aACTTGTGA 1860  
 tcttcactg ctggaaaaaa ctgactcctt ctGcAGcAG atttTTGc tttacacaca 1920  
 agtCTGAATG tccttatttt aaAGTTTCC tcaaAGGTGc AACATTcATG gaATAGCTG 1980  
 ccaggaAGAT gtGAAACTT tctACAGACC ttGAAATGG AtGAGAAACA ttGtATGTAG 2040  
 ggatGTTAG caATCAGTGT tttAATAGAC AGCCCACATT gttcAGTTt ATTtCATGAA 2100  
 gtgtctgagg cagaAGCTGA tgataATTt gggAGCAGTA ttCGTGTGTG atttAAAAGA 2160  
 ctgcaggAAAT actGCAAAAGA tagAAATCCt ttAttttCAC cactTAAGGC agCTTCATGT 2220  
 gatttCTCG tATCATAGAA aATAGAGAAg gAACATGGAT agcATTAGCA ctAAATAATAC 2280  
 acacttGAAG ttctcAGAAT ACTGATGATT gAAAActCAA ACAACTGTC tGTTGAAGTC 2340  
 ttctttgt gAGATGCCtA tgTTAGCTGA CGACATTcAC tttAAGGcT tCTTcACTGG 2400  
 atttCCCTC tCCTGTTA TAATGcAGCA cAGTGTtTTt atttttCCt GTCTGAGAAG 2460  
 cacagattat ctgttAAATG ctgacttCTT tCCCTGCTG tGtGtCTCA tGtAAcAGTT 2520  
 tctcacccac ggataATAAA ttGTCATGAT GCTCTGATGA CGGCACTGTt AGAAATCTGGG 2580  
 actttCTCG ttGccATGAG gAAAGAATTc TCCGAGGTAC tGtGACTAAC AGTACTGATT 2640  
 ggaatATAA aATAGGGAAg acATTtGTT gtaAAATCtAC acAAAACAC aAAACTGGCT 2700  
 tacacCTCA ttCAATTtTT ttTACATATA cacACCGTCT cAGGCTCTC AAAAaACCC 2760  
 agcacttCTC ctgactcaca gtcattttGT agGTTTTAC tAccAGTGTt ATCTTGAAT 2820  
 ttttcAGCTG tAAATTAAT ACAAGAGTGC CTCCCCCTA CTGCTTATC tGtATGcATC 2880  
 ttttagggct gtattcCTT tCCTTCTTg tagCCAGGGT acttGTTccc AACATATTGA 2940  
 cactgtggTT tgatttagat agCCGTCATT CTCCtGGCAG tCCTTTACA ATATGAATTa 3000  
 accgacaAGA tagAGGTATC AAAGCTACAC ttCTTAGTGT tactATTtTt gAAAGCAGTT 3060  
 gtttttCAG tacACCCACAT ttGtACTACA tGGCCGGCTT gttACTAAGT tcGGGTGGCA 3120  
 ttGCTGCTTg ttTACTTTTg ttGATTtTTtA ATTAATAAA CCTCTATGAA ATTAcTCTAT 3180  
 tccgtAACTG aaaaaaaaaaaaa aaaaaaaaa 3206

&lt;210&gt; 104

&lt;211&gt; 921

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

<223> Incyte ID No: 2942212CB1

<400> 104  
ggtgctgatg ctgtcgccat ttcatcacct ttgcgagcgc acatccatcc ctcgcgtctc 60  
ccggcgctg ggcattaccca gttcgggct cccaggccag cgatgcgtc gggctgagc 120  
tagatccgtc cgagccgccc tctctgaggc gtccgggggg cgcggcccc 180  
ggtccgggcc aaggagacat gcagagccgc ggccatggag gccatctggc tgtaccagg 240  
ccggctcatt gtcatcgaaa attccacagt gggcaagtcc tgccgtatcc gccgcttac 300  
cgagggtcgc ttgtccccagg ttctgaccc caccgtgggg gtggataaaa tctcccggtt 360  
ggtggagatc gagccaggaa aacgcataa gctccagatc tggataccg cgggtcaaga 420  
gagggttcaga tccatcaactc gcgcctacta caggaactca gtaggtggtc ttcttattt 480  
tgccattacc aaccgcaggc cttccagaa tgtccatgg tggtagaaag agaccaaagt 540  
acacgttcag cccttacccaa ttgtatgtt tctgggggtt cacaagtgtg acctggatac 600  
acagaggccaa gtgactcgcc acgaggccga gaaactggct gctcatacg gcatagaata 660  
cattggaaacg tcagccccgg atgcattaa tgtggggaaa gccttcacag acctgacaag 720  
agacatatat gagctggta aaaggggggg gattacaatc caggagggtt gggagggggt 780  
gaagagtttta ttgttaccaa atgtggttca ctcttcagaa gaggttgtca aatcagagag 840  
gagatgtttt tgcttagtcg ttctttatt tccaaaacat gcttcctac ttgaactgaa 900  
aagaatagaga aataaaataga a 921

<210> 105

<211> 1367

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 3685151CB1

<400> 105

aaggaggcacg	tgcgtctgt	aatggagctg	gtcgctgtt	gctacgagca	gtcctcttt	60
gggttcgttg	tacaccggaa	gcccgaggct	tgcggcgacc	acgagcagca	atggactctt	120
gtggctgact	tcactcacca	tgctcacact	gcctccctgt	cagcagtgc	tgtaaatagt	180
cgttttgtgg	tcactggag	caaagatgaa	acaattcaca	tttatgacat	aaaaaaagag	240
attgagcatg	gggcgttagt	gcatacagat	ggtaacataa	cttcgcgtac	attctatggc	300
aacaggcact	taatcagtgg	agcggaaagat	ggactcatct	gtatctggga	tgcaaagaaa	360
tgggaatccc	tgacgtcaat	taaagctcac	aaaggacagg	tgaccttcct	ttctattcac	420
ccatctggca	agttggccct	gtcggttgg	acagataaaa	ctttaagaac	gtggaatctt	480
gtagaaggaa	gatcagcatt	cataaaaaat	ataaaaacaaa	atgctcacat	agtagaatgg	540
tccccaaagag	gagagcagta	tgttagttatc	atacagaata	aaatagacat	ctatcagctt	600
gacactgcat	ccatttagtgg	caccatcaca	aatggaaaaga	gaatttcctc	tgttaaattt	660
ctttcagagt	ctgtccctgc	agtggcttgg	gatgaagag	ttataagggtt	ttttgactgt	720
gattcaact	tgtccctctg	cgaaattttaa	gctcatgaaa	acaggtaaa	ggacatgttc	780
agttttgaaa	ttccagagca	tcatgttatt	gtttcagcat	cgagtgatgg	tttcatcaaa	840
atgttggaaagc	ttaaagcagga	taagaaaagtt	ccccccatctt	tactctgtga	aataaacact	900
aatgccaggc	tgacgtgtct	tgagggtgtgg	ctagacaaaag	tggcagacat	gaaagaaaagc	960
cttcctccag	ctgcagagcc	ttctccctgt	agtaaagaac	agtccaaaat	tggcaaaaag	1020
gagccctggtg	acacagtgc	caaagaagaa	aagcggttca	aacctaaccac	aaagaaaacgc	1080
ggtttaacag	gtgacagactt	gaaaggcaaca	aaagaaaagtg	gcctgtatcc	acccaagaagc	1140
aggaaaatgg	tagaaatgtt	ggaaaagaag	agggaaaaaaa	agaaaaataaa	aaacatcgac	1200
tgaatccacag	atgttccctg	aaagaactct	tttagatgaa	atccatctac	tcaaatgtac	1260
cttaattttt	ttttttcccc	tgtagaaaaag	caagaatttt	cttcctttgg	aaaaaaatata	1320
tatataaaaa	aaccactttt	agatggttt	ttttaaaaaa	aaaaaaaa		1367

<210> 106

<211> 1560

<211> 1500

<212> DNA

<220>

<221> misc feature

<223> Incyte ID No: 4881515CB1

<400> 106  
 aggccgactg gggagggcgc ggcctggctc ggcctggct ggcctgtcag ggcgcggcg 60  
 gcggcggtc cagcacccatg tcctctgcagt acggggcga ggagacgccc ctcgcggca 120  
 gttacggcgc gggccgattcg ttcccaaaagg acttcggcta cggcgtggag gaggagaag 180  
 aggaggcggc ggcggcgccc ggaggggtt gggcaggggc aggccgtggc tgggtccgg 240  
 gggggcgctga cagctccaag ccggaggattc tgctcatggg actccggcgc agccgcaagt 300  
 ctcatccatca aagggttgtt ttccataaga tgtcacccaa cgagaccctc ttttgaaa 360  
 gtaccaacaa gatttataag gatgacattt ccaatagctc ctttgtaat ttccagat 420  
 gggatttcc tgggcaaatg gactttttt acccaacatt tgactatgag atgatcttca 480  
 ggggaacagg agcattgata taegtattt acgcacagga tgactacatg gaggcttaa 540  
 caagacttca cattactgtt tctaaagcct acaaagttaa cccagacatg aattttgagg 600  
 ttttatcca caaagtgtat ggtctgtctg atgatcaca aataaaaaaaca cagaggaca 660  
 ttcatcaag ggccatgtat gaccttgcag atgctggct agaaaaaactc catcttagct 720  
 tttatctgac tagtactatc gaccattttt tatttgaac ctttagtaag gtgggtcaga 780  
 aactcatccc acaactgcgc accttggaaa accttattaa tatcttata tcaaattcag 840  
 gtattgaaaa agctttctc ttgtatgtt tcagcaaaat ctacattgca acagacagtt 900  
 cccctgtgga tatgaatct tatgaacttt gctgtgacat gatcgatgtt gtaattgtat 960  
 tgtcttgtat atatgggta aaggaagatg gaagtggaaag tgctttagac aaagaatcta 1020  
 tggcaattat caagctgaat aatacaactg tccttttattt aaaggaggta actaaattt 1080  
 tggcacttgtt ctgcattcta agggaaagaaa gctttgaaag aaaagggtta atagactaca 1140  
 acttccactg ttccgaaaaa gtatttcatg aggttttta ggtgggtgtg acttctcaca 1200  
 ggagctgtgg tcaccagact agtgcctcca gtctgaaage gctgacacac atggcacgc 1260  
 cacgaaacgc catcttagct gaatccccagc gtccgggttc tggtccagct tactcttcac 1320  
 tccagggtcg gatgccacgt gtacagac gatggagctg ctgcattgtgg gaatctgggt 1380  
 cctttccac tagagacaag gggtagagtt ttcattttt atgaaaaccc cttcaactgg 1440  
 tggtgtacaa ctgaagctac tatatctttt tgaaaatgg caaaaaaaaaaaa aaaaaaaaaat 1500  
 tctggagacc acagaactca agtgtgtgtt ttcctcttt tgggtccccc ttaagttagt 1560

210 <210> 107

<211> 1495

<212> DNA

<213> Homo sapiens

<220>

## <221> misc\_feature

<223> Incyte ID No: 5324681CBI

<400> 107

aaagaggcgc	tgggtggca	catgtgtatg	ggggtaggc	gggcgggtac	atggccggct	80
ctgtggact	ggcggtgtc	ggcagacgt	ttgtgttgcg	ggggccgcgc	catttccttg	120
ccacctccat	agcaagcgt	gtatgtaca	gcctttcat	ctatgactgc	agtgtgtcag	180
aaaagaatgt	acaagaaaaat	aaaggggggg	acgcggccct	ggaccagggg	agcgggtgcga	240
ttctggcgtc	cacccctcc	aagtctggca	gttattttgc	ttaaccgat	gacagtaagc	300
gtctgatctt	tttccgtaca	aaaccatggc	aatgtcttag	tgtcaggacc	gtggcaaggg	360
ggtgtacagc	cctgacttto	ataggctcg	aggagaaggt	cttggtgccc	gacaagtctg	420
gagacgtcta	ctccctttcg	gtgtggagc	cacacgggtg	tggccgtcta	gagctggggc	480
acctgtctat	gcttttagat	gtggctgtga	gtccgtatga	ccgcttcata	ctcaactgccc	540
accggggacga	gaagatccga	gtcagctggg	ccggggccgc	ccatagcatc	gagtccttc	600
gcttggggca	cacagagttt	gtgagccgt	tctccgtgt	gccaactcag	ccccggctgc	660
ttctgtctc	ctctggggac	ggcacccctg	ggctctggga	gtacaggagc	ggccggcagc	720
tgcactgtgt	tcacccgtcc	agtctggagg	agctgttgg	ccccccaggcc	ccccagaagt	780
ttggccgtc	caggatttca	tttggtgcc	aggagaactg	cgtggcgctc	ctgtgcgacg	840
gcactccgt	ggtctacatc	ttccagctgg	acgccccgcag	acagcagttg	gtgtacaggg	900
agcagctggc	gttccagcac	caagtgtggg	acgtgggtt	cgaggagacc	caggggctgt	960
gggtgctcca	ggactgcccag	gaagcccccc	ttgtgtctca	caggccgtg	ggcgcaccagt	1020
ggcagtcgt	tcctgagagc	accgtgttaa	agaaaatctc	tggtgttctt	cgtgggaact	1080
gggcatgtct	ggaaggctct	ggccggcgcag	acgcccagtt	cagcagtc	tacaaggcct	1140
cgttgcacaa	cgtgacccctc	tacccgttaga	agaaaagagg	gagactgcag	cagcagtcgt	1200
agaagaagca	gcggggccgg	agtccccccgc	ctggggcccg	cgggcgtgcc	aagaagatga	1260
gaccggggga	ggcgcacgtca	agtgtgtat	cgtggccgtc	tgttctgtc	gactgtggac	1320
cacttatgt	cgatccgtgg	accactgtcg	tgcgtatgt	cggccgacga	tgagcttgg	1380
cggatgtac	tccatcgtaa	gtcgaggaggc	atctgttatt	tgtctctgc	ttatgggata	1440
tgtttttccg	ctactgagtc	tgtgttagtaa	atttttgact	aggaaaaaaaa	aaaaaa	1495



gattctgtgt	ctctgcttat	agaccatgtt	tgttagtagga	ggcagttccc	atgttatacg	660
cacgcgat	ttacgggaca	ttgtaatgaa	gtgtggttct	gtaaattctc	taatgatggc	720
actaaaactag	caacaggatc	aaaagataca	acagttatca	tatgcaagt	tatccggat	780
acacacctgc	taaaaactgct	taaaacatta	gaaggacatg	cttatggcgt	tttttatatt	840
gcatggagtc	cagatgacaa	ctatcttgtt	gcttgtggcc	cagatgactg	ctctgagctt	900
tggcttgg	atgtacaaac	aggagaacta	aggacaaaaa	tgaggccagtc	tatgaagac	960
agtttgacaa	gtgtggctt	gaatcccgat	gggaagcgt	ttgtgactgg	aggtcgct	1020
gggcgtt	atcagtgtga	cttagatgtt	aatcccttgc	actcctggga	aggggtaaga	1080
gtgcaatgcc	tttgggtcgt	gagtgtatgga	aagactgttc	tggcatcaga	tacacaccag	1140
cgaattcggg	gctataactt	cgaggacctt	acagatagga	acatagtaca	agaagatcat	1200
cctattatgt	cttttactat	ttcaaaaaat	ggccgattag	ctttgttaaa	ttagcaact	1260
caggggaggc	atttatggga	cttgcagac	agagttttag	taagaaaagta	tcaagggttt	1320
acacaagggt	tttatacaat	tcattcatgt	tttggaggcc	ataatgaaga	cttcatcgct	1380
agtggcactg	aagatcaca	ggtttacatc	tggcacaac	tgtagtgaact	gccaattgcg	1440
gagctgacag	ggcacacacg	tcagttaaac	tgttgagct	ggaacccacac	gattccatcc	1500
atgatggcca	gcccctcaga	tgtggcact	gttagaatat	ggggaccagc	acctttata	1560
gaccaccaga	atattgaaga	ggaatgcagt	agcatggata	gttgatggtg	attttggac	1620
agacgacttc	tgtttaactt	aaaatttagt	gtatTTTaa	ggcttggat	ttggtgcaaa	1680
caaacatgt	tgatagctgg	acagacatgo	tcgtcatgaa	aaaagaacca	tttctgaagc	1740
ccgattgggg	ccaaacattt	acaccttgc	tcatagtaac	cagttgagat	gaagcacgtc	1800
gttagaacgt	tgttggacac	catgttgaat	tattccccca	tcgggtgtga	agaactgtgc	1860
tacatttcagg	cttaccatt	gaactcgtat	tatattttt	ttcccttc	gtcttttgtc	1920
tggcaggata	ccatTTTgt	tgtcttctgt	tgtatgaag	tttaaatgct	tgttttggaa	1980
actttat	acagttttaga	aggcttgata	gaaagagtgc	attagtctga	agagtataca	2040
ttggatagga	aagaatttcc	ttttttgtt	tctccaaatc	tttccgcctt	atttagctt	2100
agatcttgc	agctggttc	atggattcta	gccttgcgg	ttgcgcagta	tataactgatc	2160
cagatgataa	accagtgaac	tatgtcaaaa	gcactctaa	tattacattt	gacaaaaagt	2220
tttgacttt	tcacatagct	tgttgcggc	aaaaagggtt	aacagcacaa	ttttttttaaa	2280
ataaaat	aaagtatttt	aggattaaag	tgacttcatt	tgtatatact	tggaaatctaa	2340
accagctta	aaacagtttc	ctcaatgact	tagatacaca	gtataactgta	tgctcttctg	2400
gaataccaca	tgagacatgg	tcaaaaaacag	tgcttggaa	gacattacac	aagaaaattca	2460
gagtaatgt	ttgaagattt	ccccccctttt	gttttattcc	tgaaggaaca	tcagtacccg	2520
atcttgaaga	aattcaagat	tcaaaaaagaa	ttttaaatac	accaacatga	gacatcgta	2580
gtcagtgtt	tttcagtaaa	gcttggtcca	agttgttctc	aacttaggaa	gtaattttgg	2640
tgtgtatctag	aaaaagaga	ggaatcagcg	atacaaccac	tttggaaagt	tatgtataaa	2700
ttgaaattat	tagaagaatt	cagcaggat	cagacatact	taaactggga	ttaaaaacctc	2760
atagtcat	ttctttaattt	cccttaatat	tttgacat	aggatatact	aaatTTTaa	2820
aatattttt	ctcagttttt	tcagatattt	ccataactgaa	cctcattctt	aactggtgct	2880
gtggatagtc	tttcccttc	ccctccgtt	ttagtttaag	gaaaggttc	tttcatggaa	2940
a						2941

<210> 110  
<211> 710  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<223> Incyte ID No: 5782457CB1

```

<400> 110
ctcgccgtcg cctggccgtt gtcattgtcc ctccgctgtc acctttcaa gccccaggct 60
ggctgttca gaagccccgt acccccattga ggagtggac gtgccacaga tgaagaaaaga 120
ggtgtggagac ctcaagtacc agctggcatt ccagcgggag atggcgttca agaccatccc 180
cgagctgtcg aagtggatcg aggacggat ccccaaggac cccttcctgt accccgacct 240
gatgaagaac aaccatggg tgaaaaaggg caaatgcacc atcctgttag ccccgacccc 300
ggccctcttc acaccatctt gtgagaccac gccccggccc actcccacca ttgttaaga 360
ctgtggcccg ccccaactcac tccatctgtt gagtcccaact cccagccca cttccaccat 420
cctgtgagcc catggccggc cccactcaca ccaacctgtg agccccactc cggggcccaac 480
tcacaacatc ttgttaagact gtgccccggcc ccattcaactc catcctgtga gaccacgccc 540
ggcccaactc actctatctt gtgagaccac gcctggccccc actcccacca ttctgttagc 600
cccactcttg gcccccaactca caccatctta tgagcccaagc cccggccccc ctcccaaccat 660
cctgtqaacc ccactccact cgacgttat tacagtctgt aaaggtgtga : 710

```

<210> 111  
<211> 1351  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 760677CB1

<400> 111  
ccaggcctag tggatagaca gggtccaaaa tggaccctt ctaggctgg atcaccatgg 60  
ggcgcatg ggctgaggat tctcgagata ggacatcacc acggcagaga tggacagcct 120  
gagacaggag agaggtgtca gtctaggatg gccaggctgg gtccccccac cccttactca 180  
agagtcaatt gttctgttagg gcaagtctca catgaagcta ctcatcattt gtttcgtgtc 240  
ctccgagctc cgagagtgg caaagtgtat gaaggagcag tagacagcga cccaagcaca 300  
ccacttcagc tagggaaaga ccgatttaag gctgcaagga aggagtctg ggagcatggc 360  
tttccctgag ccaaagccgc ggcctccaga gctgcccgag aaacggtta agacgtgg 420  
ctgcgggcaag gggcagtgca gggcgttacg attaatgtg gatggcaatt actgcctgac 480  
gtgcggcagt gacaagacgc tgaagctgtg gaaccggctt cgggggacgc tgctcggac 540  
gtacagcggc cacggctacg aggtgttgg tgcggccggc tcctttgaca acagtagtct 600  
ctgtccggc ggcggggaca aggccgttgg tctgtggat gtggcatcg ggcaggtcgt 660  
gcgcatttc cggggccacg cagggaaaggta gaacacgggt cagtttagt aagaggccac 720  
agttatccctg tccggctcta ttgattccag tatccgtgt tgggattgcc gctcacggag 780  
gcctgagcca gtgcagacgc tggatgaggc cagagatggc gtgtccagt gtaaggtgtc 840  
agaccacgag atcctggcag gctccgttgg tggccgcgtg agacgctatg acctaaggat 900  
ggggcagctc ttctcagact acgtggcag ccccatcacc tgcacccgtc tcagccggg 960  
tgggcgtgc acccctgtgt ccagccttgg cttccacattt cggctccgg acaaagacac 1020  
aggggagctg ctggggcagt acaaggggcca taagaaccag gaataacaagc tggactgctg 1080  
cctgagcggc cgtgacacac atgtgttgcg ctgttcttgcg gacgggaagg tggtttctg 1140  
ggacacctggg gagggtgcgc tggctcttgcg cttgcctgtg gttccgggt tggtgcagtc 1200  
gctggactac caccacaacag agccctgcct gctgaccggc atgggaggca gcgtccagt 1260  
ctggcgagag gaggcctatg aggcagagga tggagcaggc tgaagccagg ggacccacca 1320  
acaggaccaa ggaccgagac acagacatgg c 1351

<210> 112  
<211> 1783  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1348567CB1

<400> 112  
cccacgcgtc cgccggacgcg tgggtgttgg gctgtggcgc gggctgtcc ccattccac 60  
gtgaagcgct acgcttagcat cgctcggtc gggctccca gtcgcggc gaggcgtccc 120  
ggcagcagcg ggggaccgga agtggctcgc ggaggctcag aagctgtcc cggagccgg 180  
cgtgtggcgc ctggagcgc ggtgacggcg ccatgtccct aatctgttcc atctctaacc 240  
aagtgcggga gcaccatgt gtatccctg tctctaattca ttttatgag cggccgtca 300  
tcgagaagta cattgcggag aatggtaccg accccatcaa caaccaggct ctctccgagg 360  
agcagctcat cgacatcaa gttgttgcacc caatccggcc caaggctccc tcagccacca 420  
gcattccggc cattctgaaa gctttgcagg atgagttggg tgcagtcgt ccgcacagct 480  
tcactctgcg ccagcgtcg cagacaaccc gccaagagat gtcacacgt ctgtaccaggc 540  
acgtggcgc ctggcggttc attggccgtc tcaccaaggaa agtcaatgt gcccggaaag 600  
ctctggctac cttgttgcacc caggctggcc tcattgttgcg ccaggctgtg ccaagttccc 660  
aaccatgt tttgggttgcg ggtgagccaa tggatgggg tgagctgtg ggaatgaccc 720  
cagagattat tcagaagctt caagacaaag ccactgtgt aaccacggag cgcaagaaga 780  
gagggaaagac tttggcttgcg gagctgttgcg agccagaaga gtcagccaa taccggcagg 840  
tggcatccca cttgttgcacc cacgttgcacc gtcattccgtt gatccctggcc ctggaccc 900  
gcccgtccga caccacaacat atccctactg gttggggcggtaaaaaatgtc gttgttttgc 960  
acaaaatgttca tgaacaaatc ctggcttgcacc taaaaggccca taccagaag gtcaccaggc 1020  
tttgtttca cccttcccaag gacctgggtgt tttctgttgc ccccgatgcc actatcaggaa 1080  
tttgttgcgtt ccccaatgttcc tttgttgcacc aggtgttgcg gggccatgttgc agtgcgtgtca 1140

caggcctcg cttcatgcc actggcgact atccctgag ctccctccat gatcagtact 1200  
 gggcttctc tgacatccag acagggcgta tgctcacca ggtgacagat gagacccctcg 1260  
 gctgtctct cacatgtca cagttccacc ctgacggact catcttggaa acaggaaacca 1320  
 tggactctca gatcaagatc tgggacttga aggaacgtac taatgtggcc aacttccctg 1380  
 gccactcgaa cccccatcaact agcatcgct tctctgagaa tggttactac ctggctacag 1440  
 cggtgtgaa ctccctgtgc aagctctggg atctgcgcaa gcttaagaac tttaagactt 1500  
 tgcagctgaa taacaactt gaggtaaagt cactgtatct tgaccaggat ggtacccatt 1560  
 tggcttctgg gggcaggat gtccagatct acatctgcaa acaatggacg gagattttc 1620  
 acttacaga gcatagcgcc ctgaccacag gggtggcctt cgggcatcac gccaaggttca 1680  
 tcgcttcaac aggcattggac agaaggctca agttctacag cctgttaggccc ctggcccttc 1740  
 tggatggaaac tggccctcat ctcagtagag gggtagaatt agg 1783

<210> 113  
 <211> 3453  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1751354CB1

<400> 113  
 ggcttgcgca ctacgtcccc agccagaggc tcctacccgg tcggggactt ccggaaacgcc 60  
 ggggtgttgt tccgggttgt gtccggctcg gggtaatagg gctgtgtctc ggccggccgg 120  
 cggccggcgag cagcaggggc atgagggcta acccgggaag cggcagctga gcggggccgg 180  
 aggagcgccg gtcccccgtgg atcccgagag tgcagagctc ggggcagggg ccgggaggcg 240  
 tgggggagcc gggccctccc ctcaaggaaacg tggcccccggg ccggaccggc ccgttagtgt 300  
 gaagcagctt caggttaggtg agtctgtgaa acaatatgaa gaggagaaaa tagctttta 360  
 agggaaattgg cccacacaaa ggtatggcctt cttggacata ccaactata ttctagctca 420  
 tattcgacag tcacatgtca ccagtgtatc cttggaaatg tttgatggatgg ttcttattga 480  
 tcataatgtt gaccttagaga agatcatcc tccttcaatg cttggagaca gtgggtcaga 540  
 aattcaggga agcaatggtg agactcaggg ctatgtatata gcccagttag tcgatattac 600  
 ctcaagttgg gactttggta tttagaagacg ctcaaaacaca gctcaaagat tagaacact 660  
 ccgaaaagag agacaaaacc agatcaaatg caaaaatatt cagtggaaag aaagaaattc 720  
 taagcaatca gcccaggagt taaatgtact gttgaaaaaa aaatctctca aagagaagcc 780  
 tccaaatttct gggaaaggat cgtatattatc tttttttttt gttttttttt 840  
 gaataaccct tttttttttt tttaacgtt attttttttt tgatggcaag ggtttttttt 900  
 aaccaagaag atcgatgtt acctcccttgc gactctggc caggacagac tgctggcaat 960  
 gaccgtggc acaatggcca ggcggcagggt gcaggacactg atcgggctca tctgctggca 1020  
 gtatacaagc gaaggacggg agccgaagct caatgacaat gtcagtgct actgcctgca 1080  
 tattgtctgag gatgtatggg aggtggacac cgatccccc ccgtgttgcattt ccaatgagcc 1140  
 cattcataag tttggcttca gtactttggc cctgggttggaa aagtactcat ctctttttt 1200  
 gacatccaaa gagtcaactt ttgttgcattt aaatgtctgtt catggattt cccttattca 1260  
 ggtggacaac acaaagggtt ccatgaagga aatcttactg aaggcagtttga agcgaagaaaa 1320  
 aggtatcccgg aaatgtttag gcccctgtttt ccgtttttttt aaggcagggc agcccaatgt 1380  
 cggccgttgcac ctggacagca cttttttttt ccagacggc tttttttttt tttttttttt 1440  
 cgagaacagt tcaagggcag acggggttttt tgaggaggat tcgcaaatgg acatagccac 1500  
 agtacaggat atgcttagca gccaccatca caagtcttccaa aaagtctggca tgatccacag 1560  
 actgcgttcc acaaccggcag tacacttggg tatctctggaa gacaaaggtag agatagaccc 1620  
 tttttttttt cttttttttt cttttttttt cttttttttt cttttttttt cttttttttt 1680  
 tttttttttt cttttttttt cttttttttt cttttttttt cttttttttt cttttttttt 1740  
 tttttttttt cttttttttt cttttttttt cttttttttt cttttttttt cttttttttt 1800  
 taaacttcacg tatcttaagca atcactttttt tttttttttt tttttttttt tttttttttt 1860  
 taccgtcaat gaaatgttgc tcaaggatttt cttttttttt cttttttttt cttttttttt 1920  
 cccggctgtac tttttttttt cttttttttt cttttttttt cttttttttt cttttttttt 1980  
 ccagaaggag aagaaatccg ggcaggcgttccaa acactggccctt ccaggcttcaat tttttttttt 2040  
 agtctggatc ctggcttgc gggccaaatgg cttttttttt cttttttttt cttttttttt 2100  
 tcgggggggg gccaggccctt ggcttactggc cacaggggcag tttttttttt cttttttttt 2160  
 tcggggggccctt cttttttttt cttttttttt cttttttttt cttttttttt cttttttttt 2220  
 agtggctttt cttttttttt cttttttttt cttttttttt cttttttttt cttttttttt 2280  
 ccaggccacctt tcaatgttgc cttttttttt cttttttttt cttttttttt cttttttttt 2340  
 tccttgcacac tttttttttt cttttttttt cttttttttt cttttttttt cttttttttt 2400  
 cttttttttt cttttttttt cttttttttt cttttttttt cttttttttt cttttttttt 2460  
 gaggatttatc tttttttttt cttttttttt cttttttttt cttttttttt cttttttttt

aagctatgtt	tcgatttctc	agaagaaaatg	tttaggtctt	agtcaatagt	tttaactatg	2520
ccattttttt	aaatgagtgc	atttgcttcg	agggtagtgt	cttactaaaa	gttaggaaca	2580
gagacctagt	ggtgtgtcca	aggccgtgtc	actttccccct	tcagcacacc	ccagcttctg	2640
acctcagagc	ccaggagctg	cgtggacagt	gtgggggtgcc	aggaggaggg	ggcgggtggctg	2700
gtcctcaggc	acgtcgact	cccaggccga	catggtcttt	ccgttttctta	agtgcagaat	2760
gttagtttca	gctggcagg	ccacctgtcat	gttctctgtct	tcgtgtccct	ggaagggggccc	2820
acattccccca	ttccctttt	cttacagcg	cgtgcctct	tttcaagca	ggcggaaagc	2880
tgctgtttct	cacgtttcag	ggagaggggt	gagcggaggg	agacctgtgt	ccgtgcgcgtc	2940
cggctccctg	ggtggaaaca	ggcaagggat	cagatggccc	tgacaccacg	cctctggcca	3000
caccagatgc	ctctgcagtc	ctcgacagcc	tcttcagtgt	ccctcctgcg	gtgatgtcct	3060
tactgtcccc	agccaggggcc	ggggaccgggt	gtttcaactga	ggacactgcatt	tagaaacatt	3120
ttttaaattt	ttgtacagga	agagatgtgt	ctaaaacagc	atcttaaagc	tgatgtgtatt	3180
tctttgcaca	aggggtcatg	ctgtatgaatt	cttcttccat	tctgtatttt	gttcagccaa	3240
caggaggtgc	cttttctta	gtcttccat	cctacccccc	acccaaaaaaac	aaaaaaaataa	3300
ttttagctt	gtctatgtta	tttgaatttt	tagcaatttt	atatttagat	actttgaaaa	3360
atgttaatgt	ctaatttgg	cattaaatct	tgtgacatat	tcgatattaa	aatgatatta	3420
aaataaaaatg	catataaata	cacaaaaaaaaa	aaa		"	3453

<210> 114  
<211> 2663  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Invcte ID No: 1976780CB1

<400> 114  
 gaaaaaagggtt cgaaaagaact ggttgtcttc ttggggcggtg ttgcagggtt catctttact 60  
 ttttacccaaa actcaaggaa gtagcacaag ttgggttggc agtaatcagt ccaaaccaga 120  
 gttcacagtg gacctcaagg gggcaacaat tgagatggct tcaaaggata aatcccgaa 180  
 aaagaatgta tttgagctga aaactcgta aggaacagaa ctgctaattc agtgtgacaa 240  
 tgacactgtt attaatgatt gtgtttaaagt tcttagtagt acaatcaata atcaggcagt 300  
 agaaaactgtt gaagaattg aagaggagat accggattca ccagaataag aaaagcatga 360  
 taaaagaaaag gaacaaaagg atccccaaaaa gcttcgttcc tttaaagtat cttagcataga 420  
 ttcttcagaa cagaaaaaaaaa ccaagaaaaa cttaaagaag ttcttacac gacgccccac 480  
 tttgcaagct gttcgtaaaa aaggttatat taaagatcag gtatggat ccaatctcgc 540  
 taatctgtt cagagagaga atggcacagt accaaagttt gtgaagttat gtattgaaca 600  
 tggtaagaa catgtttgg atattgtatgg gatatacaga gtaagtggca acctcgcagt 660  
 gatccagaaa ctaagggtt cagtcaatca tgatgagaaa ttgactgtt atgacagataa 720  
 atgggaagat attcatgtca ttactggac cctcaaatg tttttcgat aatttaccca 780  
 acctctttt acatttaatc attttaatga ttttgttaat gcaattaagc aagaaccaaa 840  
 acagcgatc gctgtgtt aggacataat cagacatgtt ccaaagccaa accaagacac 900  
 aatgcagatt ctttccgac atctcagaag agttatagaa aatggagaga aaaatcgaat 960  
 gacctatcg agtatacgaa ttgttttgg tcccactcta taaaaccag aaaaagagac 1020  
 tggtaatata gcagttcata ctgtgtacca gaatcagatt gtagaattaa ttcttctgga 1080  
 actgagttcc atcttcggac gttgattctt actgaagaca acctgtggaa tagaagctgg 1140  
 attccatcg atttcaaattg ttatcacaca atgtattttt tttttggac caagcagtga 1200  
 ctctttgatt ttgcactttt ttttgaggg atcagaaggg aaggggagag tcgagatgt 1260  
 tggtagggcc tcattttgc tgctttgtt caagttgata taactcggtg taattatgaa 1320  
 ttccattttt cctgaatgtt tgcatattcat actctgaatt tcagttaaaaa taaaaacttca 1380  
 aaattctaac cagtcataat cactggataa ttggtaaga aaactgtatt tttttccct 1440  
 gaaattggat aatgtacttt cttctcaaga ttcatgactt gatagaacaa tactttcagt 1500  
 tatgttgc当地 aggtcttgg gcattttaaa caaaatgaag tatatccatt ttgaaacctg 1560  
 tgtattttttt ttccgggtt tctgcatttca gttggcgtt taagtggccaa aatttattat 1620  
 aaccccaaaa taaccccttg atgaaggctt gctgtctttt actgtgttac acagcatct 1680  
 tactggatatt ctttagttgtt tggttggca gcacactaat attacttaaa acactgtgt 1740  
 atactggagt ttttagtttagc ggaagtcaagt tcagggcatt ttagggctgt cttgtatata 1800  
 tgaattgttag ctaacaatcc taatttatattt tagtacata ctgaggattt ggtatgaccc 1860  
 tggtaaaca cacattttt tagttaaaa taggtttaaag acttaatgtc ctttagcttg 1920  
 tggatataat tggttgtat agtctcagag tacattctaa ccctacattt ctaatcattt 1980  
 ttatggtaa tttttctgtt gaatattagg ttccctccag aaatggtccg ttatgggaa 2040  
 aagtttaactg tggcacttt tagatattaa ctacatttac aggcaaatca ctgtatag 2100

aatggtactg	aaaaaatact	aatagactt	gctaaatggc	acatgcacta	caagaggaac	2160
cttttgggtt	atthaatatg	tacagaaaac	attagaaaaa	atttattaca	gaattctaatt	2220
tccagtatga	atagtggaaa	cccatctgt	aatttagatgg	atgttggatg	aaaaatgaca	2280
ttgctaaatt	tgagaatttc	tttttaccta	ctaattgt	ttgttggatg	taataaaaaca	2340
cagggttgg	aagggtttgt	tacagggagc	atggctgtt	gaagatttt	aaaaatgttt	2400
tttctgatt	aacctctgt	catgaaatgt	ctaataaaaac	tataaagggt	ttagagattt	2460
ttccatttgt	aatgtcgatt	ttgttttctta	attttttgtt	tttttcattt	actggcatac	2520
tgttatatcc	cattttaaa	aatcaactga	atccaatatt	tcctgtggca	ataaacactt	2580
tcctcatttc	ataccctttc	tcctcttctt	catgccaaca	tttctccacc	cacaacgtac	2640
actgtttatt	tctcatcaat	att				2663

<210> 115  
<211> 1218  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incvte ID No: 2048234CB1

<400> 115  
gcctgttca gccatgggtgc attgcagttg cgtgttggc agaaaagtatg gaaatttcat 60  
cgataagcta agactcttca ccaggggagg atccgggtga atgggttac ctcgtttagg 120  
tggagaaggt ggaaaaggtg gtatgtctg gttttagcc cagaacagaa tgactttaaa 180  
acaataaaaa gacaggatc ctccggaaacg gttttaggtt ggagtaggag caaacagcaa 240  
aattagtgtca ctgaaaggct cccaaaggaaa agactggaa atccccgtgc ctgtgggtat 300  
ttcagtaatc gatgaaaatg gtaaaattat aggagaactc agtaaagaaaa atgacacaaat 360  
tttggtagct caaggaggct ttgggtgtaa attacttaca aatttcttac cattgaaagg 420  
ccagaaacga ataattcacc ttgatctaaa acttataagct gatgtaggcc tagtaggatt 480  
ccccaaatgtc ggaaaatctt ctgtgtctaa tttgttttct catgcaaaac ctgcaattgc 540  
agattacgc tttcacacat taaagctgaa gctcgaaag ataatgtaca gtgatttcaa 600  
acagatataa ttagctgtat ttccgggtt aatagaagga gcacatatac acaaaggaaat 660  
ggccacacaa ttccctcaagc atataaaaaa aactagacaa ctacttttg ttgttat 720  
ttctggattt cagtttctt ctccacactca atacaggaca gctttgaaa ccataataact 780  
gcttacaaaa gagttggaat tgtaaaaaaa ggaacttcag acaaaacctg cactcttggc 840  
agttaaaaa atggacttc cagatgccca agataaggc catgaattga tgagccagct 900  
ccagaatctt aaagatttc tgcatattt tgaaaaaaac atgttccag agaggactgt 960  
agagttccaa catatcatcc cccatctgc agttacttgg aaaaaatctg aagaattaaaa 1020  
gaatttgtata agaaatgtc tggatgaaaca ggccaaaccc gaaaatgtatc cacttcataa 1080  
gaaacagttt cttatatttgg gatattctga tacaatgtct tctactgagc caccatcaaa 1140  
gcatgctgtt actacttcca aatggatata aatttaaata tttttttttt ggtattgtat 1200  
qaacagtaaa aaaaaaaaaa 1218

<210> 116  
<211> 1286  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2111754CB1

```
<400> 116
ccgcctga acttctggac tagccccctcg attgttgtag atgccaagcg gacctcgcg 60
cgctctgcgt tggggcagcc cctcacagct ggtttcttac cacgtattgc gcaacggaa 120
ctatgcctgt tacccacact ccctgcgccc ccgcaccccg ctccgtgcg caagtccgaa 180
tataaaaacccg cgaggaggatg agctcttggg gtgtcccaattt gggtcccgcg gcaatcttc 240
cgagcagcgc atttgtcttc taggtctgtt gggttcgtcc tccgagaaag gggtgtctc 300
ctgcgcgacta agtgtgggag aacttgcgta cgtatctccc ctccgaatcc caacatggg 360
taacgccagc ttgtgtctcca aggaacagaa gctgctgaag cgggtccggc ttctgtccgc 420
cctgtttatc ctccgcgcct tcaagccccca caggaagatc agagattacc gcgtcgttgtt 480
agtcggcacc gctgggtgtgg ggaaaaagtac gctgctgcac aagtggcga gcggcaactt 540
ccgtcatgat tacctgcccga ccattgaaaa tacctactgc cagttgtctgg gctgcagcca 600
```

cggtgtgctt	tccctgcaca	tcaccggacag	caagagtggc	gacggcaacc	gcgctctgca	660
gcgccacgtt	atagccccggg	gccacgcctt	cgtcctggtc	tactcagtca	ccaagaagga	720
aaccctggaa	gagctgaagg	ccttctatga	gctgatctgc	aagatcaaag	gtaacaacct	780
gcataaggtc	cccatctgtc	tggtgggcaa	taaaagtgtat	gacaccccacc	gggaggtggc	840
cctgaatgtat	ggtgccacct	gtgcgtatgg	gtggaatatgc	gcctctatgg	agatttcagc	900
caagaccgt	gtgaatgtgc	aggagctgtt	ccacatctgc	ctgaattaca	aaaaaaagcc	960
caccaccggc	ctccaggagc	ccggaaagaaa	atccccatgc	cccaacacca	ctggagaagct	1020
gcttgcacaaag	tgcataatca	tgtgaggccct	gggccttaag	agccagctct	ttcttatccctg	1080
tagctgttag	aaaacgttga	ctcattttcac	tatgttacat	gtacatggtt	gattttgtgc	1140
tgttgttgg	actgttaacat	ccatgttgc	aatacgtata	ccttgcatagt	ggataacttt	1200
tctttttccc	aggccagaga	attcaaatttgc	ttaaaacatttgc	ggcatttgaa	gaggagaaca	1260
aaatgttagca	tgtatgtattt	aaagta				1286

<210> 117

<211> 3057

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 2123286CBI

<400> 117

caaggctccg gcctgcgagg agtcacatta acttgcctt agaagacaac ttacadaaga 00  
tctaaaagga acaggattaa agatgactga atactgggtt ccagaaattt aaaaacaatca 120  
gcttagcaa tcatatattc ttctgtggag ctgagaattt atgtccgctc ttcccccgtga 180  
tttggaaactt tccaatccca gagaaaaattt gacaaaaggag ctgcccaggag ctgagtccat 240  
atggagaag aacttcctct ttctcttggaa gacagtggca agccagtaca ggctactctg 300  
tcatcttga agatgttaga tggtggaaag tggccaattt ttcccttgg ttctgaagaa 360  
gaactacagt taattcgta ggcttgcgtc tttggcagtg ctggcaatga agttttatac 420  
actacagtaa atgatgagat ttgtgtgtt ggcacaact gctgtggctc ttgggggtt 480  
ggtgcacgtcc agagaccat tgaacctcggtt agactggatt cttaaatgg caaaaaaaaa 540  
gcctgcctca gctatggag tggtccacat attgtcctt caacaacaga aggagaagt 600  
tttacccgtt gtcataatgc ttatagccag ctggcaatgg ggacaactaa tcattgttta 660  
gtgcctgtc atatctctac taatctgtca aacaaacaag tcattgtttaa tgccctgtggg 720  
tcttaccatt ctttgggtt aacatctgtat ggagaggat ttgcctgggg ttataataaac 780  
tctgggcagg taggatcttgg atcaacagtt aatcagccaa tccctcgaag agtcaactggc 840  
tgcctacaaa ataaaagtatg tttgaccata gcatgtggc agatgtgtc catggcagta 900  
gttagacacgg gggaggctta ttgtctgggt tacaacggaa acgggcagct tgactcgcc 960  
aacagtggca accagccaa cccctgcaga gtggcagtt tgcaaggcat ccgtgtccag 1020  
agggtgcgcct gtggcttaacg acacacatc gatthaacag atgaaggcc agtgtatgt 1080  
tggggcgcctt attttatgg gcaatggggc actcgatcc atcgacatc aacgaaccca gtcctatctt 1140  
actctctgtca ctgtggaaaaa gggaggatt atcgagattt cagccgttca cttcacacac 1200  
acgtctcggtt ccaagacgca ggggtggcactt gtttgcattt tggtacatgt gggggcagtg 1260  
tccgtatcc tcccccaactt caccacttc tccctgcactt acgacgtt tgccctgttt 1320  
gccacgcggc cggcacgtg ggccttcctt tccgtggaa ctgatgacca cctcacagtg 1380  
gctgagtcac tgaagaggga atttgacaaac ccggacactg cagacctgaa gtttctgtt 1440  
gatggaaagt acatttatgc acataaaagtc tttctcaaga ttccatgttgc gcattttcgt 1500  
tcgtcattgg aagataacga ggtatgtatt gtagaaatgt gtgaattttt atatctcttt 1560  
taccgggcct tccttggaa ctatatacaca gacagcatc gcctttcc tggaggggca 1620  
gttaggtatgc tagactttgg tacatctttt agaaaaaaatc gtttggaaaaa gctctgccaa 1680  
caaactatca agcaaggcat ctggcaggag aatggccatcg ctctgtctc ggctgcggtg 1740  
aagtatgtatc cacaggattt agaagaattt tgcttcaggat tttgcataaa ccatctgact 1800  
gttagtaacac aaacatcagg ttttgcagaa atggaccatg atctctgttgc gaaactttatc 1860  
agcaaagcaa gcagagttgg agcctttaaa aattgatccc atctgcaggaa aatgttttga 1920  
gcctttccat ttccctgtca aaagccagag atgaatcatc tctctttaat taatgtatg 1980  
tatgtatgtatc tatgtttggc tgtagtacttg taactgtcg aagaaggatg gtgggtgggt 2040  
gtctttgtct gcctaaaccc agatgtttttt tagaaagcat tgaatgttcat gatcaggatgt 2100  
gactaagggtc aaggaaaaaaa aatttggaaata tcttattttac cattttctt ttttgggtca 2160  
cttaaatttgg acacctttgg taccctggc ttagtataatc ctattcttgc ccaaatgttc 2220  
cattatttcgat ctggctgtata cccatagat agcttgacaa ggaggctgtt ctgtcccttac 2280  
cacattttca gcactcagca cagtgcccttgc ttttgc ttttgc ttttgc ttttgc ttttgc 2340  
cttcagatgtatc tccttggaaac agcttttagtc atggaaatact gggagaagga ataactttca 2400

caaaaataaac taaaacagg ctgtaattat tgaggttcat attcttctgg tatatcattc 2460  
 tgagaaattg tggctaattt agaacattgt tttagaattga caaaaggccc tggcaattaa 2520  
 attgtcaagg cccaagggcgt aatttttaatt ttcttttac ttggagtcat tcattaattt 2580  
 ctacatggg attatggagt atgaagtatt atctttgaat gaaattccctg ggctgatctg 2640  
 cttacataaa tcacataagg tcctttgtt ttctttgtgt taagaggac ttgcctctgt 2700  
 aaatggaaat gacaatgtgc ttttcttgc gttgactttc atgtcactca ctataaaata 2760  
 ggtctcttaa cttggcacca gtataactat aaagcactag ctgagaagga actgataactt 2820  
 acatttcattt gacagcatta acaagaatga gataaatttg tacttttag atcaaaccac 2880  
 attacctaattt tgcaaaagag aaactgaaat ggaacatagt cttagatttct tctaattgtgt 2940  
 attcacaat gtcataatgt gtaaaggaaa cccttttggaa attagaatttctt ttgttctgtat 3000  
 gctgaactat ttgtaataaa agtgcttattt tgcaagataac agaaaaaaaaaaaaaaa 3057

<210> 118  
 <211> 1803  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2477507CB1

<400> 118  
 ggtcgccggcc ttcacgggtt cctcgccgt cctgagtcgg aaatcccaag ctggagccgt 60  
 tcagctcccc tccaccgtt agagatttg ggggctctgg ccccgctcgtt gcggaccatt 120  
 ccgaggggag tccagaggtt agggcagggaa acotccctga ctttgcgggg cgccgcgtc 180  
 ctgcgtctcc tgccagtctc ctttccttctt ttccgttcaa caattgaaaa caaaacgagg 240  
 aacagcagag gagctactgt ataccggccctt ctcagcattt ttcgttaatctt ccgcctgtca 300  
 acagccttgtt gaagaagggtt ctatctttt caacacttta cagatggaa cacttgggt 360  
 tcgagacgt ggagcccttgc acagctgc ttaatgtgtt gtagagccga gatttgaacc 420  
 ctccatacca ttcccttgc cccctactt cagctccctt cagatgtat tgaacttttgc 480  
 ctccgggttag ggccccccagg tgcgttataat taacactgtt gataaccttcc atgaggacat 540  
 gattcacgac gcccagatgg actactatgg caccggccctt gcaacctgtt catcagacag 600  
 gtcgtcaaa atctttgtt tgccaaatgg agggcagatc cttatcgccg acctcagggg 660  
 tcatgagggtt cctgtgtggc aagtggccgtt ggctcaccccc atgtacggca acatcctggc 720  
 atcgtgtcc tatgaccggaa aagtccattt ctggagagag gaaaacggca cctggagaa 780  
 gagccacgag catgcgggac acgactctt cgttgcgttccatcgttgc gttgtctggg ccccccattga 840  
 ctacggccgtt atccctggcgtt gttggagctt ggtggggccctt atctccctgtc tgacttacac 900  
 cggggaaaggcc caatggaaat taaaaggat caacaacgtt cacaccattt gctgcaatgc 960  
 cgtcagctgg cccctgttgc ttgttacctgg aagccctata gaccacccat cggggcagaa 1020  
 acccaattttt atcaagaggtt ttgcatttgc tggctgttgc aaccttcatca agctgtggaa 1080  
 ggaggaggag gacggccagt ggaaggagga gcagaagctt gaagcgcaca gtacttgggt 1140  
 tcgagatgtt gcctgggccc cctccatgg cctggccacc agcaccatcg ccagctgttc 1200  
 ccaggatgtt cgtgtttca tttggacccgt tgatgttgc tcaaggaaata cgtggcccc 1260  
 taaaattgtt cacaagggttca acgtatgtgtt gttgcatttgc agctgttgc tcaacggccaa 1320  
 catcctgggtt gtctctgggtt gagacataaa ggtgaccctt tggaaaggagt cagttgttgc 1380  
 gcaatgtgtt tgcatcattttt atgtcaacaa gggccaggcc tccgttatcatc catcattgttgc 1440  
 agagggccatc cagaacggatc agtgcataatgg caggtggggcc ctggctcccc acccgccagc 1500  
 tccaggactt ccccttccttggccactaa ccagacaactt gggaaaggcc cccaaacttca 1560  
 acaggattttt tttccctggaa ggagtttacatc atgcacccatc agattgtatca tctgcctttaa 1620  
 cgtgtatggaa gatgtttttt aatctactgtt ccagctgaaa gcacttcatgt tacggagga 1680  
 aaactacaatg ttagtggccaa atcttattttt ggtcattttt atgttacccctt gggttcaggc 1740  
 attatgggggg ggtttttttt tccaaaggaa ctaaaataaaatc tcatattgttcatataaaaaaa 1800  
 aaa 1803

<210> 119  
 <211> 4407  
 <212> DNA  
 <213> Homo sapiens  
 ;  
 <220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2759119CB1

<220>  
<221> unsure  
<222> 4373, 4379  
<223> a, t, c, g, or other

<400> 119

ggtcgtcatt ggacaaccgc cgcgcccccc tggtctctgc tacctgtac tgagggtgct 60  
gttcatgggc agcgccgcg cgtggaaagg ctcgttctcg cgagagttca gctcccttct 120  
ataccctgtt ctgcctcagc acctcgagga tcgacatgga cgctctcgag gactacgtt 180  
ggccgcgggc aacctcgag cttatactcc tcccagtac gggcttgagat tgcgtgggg 240  
accggctgtt ggcgggtgag gttcccgatg tccctggta cagcttgac tttgggtggc 300  
atctcgccat gataaagcga gtgcagaacc tgcttggcca ctatcttatac catggcttc 360  
gggtacggcc agagcctaat gggacacccctt acttggaggc catggtggtc gtgtttggaa 420  
gcaagggtt ccggatgtt aaaaatttagct ggggacaggc ccacattctgg gagctttggc 480  
gctctggct gtggAACATG tctgactggg tttggatgc acgctggctt gaggaaata 540  
tagccttggc cctggggcac aactcagtgg tgcttatatga ccctgttagta ggtgtcatcc 600  
tgcaagaggt gcccgtcaca gacagggtca ccctcttcc agcgtgcctg attggagacg 660  
cctggaaaggc gctgaccata gtggcagggtg ctgtttccaa ccgacttcttg gtcgtgttacc 720  
cagcaactgc cttagcagac aacaaacccctg tagcacatgga ccgacgaate agtgggcatc 780  
tgggcattcat cttcagcatg tcatacttgg aaaaacaaaggg attgtgtgtt ggtgtcatcc 840  
aagaccgaag cgttcgttgg tggaaagggtt ggcacccgtg agtgcctggg ggtcgggtgc 900  
agaatattgg gcaactgtttt gggccacaggc cccgtgtgtg gcaggtcaag cttctagaga 960  
attaccttat cagtcagga gaggattgtt tctgcttgggt gtggagccat gaagggtgaga 1020  
tcctccaggc ctttccggga caccaggggac gtgggatccg ggccatagct gcccattgaga 1080  
ggcaggcctg ggtgatcaact ggggggtgatg actcaggcat tcggctgtgg cacttggtag 1140  
ggcgtgggtt ccggggattt ggggtctcggt ctctctgtt caagtcccgat ggtggatgtt 1200  
gtacactcaa ggctgtact ctggctggctt ctggcgact gtcggactg gtcgtgttacc 1260  
ggggccctgtt tctctatgac gtccagggttca agtgcgttggg gcaactgtt gaggataaac 1320  
atttccagtc ctactgcgtt ccgtggggatc ctccctggatcc cgagggcttc ggattgtgtt 1380  
ctatggccaa tggggaaagggtt cgtgtcaagg ttgtcccat caacacttcca actgctgtt 1440  
tggaccagac cctgtttccctt gggaaagggttgc acagcttggat ctggggccctg cgtgttatg 1500  
aggagcttctt gttgttggca tcggggccctt ggggggtttagt agcttgcctt gagatctca 1560  
ccgacccttc tggcaaggcc atctttgtca aggaacatgtg tcgttacccctt ctggccctt 1620  
gcaaggcagag atggcacaca tgcagtgcctt tccttacccccc aggtgacttcc ctgggtgtt 1680  
gtgaccggcc gggctctgtt ctgttattttcc cctccggaccc aggtgttccctt aaggaccctg 1740  
gggtggggagg caaggctcggtt gttgtgttgc gggccatgtt agtgggtttagt ggttagttagt 1800  
gggggtggggaa tgcttctactt ggggtggccctt cagtgttcttcc cctggcccttctt ctgcacggga 1860  
agcagggtgtt gacccatgtt acatgccatg gtggctatgtt gtataccata gggcgtatgt 1920  
gagcctacta ccagctgtttt gtacggagac gccagcttcca gccagttccat aggccagaat 1980  
cctgtcgagg catgaaacttcc ttagctgggatcc tccgtatagt gcccgtatggg agcatggta 2040  
tcctgggtttt ccattgttcaat gagggttgc tttggaaaccc tcgggtcacac gagaagtcg 2100  
acatcgtaa ctgtgttgggaa gggccacccgtt cgtggccattt ctctgttactt gggccgtt 2160  
tggcccttgc ttacctcaag gatggggatcc tcatgttgc tccggctctt ggtgttccctt 2220  
ccggccaca cgttattttcc cgggggggtt tgcgttggcc ttagatcaactt ggtgtaaagc 2280  
gtgtggggac cattaccctt gggccatgtt atgggttgc cagttcatg cagccctgtt 2340  
acctggagcc tggcagtgtt gggccggactt tgactgtacat tttgtatcaca tttgtatgtt 2400  
acactactgt ctgtgttccca gcaactccctt caaccacagg cttagcccttcc gcaactcacat 2460  
ctgtttgttccat ccattatctcc tcggtacgtt ctgtggctgtt gttggggatcc ggcacccctt 2520  
gtggccctca ggatcccttag ccaggcccttga ctggccatgtt ggtgttctgg ggggggggggg 2580  
ctgagatgtca ctgttccatcc atcatgttta ctccggaccc cagccacccca agccgttccctg 2640  
cctggccatgtt catgacccatcc tttgttccctt ggttagatgtt gttttggggatcc cggccaaacgc 2700  
atccggatcg gatgggtttagt gtagggccatcc agacccatgtt catgttccctt gttgtgttgc 2760  
aacttggacca gcccggccctt gggcccttgc tggctgttgc ctgtgtttagt gggccgttac 2820  
gctttttttt ttggcaggattt ctggggggat tttgttgc tttgttgc gggcccttccatcc 2880  
taaggcatgtt gtcttcaagg ttttttttttcc tacacacgg gcaacccaaacc agaggccggag 2940  
gctccctcttgc tggcaggccatcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc 3000  
gttagaccat gactccactg ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc 3060  
tggcacccttcc tcccttgc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc 3120  
gcccacccgtt gaggccggccatcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc 3180  
cttctgttccatcc gttgttgggatcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc 3240  
accccgactg ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc 3300  
aggcctcaag atcttaagcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc 3360  
cttctggcgtt ctggggatcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc ttttttttttcc 3420

tgatgtggct gacatggact gctggcctgt gaggccctgag tttggccacc gttgtgccct 3480  
 tggggtcag gggcttgagg tttacaactg gtatgactga ggtatcctgc ggtggctggc 3540  
 gtgtctggca tggggcctgc tcacagacag catggagcag ggaagggctg tctgtgccca 3600  
 tgctcagcat gcctttaggg gaggaggtgg tggccgtgg ttccctgatgt cggtgccagga 3660  
 gctgaagggt agtggagtgc tgccaagaat atgcccact ccccatgaca agacagaact 3720  
 ttgttaaaaa cagtagccaaat ttatTTTGGC cgtgggtttt tgctttttt ccagttgatg 3780  
 actttgtgaa cattccccagg tattggagcc tctgtggct taaaatgtggc tcagtggagg 3840  
 gagaccacgc atagccaggc cagtagggag cacccacgc acagctctca gaagctcgag 3900  
 gcgacgaaac atctgaccaa agaggtgtgg tcgaggctcc taaaagagaaa agggcctgct 3960  
 ggctctatcc tctgttttac ttgcctttac cctataccctc tctgcacgtc ccaccccggt 4020  
 ttgtctgtg ctcaccccca ggtatgttac ccgttggtag taggagctga aatccatgtct 4080  
 gagctgtacc aggaacctgc atatcttagag acagagactg agtcaactggc ccatctctt 4140  
 gctcttgc cccaggccag aataaagaat agagtgtaga gtgtcctggt tgtctatgccc 4200  
 tcaccatctc tggctgtaca gcaatgtgg ccccggggt gtgcagtcca gcactgtgt 4260  
 ccggctcagc agatccggaa agggaggata ctgttgaaga gcaacaacca ctcacccctgt 4320  
 ttggggagaa aagtgtttgg aaggggatc caggctcctt gtgcccgtaa cangagggnc 4380  
 aatcaactcat catgttagcag tgagaag 4407

<211> 120  
 <211> 959  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2823818CB1

<400> 120  
 cccacgcgtc cgccccacgcg tccggggagcg tggagcgccg ggactgtgca cgcttgaccg 60  
 gaagcccaga ccagtgcgtt cctagccaga gagaaggac atttgcacac aatgagacac 120  
 gaagcggcca tgcagatggc ctctgcccac gatgccaggc acggccagaa agactccct 180  
 gatcagaact ttgactacat gttcaatttca ctcacatcatcg gcaatagcag tggggggaaa 240  
 acatcttttcttattccgtt tgcaaatgttgc tcctttacat ctgcatttgtt cagcacagtt 300  
 gggatcgatt tcaaagtaaa aactgttattc aaaaatgtaa agagaatcaa gcttcagatt 360  
 tgggacacag caggccagga aagatacagg actatccacca cagccatattt tcgtggagcc 420  
 atgggcttta tttaatgtt tgacattaca aatgaagaat ccttcattatgc agtacaagat 480  
 tggcaactc aaatcaaaatc atactttgg gacaatggcc aagtttatttctt ggttggaaac 540  
 aagtgtgaca tggaaagacga gcgggtcattc tcaactgagc gaggtcaaca tttaggagaaa 600  
 cagcttgggt ttgatTTTTTGAAACAAAGT gccaaggaca acattaatgtt caagcagaca 660  
 tttgagcgcc ttgtggatat catctgcgc aaaaatgtcg agagtttggg gactgtatctt 720  
 gccatcaactg ctgcaaaagca gaacacgaga ctcaaggaaa ctccctccccc accgcagccc 780  
 aactgtgcct gctagtgccc ccgtgcacac aggccgtcc agggggctct ggttgcacac 840  
 aaacagcatt tggtaatgtt ctattagct tcattttatc tgcctaacaat ttatttgaag 900  
 gaataaaattt atgtcaatgg ctgtaaaaaa aaaaaaaaaa aagtaaaaaaa aaaaaaaaaa 959

<211> 121  
 <211> 1809  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2859730CB1

<400> 121  
 ggcagcggtt ggaggcttgc cccggctttg cagcggggac ttcggcgccg gcgcctcagg 60  
 cacctcgccc cggacacgtt gaggcgatgt gtacgcacaga gcaatTTTGCA gcatgtatTTT 120  
 gggcaagcggtt tgaaaaatgtt ccagtgttat gatgcacatcc gggTTTCTCG tggacactgg 180  
 gatagttccct ttgtgtgtt caatcccaga ttgttgcac taatcataga ggcaagtggg 240  
 ggaggagcgtt cccttgcgc aagactgttc gaatttgacaa atcttaccct 300  
 acagtatgtt gcccacacagg accagtgttgc gacatagact ggtccccaca taacgtatcg 360  
 gtcattgcacca gcggttgcaga ggactgcacg gtcatgttat ggcagatccc agaaaaatgg 420  
 ctccccctttt ccctgtactga acctgtggtg attttggaaag gcccactcaaa gagagtccgc 480

atcggtggctt	ggcatccaa	ggccccgcaat	gtgcatttta	gtgcaggctg	tgataatgcc	540
attatccatct	ggaatgtggg	aacaggggaa	gcccttataa	acttggacga	tatgcattca	600
gacatgattt	acaatgttag	cttggaaaccgg	aatggcagtc	tgatctgcac	agcttccaaa	660
gacaagaaaag	tgagagtcat	tgtatcccagg	aaacaagaga	ttgttgcgtg	gaaggagaaa	720
gcacatgaag	gagcaagacc	catggagagcc	atcttccctgg	ccgatggcaa	tgtcttcacc	780
actgggttca	gcccgcattgg	cggagccgg	ctggctctt	ggaatccggaa	aaatatgcag	840
gaaccaatttgc	cttttgcattg	gtggacact	agaatgggg	ttgttgcgtcc	tttctatgac	900
cctgacacacca	gcattttttttt	ctttatgtggaa	agggtgtaca	gcagttttcg	ctatttttag	960
atcacggatg	aatccccgtt	cgtttttttttt	ctcaacacat	tcagcagcaa	ggagcccttag	1020
agagggatgg	gttacatgtttt	caagagggaa	cttgatgtta	acaaatgtga	gattggccaga	1080
ttcttcaaac	ttcatgtttttt	aaagtgtgaa	ccttattttt	tgactgttcc	caggaagtct	1140
gacctttttcc	aaatgtttttt	gtatctgtttt	acagcggggc	cagggccgc	gttggaggca	1200
gaagagtgtt	tgcgtttttttt	gaatgtttttt	ccaatctttt	tcttcgttta	gcacgggttc	1260
atcccgatgtttt	aaaacgggtttt	gtttttttttt	gtcaagaaaga	acattttttt	tagcaagcccc	1320
actgcacaaata	agaatgtttttt	cctttttttttt	atcccccaaga	aaaccacaga	cacggccagt	1380
gtgcacaaatgtt	aaaggccatgtt	ggatgtttttt	ttaaaaagaga	tcaaatcttat	aaaagacaca	1440
atctgcattttttt	aaatgtttttttt	tattttttttt	tttagaacacg	agatggcaaa	gatagcagcc	1500
tgcgtttttttttt	accccccaccc	ctttttttttt	aatggggatca	agaactttgt	tttggggagct	1560
ggtttattttgtt	gttgcattttttt	ggagggccgg	aaaggagggca	ctgcattttt	gagacatttc	1620
atttcagattttt	tgtaaccatgtt	cgataggccca	cattttttttt	agaactcaat	tttgtcttcctt	1680
aattttccatgtttt	aaacaaaatgtt	gattttttttt	ctggatctttt	tatcagaaag	ttttttttgt	1740
gtttttttttttttt	ttatgtttttttt	ttttttttttt	ttttttttttt	gtctacttttta	aaatcccaga	1800
tactctgtttttt						1809

<210> 122  
<211> 2028  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2861155CB1

<220>  
<221> unsure  
<222> 1943, 2003  
<223> a, t, c, g, or other

<400> 122	tggcggggttc	cgtgggtcgc	ccgcgaaatc	tgatccggga	tgcggcgccc	caatcggaaag	60
gtggaccgaa	atcccgcgac	agaagaggc	ccgttagcgac	ccggcgtgtct	aaggaaacaca	120	
gtgctttca	aagaatttgc	gtccgctgtt	cgccctctct	ccccggagtc	ttctgcctac	180	
tcccagaaga	ggagggaaagc	acagggtgggt	ttcttttagt	tcgcgtcgga	tccctgagaaa	240	
cttgcgaagcc	atccctggctg	aggttaatct	ccgctgtgtct	tcctctgcag	tatgaagact	300	
ttggagactc	aaccgttagc	tccggactgc	tgtccttcag	accaggaccc	agctccagcc	360	
catccttctc	cccacgttcc	cccgatgaat	aaaaatgcgg	actctgaact	gatgccaccc	420	
cctcccgaaa	ggggggatcc	gccccgggtt	tccccagatc	ctgtggctgg	ctcagctgt	480	
tcccaggagc	tacgggaggg	ggaccaggat	tctctctcca	ctccctgg	aacagagt	540	
gttcccccta	gtgagtttag	tcctcgaatc	gaggagcaag	aactttctga	aaataacaagc	600	
cttcctgcag	aagaagccaa	cgggagccctt	tctgaagag	aagcgaacgg	gcccagatgt	660	
gggtctgaa	aaggccatgg	agataccatc	ggggaaaccgg	ctgcagagga	cgagggagac	720	
accgcttgg	actacagtt	ctcccaagot	cctcgatattc	tcagtggttc	ctggtcagag	780	
ttcagcaccc	aaccctgagaa	cttcttggaa	ggctgttaagt	gggctccctga	cggttccctgc	840	
atcttgcacca	atagtgtga	taacatcttgc	cgaattttata	acctgc	cccccc agagctgtac	900	
catgaggggg	agcaggtgg	atatgcagaa	atggccctgt	tcctcgaat	ggtggaaaggt	960	
gataccatct	atgattactg	ctggatttct	ctgatgtctt	cagcccagcc	agacacccctcc	1020	
tacltgccca	gcagcagccg	ggagaaccccg	attccatatct	gggacgcatt	cactggagac	1080	
ctccggggtt	ccttcgcgc	ctacaaccc	ctggatgtac	tgacggcgc	ccatctcgctc	1140	
tgcttctccc	cggatggctc	ccagcttcc	tgtggcttca	accggactgt	gctgttttt	1200	
tccacggccc	ggcctggccg	agactgcgag	gtccgagcca	catttgcaaa	aaagcagggc	1260	
cagagcggc	tcatctcttc	catagcccttc	agccccagccc	agccccctcta	tgccctgtggc	1320	
tccttacggcc	gctccctggg	tctgtatgcc	tgggatgtat	gctcccccct	ccgcttgcgt	1380	
ggaggggacc	aagggggcat	caccaccc	tgctttcatc	ccgatggcaa	ccgcttcttc	1440	

tcaggagccc gcaaggatgc tgagctcctg tgctgggatc tccggcagtc tggttaccca 1500  
 ctgtggtccc tgggtcgaga ggtgaccacc aatcagcgc aactacttgc tctggacccg 1560  
 accgggcagt tcctagttag tggcagcacg agcggggctg tctctgtgt ggacacggac 1620  
 gggcctggca atgatggaa gccggagccc gtgttgagtt ttctgcccc gaaggactgc 1680  
 accaatggcg tgagcctgca ccctagcctg ccttcctgg ccactgcctc cggtcagcgt 1740  
 gtgttccctg agccacaga gagtggggac gaaggaggg agctggccct tcccttgctc 1800  
 tccacgcgc acgtccacct tgaatgtcg cttcagctt ggtggtgtgg gggggggcca 1860  
 gactccagca tccctgtatc tcaccaggc gagaagggc aggaggaaac aggaggggagg 1920  
 tcgtgggggg cgtatataa aanggtttt gagtggtgt gactccttcc tacacaggc 1980  
 cctgataagc ctaggaatgc canagcccag ctgtagggtc ccagtccc 2028

<210> 123  
 <211> 2223  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3002667CB1

<400> 123  
 gcgcgcacgt gggggccgggg cggagagagg cgagcacccg gaaggggagc gtggggccgc 60  
 tggatgggt gaatttaagg tccatcgagt acgtttctt aattatgttc catcaggaat 120  
 ccgctgtgt gcttacaata accagtcaaa cagattggct gtttacgaa cagatggcac 180  
 tgtggaaatt tataacttgt cagcaaacta ctttcaggag aaattttcc caggtcatga 240  
 gtctcgggct acagaagctt tgcgtgggc agaaggacag cgactctta gtgcgtggct 300  
 caatggcgag attatggagt atgattaca ggcgttaaac atcaagtatg ctatggatgc 360  
 ctttggagga cctatttgc gcatgctgc cagccccagt ggctctcaac ttttgggtgg 420  
 ttgtgaagat ggatctgtga aactattca aatttaccca gacaaaatcc agtttggaaag 480  
 aaattttgtat cggcagaaaa gtcgcactt gactctcagc tggcatccct ctggtaacca 540  
 cattgcagct ggttccatag actacattag tgcgtttgtat gtcaaatcag gcagcgctgt 600  
 tcataagat attgtggaca ggcagtatat gggcgtgtct aagcggaaatg gcatcggtg 660  
 gggtgtcgcc ttcttgcg atggcactat cataagtgtg gactctgtg ggaaggtgca 720  
 gttctgggac tcagccactg ggacgcttgc gaagagccat ctcatcgcta atgcgtacgt 780  
 gcagtcatt gctgttagctg accaagaaga cagtttgcgt gttggccacag ccgagggaaac 840  
 agtctccat ttccagctgg tccctgtgac atctaaccagc agtgagaagc agtgggtgcg 900  
 gacaaaacccg ttccagcatc acactcatg cgtgcgcact gtggccacaa gcccaacagc 960  
 gctgatatacctt ggaggcactg acaccactt agtcttcgtt cctctcatgg agaaggtgga 1020  
 agtaaaaatg tacgatggcc ctctccaaa aatcacctt ccccacggat gtctcatctc 1080  
 ctgttctaaa aagaggcagc ttctcttcc ccagtttgcgt catcacttag aactttggcg 1140  
 actggatcc acagttgcaaa caggaagaa tggggataact ttccactct ctaaaaatgc 1200  
 agatcattt ctgcaccaa agacaaaggc ttctgagaac attatctgtt gctgtatctc 1260  
 cccatgtgga agttggatag cctattctac agtttctcggtt tttttctt atcggtgtaa 1320  
 ttatgaacat gacaacataa gctccaaaag gttttccaaa atgcccacat tccttcgctc 1380  
 tgcccttcag atttttgtt ctgaagatc aacaaagctc ttgttagcat caaatcaagg 1440  
 agctctgcat atttttcagc tgtcaggagg aagcttcagc cacctgcattt cttttcagcc 1500  
 tcagtcgatc acatggggg ccatgtgtct ttggcagtc agtccagatg ggaattggct 1560  
 agctgcatac ggttccactg ctggagtc tgcgtacaac gtaaaacagc taaagcttca 1620  
 ctgcacggtg cctgttaca atttcccaact gactgtatg gctattggcc ccaataccaa 1680  
 caaccctgtc atcgcattt cggaccagca ggtatttgag tacagcatcc cagacaaaca 1740  
 gtatacagat tggagccgga ctgtccagaa gcagggtttt caccacccggcttcaaaag 1800  
 ggatactctt atcacacaca tcagtttca tcctcaagaga ccgtatgcaca tccttc 1860  
 tgatgcctac atgttctgca tcattgacaa gtcattggcc ctcccaatg aaaaaacctt 1920  
 actctacaat ccatttcctt ccacgaatgtt atcagatgtc atccggaggc gcacagctca 1980  
 tgctttaaa atttctaaga tatataagcc tctactcttc atggatcttt tggatgaaag 2040  
 aacactcgat gcaatggaa ggcctctggc tgacatcatt gtcagctcc caccacccat 2100  
 taaaaagaag aaatttggaa cctaaaacag ggcactgtct gtgtccttcc ttgaactgtc 2160  
 taccctgttgc ttttcacaa atcatggtaa taaaacaatg tatttttgag gaaaaaaaaa 2220  
 aaa 2223

<210> 124  
 <211> 728  
 <212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 3043734CB1

<400> 124

gcggcgtttc tggtgccag gcatcccggt cctcgccgt ggccgagctc ccatcgccgg 60  
accgacccat gtcgcgccc cattgggtcc cgggaccccg gcgggagtgc cgctccgtc 120  
cttccagtc gccgggagtc tgagtcgccc gcaacgcggg agtggcggtg gagagccccgc 180  
cggtcggtat gaggacggat ctaaaatgac cagcaaacgg aaaccttgc aaacgcagct 240  
cagagatcc atcagttagc agttgcggga cttcacggcc agagccttggg atctgtgtg 300  
gaagaacgtc cgggagagc ggctggcaga aattgaggca aaagaagcat gtactggct 360  
ccgtcgcc ggggtccccc aatacgtca gtatatatgag gattcacaat ttccatcaa 420  
catttgtgcgt gtcaagaatg atcatgattt tcttggaaaag gacccttgcg aacccctttg 480  
cagtaaacc atgtgaagta tttttgttc ttccactgt tcagtctgc acaggcatca 540  
ctatactgaa gggcgagctc agctattcgg caagtattca ctgagtgcct accatgtgcc 600  
tgacccaggt gcaggttcta aatgtactac tggtaatgag catgatcagt ttgtgtttc 660  
atggagctta aatcctagca ggggccttg gacactagat tagaaaaatg acagagaaaag 720  
aagagaga 728

<210> 125

<211> 2161

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 3294893CB1

<400> 125

gaggcggaaag agcttctcggt ctctaggctc tggagtcccg ggagcagtga gggggccaccc 60  
ggggcacagg aaagggcccg taggggaggc cgggggtgcac tcgggggtgc tggggccgg 120  
gtctgaggga tgaggagggg ccatggccag cgacggggcc aggaagcaat tctgaaagcg 180  
cacaacagca agctcccggt cagcatccag cacgtgtatg gtgcccagca ccccccccttt 240  
gatccactgt tacatggcac tttgtcagg tccacggccca agatggcgcac cacaccgtg 300  
aaggccaaaga gggtcagcac cttccaggag ttgagagca ataccagcga tgcctgggac 360  
gctggggaggc acgacgtaca gtcctggcc atggcggcg agagcctgaa ctccgaggtg 420  
gtcatggaga cggccaaaccc tgcgtcggt aaccacagcc agccggcaggg gcccggccac 480  
ctgcaggagg gggcagggtc tcagcagaag cccaggcccc aggcagagcc gcccctcacc 540  
cccaacggcg acctccgggt ggtgaagtcg gtcagtggaa gccacacgtc ctgtctgca 600  
gaaagtggcca gcgatggccgc ccctctgcag aggtcccaat ctctcccaca ctcggccacc 660  
gtcacgttgg gtggcacatc tgaccccagc acttcagca gtcagcgct gagcggaaaga 720  
gaggccctccc ggctcgacaa gtcaagcagc ctgcgtgcgc gcccccaacac ggaccttgag 780  
gaattacggaa gtttgagctg gtccggaaat cctaaggccag tgcgtccaat gacgtggaaag 840  
ctctctctcg gttacccctcc cgccaaatgtt gacggagac cagccactt ccagagaaaa 900  
caaaaagaat attttgcatt tatttagcatt tattacgatt cttaggaacga cgaagttcac 960  
caggacacat acaggcagat ccacatagac atccctcgca tgagccctga agcgttgc 1020  
ctgcagccca aggtgacgga gattttgaa aggatcttgc tcatatgggc gatccggccac 1080  
ccagccagtgt gatacggtca gggtataaat gatctcggtca ctcccttctt tgggtcttc 1140  
atttgtaat acatagaggc agaggagggtg gacacgggtt acgttcccg cgtgccccca 1200  
gaggtgctgt gcaacatcgaa ggccgacacc tactggtca tgagcaagct gctggatggc 1260  
attcaggaca actacaccc ttcccaacct gggattcaaa tggaaatggaa aatgttagaa 1320  
gaactcggtg gccggattgt tgagcaatgt caccggcacc tggaccaaca cgaagtggaa 1380  
tacccgttgcgt ttgccttccg ctggatgaac aacctgtca tgaggagggtt gcccctgcgt 1440  
tgttacccctcc gcctgtggaa cacctaccag tctgaaccgg acggctttc tcatttccac 1500  
tttgatgtgt ggcgtcgctt tctcggtca tgagctggc tggaggaggaa aatactaga agaaaaaaat 1560  
tttcaagagc tgctgtctt cttccagaac ctgcccacag cccactggga tgatggaggac 1620  
atcaggctgt tgctggccga ggcctaccgc ctcaagtttgc ttttgcga cgcccccaat 1680  
caactacaaga aatgagccca gggccaccccg cagctggcct cactgtcccg ggtggcgcgc 1740  
cccacctgccc tggctgggg tagggccctg tgagctggc ccgggctgtc aaaaggcctt 1800  
gtgaggtggc cccacccctcc aggggagctg gtgaagatgg gccacagacc tggcttaggg 1860  
ctgacaaaga cagggacacgc ctgggtttc tgagatacca aagagagcca ggggaggcc 1920

ccgggttcgg cggccagagg caggtcaggg gtcccccttc ccttccttcg caatgtcctt 1980  
gccaatgac tgcctcctgc tgcccttagt ccggggcagc cttaggaggcc caccctcttt 2040  
ggagtcctgc tgtctgggtg ccagggccgg aacgaggtag tggccatctc atacctactc 2100  
tgaaaatgcaa aacttctatt ctgttgagtg aaaaaataaa atgtagacaa aaaaaaaaaa 2160  
C 2161

<210> 126  
<211> 2782  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3349052CB1

<210> 127  
<211> 3019  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3357264CB1

<220>  
<221> unsure  
<222> 985  
<223> a, t, c, g, or other

<400> 127

tggctgggtc cgccggcgaaa ggaagggtgtc ctagcggccc gagcctgcgc tccggattct 60  
caggcccatc ctgtggtagg ccgtccccagg caggagttgc ctcggaggat ttggcagcca 120  
cgacatccca tcctagcccc gcgatgtgcg gggctgtaaat ccccttgcac aaaccggccg 180  
gacgtaaatt gcagaatcaa agagctgttt tgaatcagca gatcctgaaa gccgtgcggaa 240  
tgaggacccg agccggaaaaac cttctgaaag tggccacaaa ctcaaaagggtg cgggagcaag 300  
tgccgtctgg a gctgagcttc gtcaacttc acctgcagat gctcaaggaa gagctggagg 360  
ggctgaacat tcctggggc gtctatcaga acacagagga ggcatttacg attcccttga 420  
ttcctcttgg cctgaaggaa acgaaagacg tgcactttc agtgcgtctc aaggattta 480  
tcctggaaaca ttacagtgtaa gatggctatt tatatgaaga tgaatttgc gatcttatgg 540  
atctgagaca agcttgtcgg acgcctagcc gggatgaggc cgggttggaa ctgctgtatga 600  
catacttcat ccagctggc ttgtcgaga gtcgattttt cccggccaca cggcagatgg 660  
gactcctgtt cacctggat gactctctca cgggggttcc ggtcagccag cagaacctgc 720  
tgctggagaa ggccagtgcc ctgttcaaca ctggggccct ctacaccagg attgggacc 780  
ggtgtgtatcg gcagacgcg gctgggctgg agatgtccat agatgcctt cagagagccg 840  
cagggtttt aaattactcg aaagacatcat ttacccatata tccaagttac gacatgagcc 900  
ctgcatctgt cagcgtgtc gtcaaaatgt tgcttgcaca agccaagaa agcgtgtttg 960  
agaaaatcg ctttctggg atccngaatg aattttcat gctgtgtaaag gtggctcagg 1020  
aggctgttaa ggtgggagag gtctaccaac agtacacgc agccatgagc caggccggccg 1080  
tgaagagaa catcccttac ttctgggcca gcttagctg cgtgaaggcc caccactacg 1140  
cgcccttgc ccactacttc atgcctatcc ttctcatcgta ccacagggtg agccaggca 1200  
cgatctgg ccacaggag aagtgcctgtt ccagctta cgaccatcat ccgaggggc 1260  
tgacacccctt ggccaaactcg aagaatgtac agcagccgc acagctgggg aagtcccact 1320  
tgccagacgc catgctcat cacgaggagt cgggtgcggga ggcgagcctc tgcaagaaggc 1380  
tgccggacat tgaggtgtca cagaagggtc tgggtgcgc acaggaacgc tcccggtctca 1440  
cgtacgccc gcaccaggag gaggatgacc tgctgaacct gatgcacgccc cccagtgttg 1500  
ttgctaaac tgagcaagag gttgacatta tattggccca gttctccaag ctgacagtc 1560  
cggaacttctt ccagaagctg ggcccattat ctgtgtttt ggcttacaag cgggtggacgc 1620  
ctctcgaaag catccgttc actgcagaag aaggggactt ggggttcacc ttgagaggga 1680  
acgccccctgt tcaggttccat ttcttggatc cttaactgtc tgcctcggtt gcaggagccc 1740  
ggaaaggaga ttatattgtc ttccattcgc ttgtggattt taatgtgtc acgctgtgtg 1800  
aggttatgaa gctgtgtaaag agctttggcg aggacgagat cgagatgaaa gtcgtgagcc 1860  
tcctggactc cacatcatcc atgcataata agagtgcac atactccgtg gaaatgcaga 1920  
aaacgtactc catgatctgc ttagccattt atgatgacga caaaactgtat aaaaccaaga 1980  
aaatctccaa gaagetttcc ttcttggatc ggggcaccaa caagaaacaga cagaagtca 2040  
ccagcacctt gtgcctccca tcggcgggg ctgcacggcc tcaggtcaag aagaagctgc 2100  
cctcccccctt cagccttcactcagaat gttcttgc ttaatgtgtg gaaacaaacaa 2160  
tggtcaggcc ccgaacattt cccgtgtca ctggccctt aacgtttgtc cccataatgg 2220  
aaatatctt ctatctgttc tcaaatctgtt ttttctcat atgtaaactt cacatgttcat 2280  
gtgtttttt gaagaaagt aaccaagaaa cctcttagaa ttatgtaaaaa aagaactttt 2340  
ttgagggtgtt ttactataact gctgtaaattt atttattata taaatgtttaa taaatagaat 2400  
agtgtgtaaat atatgtaaata tggcttatttt taatgtgtc aattatgtact tttagtcaact 2460  
attaaattttt ggttacctat atcagttacaa ttgttagtt tttccagggtt tggctaataa 2520  
tcattcccttta acctagaattt cagatgtatcc tggaaatthaag gcagggtcaga ggactgtat 2580  
gatagaattt aattatgttca actaaaaat gtcggccaaat gctgtttcc aataggaaat 2640  
cattaaacctt aaacaaatgtt tttactattat atcagatgtact taaatgttcat ttttcttct 2700  
aaatgttcat gccaaattttt tttttttttaaaataaaat gtaggagcag ctttttcttct 2760  
agttgtatgtt cattaaagaa ttactaaacac agtggcgtt gttatgtaaag atgctgtctt 2820  
caaggtagat aatataactgtt tttatgtatca aaacattttt cattttgtttt aaatgttcat 2880

ttacataatt ctatattttt agtctgggt aaaaaagtag ttttacattt tataaagtaa 2940  
 agatgtaaat gattcagctt taaagctcta ttgacttcc ttctttgtc tgagatagcg 3000  
 tccagactgc gaaaagcga 3019

<210> 128  
 <211> 2312  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3576329CB1

<400> 128  
 gccggcgcgc ggtggggcat ggccccgtcg cgggggtgcgg ggcgcacggc ggcgccgagc 60  
 gtgcggccgg agaagcggcg gtcgtggccc gaactggagc ctgagccca gccggagccc 120  
 cccctcttc gcacctctcc ttcagccac agcacccggca gcgattctgg cgtctccgac 180  
 agcgaggaga gtgtgttctc aggctggaa gatccggca gtgacagcag tgaggatgat 240  
 gacaaggcg acgaggaggag agaggacgga gcccctgtatg acgaggggcca cagtgggatt 300  
 aaaaagacca ctgaggagca ggtgcggcc agcaactccctt gcccggggac agagatggcg 360  
 agcggccggaa ttggggatgtatgatg gatgcggag gacagctctg atggggggatg catccggAAC 420  
 acggtggggca acgtggccctt ggagtggatc gatgacttcc cccacgtggg ctacgacctg 480  
 gatggcggcgc gcatctacaa gcccctggcg accccggatg agctggacca gttctggac 540  
 aagatggacg atcctgacta ctggcgaccgtcaggacc cgatgacagg gcgggacctg 600  
 agactgacgg atgagcagggt ggcctgtgt cggcggtgc agagtggcca gtttgggat 660  
 gtgggcttca acccctatga gccggctgtc gacttcttca gccggggacgt catgatccac 720  
 ccggtgacca accggccggc cgacaagcgc agcttcatcc cccctctgtt ggagaaggag 780  
 aaggtcttc gcatggtgcg cggccatcaag atgggctggatccagcccgcccg 840  
 gaccccaaccc ccagcttcta tgacctgtgg gcccaggagg acccccaaccc cgtgctcg 900  
 cgccacaaga tgcacgtacc tgctcccaag ctggccctgc caggccacgc cgagtcgtac 960  
 aaccaccccc ctgaataact gtcagcggag gaggagcgc tggcgtggga acagcaggag 1020  
 ccaggcgaga ggaagctggg ctttttgcgcg cgaaggatcc cggagctcgccg 1080  
 gcctacggac gcttcatcca ggaacgttc gagcgctgcc ttgacctgtatccgtggcc 1140  
 cggcagcgcgca agatgaggtt gaatgttagac cctgaggacc tcatccccaa gctgctcg 1200  
 ccgaggggacc tgcagccctt ccccaacgtgc cagggccctgg tctacagggg ccacagtgac 1260  
 cttgtccgggt gcctcgtgt ctctctgggg ggcaggtggc tgggttcagg ctctgacgac 1320  
 ggctccctgc ggctctggga ggtggggact gcccgtgt tgaggactgt tcccgtgggg 1380  
 ggcgtggta agatgtggc ctggaaacccc agccggctg tctgcctgtt ggctgcagcc 1440  
 gtggaggact cgggtgtgt gctgaaccca gctctggggg accggctgtt ggccggcage 1500  
 acagatcgc tggtgagcgc cttcgccccc cctgaggagc ccccttgca gccggcccg 1560  
 tggctggagg cctcagagga ggagcgcacaa gtggggctgc ggctgcgcattgcac 1620  
 aagccagtga cgcaggtgac ctggcacggg cgtggggact acctggccgt ggtgtggcc 1680  
 acccaaggcc acacccagggt gctgattcagc cagctgagcc gtcggccgcag ccagagtccg 1740  
 ttccggccga gccacggaca ggtgcgcgca gtggcccttc accctggccg gcccttcctg 1800  
 ttggggcgtt cccagcgcag cgtccgcctc taccacctgc tgcgcccaggaa gctcaccac 1860  
 aagctgtatgc ccaactgcac gtgggtgtcc agcctggcg tgcacccctgc aggtgacaac 1920  
 gtcatctgtg ggagctacga tagcaagctg gtgtgggtt acctggatct ttccaccaag 1980  
 ccatacagga tgctgagaca ccacaagaag gctctgcggg ctgtggccctt ccacccgcgg 2040  
 taccactctt tgctgcagg ctcggacgc ggcaggtgtca tgcgtctgcca tggcgtgg 2100  
 tacaatgacc ttctgcagaa cccctgtctg gtgcccgtca aggtgctgaa gggacacgtg 2160  
 ctgaccggag atctggggatg gctggacgtc atcttccacc ccacccagcc gtgggtcttc 2220  
 tcctcggggg cagacgggac tgctccgcctt tcacacccatgc tgggtcgctt ccctggggct 2280  
 ggggtggtcg tgctgaagtc aacagacgcct tc 2312

<210> 129  
 <211> 921  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3805550CB1

```

<400> 129
aggcggagtc gggccgtgt gctgagggtgg gcctgagggc ggagtcgagg tcgggctgaa 60
ggcgaggatcg gggagggtctg aggtggccgt gaaggcagag tcgaggccat ggcaggccg 120
ggccccaggcc cgggggaccc ggacgagcag tacgattcc tggtaaagt ggtctgttg 180
ggcgacgcaa gctggggcaa gacgtgcgtg gtgcagcgct tcaagaccgg cgccctctc 240
gagcgccagg gaagcaccat cggcgtcgac ttccatcgtga agacgctggg gatccagggc 300
aaggggtca agctcgatg ctgggacacg gcccggcagg agcggttccg caccatcacc 360
cagagctact accgcagtgc caatggggcc atccctgcct acgcacatcac caagaggagc 420
tccttcctgt cgggtcctca ctggatttag gatgtgagga agtatgcggg ctccaacatt 480
gtgcagctgc tgatcgaaa caagtccagac ctcagcgagc ttccggaggt ctccctggct 540
gaggcacaga gcctggctga gcactatgac atccctgtg ccattgagac gtctgccaag 600
gactcgagca acgtggagga ggccttctg agggtggcca cggagctcat catggccgac 660
ggggggccct tggtcagcga aaagagcccc gaccacatcc agctgaacat caaggacatc 720
ggagaaggct ggggtcgccc gtgtcgacca ggggcccccc cggcagactg ggggttcccc 780
accttcctgc tctcccccagc ctgccaagcc cagccctcca gagccagccc tcctgggtac 840
cgccaactac agcagccggg tgaagctctg gagctctgca tcctgtggcc tggctgcggg 900
atggaggct tccttgagga a 921

```

<210> 130

<211> 1291

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 4546403CB1

<400> 130

tcggagcgaa	tcggctcgag	agatggctcc	ttggcggcat	gtgcatttc	tcctaattggaa	60
agcttcttg	tcactggcac	tcatgtggt	gatttaacag	tgtgggatga	tcaaataggagg	120
tgtctgcata	gtggaaaaggc	acatgtatctt	ggaatttacct	gctgcgattt	ttcttcacag	180
ccagtttctg	atggagaaca	aggtcttcag	tttttcgc	tggcatcatg	tggtcaggat	240
tgccaaagtca	aaatttggat	tggttctttt	accatatactt	taggttttga	attaaaatat	300
aaaagtacac	tgagtgggca	ctgtgctctt	gttctggctt	gtgttttc	ccatgatggg	360
cagatgttag	tctcagggtc	agtggataag	tctgtcatag	tatatgatac	taatactgag	420
aatatacttc	acacattgac	ttagcacacc	aggtatgtca	caacttgtgc	ttttgcacct	480
aatacccttt	tacttgcac	tggttcaatgt	gacaaaacag	tgaacatctg	gcaatttgac	540
ctggaaacac	tttggcaagc	aaggagcaca	gaacatcagc	tgaacatgt	tacccaatgt	600
tggtcagagg	aggatgtctc	acatggctt	tgtgcacaag	attttaaaaga	tcttgttgtt	660
attttcaaga	tgaataacat	tgatggaaaa	gaactgttga	atcttacaaa	agaaaagtctg	720
gctgtatgatt	tgaaaatttga	atctcttagga	ctgcgttagta	aagtgtctgag	gaaaatttggaa	780
gagctcagga	ccaaaggtaa	atccctttct	tcaggaattt	ctgtatgaatt	tatatgtcca	840
ataacttagag	aacttatgaa	agatccggtc	atcgcacatcag	atggcttattt	atatgaaaag	900
gaagcaatgg	aaaatttggat	cagcaaaaag	aaacgtacaa	gtcccatgac	aaatcttgg	960
cttccttcag	cggtaacttac	accaaataagg	actctgaaaa	tggccatcaa	tagatggctg	102
gagacacacc	aaaatggaaaa	ttgttgatata	tgttattttt	atattttcag	tgatcttccat	108
tgaatgttt	atagttaaaat	actaaatcaga	cattttaaa	agcggaaaacag	aaaaaaaggta	114
aacttcttaa	atttagttac	ctataaaaaat	tgtcaatttt	cattttttaa	aaacacatgg	120
acttactata	aaaggctttt	tgtacttagtgc	aaaagaatct	tcaatgtat	agaaaataaag	126
tttatacttta	aatttgcaaaa	aaaaaaaaaaa	a			129

<210> 131

<211> 1836

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 4767318CB1

<400> 131

ttttagaagg ttagtgttgg ttcttttatt cgattaaaca ggaatacaca tatgtctacc 60  
aaagaatagg taagggagaa ataagaacac taaaaaaact cggaatcggt aagtgtgaag 120

catattttgg	gttaaaagaa	ccaaatatta	ctaagtaa	gacgcgggc	acgcgcgtca	180
taccgggatt	tgttagtcct	tccggggcgg	ggtagcgc	gcctgcgcag	agggccgtc	240
gctcttcgg	gcgcatcggt	ggggcagcgg	cggcaggact	gactgcgcgg	tggaggctgc	300
tgcaagtgg	tgagttggaa	gctggggagc	tcggcatggc	ggtccccgct	gcagccatgg	360
ggccctcg	gttgggcag	agcggcccc	gctcgatggc	cccgtgtgc	tcagttagac	420
gccccccgtc	gcgcatacg	cttgggatgc	aggagctgtt	ccggggccac	agcaagacgc	480
gcaagttct	ggccacacag	gccaagggtc	actcggtgc	ctggagttgc	gacggccgtc	540
gcctagctc	ggggcttcc	gaaagacgg	ccagcgtt	cttgcggag	aaggaccgt	600
tgttcaaaga	aaacaattat	cggggacatg	gggatagtgt	ggaccagctt	tgttggcattc	660
caagtaatcc	tgacctattt	gttacggcg	ctggagataa	aaccattegc	atctggatg	720
tgaggactac	aaaatgcatt	gccactgtga	acactaaagg	ggagaacatt	aatatctgt	780
ggagtcctga	tggcagacc	attgctgtag	gcaacaagga	tgtgtggtg	accttattt	840
atgccaagac	acaccgttcc	aaagcagaag	agcagttcaa	gttcgaggtc	aacgaaatct	900
cctggaacaa	tgacaataat	atgttcttc	tgacaaatgg	caatggttgt	atcaacatcc	960
tcaagctaccc	agaactgaag	cctgtgcagt	ccatcaacgc	ccatcccttc	aactgcacat	1020
gtatcaagtt	tgaccctatg	ggaaagtaact	ttgcccacagg	aagtgcggat	gctttggtca	1080
gcctctgg	tgtgatgatg	ttagtgtgt	ttcggtgtt	ttccaggctg	gattggctg	1140
taagaaccc	catgttcagc	catgtggga	aatgtggc	gtcagcatcg	gaagatcatt	1200
ttattgcacat	tgctgaagt	gagacagggg	acaaactatg	ggaggtacag	tgtgagtctc	1260
cgaccttcac	agtggcgtgg	caccccaaaa	ggcctctgct	ggcatttgcc	tgtgatgaca	1320
aagacggcaa	atatgacagc	agccggaaag	ccgaaactgt	gaagctgttt	gggcttcata	1380
atgattctt	agaggagg	gtagggagag	gaggccccgg	cagaggctt	ccttcatgt	1440
gttagttgg	tctgttct	cgaggttgtt	gggcacccct	aatatttgta	agtgtgtata	1500
aattgttaac	gtctctgg	aggctgcgc	tttcgttctt	ttgtttgtc	tgtgttattag	1560
ctctttccat	tctttggcc	cacgtatgat	taactcgct	ggactctgc	gtgcgagtag	1620
tgacccca	ataccttgc	ctctggacat	cctgtttct	ctgttctgg	gtgcatgtt	1680
gactttgtt	catttgatac	aacttggaca	atacctagt	tggagggagg	ggaatggaa	1740
ggcatggaa	tttttttaaa	taattaaaaaa	tatatacata	taattttgag	aattgaggcat	1800
ttaataaaact	gactttgtt	attatggaaa	aaaaaaa			1836

<210> 132

<211> 2136

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 4834527CB1

<400> 132

ggcgcgcccc	gagccggcag	acatgccaca	gacgctgagt	gcctccgaca	tggtcacccc	60
aggcagccctc	agcccacccc	ccaccggagcc	cacagatgac	gaacaggctg	ggcagccccct	120
cctggatgga	gegcacatct	cagccctccct	ggaaacactg	atccacgacc	tggtggccca	180
agccgactac	taccccgaga	aagccatcacat	cttcacccctc	ctgctgagct	ctcgcccttt	240
catcgagcc	cgggagctcc	tggccgggt	ctggcacctg	tgcacgagc	agcagcagct	300
ggacaaggcg	tgctggagca	aggccgggt	ccggaagttc	ggccccaaac	tgctgcagct	360
gttggccgag	tggaccgaga	ccttcccaag	ggacttccag	gaagagtcga	ctatcgggca	420
ccttaaggac	gtcggtggcc	gcatcgcccc	ctgtgacgag	gcataccgga	agaggatgca	480
tcagctctta	caggctctgc	accagaagct	ggcggtctg	cgccaggggc	cagaaggtct	540
ggtgtgggtcc	gacaagccca	tctccatag	gaccaaggca	ccagccctcca	ccacaggga	600
gctcttgggt	gtctgcagcg	acccctacac	actggcccaag	cagctgaccc	acgtggaaact	660
ggagcggctg	cggcacatcg	ggcctgaggaa	gttggccatcg	gcctttgtga	acaaggacc	720
tctggccac	acaaaaggcc	gttgcattgt	caagaccgc	aaacctggagg	cttatgtgaa	780
atgttcaac	aggctgtgt	acctgggtgc	aactgagatc	tgcacgacag	ccaagaagaaa	840
gcagaggggcc	cagggtattt	agttcttcat	cgacgtggcc	cgcgagtgtct	tcaacatcg	900
caacttcaac	tccctcatgg	ccatcatctc	cgccatgaac	atgagccctg	tctccaggct	960
gaagaagacc	tggcccaaag	tgaggacggc	caagtttttc	atcctcgagc	accagatgga	1020
cccaacgggg	aatttctgca	actacaggac	agccctgcgc	ggggccggcc	accgctccct	1080
gacggcccac	agcagccgag	agaagatgt	catttccttc	ttcagectgc	tcatccaaaga	1140
catctacttc	ctgaatgagg	gtcgcccaa	ccgcctttcc	aatggacacg	tcaactttga	1200
gaaattctgt	gagctggcca	agcagggtgg	ggagttcac	acctggaaac	aagtggagtg	1260
tcccttcgag	caagacgcca	gcatcaccca	ctacctgtac	accggccccc	tttcagtgaa	1320
qqatgggtctt	tatgggttt	cttatgaaag	ttagagccca	gagaacaaa	cagaaaaaga	1380

aagatggaaa gctctaagat cttctatTTT gggaaagaca tgaaggcgct gagctgaggg 1440  
acgaggaaga gctggagc~~c~~ gcagaagccg tccacagccc tgcctcagtg gcccagtggg 1500  
cagaggccag ggagtgcctc actatttgc aaatgccac cctgtggct gctgcccggc 1560  
cccccccccc cacagtggcc atacggcac aggagacTT ttatggact ttggccctgg 1620  
cagggccag ggcctccaga cgtgcggcg gcacatgcct tggggacate ctgccttcag 1680  
gaccgtgggg cctggtcagt ctgtccatcc tcggcaagga cacaacactg ccccaagaggg 1740  
tggaccact gcaagctcg~~a~~ gaccttgctt ggtgacatgt gccaacttgg ccaccaccca 1800  
cagtctgtca ccacgtggct tgggaacttc tggagccaca gcaggcatca cggtgcgacg 1860  
tgagatgcct gcgccagccc cgagccact ggagccact gccattccac ccatggtccc 1920  
tcacctgccc ctgcccacga gcttgtctct gcagcccccag gtacccctt cctggatgct 1980  
gctggcccca ggagatagct ttccggtgac agctgtggaa cgegtcagca ggacaaactg 2040  
gacacatgga gttacagttt gtacacggca gtcccgccac ccagccccc~~t~~ tgtaaactct 2100  
agtactata aacacacccg tacgcctaaa aaaaaaa 2136